FORM 10-Q

0001493152-15-005299.txt : 20151112 0001493152-15-005299.hdr.sgml : 20151112 20151112063231 ACCESSION NUMBER: 0001493152-15-005299 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151112 DATE AS OF CHANGE: 20151112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDAX, INC. CENTRAL INDEX KEY: 0001544238 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454484428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-181719 FILM NUMBER: 151221304 BUSINESS ADDRESS: STREET 1: 2800 WOODLAWN DRIVE STREET 2: SUITE 129 CITY: HONOLULU STATE: HI ZIP: 96822 BUSINESS PHONE: 808-457-1400 MAIL ADDRESS: STREET 1: 2800 WOODLAWN DRIVE STREET 2: SUITE 129 CITY: HONOLULU STATE: HI ZIP: 96822 FORMER COMPANY: FORMER CONFORMED NAME: Koffee Korner Inc. DATE OF NAME CHANGE: 20120308 10-Q 1 form10-q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File No. 333-181719

CARDAX, INC.

(Exact name of registrant as specified in its charter)

Delaware		45-4484428
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822

(Address of principal executive offices, zip code)

(808) 457-1400

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year,

if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

As of November 9, 2015, there were 69,623,715 shares of common stock, $0.001 par value per share (“Common Stock”), of the registrant outstanding.

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	4
Item 1. Financial Statements.	4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	5
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	7
Item 4. Controls and Procedures.	8

PART II. OTHER INFORMATION	9
Item 1. Legal Proceedings.	9
Item 1A. Risk Factors.	9
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	9
Item 3. Defaults Upon Senior Securities.	9
Item 4. Mine Safety Disclosures.	9
Item 5. Other Information.	10
Item 6. Exhibits.	10

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

There are statements in this quarterly report that are not historical facts. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “will,” or any similar expressions. You should be aware that these forward-looking statements are subject to risks and uncertainties that are beyond our control. Although we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance, and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used for the purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the development, acceptance and sales of our products and our ability to raise additional funding sufficient to implement our strategy. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this quarterly report will in fact transpire. These forward-looking statements are not guarantees of future performance. You are cautioned to not place undue reliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise any forward-looking statements.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Condensed Consolidated Financial Statements

Cardax, Inc., and Subsidiary

September 30, 2015 and 2014

Contents

		Page

Condensed consolidated financial statements:

Condensed consolidated balance sheets		F-1

Condensed consolidated statements of operations		F-2

Condensed consolidated statements of cash flows		F-3

Notes to the condensed consolidated financial statements		F-4

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2015			December 31, 2014
	(Unaudited)
ASSETS

CURRENT ASSETS
Cash	$	413,145		$	35,696
Inventory		958,575			958,575
Deposits and other assets		87,727			92,829
Prepaid expenses		7,473			19,862

Total current assets		1,466,920			1,106,962

PROPERTY AND EQUIPMENT, net		15,603			20,611

INTANGIBLE ASSETS, net		427,005			419,518

TOTAL ASSETS	$	1,909,528		$	1,547,091

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accrued payroll and payroll related expenses		3,469,219		$	3,555,961
Accounts payable		635,365			651,991
Fees payable to directors		418,546			418,546
Employee settlement		50,000			50,000
Other current liabilities		-			85,004

Total current liabilities		4,573,130			4,761,502

COMMITMENTS AND CONTINGENCIES		-			-

Total liabilities		4,573,130			4,761,502

STOCKHOLDERS’ DEFICIT
Common stock - $0.001 par value; 400,000,000 shares authorized, 69,011,494 and 63,885,930 shares issued and outstanding as of September 30, 2015, and December 31, 2014, respectively		69,012			63,886
Additional paid-in-capital		49,603,549			46,908,249
Deferred compensation		-			(294,264	)
Accumulated deficit		(52,336,163	)		(49,892,282	)

Total stockholders’ deficit		(2,663,602	)		(3,214,411	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,909,528		$	1,547,091

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

F-1

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the

	Three-months ended						Nine-months ended
	September 30,						September 30,
	2015			2014			2015			2014
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)

REVENUES	$	-		$	-		$	-		$	-

OPERATING EXPENSES:
Stock based compensation		256,959			786,747			1,534,468			10,783,948
Selling, general, and administrative expenses		266,018			724,454			681,059			3,327,010
Research and development		216,228			357,519			352,328			921,106
Depreciation and amortization		4,373			9,435			19,373			28,196

Total operating expenses		743,578			1,878,155			2,587,228			15,060,260

Loss from operations		(743,578	)		(1,878,155	)		(2,587,228	)		(15,060,260	)

OTHER INCOME (EXPENSES):
Interest expense		(477	)		-			(1,619	)		(117,042	)
Other expenses		-			(3,069	)		-			(14,585	)
Interest income		594			830			1,762			3,068
Other income		-			-			48,204			-
Gain on sale of assets		-			-			95,000			2,426

Total other income (expenses)		117			(2,239	)		143,347			(126,133	)

Loss before provision for income taxes		(743,461	)		(1,880,394	)		(2,443,881	)		(15,186,393	)

PROVISION FOR INCOME TAXES		-			-			-			-

NET LOSS	$	(743,461	)	$	(1,880,394	)	$	(2,443,881	)	$	(15,186,393	)

NET LOSS PER SHARE
Basic	$	(0.01	)	$	(0.03	)	$	(0.04	)	$	(0.26	)
Diluted	$	(0.01	)	$	(0.03	)	$	(0.04	)	$	(0.26	)

SHARES USED IN CALCULATION OF NET INCOME PER SHARE
Basic		67,955,379			63,610,949			66,000,101			59,019,453
Diluted		67,955,379			63,610,949			66,000,101			59,019,453

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

F-2

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the nine-months ended September 30,

	2015			2014
	(Unaudited)			(Unaudited)
Cash flows from operating activities:
Net loss	$	(2,443,881	)	$	(15,186,393	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		19,373			28,196
Stock based compensation		564,399			10,783,948
Amortization of debt discount		-			4,592
Gain on sale of assets		(95,000	)		(2,426	)
Changes in assets and liabilities:
Deposits and other assets		5,102			1,989
Prepaid expenses		12,389			(50,194	)
Inventory		-			28,099
Accrued payroll and payroll related expenses		883,323			(198,989	)
Accounts payable		(16,626	)		(153,510	)
Accrued interest		222			(101,553	)
Fees payable to directors		-			(50,000	)
Patent license payable		-			(10,000	)
Other current liabilities		-			(12,613	)

Net cash used in operating activities		(1,070,699	)		(4,918,854	)

Cash flows from investing activities:
Purchases of property and equipment		-			(1,634	)
Proceeds from sale of property and equipment		10,000			2,426
Expenditures on patents		(21,852	)		(20,419	)

Net cash used in investing activities		(11,852	)		(19,627	)

Cash flows from financing activities:
Proceeds from the issuance of common stock		1,430,000			3,923,798
Proceeds from the issuances of notes payable		30,000			2,076,000
Repayment of principal on notes payable		-			(550,408	)

Net cash provided by financing activities		1,460,000			5,449,390

NET INCREASE IN CASH		377,449			510,909

Cash at the beginning of the year		35,696			222,410

Cash at the end of the period	$	413,145		$	733,319

NON-CASH INVESTING AND FINANCING ACTIVITIES:

Conversion of notes payable and accrued interest into common stock	$	30,222		$	11,125,167
Conversion of accrued payroll and payroll related expenses into stock options	$	970,069		$	-

SUPPLEMENTAL DISCLOSURES:

Cash paid for interest	$	-		$	188,382
Cash paid for income taxes	$	-		$	-

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

F-3

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – COMPANY BACKGROUND

Cardax Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.

In May of 2006, Hawaii Biotech, Inc., contributed its anti-inflammatory, small molecule line of business into Holdings. Holdings issued (i) 9,447,100 shares of common stock of Holdings, (ii) 14,440,920 shares of Series A preferred stock of Holdings, (iii) 11,113,544 shares of Series B preferred stock of Holdings and (iv) 13,859,324 shares of Series C preferred stock of Holdings to Hawaii Biotech, Inc., in exchange for the assets and liabilities contributed to Holdings. The above shares were then distributed by Hawaii Biotech, Inc. to its shareholders. An additional 704,225 shares of Series C preferred stock were issued as part of the initial capitalization of Holdings. On January 30, 2007, all outstanding shares of Series A, B, and C preferred stock were converted into shares of Series A preferred stock.

Holdings was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. Holdings’ platform has application in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. Holdings’ current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has robust anti-oxidant and anti-inflammatory activity.

In May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (“Pharma”). Pharma was formed to maintain Holdings’ operations going forward, leaving Holdings as an investment holding company.

On November 29, 2013, Holdings entered into a definitive merger agreement (“Merger Agreement”) with Koffee Korner Inc., a Delaware corporation (“Koffee Korner”) (OTCQB:KOFF), and its wholly owned subsidiary (“Koffee Sub”), pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings. At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of common stock of Koffee Korner.

On February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the “Company”) (OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for the issuance and sale of an aggregate 6,276,960 of shares of the Company’s common stock, together with five year warrants to purchase an aggregate of 6,276,960 shares of the Company’s common stock at $0.625 per share, (ii) the notes issued on January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into 3,353,437 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled and substituted with stock options to purchase 6,889,555 shares of the Company’s common stock at $0.155 per share, (v) additional stock options to purchase 20,867,266 shares of the Company’s common stock at $0.625 per share were issued, and (vi) the notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off agreement on the closing date.

F-4

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – COMPANY BACKGROUND (continued)

The share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information of Holdings and Pharma. Under U.S. GAAP guidance ASC 805-40, Business Combinations – Reverse Acquisitions, the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Company’s assets and liabilities.

On August 28, 2014, the Company entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with its principal stockholder, Holdings, pursuant to which Holdings merged with and into the Company (the “Holdings Merger”). On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There will not be any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings will receive an aggregate number of shares and warrants to purchase shares of the Company’s common stock equal to the aggregate number of shares of the Company’s common stock that are held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings will be cancelled upon the closing of the Holdings Merger. Accordingly, there will not be not any change to the Company’s fully diluted capitalization due to the Holdings Merger. As of September 30, 2015, the Holdings Merger had not been completed.

Going concern matters

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss of $743,461 and $2,443,881 for the three and nine-months ended September 30, 2015, respectively, and a net loss of $1,880,394 and $15,186,393 for the three and nine-months ended September 30, 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $52,336,163 as of September 30, 2015, and has had negative cash flows from operating activities since inception. The Company anticipates further losses in the development of its business. As a result of these and other factors, the Company’s independent registered public accounting firm has determined there is substantial doubt about the Company’s ability to continue as a going concern.

In addition to the $1,460,000 raised during the first nine-months of 2015, the Company plans to raise additional capital to carry out its business plan. The Company’s ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014.

F-5

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Basis of presentation (continued)

Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.

The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015.

The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Recent accounting pronouncements

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company’s consolidated financial statements.

NOTE 3 – INVENTORY

Inventory consists of the following as of:

	September 30, 2015		December 31, 2014
	(Unaudited)
Processed materials	$	958,575	$	958,575
Total inventories	$	958,575	$	958,575

At September 30, 2015, and December 31, 2014, inventory in the amount of $924,452 is stored at one of the Company’s suppliers, which is located in Germany, with the balance of the inventory maintained in the United States.

During the year ended December 31, 2014, the Company utilized $28,099 in Astaxanthin as part of commercial product research and development.

The Company has determined that no inventory reserves are necessary as of September 30, 2015, and December 31, 2014.

F-6

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – PROPERTY AND EQUIPMENT, net

Property and equipment, net, consists of the following as of:

	September 30, 2015			December 31, 2014
	(Unaudited)
Information technology equipment	$	31,892		$	31,892
Furniture and office equipment		10,161			10,161
		42,053			42,053
Less accumulated depreciation		(26,450	)		(21,442	)
Total property and equipment, net	$	15,603		$	20,611

Depreciation expense was $1,670 and $5,008, for the three and nine-months ended September 30, 2015, respectively. Depreciation expense was $1,783 and $5,241, for the three and nine-months ended September 30, 2014, respectively.

During the year ended December 31, 2014, the Company wrote off $992,797 of fully depreciated property and equipment. There was no effect on the statement of operations for the year ended December 31, 2014.

On December 16, 2014, the Company entered into an agreement to sell laboratory equipment with a net book value of $0 for $95,000. One payment of $85,000 was received on December 26, 2014 with the balance being received on January 7, 2015. Final sale took place upon delivery of the equipment in February 2015.

NOTE 5 – INTANGIBLE ASSETS, net

Intangible assets, net, consists of the following as of:

	September 30, 2015			December 31, 2014
	(Unaudited)
Patents	$	393,370		$	393,370
Less accumulated amortization		(214,637	)		(200,272	)
		178,733			193,098
Patents pending		248,272			226,420
Total intangible assets, net	$	427,005		$	419,518

Patents are amortized straight-line over a period of fifteen years. Amortization expense was $2,703 and $14,365, for the three and nine-months ended September 30, 2015, respectively. Amortization expense was $7,652 and $22,955, for the three and nine-months ended September 30, 2014, respectively.

The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved.

The Company owns 20 issued patents, including 13 in the United States and 7 others in China, India, Japan, and Hong Kong. These patents will expire during the years of 2023 to 2028, subject to any patent term extensions of the individual patent. The Company has 1 patent application pending in the United States and 5 foreign patent applications pending in Europe, Canada, and Brazil.

F-7

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 – NOTE PAYABLE

On January 28, 2015, the Company received a short-term loan of $30,000. The loan accrued interest at the rate of 3% per annum. Principal and interest were due on April 28, 2015. Interest accrued and expensed on this short-term loan was $69 and $222 for the three and nine-months ended September 30, 2015, respectively.

This note and accrued interest were converted on April 28, 2015 into securities of the Company at $0.30 per unit. Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. “Most favored nation” rights are available to the purchaser of such units as described in the Subscription Agreement.

NOTE 7 – STOCK ISSUANCE

During the nine-months ended September 30, 2015, the Company sold securities in a self-directed offering in the aggregate amount of $1,460,222 at $0.30 per unit, which included the conversion of the $30,000 note payable and $222 in accrued interest. Each unit consisted of one share of restricted common stock (4,867,394 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Warrants issued to date in this offering totaled 13,385,342. “Most favored nation” rights are available to the purchasers of such units as described in the Subscription Agreement.

NOTE 8 – STOCK OPTION PLANS

On May 15, 2006, the Company adopted the 2006 Stock Incentive Plan. Under this plan, the Company may issue shares of restricted stock, incentive stock options, or non-statutory stock options to employees, directors, and consultants. The aggregate number of shares which may be issued under this plan was 16,521,704, which was increased by 1,456,786 to 17,978,490 as part of the Series B Offering in 2007. This plan was terminated on February 7, 2014.

On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that may be issued under this plan is 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares.

Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years.

F-8

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 – STOCK OPTION PLANS (continued)

A summary of stock option activity is as follows:

	Options			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2014		15,290,486		$	0.07		3.89	$	305,810
Exercisable January 1, 2014		15,290,486		$	0.07		3.89	$	305,810
Canceled		(15,290,486	)
Granted		27,756,821-
Exercised		(4,506	)
Forfeited		-
Outstanding December 31, 2014		27,752,315		$	0.51		8.02	$	1,963,523
Exercisable December 31, 2014		26,156,553		$	0.50		7.95	$	1,962,239
Canceled		-
Granted		5,365,729
Exercised		-			-
Forfeited		-
Outstanding September 30, 2015		33,118,044		$	0.47		6.87	$	3,418,084
Exercisable September 30, 2015		33,118,044		$	0.47		6.87	$	3,418,084

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2015, based on a valuation of the Company’s stock for that day.

A summary of the Company’s non-vested options for the nine-months ended September 30, 2015 and year ended December 31, 2014, are presented below:

Non-vested at January 1, 2014	-
Granted	27,756,821
Vested	(26,156,553	)
Exercised	(4,506	)
Forfeited	-
Non-vested at December 31, 2014	1,595,762
Granted	5,365,729
Vested	(6,961,491	)
Exercised	-
Forfeited	-
Non-vested at September 30, 2015	-

F-9

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 – STOCK OPTION PLANS (continued)

Under ASC No. 718, the Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options outstanding as of September 30, 2015 and December 31, 2014, were as follows:

	September 30, 2015		December 31, 2014
	(Unaudited)
Dividend yield		0.0%		0.0%
Risk-free rate		0.12% - 1.47%		0.12% - 1.47%
Expected volatility		112% - 170%		112% - 170%
Expected term		1.1 - 5.5 years		1.1 - 5.5 years

The expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The risk free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend within the relevant time frame. Due to a lack of historical information needed to estimate the Company’s expected term, it was estimated using the simplified method allowed under ASC No. 718. In calculating the number of options issued in the three-months ended September 30, 2015, the Company used assumptions comparable to December 31, 2014, with a 20-day weighted average stock price.

As part of the requirements of ASC No. 718, the Company is required to estimate potential forfeitures of stock grants and adjust stock based compensation expense accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized in the period of change and will also impact the amount of stock based compensation expenses to be recognized in future periods.

The Company recognized $206,959 and $1,169,537 in stock based compensation expense related to options during the three and nine-months ended September 30, 2015, respectively. Of these amounts, $206,959 and $970,069 were related to 5,365,729 options issued to employees, directors, and consultants in lieu of salaries, wages, and fees accrued for services during the three and nine-months ended September 30, 2015, respectively. The Company recognized $601,107 and $5,318,948, in stock based compensation expense during the three and nine-months ended September 30, 2014, respectively.

F-10

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 – WARRANTS

The following is a summary of the Company’s warrant activity:

	Warrants			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2014		3,395,833		$	0.45		5.28	$	-
Exercisable January 1, 2014		3,395,833		$	0.45		5.28	$	-
Canceled		(3,395,833	)
Granted		28,435,782
Exercised		-
Forfeited		-
Outstanding December 31, 2014		28,435,782		$	0.64		4.07	$	-
Exercisable December 31, 2014		28,435,782		$	0.64		4.07	$	-
Canceled		-
Granted		13,435,342
Exercised		-
Forfeited		-
Outstanding September 30, 2015		41,871,124		$	0.47		3.70	$	4,988,991
Exercisable September 30, 2015		41,871,124		$	0.47		3.70	$	4,988,991

Under ASC No. 718, the Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The fair value of warrants issued with debt is recorded as a debt discount and amortized over the life of the debt. The range of fair value assumptions related to warrants outstanding as of September 30, 2015 and December 31, 2014, were as follows:

	September 30, 2015		December 31, 2014
	(Unaudited)
Dividend yield		0.0%		0.0%
Risk-free rate		0.12% - 0.86%		0.12% - 0.66%
Expected volatility		102% - 159%		112% - 159%
Expected term		1.0 - 2.5 years		1.0 - 2.5 years

The Company recognized $0 and $4,000 in stock based compensation expense related to warrants for the three and nine-months ended September 30, 2015, respectively. The Company recognized $0 and $5,229,589, in stock based compensation expense related to warrants during the three and nine-months ended September 30, 2014, respectively.

F-11

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 – RELATED PARTY TRANSACTIONS

Executive chairman agreement

As part of an executive chairman agreement, a director provided services to the Company. The Company incurred $37,500 and $139,615 in fees to this director for the three and nine-months ended September 30, 2015, of which $130,385 was paid in stock options. The Company incurred $64,615 and $184,615, in consulting fees to this director for the three and nine-months ended September 30, 2014, respectively. This agreement was amended on April 1, 2015. Under the terms of this amendment, this director receives $37,500 in equity instruments issued quarterly in arrears as compensation.

Amounts payable to this director under previous agreements was $293,546 as of September 30, 2015 and December 31, 2014.

Director stock grants

On September 16, 2014, the Company granted its independent directors an aggregate of 642,200 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $597,246. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.

On July 14, 2014, the Company granted its independent directors an aggregate of 134,553 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $108,988. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.

On June 30, 2015, the Company granted its independent directors an aggregate of 111,112 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $16,667. These shares were fully vested upon issuance.

On September 30, 2015, the Company granted its independent directors an aggregate of 147,058 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $50,000. These shares were fully vested upon issuance.

The Company recognizes the expense related to these grants ratably over the requisite service period. Total stock compensation expense recognized as a result of these grants was $50,000 and $360,931 for the three and nine-months ended September 30, 2015, respectively.

Total stock compensation expense recognized as a result of these grants was $185,640 and $235,411 for the three and nine-months ended September 30, 2014.

NOTE 11 – INCOME TAXES

The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed.

The effective tax rate for the periods ended September 30, 2015 and 2014, differs from the statutory rate of 34% as a result of the state taxes (net of Federal benefit) and permanent differences.

The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes, which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. Based on the available objective evidence and the Company’s history of losses, management provides no assurance that the net deferred tax assets will be realized. As of September 30, 2015, and December 31, 2014, the Company has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred tax liabilities.

F-12

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – INCOME TAXES (continued)

The Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of September 30, 2015 and December 31, 2014, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods.

The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

NOTE 12 – BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

The following tables set forth the computation of the Company’s basic and diluted net income (loss) per share for the three-months ended:

	Three-months ended September 30, 2015
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(743,461	)		67,955,379	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(743,461	)		67,955,379	$	(0.01	)

	Three-months ended September 30, 2014
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(1,880,394	)		63,610,949	$	(0.03	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(1,880,394	)		63,610,949	$	(0.03	)

F-13

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 – BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (continued)

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for the nine-months ended:

	Nine-months ended September 30, 2015
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(2,443,881	)		66,000,101	$	(0.04	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(2,443,881	)		66,000,101	$	(0.04	)

	Nine-months ended September 30, 2014
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(15,186,393	)		59,019,453	$	(0.26	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(15,186,393	)		59,019,453	$	(0.26	)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the years presented because including them would have been antidilutive for the years ended:

	September 30, 2015		September 30, 2014
Common stock options		33,118,044		23,762,946
Common stock warrants		41,871,124		28,405,782
Total common stock equivalents		74,989,168		52,168,728

NOTE 13 – CONCENTRATION

The Company purchased all of its inventory from one vendor in Germany. Although, there were no purchases from this vendor during the three and nine-months ended September 30, 2015 and 2014, outstanding payables to this vendor were $86,255 as of September 30, 2015, and December 31, 2014.

F-14

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 14 – LEASES

Hawaii Research Center

The Company entered into a lease for laboratory and office space on May 9, 2006. This lease amended on September 7, 2011, and October 30, 2012. This lease expired on October 31, 2014, after which the terms converted to month-to-month. The Company vacated the space in February 2015. Total rent expense under this agreement as amended was $0 and $12,112, for the three and nine-months ended September 30, 2015, respectively. Total rent expense under this agreement as amended was $14,709 and $47,331, for the three and nine-months ended September 30, 2014, respectively.

Manoa Innovation Center

The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $7,931 and $23,759, for the three and nine-months ended September 30 2015, respectively. Total rent expense under this agreement as amended was $7,825 and $23,255, for the three and nine-months ended September 30, 2014, respectively.

NOTE 15 – COMMITMENTS

Patent payable

As part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting from the license. There were no revenues generated by this license during the three and nine-months ended September 30, 2015 and 2014. The remaining obligation of $20,000 as of September 30, 2015 and December 31, 2014, is recorded as a part of accounts payable on the condensed consolidated balance sheets.

Employee settlement

As of September 30, 2015 and December 31, 2014, the Company owed a former employee a severance settlement payable in the amount of $50,000 for accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully vested and extended.

BASF agreement and license

In November 2006, the Company entered into a joint development and supply agreement with BASF SE (“BASF”). Under the agreement, the Company granted BASF an exclusive world-wide license to the Company’s rights related to the development and commercialization of Astaxanthin consumer health products; the Company retains all rights related to Astaxanthin pharmaceutical products. The Company is to receive specified royalties based on future net sales of such Astaxanthin consumer health products. No royalties were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014. The license does not prohibit the Company from purchasing Astaxanthin consumer health products from BASF for consumer health applications, similar to any third-party wholesale customer.

F-15

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOTE 15 – COMMITMENTS (continued)

Capsugel agreement

On August 18, 2014, the Company entered into a collaboration agreement with Capsugel US, LLC (“Capsugel”) for the joint commercial development of Astaxanthin products for the consumer health market that contain nature-identical synthetic Astaxanthin and use Capsugel’s proprietary formulation technology, which is expected to increase the oral bioavailability of Astaxanthin. The agreement provides for the parties to jointly administer activities under a product development plan that will include identifying at least one mutually acceptable third party marketer who will further develop, market and distribute consumer health, nature-identical synthetic Astaxanthin products developed under the collaboration. Capsugel will share revenues with the Company based on net sales of products that are developed under the collaboration. No revenues were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014.

NOTE 16 – SUBSEQUENT EVENTS

The Company evaluated its September 30, 2015, condensed consolidated financial statements for subsequent events through November 9, 2015, the date the condensed consolidated financial statements were available to be issued and noted the following non-recognized events for disclosure.

Stock issuance

On October 19, 2015, the Company granted a consultant 100,000 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $45,000. These shares vested immediately.

On October 26, 2015, the Company issued 25,556 shares of common stock in the Company in connection with the cashless exercise of a stock option for 41,851 shares of common stock at $0.155 per share with 16,295 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

In October and November 2015 (through November 9, 2015), the Company sold securities in a self-directed offering in the aggregate amount of $146,000 at $0.30 per unit. Each unit consisted of 1 share of restricted common stock (486,665 shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020. “Most favored nation” rights are available to the purchasers of such units as described in the Subscription Agreement.

***

F-16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Explanatory Note

Unless otherwise noted, references in this Form 10-Q to “Cardax,” the “Company,” “we,” “our” or “us” means Cardax, Inc., the registrant, and, unless the context otherwise requires, together with its wholly-owned subsidiary, Cardax Pharma, Inc., a Delaware corporation (“Pharma”), and Pharma’s predecessor, Cardax Pharmaceuticals, Inc., a Delaware corporation (“Holdings”).

Corporate Overview and History

We acquired Cardax Pharma, Inc. (“Pharma”) and its life science business through the merger of Cardax Acquisition, Inc. (“Cardax Sub”), our wholly-owned transitory subsidiary (“Cardax Sub”), with and into Pharma on February 7, 2014 (the “Merger”), and a stock purchase agreement. As a result of these transactions, Pharma became our wholly-owned subsidiary. The only consideration that we paid under the stock purchase agreement and the Merger was shares of our Common Stock. On May 31, 2013, Pharma acquired all of the assets and assumed all of the liabilities of Cardax Pharmaceuticals, Inc. (“Holdings”). Accordingly, we have two predecessors: Pharma and Pharma’s predecessor, Holdings. Prior to the February 7, 2014 effective date of the Merger, we operated under the name “Koffee Korner Inc.” and our business was limited to a single location retailer of specialty coffee located in Houston, Texas. On the effective date of the Merger, we divested our coffee business and now exclusively continue Pharma’s life sciences business. On August 28, 2014, we entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with our principal stockholder, Holdings, pursuant to which Holdings will merge with and into the Company (the “Holdings Merger”). On September 18, 2015, we filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There will not be any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings will receive an aggregate number of shares and warrants to purchase shares of our common stock equal to the aggregate number of shares our common stock that are held by Holdings on the date of the closing of the Holdings Merger. Our restricted shares of common stock held by Holdings will be cancelled upon the closing of the Holdings Merger. Accordingly, there will not be any change to our fully diluted capitalization due to the Holdings Merger. As of September 30, 2015, the Holdings Merger had not been completed.

We currently devote substantially all of our efforts to developing consumer health and pharmaceutical products that we believe will provide many of the anti-inflammatory benefits of steroids or NSAIDs by targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. (We use consumer health products to refer to nutrients, dietary ingredients/supplements, and other consumer products designed to provide physiological benefits and improve health, which are not regulated by the FDA or similar authorities as pharmaceuticals.) The safety and efficacy of the Company’s product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

We are devoting substantially all of our present efforts to establishing our business. Our planned principal operations have not commenced and, accordingly, no revenue has been derived therefrom. We own intellectual property that we are marketing in varying stages worldwide. Our initial revenue generating opportunities are from our strategic alliances, including an exclusive license of our rights related to the development and commercialization of consumer health products containing or utilizing a nature-identical form of astaxanthin and a collaboration related to proprietary formulations of astaxanthin. We also plan to pursue pharmaceutical applications of astaxanthin and related compounds.

At present we are not able to estimate if or when we will be able to generate sustained revenues. Our financial statements have been prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, our independent registered public accounting firm has determined there is substantial doubt about our ability to continue as a going concern.

Results of Operations

Results of Operations for the Three and Nine-months Ended September 30, 2015 and 2014:

The following table reflects our operating results for the three and nine-months ended September 30, 2015 and 2014:

Operating Summary	Three-months ended September 30, 2015			Three-months ended September 30, 2014			Nine-months ended September 30, 2015			Nine-months ended September 30, 2014
Revenues	$	-		$	-		$	-		$	-
Operating Expenses		(743,578	)		(1,878,155	)		(2,587,228	)		(15,060,260	)
Net Operating Loss		(743,578	)		(1,878,155	)		(2,587,228	)		(15,060,260	)
Other Income (Expenses)		117			(2,239	)		143,347			(126,133	)
Net Loss	$	(743,461	)	$	(1,880,394	)	$	(2,443,881	)	$	(15,186,393	)

Operating Summary for the Three-Months Ended September 30, 2015 and 2014

We are a pre-revenue life sciences company with limited operations and had no revenues for the three-months ended September 30, 2015 and 2014.

Operating expenses were $743,578 and $1,878,155 for the three-months ended September 30, 2015 and 2014, respectively. Operating expenses primarily consisted of expenses for services provided to the Company, including payroll and consultation, for research and development, and administration. These expenses were paid in accordance with agreements entered into with each consultant, employee, or service provider. Included in operating expenses were $256,959 and $786,747 in stock based compensation for the three-months ended September 30, 2015 and 2014, respectively.

Other income (expenses) were $117 and $(2,239) for the three-months ended September 30, 2015 and 2014, respectively.

Operating Summary for the Nine-Months Ended September 30, 2015 and 2014

We are a pre-revenue life sciences company with limited operations and had no revenues for the nine-months ended September 30, 2015 and 2014.

Operating expenses were $2,587,228 and $15,060,260 for the nine-months ended September 30, 2015 and 2014, respectively. Operating expenses primarily consisted of expenses for services provided to the Company, including payroll and consultation, for research and development, and administration. These expenses were paid in accordance with agreements entered into with each consultant, employee, or service provider. Included in operating expenses were $1,534,468 and $10,783,948 in stock based compensation for the nine-months ended September 30, 2015 and 2014, respectively.

Other income (expenses) were $143,347 and $(126,133) for the nine-months ended September 30, 2015 and 2014, respectively. For the nine-months ended September 30, 2015, other income primarily consisted of a change in estimated accrued liabilities of $48,204 and a gain on the sale of assets of $95,000. For the nine-months ended September 30, 2014, other expenses primarily consisted of interest expense on notes payable of $117,042. Included in interest expense were $0 and $4,592 in amortization of notes payable discounts for the nine-months ended September 30, 2015 and 2014, respectively.

Liquidity and Capital Resources

Since our inception, we have sustained operating losses and have used cash raised by issuing securities in our operations. During the nine-months ended September 30, 2015 and 2014, we used cash in operating activities in the amount of $1,070,699 and $4,918,854, respectively, and incurred a net loss of $2,443,881 and $15,186,393, respectively.

We require additional financing in order to continue to fund our operations, and pay existing and future liabilities and other obligations. To conserve cash resources, we have agreed with our employees, executives, and certain vendors to pay any compensation due during any calendar quarter that has not been paid in cash in the form of shares of Common Stock or stock options, as described in the Current Report on Form 8-K dated July 7, 2015. In addition, we have deferred payment of other trade payables. We intend to continue such arrangements until it obtains sufficient financing to restore full compensation and payment amounts.

It is estimated that our limited available cash resources as of the date of this Quarterly Report on Form 10-Q, would be sufficient to continue operations on a limited budget only through December 31, 2015. In addition to the $1,460,000 raised during the first nine-months of 2015, we intend to raise additional capital that would fund our operations through at least December 31, 2016. We are currently negotiating the terms of additional financing with investors and are considering a private placement of our common stock and warrants to purchase common stock. Any financing transaction could also, or in the alternative, include the issuance of our debt or convertible debt securities. There can be no assurance that a financing transaction would be available to us on terms and conditions that we determined are acceptable.

We cannot give any assurance that we will in the future be able to achieve a level of profitability from the sale of future products or otherwise to sustain our operations. These conditions raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Any inability to obtain additional financing on acceptable terms will materially and adversely affect us, including requiring us to significantly further curtail or cease business operations altogether.

Our working capital and capital requirements at any given time depend upon numerous factors, including, but not limited to:

	●	the progress of research and development programs;

	●	the level of resources that we devote to the development of our technologies, patents, marketing and sales capabilities; and

	●	revenues from the sale of any products or license revenues and the cost of any production or other operating expenses.

The following is a summary of our cash flows provided by (used in) operating, investing and financing activities during the periods indicated:

Cash Flow Summary	Nine-months ended September 30, 2015			Nine-months ended September 30, 2014
Net Cash Used in Operating Activities	$	(1,070,699	)	$	(4,918,854	)
Net Cash Used in Investing Activities		(11,852	)		(19,627	)
Net Cash Provided by Financing Activities		1,460,000			5,449,390
Net Cash Increase for Period		377,449			510,909
Cash at Beginning of Year		35,696			222,410
Cash at End of Period	$	413,145		$	733,319

Cash Flows from Operating Activities

During the nine-months ended September 30, 2015 and 2014, our operating activities primarily consisted of payments to, or accruals for payments to, employees, directors, and consultants, for services related to research and development and administration. The decrease in net cash used in operating activities of $3,848,155 from September 30, 2015 to September 30, 2014, was primarily attributable to a combination of (i) a decrease in professional and financing expenses in the aggregate amount of $1,843,415 from the nine-months ended September 30, 2014, which were the result of increased costs associated with the Merger and financing activities, and (ii) a decrease in cash payments of accrued payroll, accounts payable, accrued interest, and fees payable to directors in the aggregate amount of $1,370,971 from the nine-months ended September 30, 2014.

Cash Flows from Investing Activities

During the nine-months ended September 30, 2015 and 2014, our investing activities were primarily related to proceeds from the sale of equipment and expenditures on patents.

Cash Flows from Financing Activities

During the nine-months ended September 30, 2015 and 2014, our financing activities consisted of various transactions in which we raised proceeds through the issuance of debt and common stock. Because of the nature of our business, capital is required to support research and development costs, as well as, our normal operating costs.

Our existing liquidity is not sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for the foreseeable future. We will need to seek to obtain additional debt or equity financing, especially if we experience downturns or cyclical fluctuations in our business that are more severe or longer than anticipated, or if we experience significant increases in the cost of components and manufacturing, or increases in our expense levels resulting from being a publicly-traded company. If we attempt to obtain additional debt or equity financing, we cannot assure you that such financing will be available to us on favorable terms, or at all.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (b) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of the our management and directors; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Based on our evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of September 30, 2015.

Changes in Internal Controls over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We entered into separate subscription agreements, registration rights agreements and warrant purchase agreements (each, a “Purchase Agreement”), by and between the Company and investors (each a “Purchaser” and collectively, the “Purchasers”) pursuant to which the Company issued and sold to the Purchasers shares of the Company’s common stock and Class D Warrants and E Warrants (each, a “Warrant” and, collectively, the “Warrants”) to purchase shares of the Company’s common stock.

Under the Purchase Agreements, each of the Purchasers purchased units (the “Unit”) that consisted of: (A) shares of the Company’s common stock at a price per share of $0.30, (B) two (2) Class D warrants, each to purchase one (1) share of the Company’s common stock at a price per share of $0.10, and (C) one (1) Class E warrant to purchase three-quarters (3/4) of one (1) share of the Company’s common stock at a price per share of $0.1667. The Class D warrants and the Class E warrants will expire March 31, 2020. In the calendar year to date (through November 9, 2015), we have sold an aggregate of 5,354,059 Units for an aggregate purchase price of $1,606,222. No placement agent or broker dealer was used or participated in any offering or sale of such Units. On September 8, 2015, we engaged a broker dealer to assist in an offering of our securities as a placement agent. Any future offering of securities may be on the same terms as the sale of the Units or on other terms.

The offering of the Units was made in a transaction that is exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and the provisions of Regulation D or Regulation S that is promulgated under the Securities Act. The Company may continue to offer securities and may use a placement agent or broker dealer in any such offering.

This Quarterly Report on Form 10-Q does not constitute an offer to sell, or a solicitation to purchase, any our securities.

Under the terms of the Registration Rights Agreement, the Company has agreed to register the common stock that is issued in the Unit and the shares underlying the Warrants shortly after March 31, 2016 or, if earlier, in connection with any registration rights that may be granted by us in an offering of securities of $250,000 or more on or prior to March 31, 2016 (a “Qualified Financing”). The Subscription Agreement also includes “most favored nation” rights to the purchasers of the Units in the event the Company issues stock on terms more favorable to the purchaser in a Qualified Financing.

The foregoing summary of the Subscription Agreement, Registration Rights Agreement, and Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of such agreements, which were filed with our Current Report on Form 8-K on March 9, 2015.

On October 19, 2015, we granted a consultant 100,000 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $45,000. These shares vested immediately.

On October 26, 2015, we issued 25,556 shares of common stock in the Company in connection with the cashless exercise of a stock option for 41,851 shares of common stock at $0.155 per share with 16,295 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

	Exhibit No.		Description

	10.1⁽¹⁾		Form of Registration Rights Agreement

	10.2⁽¹⁾		Form of Subscription Agreement

	10.3⁽¹⁾		Form of Class D Warrant

	10.4⁽¹⁾		Form of Class E Warrant

	31.1⁽²⁾		Certification of the Chief Executive Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	31.2⁽²⁾		Certification of the Chief Financial Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1⁽²⁾		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	32.2⁽²⁾		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101.INS⁽³⁾		XBRL Instance Document
	101.SCH⁽³⁾		XBRL Taxonomy Extension Schema Document
	101.CAL⁽³⁾		XBRL Taxonomy Extension Calculation Linkbase Document
	101.DEF⁽³⁾		XBRL Taxonomy Extension Definition Linkbase Document
	101.LAB⁽³⁾		XBRL Taxonomy Extension Label Linkbase Document
	101.PRE⁽³⁾		XBRL Taxonomy Extension Presentation Linkbase Document

	⁽¹⁾		Filed as an exhibit to the Current Report on Form 8-K of the Company dated March 9, 2015.
	⁽²⁾		Filed herewith.
	⁽³⁾		Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 12, 2015

CARDAX, INC.

	By:	/s/ David G. Watumull
	Name:	David G. Watumull
	Title:	Chief Executive Officer and President

EX-31.1 2 ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David G. Watumull, Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cardax, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 12, 2015	/s/ David G. Watumull
	David G. Watumull
	Chief Executive Officer

EX-31.2 3 ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John B. Russell, Chief Financial Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cardax, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 12, 2015	/s/ John B. Russell
	John B. Russell
	Chief Financial Officer

EX-32.1 4 ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cardax, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, David G. Watumull, Chief Executive Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 12, 2015

By:	/s/ David G. Watumull
	David G. Watumull
	Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cardax, Inc. and will be retained by Cardax, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cardax, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, John B. Russell, Chief Financial Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 12, 2015

By:	/s/ John B. Russell
	John B. Russell
	Chief Financial Officer

EX-101.INS 6 cdxi-20150930.xml XBRL INSTANCE FILE 0001544238 2015-01-01 2015-09-30 0001544238 2015-09-30 0001544238 2014-12-31 0001544238 2008-12-31 0001544238 2009-12-31 0001544238 us-gaap:FurnitureAndFixturesMember 2015-09-30 0001544238 us-gaap:TechnologyEquipmentMember 2015-09-30 0001544238 us-gaap:FurnitureAndFixturesMember 2014-12-31 0001544238 us-gaap:TechnologyEquipmentMember 2014-12-31 0001544238 us-gaap:SeriesCPreferredStockMember 2006-05-31 0001544238 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001544238 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001544238 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001544238 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001544238 CDXI:CommonStockWarrantsMember 2014-01-01 2014-09-30 0001544238 CDXI:CommonStockWarrantsMember 2015-01-01 2015-09-30 0001544238 us-gaap:WarrantMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001544238 us-gaap:WarrantMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001544238 us-gaap:WarrantMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001544238 us-gaap:WarrantMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001544238 CDXI:VendorMember 2015-09-30 0001544238 2014-02-06 2014-02-07 0001544238 2014-01-02 2014-01-03 0001544238 2014-01-03 0001544238 2014-02-07 0001544238 2014-01-01 2014-09-30 0001544238 us-gaap:SeriesCPreferredStockMember 2006-05-01 2006-05-31 0001544238 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001544238 2013-05-31 0001544238 us-gaap:SeriesAPreferredStockMember 2006-05-01 2006-05-31 0001544238 us-gaap:SeriesBPreferredStockMember 2006-05-01 2006-05-31 0001544238 us-gaap:StockOptionMember 2014-01-01 2014-09-30 0001544238 CDXI:TwoThousandFourteenEquityCompensationPlanMember 2014-02-06 2014-02-07 0001544238 us-gaap:ProductMember 2014-01-01 2014-12-31 0001544238 CDXI:UnitedStatesMember 2015-01-01 2015-09-30 0001544238 CDXI:ChinaIndiaJapanAndHongKongMember 2015-01-01 2015-09-30 0001544238 CDXI:GermanyMember 2015-09-30 0001544238 CDXI:GermanyMember 2014-12-31 0001544238 CDXI:TwoThousandSixStockIncentivePlanMember 2006-05-14 2006-05-15 0001544238 CDXI:TwoThousandSixStockIncentivePlanMember us-gaap:MinimumMember 2006-05-14 2006-05-15 0001544238 CDXI:TwoThousandSixStockIncentivePlanMember us-gaap:MaximumMember 2006-05-14 2006-05-15 0001544238 us-gaap:WarrantMember 2014-12-31 0001544238 CDXI:ExecutiveChairmanAgreementMember us-gaap:DirectorMember 2015-01-01 2015-09-30 0001544238 CDXI:ExecutiveChairmanAgreementMember us-gaap:DirectorMember 2014-01-01 2014-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:HawaiiResearchCenterMember 2015-01-01 2015-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:HawaiiResearchCenterMember 2014-01-01 2014-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2015-01-01 2015-09-30 0001544238 us-gaap:SubsequentEventMember 2015-11-09 0001544238 us-gaap:SubsequentEventMember CDXI:TwoClassDWarrantsMember 2015-10-01 2015-11-09 0001544238 us-gaap:SubsequentEventMember CDXI:OneClassEWarrantMember 2015-10-01 2015-11-09 0001544238 CDXI:LaboratoryEquipmentMember 2014-12-16 0001544238 CDXI:EuropeCanadaAndBrazilMember 2015-01-01 2015-09-30 0001544238 us-gaap:SubsequentEventMember 2015-10-01 2015-11-09 0001544238 2014-01-01 2014-12-31 0001544238 CDXI:LaboratoryEquipmentMember 2014-12-15 2014-12-16 0001544238 CDXI:TwoClassDWarrantMember 2015-01-01 2015-09-30 0001544238 CDXI:OneClassEWarrantMember 2015-01-01 2015-09-30 0001544238 2013-12-31 0001544238 2013-01-01 2013-12-31 0001544238 us-gaap:WarrantMember 2015-09-30 0001544238 CDXI:BasfAgreementAndLicenseMember 2015-01-01 2015-09-30 0001544238 CDXI:BasfAgreementAndLicenseMember 2014-01-01 2014-09-30 0001544238 CDXI:CapsugelAgreementMember 2015-01-01 2015-09-30 0001544238 CDXI:CapsugelAgreementMember 2014-01-01 2014-09-30 0001544238 2014-09-30 0001544238 2015-01-28 0001544238 2015-07-01 2015-09-30 0001544238 2014-07-01 2014-09-30 0001544238 2015-11-09 0001544238 2015-04-28 0001544238 CDXI:EmployeesMember 2015-07-01 2015-09-30 0001544238 CDXI:EmployeesMember 2015-01-01 2015-09-30 0001544238 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001544238 us-gaap:WarrantMember 2013-12-31 0001544238 us-gaap:WarrantMember 2014-07-01 2014-09-30 0001544238 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001544238 CDXI:ExecutiveChairmanAgreementMember us-gaap:DirectorMember 2015-07-01 2015-09-30 0001544238 CDXI:ExecutiveChairmanAgreementMember us-gaap:DirectorMember 2014-07-01 2014-09-30 0001544238 2015-03-28 2015-04-02 0001544238 us-gaap:DirectorMember 2014-09-15 2014-09-16 0001544238 us-gaap:DirectorMember 2014-06-12 2014-06-14 0001544238 us-gaap:DirectorMember 2015-01-01 2015-09-30 0001544238 us-gaap:DirectorMember 2015-07-01 2015-09-30 0001544238 us-gaap:DirectorMember 2014-01-01 2014-09-30 0001544238 us-gaap:DirectorMember 2014-07-01 2014-09-30 0001544238 us-gaap:DirectorMember 2015-06-29 2015-06-30 0001544238 CDXI:VendorMember 2014-12-31 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:HawaiiResearchCenterMember 2015-07-01 2015-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:HawaiiResearchCenterMember 2014-07-01 2014-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2015-07-01 2015-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2013-07-01 2013-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2013-01-01 2013-09-30 0001544238 2006-05-01 2006-05-31 0001544238 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001544238 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001544238 us-gaap:DirectorMember 2015-07-01 2015-09-30 0001544238 us-gaap:DirectorMember 2015-01-01 2015-09-30 0001544238 CDXI:ConsultantsMember 2015-07-01 2015-09-30 0001544238 CDXI:ConsultantsMember 2015-01-01 2015-09-30 0001544238 us-gaap:DirectorMember 2015-09-29 2015-09-30 0001544238 CDXI:CapsugelAgreementMember 2015-07-01 2015-09-30 0001544238 CDXI:CapsugelAgreementMember 2014-07-01 2014-09-30 0001544238 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2015-10-18 2015-10-19 0001544238 us-gaap:SubsequentEventMember us-gaap:StockOptionMember 2015-10-25 2015-10-26 0001544238 us-gaap:SubsequentEventMember 2015-10-25 2015-10-26 0001544238 us-gaap:SubsequentEventMember us-gaap:StockOptionMember 2015-10-26 0001544238 us-gaap:SubsequentEventMember CDXI:WithheldOptionMember 2015-10-25 2015-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CDXI:Units CARDAX, INC. 10-Q 2015-09-30 false --12-31

0.001

400000000

69011494

63885930

69011494

63885930

NOTE 10 RELATED PARTY TRANSACTIONS   Executive chairman agreement   As part of an executive chairman agreement, a director provided services to the Company. The Company incurred $37,500 and $139,615 in fees to this director for the three and nine-months ended September 30, 2015, of which $130,385 was paid in stock options. The Company incurred $64,615 and $184,615, in consulting fees to this director for the three and nine-months ended September 30, 2014, respectively. This agreement was amended on April 1, 2015. Under the terms of this amendment, this director receives $37,500 in equity instruments issued quarterly in arrears as compensation.   Amounts payable to this director under previous agreements was $293,546 as of September 30, 2015 and December 31, 2014.   Director stock grants   On September 16, 2014, the Company granted its independent directors an aggregate of 642,200 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $597,246. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.   On July 14, 2014, the Company granted its independent directors an aggregate of 134,553 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $108,988. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.   On June 30, 2015, the Company granted its independent directors an aggregate of 111,112 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $16,667. These shares were fully vested upon issuance.   On September 30, 2015, the Company granted its independent directors an aggregate of 147,058 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $50,000. These shares were fully vested upon issuance.   The Company recognizes the expense related to these grants ratably over the requisite service period. Total stock compensation expense recognized as a result of these grants was $50,000 and $360,931 for the three and nine-months ended September 30, 2015, respectively.   Total stock compensation expense recognized as a result of these grants was $185,640 and $235,411 for the three and nine-months ended September 30, 2014.

9447100

-4506

1.00

Inventory consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Processed materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="width: 22%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">958,575</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="width: 22%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">958,575</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Total inventories</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">958,575</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">958,575</td> <td style="line-height: 115%"> </td></tr> </table>

958575

42053

10161

31892

10161

31892

26450

21442

393370

214637

200272

427005

419518

2076000

8489036

704225

A summary of stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average exercise price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average remaining contractual term in years</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate intrinsic value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify; line-height: 115%">Outstanding January 1, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">15,290,486</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.07</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">3.89</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">305,810</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,290,486</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.89</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">305,810</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(15,290,486</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">27,756,821-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(4,506</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">27,752,315</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.51</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8.02</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,963,523</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">26,156,553</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7.95</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,962,239</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,365,729</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">33,118,044</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.87</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">3,418,084</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">33,118,044</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.87</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">3,418,084</td> <td style="line-height: 115%"> </td></tr> </table>

The following is a summary of the Companys warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Warrants</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average exercise price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average remaining contractual term in years</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate intrinsic value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify; line-height: 115%">Outstanding January 1, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">3,395,833</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.45</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5.28</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,395,833</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.45</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.28</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(3,395,833</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.64</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.64</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">13,435,342</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">4,988,991</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">4,988,991</td> <td style="line-height: 115%"> </td></tr> </table>

The following tables set forth the computation of the Companys basic and diluted net income (loss) per share for the three-months ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three-months ended September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(743,461</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">67,955,379</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.01</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(743,461</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">67,955,379</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.01</td> <td style="line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three-months ended September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(1,880,394</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">63,610,949</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.03</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,880,394</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">63,610,949</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td></tr> </table>    The following table sets forth the computation of the Companys basic and diluted net income (loss) per share for the nine-months ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine-months ended September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(2,443,881</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">66,000,101</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.04</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,443,881</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">66,000,101</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.04</td> <td style="line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine-months ended September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(15,186,393</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">59,019,453</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.26</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(15,186,393</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">59,019,453</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.26</td> <td style="line-height: 115%">)</td></tr> </table>

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the years presented because including them would have been antidilutive for the years ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Common stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: right; line-height: 115%">33,118,044</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: right; line-height: 115%">23,762,946</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">28,405,782</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total common stock equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">74,989,168</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,168,728</td> <td style="line-height: 115%"> </td></tr> </table>

6889555 0.155 0.625 20867266 Smaller Reporting Company 69623715 Q3

352328

921106

28099

216228

357519

5008

5241

1670

1783

P15Y

3353437

14446777

3321600 14446777 15290486

13859324

14440920

11113544

100000

41851

25556

16295

55000

500000

958575

924452

15603

20611

4573130

4761502

1909528

1547091

178733

193098

patents will expire during the years of 2023 to 2028.

-2663602

-3214411

The range of fair value assumptions related to warrants outstanding as of September 30, 2015 and December 31, 2014, were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 0.86%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 0.66%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">102% - 159%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 159%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Expected term</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.0 - 2.5 years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.0 - 2.5 years</td> <td style="line-height: 115%"> </td></tr> </table>

413145

35696

222410

733319

95000

2426

95000

4592

-12389

50194

883323

-198989

-16626

-153510

222

-101553

-50000

-12613

-1070699

-4918854

10000

2426

-11852

-19627

550408

30000

2076000

1430000

3923798

188382

222

0.30

0.1555

30420148

16521704

1456786

17978490

33118044

27752315

15290486

33118044

26156553

15290486

0.47

0.51

0.07

0.47

0.50

0.07

3418084

1963523

305810

3418084

1962239

305810

1595762

0.0

0.00

0.0012

0.0147

0.0012

0.0147

0.0012

0.0066

0.0012

0.0086

1.12

1.70

1.12

1.70

1.12

1.59

1.02

1.59

P1Y1M6D

P5Y6M

P1Y1M6D

P5Y6M

P1Y

P2Y6M

P1Y

P2Y6M

294264

28435782

41871124

3395833

28435782 41871124 3395833

-3395833

28435782

13435342

0.64 0.47 0.45 0.64 0.47 0.45 P5Y3M11D P4Y26D P5Y3M11D P4Y26D

4988991

-0.34

-2443881

-15186393

-743461

-1880394

-2443881

-15186393

-743461

-1880394

74989168

28405782

41871124

52168728

33118044

23762946

86255

12112

47331

23759

14709

7931

7825

23255

10000

0.02

20000 20000 0.10 0.1667 0.10 0.1667 2020-03-31 2020-03-31 2020-03-31 2020-03-31

-5102

-1989

30222

11125167

P5Y P5Y P5Y

0.625

20 13 7 1 5

486665

1460222

146000

87727

92829

7473

19862

1466920

1106962

427005

419518

1909528

1547091

635365

651991

418546

50000

85004

4573130

4761502

69012

63886

-52336163

-49892282

21852

20419

992797

1634

85000

0.07

-15290486

5365729

27756821

642200

134553

111112

147058

P8Y7D

P3Y10M21D

P7Y11M12D

P3Y10M21D

-6961491

-26156553

-4506

14365

22955

2703

7652

30000

2015-04-28

NOTE 7 STOCK ISSUANCE   During the nine-months ended September 30, 2015, the Company sold securities in a self-directed offering in the aggregate amount of $1,460,222 at $0.30 per unit, which included the conversion of the $30,000 note payable and $222 in accrued interest. Each unit consisted of one share of restricted common stock (4,867,394 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Warrants issued to date in this offering totaled 13,385,342. Most favored nation rights are available to the purchasers of such units as described in the Subscription Agreement. Each unit consisted of 1 share of restricted common stock ([486,665] shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020.

1.00

0.10 1.10 1.00 P4Y26D P3Y8M12D P4Y26D P3Y8M12D

139615

184615

37500

64615

CDXI 2015

0.30

1460000

5449390

377449

510909

970069

NOTE 1 COMPANY BACKGROUND   Cardax Pharmaceuticals, Inc. (Holdings) was incorporated in the State of Delaware on March 23, 2006.   In May of 2006, Hawaii Biotech, Inc., contributed its anti-inflammatory, small molecule line of business into Holdings. Holdings issued (i) 9,447,100 shares of common stock of Holdings, (ii) 14,440,920 shares of Series A preferred stock of Holdings, (iii) 11,113,544 shares of Series B preferred stock of Holdings and (iv) 13,859,324 shares of Series C preferred stock of Holdings to Hawaii Biotech, Inc., in exchange for the assets and liabilities contributed to Holdings. The above shares were then distributed by Hawaii Biotech, Inc. to its shareholders. An additional 704,225 shares of Series C preferred stock were issued as part of the initial capitalization of Holdings. On January 30, 2007, all outstanding shares of Series A, B, and C preferred stock were converted into shares of Series A preferred stock.   Holdings was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. Holdings platform has application in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. Holdings current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has robust anti-oxidant and anti-inflammatory activity.   In May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (Pharma). Pharma was formed to maintain Holdings operations going forward, leaving Holdings as an investment holding company.   On November 29, 2013, Holdings entered into a definitive merger agreement (Merger Agreement) with Koffee Korner Inc., a Delaware corporation (Koffee Korner) (OTCQB:KOFF), and its wholly owned subsidiary (Koffee Sub), pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings. At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of common stock of Koffee Korner.   On February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the Company) (OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for the issuance and sale of an aggregate 6,276,960 of shares of the Companys common stock, together with five year warrants to purchase an aggregate of 6,276,960 shares of the Companys common stock at $0.625 per share, (ii) the notes issued on January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into 3,353,437 shares of the Companys common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Companys common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled and substituted with stock options to purchase 6,889,555 shares of the Companys common stock at $0.155 per share, (v) additional stock options to purchase 20,867,266 shares of the Companys common stock at $0.625 per share were issued, and (vi) the notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off agreement on the closing date.    The share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information of Holdings and Pharma. Under U.S. GAAP guidance ASC 805-40, Business Combinations Reverse Acquisitions, the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Companys assets and liabilities.   On August 28, 2014, the Company entered into an Agreement and Plan of Merger (the Holdings Merger Agreement) with its principal stockholder, Holdings, pursuant to which Holdings merged with and into the Company (the Holdings Merger). On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There will not be any cash consideration exchanged in the Holdings Merger.  Upon the closing of the Holdings Merger, the stockholders of Holdings will receive an aggregate number of shares and warrants to purchase shares of the Companys common stock equal to the aggregate number of shares of the Companys common stock that are held by Holdings on the date of the closing of the Holdings Merger. The Companys restricted shares of common stock held by Holdings will be cancelled upon the closing of the Holdings Merger.  Accordingly, there will not be not any change to the Companys fully diluted capitalization due to the Holdings Merger. As of September 30, 2015, the Holdings Merger had not been completed.   Going concern matters   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss of $743,461 and $2,443,881 for the three and nine-months ended September 30, 2015, respectively, and a net loss of $1,880,394 and $15,186,393 for the three and nine-months ended September 30, 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $52,336,163 as of September 30, 2015, and has had negative cash flows from operating activities since inception. The Company anticipates further losses in the development of its business. As a result of these and other factors, the Companys independent registered public accounting firm has determined there is substantial doubt about the Companys ability to continue as a going concern.   In addition to the $1,460,000 raised during the first nine-months of 2015, the Company plans to raise additional capital to carry out its business plan. The Companys ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Companys contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Companys ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the SEC) for interim financial information. In the opinion of the Companys management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014.    Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.   The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015.   The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.   Reclassifications   The Company has made certain reclassifications to conform its prior periods data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.   Recent accounting pronouncements   In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial StatementsGoing Concern. The provisions of ASU No. 2014-15 require management to assess an entitys ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of managements plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of managements plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Companys consolidated financial statements.

NOTE 3 INVENTORY   Inventory consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Processed materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="width: 22%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">958,575</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="width: 22%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">958,575</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Total inventories</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">958,575</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">958,575</td> <td style="line-height: 115%"> </td></tr> </table>   At September 30, 2015, and December 31, 2014, inventory in the amount of $924,452 is stored at one of the Companys suppliers, which is located in Germany, with the balance of the inventory maintained in the United States.   During the year ended December 31, 2014, the Company utilized $28,099 in Astaxanthin as part of commercial product research and development.   The Company has determined that no inventory reserves are necessary as of September 30, 2015, and December 31, 2014.

NOTE 4 PROPERTY AND EQUIPMENT, net   Property and equipment, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Information technology equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">31,892</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">31,892</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Furniture and office equipment</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">10,161</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">10,161</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">42,053</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">42,053</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(26,450</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(21,442</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,603</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">20,611</td> <td style="line-height: 115%"> </td></tr> </table>   Depreciation expense was $1,670 and $5,008, for the three and nine-months ended September 30, 2015, respectively. Depreciation expense was $1,783 and $5,241, for the three and nine-months ended September 30, 2014, respectively.   During the year ended December 31, 2014, the Company wrote off $992,797 of fully depreciated property and equipment. There was no effect on the statement of operations for the year ended December 31, 2014.   On December 16, 2014, the Company entered into an agreement to sell laboratory equipment with a net book value of $0 for $95,000. One payment of $85,000 was received on December 26, 2014 with the balance being received on January 7, 2015. Final sale took place upon delivery of the equipment in February 2015.

NOTE 5 INTANGIBLE ASSETS, net   Intangible assets, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Patents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">393,370</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">393,370</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(214,637</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(200,272</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">178,733</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">193,098</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Patents pending</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">248,272</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">226,420</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total intangible assets, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">427,005</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">419,518</td> <td style="line-height: 115%"> </td></tr> </table>   Patents are amortized straight-line over a period of fifteen years. Amortization expense was $2,703 and $14,365, for the three and nine-months ended September 30, 2015, respectively. Amortization expense was $7,652 and $22,955, for the three and nine-months ended September 30, 2014, respectively.   The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved.   The Company owns 20 issued patents, including 13 in the United States and 7 others in China, India, Japan, and Hong Kong. These patents will expire during the years of 2023 to 2028, subject to any patent term extensions of the individual patent. The Company has 1 patent application pending in the United States and 5 foreign patent applications pending in Europe, Canada, and Brazil.

NOTE 6 NOTE PAYABLE   On January 28, 2015, the Company received a short-term loan of $30,000. The loan accrued interest at the rate of 3% per annum. Principal and interest were due on April 28, 2015. Interest accrued and expensed on this short-term loan was $69 and $222 for the three and nine-months ended September 30, 2015, respectively.   This note and accrued interest were converted on April 28, 2015 into securities of the Company at $0.30 per unit. Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Most favored nation rights are available to the purchaser of such units as described in the Subscription Agreement.

NOTE 8 STOCK OPTION PLANS   On May 15, 2006, the Company adopted the 2006 Stock Incentive Plan. Under this plan, the Company may issue shares of restricted stock, incentive stock options, or non-statutory stock options to employees, directors, and consultants. The aggregate number of shares which may be issued under this plan was 16,521,704, which was increased by 1,456,786 to 17,978,490 as part of the Series B Offering in 2007. This plan was terminated on February 7, 2014.   On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that may be issued under this plan is 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Companys 2014 Equity Compensation Plan by 15 million shares.   Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the Plans), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years.    A summary of stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average exercise price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average remaining contractual term in years</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate intrinsic value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify; line-height: 115%">Outstanding January 1, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">15,290,486</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.07</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">3.89</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">305,810</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,290,486</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.89</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">305,810</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(15,290,486</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">27,756,821-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(4,506</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">27,752,315</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.51</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8.02</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,963,523</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">26,156,553</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7.95</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,962,239</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,365,729</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">33,118,044</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.87</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">3,418,084</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">33,118,044</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.87</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">3,418,084</td> <td style="line-height: 115%"> </td></tr> </table>   The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2015, based on a valuation of the Companys stock for that day.   A summary of the Companys non-vested options for the nine-months ended September 30, 2015 and year ended December 31, 2014, are presented below:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Non-vested at January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; text-align: justify; line-height: 115%">Granted</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">27,756,821</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(26,156,553</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(4,506</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Non-vested at December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,595,762</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,365,729</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(6,961,491</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Non-vested at September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   Under ASC No. 718, the Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options outstanding as of September 30, 2015 and December 31, 2014, were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 1.47%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 1.47%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 170%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 170%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Expected term</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.1 - 5.5 years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.1 - 5.5 years</td> <td style="line-height: 115%"> </td></tr> </table>   The expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The risk free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend within the relevant time frame. Due to a lack of historical information needed to estimate the Companys expected term, it was estimated using the simplified method allowed under ASC No. 718. In calculating the number of options issued in the three-months ended September 30, 2015, the Company used assumptions comparable to December 31, 2014, with a 20-day weighted average stock price.   As part of the requirements of ASC No. 718, the Company is required to estimate potential forfeitures of stock grants and adjust stock based compensation expense accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized in the period of change and will also impact the amount of stock based compensation expenses to be recognized in future periods.   The Company recognized $206,959 and $1,169,537 in stock based compensation expense related to options during the three and nine-months ended September 30, 2015, respectively. Of these amounts, $206,959 and $970,069 were related to 5,365,729 options issued to employees, directors, and consultants in lieu of salaries, wages, and fees accrued for services during the three and nine-months ended September 30, 2015, respectively. The Company recognized $601,107 and $5,318,948, in stock based compensation expense during the three and nine-months ended September 30, 2014, respectively.

NOTE 9 WARRANTS   The following is a summary of the Companys warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Warrants</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average exercise price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted average remaining contractual term in years</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate intrinsic value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify; line-height: 115%">Outstanding January 1, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">3,395,833</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.45</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5.28</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,395,833</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.45</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.28</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(3,395,833</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.64</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">28,435,782</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.64</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Canceled</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">13,435,342</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Outstanding September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">4,988,991</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercisable September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.47</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">4,988,991</td> <td style="line-height: 115%"> </td></tr> </table>   Under ASC No. 718, the Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The fair value of warrants issued with debt is recorded as a debt discount and amortized over the life of the debt. The range of fair value assumptions related to warrants outstanding as of September 30, 2015 and December 31, 2014, were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 0.86%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 0.66%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">102% - 159%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 159%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Expected term</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.0 - 2.5 years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.0 - 2.5 years</td> <td style="line-height: 115%"> </td></tr> </table>   The expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The risk free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend within the relevant time frame. The expected warrant term is the life of the warrant.   The Company recognized $0 and $4,000 in stock based compensation expense related to warrants for the three and nine-months ended September 30, 2015, respectively. The Company recognized $0 and $5,229,589, in stock based compensation expense related to warrants during the three and nine-months ended September 30, 2014, respectively.

NOTE 11 INCOME TAXES   The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed.   The effective tax rate for the periods ended September 30, 2015 and 2014, differs from the statutory rate of 34% as a result of the state taxes (net of Federal benefit) and permanent differences.   The Companys valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes, which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. Based on the available objective evidence and the Companys history of losses, management provides no assurance that the net deferred tax assets will be realized. As of September 30, 2015, and December 31, 2014, the Company has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred tax liabilities.   The Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (uncertain tax positions) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.   As of September 30, 2015 and December 31, 2014, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods.   The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

NOTE 12 BASIC AND DILUTED NET INCOME (LOSS) PER SHARE   The following tables set forth the computation of the Companys basic and diluted net income (loss) per share for the three-months ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three-months ended September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(743,461</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">67,955,379</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.01</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(743,461</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">67,955,379</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.01</td> <td style="line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three-months ended September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(1,880,394</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">63,610,949</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.03</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,880,394</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">63,610,949</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td></tr> </table>    The following table sets forth the computation of the Companys basic and diluted net income (loss) per share for the nine-months ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine-months ended September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(2,443,881</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">66,000,101</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.04</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,443,881</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">66,000,101</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.04</td> <td style="line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine-months ended September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Loss (Numerator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares (Denominator)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Per share amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(15,186,393</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">59,019,453</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(0.26</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Effect of dilutive securitiesCommon stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(15,186,393</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">59,019,453</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.26</td> <td style="line-height: 115%">)</td></tr> </table>   The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the years presented because including them would have been antidilutive for the years ended:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Common stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: right; line-height: 115%">33,118,044</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: right; line-height: 115%">23,762,946</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">41,871,124</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">28,405,782</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total common stock equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">74,989,168</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,168,728</td> <td style="line-height: 115%"> </td></tr> </table>

NOTE 13 CONCENTRATION   The Company purchased all of its inventory from one vendor in Germany. Although, there were no purchases from this vendor during the three and nine-months ended September 30, 2015 and 2014, outstanding payables to this vendor were $86,255 as of September 30, 2015, and December 31, 2014.

NOTE 14 LEASES   Hawaii Research Center   The Company entered into a lease for laboratory and office space on May 9, 2006. This lease amended on September 7, 2011, and October 30, 2012. This lease expired on October 31, 2014, after which the terms converted to month-to-month. The Company vacated the space in February 2015. Total rent expense under this agreement as amended was $0 and $12,112, for the three and nine-months ended September 30, 2015, respectively. Total rent expense under this agreement as amended was $14,709 and $47,331, for the three and nine-months ended September 30, 2014, respectively.   Manoa Innovation Center   The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $7,931 and $23,759, for the three and nine-months ended September 30 2015, respectively. Total rent expense under this agreement as amended was $7,825 and $23,255, for the three and nine-months ended September 30, 2014, respectively.

NOTE 15 COMMITMENTS   Patent payable   As part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting from the license. There were no revenues generated by this license during the three and nine-months ended September 30, 2015 and 2014. The remaining obligation of $20,000 as of September 30, 2015 and December 31, 2014, is recorded as a part of accounts payable on the condensed consolidated balance sheets.   Employee settlement   As of September 30, 2015 and December 31, 2014, the Company owed a former employee a severance settlement payable in the amount of $50,000 for accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully vested and extended.   BASF agreement and license   In November 2006, the Company entered into a joint development and supply agreement with BASF SE (BASF). Under the agreement, the Company granted BASF an exclusive world-wide license to the Companys rights related to the development and commercialization of Astaxanthin consumer health products; the Company retains all rights related to Astaxanthin pharmaceutical products. The Company is to receive specified royalties based on future net sales of such Astaxanthin consumer health products. No royalties were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014. The license does not prohibit the Company from purchasing Astaxanthin consumer health products from BASF for consumer health applications, similar to any third-party wholesale customer.   Capsugel agreement   On August 18, 2014, the Company entered into a collaboration agreement with Capsugel US, LLC (Capsugel) for the joint commercial development of Astaxanthin products for the consumer health market that contain nature-identical synthetic Astaxanthin and use Capsugels proprietary formulation technology, which is expected to increase the oral bioavailability of Astaxanthin. The agreement provides for the parties to jointly administer activities under a product development plan that will include identifying at least one mutually acceptable third party marketer who will further develop, market and distribute consumer health, nature-identical synthetic Astaxanthin products developed under the collaboration. Capsugel will share revenues with the Company based on net sales of products that are developed under the collaboration. No revenues were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014.

NOTE 16 SUBSEQUENT EVENTS   The Company evaluated its September 30, 2015, condensed consolidated financial statements for subsequent events through November 9, 2015, the date the condensed consolidated financial statements were available to be issued and noted the following non-recognized events for disclosure.   Stock issuance   On October 19, 2015, the Company granted a consultant 100,000 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $45,000. These shares vested immediately.   On October 26, 2015, the Company issued 25,556 shares of common stock in the Company in connection with the cashless exercise of a stock option for 41,851 shares of common stock at $0.155 per share with 16,295 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.   In October and November 2015 (through November 9, 2015), the Company sold securities in a self-directed offering in the aggregate amount of $146,000 at $0.30 per unit. Each unit consisted of 1 share of restricted common stock (486,665 shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Most favored nation rights are available to the purchasers of such units as described in the Subscription Agreement.

Basis of presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the SEC) for interim financial information. In the opinion of the Companys management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014.    Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.   The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015.   The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassifications   The Company has made certain reclassifications to conform its prior periods data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Recent accounting pronouncements   In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial StatementsGoing Concern. The provisions of ASU No. 2014-15 require management to assess an entitys ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of managements plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of managements plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Companys consolidated financial statements.

Property and equipment, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Information technology equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">31,892</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">31,892</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Furniture and office equipment</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">10,161</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">10,161</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">42,053</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">42,053</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(26,450</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(21,442</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,603</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">20,611</td> <td style="line-height: 115%"> </td></tr> </table>

Intangible assets, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Patents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">393,370</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">393,370</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(214,637</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(200,272</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">178,733</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">193,098</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Patents pending</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">248,272</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">226,420</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total intangible assets, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">427,005</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">419,518</td> <td style="line-height: 115%"> </td></tr> </table>

A summary of the Companys non-vested options for the nine-months ended September 30, 2015 and year ended December 31, 2014, are presented below:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Non-vested at January 1, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; text-align: justify; line-height: 115%">Granted</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">27,756,821</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(26,156,553</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(4,506</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Non-vested at December 31, 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,595,762</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,365,729</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(6,961,491</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Non-vested at September 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

The range of fair value assumptions related to options outstanding as of September 30, 2015 and December 31, 2014, were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2014</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">(Unaudited)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; text-align: justify; line-height: 115%">Dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 22%; text-align: center; line-height: 115%">0.0%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 1.47%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">0.12% - 1.47%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 170%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">112% - 170%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Expected term</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.1 - 5.5 years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1.1 - 5.5 years</td> <td style="line-height: 115%"> </td></tr> </table>

248272 226420

0.03

30000

P6Y10M13D P8Y7D P6Y10M13D P7Y11M12D

564399

10783948

360931

50000

235411

185640

4000

5229589

130385

37500

597246

108988

16667

50000

2014-10-31

49603549

46908249

3469219

3555961

6276960

3923100

1460000

222

1169537

5318948

206959

601107

206959

970069

206959

970069

206959

970069

6276960 3321600

293546

-2443881

-15186393

-743461

-1880394

-2443881

-15186393

-743461

-1880394

143347

-126133

117

-2239

48204

1762

3068

594

830

14585

3069

1619

117042

477

-2587228

-15060260

-743578

-1878155

2587228

15060260

743578

1878155

19373

28196

4373

9435

681059

3327010

266018

724454

1534468

10783948

256959

786747

-0.04

-0.26

-0.01

-0.03

-0.04

-0.26

-0.01

-0.03

66000101

59019453

67955379

63610949

66000101

59019453

67955379

63610949

100739

13385342

45000

-10000

-28099

0001544238

EX-101.SCH 7 cdxi-20150930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Company Background link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock Issuance link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Option Plans link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Basic and Diluted Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Concentration link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock Option Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Basic and Diluted Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Company Background (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventory - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock Issuance (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stock Option Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock Option Plans - Schedule of Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Warrants - Schedule of Stock Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Warrants - Schedule of Fair Value Assumptions Related to Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Basic and diluted Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Basic and Diluted Net Income (Loss) Per Share - Schedule of Computation of Diluted Net Income Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Concentration (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cdxi-20150930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cdxi-20150930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cdxi-20150930_lab.xml XBRL LABEL FILE Common Stock $0.001 Par Value [Member] Equity Components [Axis] Furniture and Office Equipment [Member] Property, Plant and Equipment, Type [Axis] Information Technology Equipment [Member] Preferred Series C [Member] Class of Stock [Axis] Minimum [Member] Range [Axis] Maximum [Member] Common Stock Warrants [Member] Warrant [Member] Vendor [Member] Related Party [Axis] Common Stock Options [Member] Plan Name [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Directors [Member] 2014 Equity Compensation Plan [Member] Commercial Product Research and Development [Member] Products and Services [Axis] United States [Member] Geographical [Axis] China, India, Japan And Hong Kong [Member] Germany [Member] 2006 Stock Incentive Plan [Member] Executive Chairman Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Director [Member] Title of Individual [Axis] Lease Settlement Agreement [Member] Lease Arrangement, Type [Axis] Hawaii Research Center [Member] Manoa Innovation Center [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Two Class D Warrants [Member] One Class E Warrant [Member] Laboratory Equipment [Member] Europe, Canada, and Brazil [Member] Two Class D Warrant [Member] BASF Agreement And License [Member] Arrangement, Type [Axis] Capsugel Agreement [Member] Pharma [Member] Business Acquisition [Axis] 2008 Unsecured promissory Note Debt Instrument [Axis] TowThousandNonMandatorilyConvertibleMember Additional Paid-In Capital [Member] Research and development equipment [Member] Leasehold Improvements [Member] Software [Member] 2008 Unsecured Promissory Note [Member] 2009 Non-Mandatorily Convertible, Unsecured Note [Member] 2013 Bridge Loan [Member] 2014 Bridge Loan [Member] Employees [Member] Consultants [Member] Restricted Stock [Member] Stock Option [Member] Withheld [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Inventory Deposits and other assets Prepaid expenses Total current assets PROPERTY AND EQUIPMENT, net INTANGIBLE ASSETS, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accrued payroll and payroll related expenses Accounts payable Fees payable to directors Employee settlement Other current liabilities Total current liabilities COMMITMENTS AND CONTINGENCIES Total liabilities STOCKHOLDERS' DEFICIT Common stock - $0.001 par value; 400,000,000 shares authorized, 69,011,494 and 63,885,930 shares issued and outstanding as of September 30, 2015, and December 31, 2014, respectively Additional paid-in-capital Deferred compensation Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Common stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] REVENUES OPERATING EXPENSES: Stock based compensation Selling, general, and administrative expenses Research and development Depreciation and amortization Total operating expenses Loss from operations OTHER INCOME (EXPENSES): Interest expense Other expenses Interest income Other income Gain on sale of assets Total other income (expenses) Loss before provision for income taxes PROVISION FOR INCOME TAXES NET LOSS NET LOSS PER SHARE Basic Diluted SHARES USED IN CALCULATION OF NET INCOME PER SHARE Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation Amortization of debt discount Gain on sale of assets Changes in assets and liabilities: Deposits and other assets Prepaid expenses Inventory Accrued payroll and payroll related expenses Accounts payable Accrued interest Fees payable to directors Patent license payable Other current liabilities Net cash used in operating activities Cash flows from investing activities: Purchases of property and equipment Proceeds from sale of property and equipment Expenditures on patents Net cash used in investing activities Cash flows from financing activities: Proceeds from the issuance of common stock Proceeds from the issuances of notes payable Repayment of principal on notes payable Net cash provided by financing activities NET INCREASE IN CASH Cash at the beginning of the year Cash at the end of the period NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of notes payable and accrued interest into common stock Conversion of accrued payroll and payroll related expenses into stock options SUPPLEMENTAL DISCLOSURES: Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] Company Background Summary of Significant Accounting Policies Inventory Disclosure [Abstract] Inventory Property, Plant and Equipment [Abstract] Property and Equipment, Net Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net Debt Disclosure [Abstract] Note Payable Equity [Abstract] Stock Issuance Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Option Plans Warrants Warrants Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Earnings Per Share [Abstract] Basic and Diluted Net Income (Loss) Per Share Risks and Uncertainties [Abstract] EX-101.PRE 11 cdxi-20150930_pre.xml XBRL PRESENTATION FILE XML 12 R39.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding, Beginning balance	27,752,315	15,290,486
Options Exercisable, Beginning balance	26,156,553	15,290,486
Options, Canceled		(15,290,486)
Options, Granted	5,365,729	27,756,821
Options, Exercised		(4,506)
Options, Forfeited
Options Outstanding, Ending balance	33,118,044	27,752,315
Options Exercisable, Ending balance	33,118,044	26,156,553
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.51	$ 0.07
Weighted Average Exercise Price, Exercisable, Beginning balance	$ 0.50	$ 0.07
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending balance	$ 0.47	$ 0.51
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.47	$ 0.50
Weighted Average Remaining Contractual Terms (Years), Outstanding Beginning	8 years 7 days	3 years 10 months 21 days
Weighted Average Remaining Contractual Terms (Years), Outstanding Ending	6 years 10 months 13 days	8 years 7 days
Weighted Average Remaining Contractual Terms (Years), Exercisable, Beginning	7 years 11 months 12 days	3 years 10 months 21 days
Weighted Average Remaining Contractual Terms (Years), Exercisable, Ending	6 years 10 months 13 days	7 years 11 months 12 days
Aggregate Intrinsic Value, Outstanding Beginning balance	$ 1,963,523	$ 305,810
Aggregate Intrinsic Value, Outstanding Ending balance	3,418,084	1,963,523
Aggregate Intrinsic Value, Exercisable Beginning balance	1,962,239	305,810
Aggregate Intrinsic Value, Exercisable Ending balance	$ 3,418,084	$ 1,962,239

XML 13 R48.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Share - Schedule of Computation of Diluted Net Income Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Total common stock equivalents	74,989,168	52,168,728
Common Stock Warrants [Member]
Total common stock equivalents	41,871,124	28,405,782
Common Stock Options [Member]
Total common stock equivalents	33,118,044	23,762,946

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`#DT;$>\#5@"[P$``"T@```3````6T-O;G1E;G1?5'EP97-= M+GAM;,W:S4[C,!`'\%>IR$-6Y(-*1I*CFJB_/;#85@6II<[@(E]Z+2WO>FT5?CYWM6!^G%-[(Q_+G6]S5EB_FU1Y6A\ M4X7]C?_KS-@R-#^L_MI1SC]X+7LW<6/[JZ`?S5Z!S='&5(ZUU68X-*I'%]:_ MG%M_Y6-"Y:I::J<^Y(4AF0-/25Y\EZ.1Y=2?JOWRI#0NT)L*EH5'?"DZ':C] MF4*>[^%WX\\%Q^NCS'7\_J^AC\'(QL,1D7A7'P*D#PG2AP+I8P[2QPE(']]! M^O@!TLQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH` MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`.31L1[>K)I[H`0``V1\``!H` M``!X;"]?FN'T]-F2['?1B:S6NS M3T'K>AG&RSG5X\/'V8OG[;H:G[=2+7XVXSZ5=?6['U]SFU+)X7R2FVF!Z?'; MD+ZS?+_;'3;IJ=_\.J6N?%$1_BU0A?D@G0]22I#-!QDER.>#G!(4YX,B)6@Y M'[2D!-W.!]U2@N[F@^XH0??S0?>4(*F!C#4G"6'-T5H`U\+Q6@#8PA%;`-G" M,5L`VL)16P#;PG%;`-S"D5L`W<*Q6P#>PM%;@=[*T5N!WDKZUD8?VQR]%>BM M'+T5Z*TBM'+T5Z*TBM'+T-Z&TAM MI+T2M%G"T=N`WL;1VX#>QM';@-[&T=N`WL;1VX#>QM';@-[&T=N!WL[1VX'> MSM';@=[.T=N!WD[:ZT:;W1R]'>CM'+T=Z.TCM'+T=Z.TKOS7GJ7]#PJ>_^(_O4$L#!!0````(`#DT;$>`B^NO'0,``.@, M```0````9&]C4')O<',O87!P+GAM;+U746_:,!#^*Q9/G;0VE-%M0C12"YV& MU%$T6/OL.@=8.'9J.XCLU^^<``W%!,+#^E+'_KX[WWUWE]"5IMD9:96`MAP, M6<5"F@YNWC;FUB:=(#!L#C$U5PB1>#I5.J86'_4L4-,I9]!7+(U!VJ#5;'X- M8&5!1A!=)ENCC;#KO-PEB>",6JYD^(LSK8R:6O*P8B"ZP4=`SD#+8V"IYC8+ MFP6FO)5CQHP*Z*&O<$J%@0+UOIEC>BI.J,R"XNF1RX7YDTQ4GUHHLW8/"NMS MJB%"ISO6MYLYYF>&<0K'[BW3TIZK4J28$]T\3_!^ID%>J0&WO&TLJ>94V@8Q_"\^ MMAJ%VV(W7XO$6!V^*+TP4U;X4R;1-RL,U$$NC%!J(S(@[18CF0@"U.KST7J+&,&R)IV\7BH M)ACF51^NZ$?`7O$[Q.*(N76Z^,_'Z:N!M]2UT,.R`E51.ZU6=>V0BXF3T7RJ M6T2.6*.0JOWL5T,U?E,6U:A*/5O?3^Q7&@"WS-1.G1*>))W`F#98]UWF&9SK([5_8K%M">40<%;DOE_\37R`\P,_-<@S%37'<7[5 MHS/YU")X;^MHOZW;W^J/@O:A45`:[?N7JQCV)TM3>@&PR]SXTRU^, M'[X/@]W?->$_4$L#!!0````(`#DT;$=>H2P-/@$``&D#```1````9&]C4')O M<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+L\*0HJX'0)R8A,00B%M(O"VL^5#B MJ>N_)\M*RX#+;MSJVN_CUW%2"<>$]?#HK0./"L+%7C M[7R38%(0:$"#P4#HA)*L?C9;8UM3D5%?5]%QPP,NK%0K!?*F&\M^IV)G!*_# M40YR:)_^_NDA94C65^Z#&JK:MIVT9:J+`U/RNGAX2F>3*Q.0&P%1%13#SL$\ M^^K\4M[>+>^S>EK0JYS2G$Z7Q8R5);N\?CM,=N)O-*S[(?ZMXR^#:;NHL($S M=YLT,BTW?2:0A""\&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNT MF83M3A^%$5B-;'EDD81_OTV23;J;/`0LZ?O.14?GZ#AY\^XN8NB& MB)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2- M9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG M/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@X MMLO2BW`A(5M>5` MTR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4. M`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K M;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5 MP/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M" M/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^ M8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_ MZ3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K M^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU33 M93>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&& MF,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& M`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/ M55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7 M&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP M#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[ M&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D M*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F- M"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04 M````"``Y-&Q':C:IN%4"``#:"@``#0```'AL+W-T>6QE9A;T6V94>@#T^6,Z>_?OIP[,20IDG3TKSH MZNC> M54J,LLH$,>I-?'_J,40XC$->LQE3%4A%S54$OW8033R'R]NAOBY7;B`P''\S"(83"^A]W+2L>_O)C:+`_+I@>3/<0^HKP[5 M_;SP(?VUH??:\X_#7/#^&B;0`7%8/8$EHMH_,.ZIH$("I>]9Z[`(1PP[CUM$ M22*)`7/$"%TY>&(`6QJM'R-<2)O;91CF&?M])EDD$?3;W\O3)3V['PU^2Z%QV[Y+36= M_M1Z-;H$W_MXCDYNH;N:)5C.[)_CX9*^7.V_,OMUPH',]ZV:(R2"W=&-]WJ"WWCT9Q9 MT_<+R7B2C")LV]5S)TI;J0ULL=+^\O%!(BJUE&T=%M38[7>G M29H56;:W8<37+K2Z\PB,-X0L@[Y5"WDU3<:)D&VPWW4=E#N60?WM;+O6YII8 MB5AJY\,\=K=[L]%&-_IW;#==^96]^\]%X.\^AEG8IKLC0EXJ[V^TK4.#].D.Z]5[,GH15>ZX7\^$Z8;G.T4"VDJ M<6("4<3,;":/AB:V@5Z>5=V'W:&F$S>KTLU0(>B;-94R7E6"SKRM=46C4HDC M64M3*@&@#$#9>T$Y@'(`Y6\&S0,=J,L`*@!4O!:"^E#?7 M)(RI('8/8O=V8^=MTTCW(.Q2S/6UT;0^)4W;U[(D3M``V@?0_BYH9FYIOJU[ M@)`#"#G8#3EWM*@=F=%)\JO5ZZC,G^),!8!\`L@G[KM!FNMHI_CJ/:GX,CX= MHV'C7<*9#4JXGIF,FO-@RQLQ\[Z-!F$DJI@R+FXB?ZSC4A#G)*#' M:/0O902\E,[1'/5B4+64<>UG3+(DU[F,X[V@>!_3CNU_&3U+&=%FIK2-$@MY MKWIQZ%C*2'8DO2Z[63[6=1O;05,D'FD?3A&%EJ6,9K142I+$[:01="UE9#M5 MTO=;C6*EC%FTK!H=HI(8EJ%.&:/3O+WRZE<;D]_)[X(HE#EG9!YTZ!@S9HXRYXS,0ZB/8HZHWN^; M,?O_='P<-D2AV?G;S:8&4=%:M8A"LW/&;/P),5.(*+0[YW[IO?_2#@Q1Z'K. MN,ZM-U[0'%W/&=<9U':AZSK@^B"K&6(&A[067K`=1*:+0]H*Q_3FI M#"[``E4O&-6?.#@\]#OH6GJ)F;=`U8N!2N$%ZKO43ES(&E&]6O5=!4377T2A MZL4K5<2PZ@6J7@P6%M5N+B[V$86J%^]-ZP6F]0)5+]BT#C7*;@\1A:H7C.J; MJN45I29H^82Q'"J9UU!H^80M4%Y4-WT@HE#T2?:X=WS>+M*.61M5Q+UO[3KGB9Q:TR[X+:NO]&]'^;4RFX#N2%O]]1?_@-0 M2P,$%`````@`.31L1Q/TZCY+`@``]`<``!@```!X;"]W;W)KYCKVR(J*/E+ZK MQ<_SU@]5#9C@DU`ID!SN^(`)49DD^:]-^LE4QO&\S_ZLVY7E'Q''!TK^5&=1 MRFI#WSOC"[H1\4:[%VQ[2%3"$R5<_WJG&Q>T[BV^5Z,/,U:-'COS)`;6YC9` M:X"#`::3AL@:HL%@7EU@*M-]_4`"%3FCG<=;I/YML)%RII+(S![7V61+7`=W M*GHOPCRXJS16`4>*O5&`01'(W$X`]%UVJ.WP>\#!**)Y0-0#HG$'D;;'\_:X MM\=C>ZSMR6-]8\7>*-)Y0.($)-J>/0(2K6@,P"A`$LD#D!F:DRG"!8R8)O9>5$K(P?3B"L9,'7LG8BUL8?3R"L))E'@-#)T&&9 M(9V`])IL`06X*79CKK[_L@Y6DZY3&&6+.H)NEMFC8#W5D=WIX0)*Y*:8K0S! M(R5]H%@-7$!Q;WA@]C.,)G9DKPF_O+-@=,C6F%WUY<.]$[TUPIRQ0W2XX'90 M']*?\B)OT17_0NQ:-=P[4B&/>GTN7R@56!80/LER2GD%#PN"+T)-,SEGYE(R M"T';_HX=+OKB/U!+`P04````"``Y-&Q'N(.3ZY\#```7$```&````'AL+W=O MK667DM9G]KN1W\P9DA^U573WZ\. MPW"\2]/^\6#JHG_;'DUCO]FW75T,]K9[2OMC9XK=%%17*25$IG51-JO->FK[ MTFW6[?-0E8WYTB7]^MJ=K3_0I6H>%K^708QH9TLT[/<;NR-DU?MDW2 MF?W]ZAWFC\6,0 M8\+'MNJG_\GCA7@^CVH++LNX(48 M1VFJ9KEN:I%1+=(5ER!:')+QC"%2'`1:2?JZE"PJ)7-2`)'B$.!2:HI(SCT' MQ,Z9!7I45(]R>BBBQR$@),%JXRA*),#K6G14BW9:D%ZV#N$T(P2;P!X#+4"] MK@9(5,[4;/5P1(]G0!,ML)67!U#PC.@%%8*S:UX8%H#WB049:'Q4SO.8Q$;E M&6YG("`K.`^@$$++):.*VRAX]T-L8.L9R023V*,/G`"]J,YQ+P5G@0PS4\]P M4((CU9BGGDC*&,2)+;I""C72E.[0UR@*^ZN-%@B-IF$+X&4 M3!)T/GF24>!\R7Z(QCV6.F\4@%4K;$HC.Y"+A1O`Z`XDG1WACL63^5QT3V73 M)P_M8$^#T]%MW[:#L8G(6SO6@SVEGV\JLQ_&R\Q>=^[??`C9_ M`%!+`P04````"``Y-&Q'XI<]FMP!``!H!0``&````'AL+W=O71KY7J#@C)&DNM3(%E&=H\I4-@U8VO/4$5$?_(3@4J5%8P:\&>CF;>X;]Q/FK6?PH MCSXV"$#AK$P"T<,-"J#4!.F-WX;,?UL:XWP^IC_9;C7]B4@H./W=E*K6L-CW M2JC(E:H7WG^'H87$!)XYE?;MG:]2<39:?(^1=SN: M8G"3= MXR"(]_$*TB",=KMD'WV!*%TD2AW1=H4H_2I1ND:$9H>B(Q?X2<2E::5WXDJ? M+WL8*LX5Z""\T;&UOO:F!85*F>E6SX6["=Q"\6Z\UZ;+-?\+4$L#!!0````( M`#DT;$=DXW3:HP0``/<6```8````>&PO=V]R:W-H965T&UL ME9C+5]@H[NI!Q7Q8:NF<54=?5B9DUB$KL:C!M(W//V`QQ!@`A9 ML[&-_)TC_;K]0IMK4?ZLCFE:KW[GV;EZ7!_K^O(0!-7+,B MS).Z>2S?@NI2ILFA"\JS@!(B@SPYG=?;35?VO=QNBOL_SI/QW MEV;%]7$-Z[[@Q^GM6+<%P783#'&'4YZ>JU-Q7I7IZ^/Z"1YBJEJD(_X^I==J M]'O5-OZY*'ZV#W\>'M>D;4.:I2]UFR)IOC[2?9IE;::FYE\FZ6>=;>#X=Y_] M6R>W:?YS4J7[(OOG=*B/36O)>G5(7Y/WK/Y17/](C0;1)GPILJK[7+V\5W61 M]R'K59[\QN_3N?N^XC^*F#![`#4!=`@8ZK$',!/`/@.X,X";`.Y;@S`!8E9# M@-J[GHN2.MENRN*ZJBY).Y_@H<'+-DF3>55UV9I.J[K"I[;T8ROT)OAH\QB$ MCI"=0<)E)$($!B)HZKQVO+3VA<1X/FVB MZI`S]@4B5,AP/O?&V!XQI:7B:AF+$`/!.)=ZF8L-1Y1F(=>WY2FK/(7RQ+0B M,9:'")62@%[&]H@IRKG@RUAD*M1`YITUQF+$&*.*@,UFLOOVF4"Z%GH\8*`(IQ[:[$8+W&R:#J<%NTE.IP`R M=XS,I]3$;A=239695,"%%A["A%T8VNY\NY@.FC#G-8>W[@VD&7$-&D*@YD>6 MB6$:JNDC#[<$^VD`C(ESUX#)VV>C!6:Z6@VC*7%4%W]-M2S*?@8`8]W")4IY MB+(S4U'(A((0QXC&!J.<^EB)W?T!;59)UQQ$IEG&KCFHS;9)F%-YX>`A7#HWD+#W$$V8:T%&/=F<\YC6CISQ MD%.`EBST4$KM9P)J_%X[YJ=AG//3@XD\F/@KLZS([O\4[54Y7A=V%#S'CH+O MV/7D[;$;.+#]"&/+6#3"^#(6 M?V(^FQ2UGP`HVJVF+G7<3QWW4\?]U/'_I<[^\DU[]_;(8#=<*JVC/SDI&T:J M4`@V7U.3-X*>9!)(R%V;>4_*QJ=@WNV3[=R0(B00KE:?G6W:=6JY?B_5SC1=50.MS9/M'V5G!6OH.'/5C*(WB( M\4;V,_UVTK^2\NUTKE;/15T7>7=Q^%H4==HTFMPW$HYILO2U;G^J M=C3P7A8?ZN+27S,/=]W;_P!02P,$%`````@`.31L1T5Y8MB.!```XA4``!@` M``!X;"]W;W)KEN>J+^<^A:>NR-X_M<=5=6UWNQZ"Z6@%C MZ:HNSY?%9CV^^]INULU;7YTO^FN;=&]U7;;_;775W)X7?.%>?#L?3_WP8K59 MKZ:X_;G6E^[<7))6'YX7+_RI0#5(1L7?9WWK[KXG@_G7IOD^//RY?UZPP8.N M]*X?FBC-Q[LN=%4-+9F>_Z5&/_H<`N^_N]9_'],U]E_+3A=-]<]YWY^,6[9( M]OI0OE7]M^;VAZ8^OZIG8ABZ0N?]C/\V7\O-G_9#F%^0.` M`F`*F/KQ!R`%X$>`&#.USL:\?BO[W[)A?KU?O0#DG@3K*U$CXI5J9Q;P^P\(7#&`Z?=U!81T#7`][G M@#8'.1\O7+RXCQH<-Z2]*8DK:5L M/C[UII3:(G,NM%!(;72F0J4*F`&2OC M+,M1B7S>3^[UD]NQS1\[NI=LK43P@!>22`7S/I37AQI;R&1@7*QDJ21C+.!% MN=4)$9/$F7?%C:_-L*B(%K@W'VY!`8$9W))&<@:!?$C%590;\+NQ5,'`N&U) MPP'ST+(CV5(RKD2$(?0;0MI*H9ZO)3D%MX"1;*6T7D31#D MD/*(60#F=0.6@@H"JX(T)N^,I<'?*Z<4BN>YC$`'3&1]8#-8'L:4$^"G(5B$ M*1$89=($1YDT9I-B3#I^$H*EG`K]\I'F<6UY_!`PHW[YP,]+L(Q3(5Z"*P!Y M+D,PF'1,\`A<@A^78!&G0K@$A\$Y1TZG4H@H)R'UKT"B9431!7Z^@>52:+]L M2<,%SDT[P5(!9E&>_)2#W"VRT$K,J9"8L61EP+(T"H?@QR$HLL1#.S6"AZ19 M2LD$BQ@B]`,1&?D)$=&)1#HS2"240BA4,><]?Z6)5!^R0.FR)1%FF>DMY&DJ M216+V++H!RQ2*SNJN+UT;?D"P]7; M3^^W_*FPEX\?S6S6U_*H_RK;X_G2):]-WS?U>`MW:)I>&UOLBUF])UWNIX=* M'_KA:V:^M_8*TC[TS=7=J$[7NIO_`5!+`P04````"``Y-&Q'2(74S:`!``"Q M`P``&````'AL+W=OZ2]<\.!,5OWH+B]PP&T_].B4=SYU'3,#@9X$TE*LBQ)OC'%A:95&6LO MIBIQ=%)H>#'$CDIQ\^\,$JE:>!5=[T*!527;>(U0H*U`30RT1WI*#^Z7*SR"E$'(-_Z[:'ZV#,1]O*K_ MC+OU[B_;4-)`RT?I7G'Z!,ZS7_R=*'=)F0+(=L(#TDT/C>*-G]PQZO2X$3LP,/LTH.'FR#BE8F-:MZA MC<53J%ZK-,U*=@U""R;;8UVGK(XDT]X50Z\@V=N M.J$MN:#SDXUC:!$=^/;)W3TEO7\_6R*A=2'\[F,S7ZDY<3BL#V1[I=4'4$L# M!!0````(`#DT;$VH0$``+$#```8````>&PO=V]R:W-H965T&ULA5/;;MP@$/T5Q`<$WS:M5EY+NZFJ]J%2E(?VF;7'-@HP+N!U^O<% M?(D5K907,S,^Y\R!@7)"\VI[`$?>E-3V1'OGAB-CMNY!DZ/ER(@(N"W@,GN8A*\7Q%?0_*S.=$D6``)M0L* MW"\W>`(I@Y!O_'?1?&\9B/MX5?\>=^O=7[F%)Y1_1.-Z;S:AI(&6C]*]X/0# MEBT<@F"-TL8OJ4?K4*T42A1_FU>AXSK-?XI\H=TG9`LAVPA?DVA\;A1M?N.. M5Z7!B=B!A]FE1P\W0<0K$QO5O$,;B^=0O55I>BC9+0@MF&R'N2R8#<&\^MT6 M&;U'SR(]^YR>K_1\[S!?'.:?"Q2K0+$7*.YO<8^YK)C'#TW8[DP5F"Y>'4MJ M'+6;CW2K;K?SG,69O,.K%2^H@$``*\#```8 M````>&PO=V]R:W-H965T&ULA5/-;N,@$'X5Q`,4VW&W4>18 M2KI:;0^5JA[:,[''-BHP7L!Q]^T7\$^M5:1>S,SX^QD8*$8T'[8#<.1326V/ MM'.N/S!FJPX4MW?8@_9_&C2*.Y^:EMG>`*\C24F6)*0I70JOHNU<*+"R8"NO%@JT%:B)@>9(3^GAG`=$!+P) M&.TF)J'W"^)'2)[J(TU""R"A*?TRIT7,?I MSRZ;:;<)V4S(5L(^B8U/1K'-G]SQLC`X$MOS,+OTX.$FB'AE8J.:[]#&XBE4 MKV6V+]@UZ,R0;`,Y3Y!T13`O?M,AH[?HV>3P/7VWT'?;!G>3>_KPO4"^".1; M@?SF#K>0'$LJ7#0;CK0M;K>S5,<(?N"ET7/6WCFIA7: MD@LZ/]QHDMA?EW`H7C@:9T*;S*IG6A MP(JX!Z6"D&_\/FM^M@S$;;RH/\9IO?NSL'"/ZJ^L7.O-)I144(M!N5< MX38(EJAL_))RL`[U0J%$BX]IE5UQ'.+MU[N`DB7IG8J.8=VE@\ANJE2--?.;L$H1G#-YC3C%D1S*M?;<'I M-3J/=/X]?;?0=UN'NZD[3[X7R!:!;"N071]QBSG-&/YU2+;94PVFB5?'DA*' MSDU;NE;7VWGD\4P^X47>BP9^"]/(SI(S.G^R\1AJ1`>^?7)S2TGKW\^:**A= M"'_XV$Q7:DH<]LL#65]I\1]02P,$%`````@`.31L1^T4TN"A`0``L0,``!D` M``!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4!SO;*G(L M)5U5NP\K57W8?2;VV$8%CPLX;O^^@"^U5I'Z8F;&YYPY,)"/:%YM"^#(NU:= M/=+6N?[`F"U;T,+>80^=_U.CT<+YU#3,]@9$%4E:,9XD/Y@6LJ-%'FO/ILAQ M<$IV\&R(';06YN,,"L M0O5:[#C/V34(S1B^P9QGS(I@7OUF"TYOT7FD\^_IZ4)/MP[3V6'ZO4"V"&1; M@>SV%K>8\X+)_FO"-F>JP33QZEA2XM"YZ4C7ZGH[3SS.Y`M>Y+UHX(\PC>PL MN:#SDXUCJ!$=^/;)W9Z2UK^?-5%0NQ#>^]A,5VI*'/;+`UE?:?$)4$L#!!0` M```(`#DT;$?:HVKZH0$``+$#```9````>&PO=V]R:W-H965TFA32TR%/MQ18Y]EY)`R^6N%YK8?]>0.%PHALZ%UYET_I8 M8$7.%EXE-1@GT1`+]8F>-\?++B(2X+>$P:UB$KU?$=]B\K,ZT2Q:``6ECPHB M+#=X`J6B4&C\/FE^MHS$=3RK/Z?=!O=7X>`)U1]9^3:8S2BIH!:]\J\X_(!I M"_LH6*)RZ4O*WGG4,X42+3[&59JT#N,??IAH]PE\(O"%\"U+QL=&R>9WX461 M6QR(ZT288X#:*!&7BDEIPZ%+Q'*NW8L/W.;M%H0G#5YC+A%D0+*C?;<'I M/3I/=/XU?3O3MVN'V\GAX]<"NUE@MQ;8W=_B&G.9,8?_FK#5F6JP3;HZCI38 M&S\>Z5)=;N>9IYE\PHN\$PW\$K:1QI$K^C#9-(8:T4-HGSWL*6G#^UD2!;6/ MX2'$=KQ28^*QFQ_(\DJ+?U!+`P04````"``Y-&Q'!2)!>Z(!``"Q`P``&0`` M`'AL+W=ONB>B3VV4<'C!1RW?U_`V+56D7HQ,^/WWCP8R$ M:>M^PA\[_J=%HX7QJ&F9[`Z**)*T8S[)O3`O9T2*/M2=3Y#@X M)3MX,L0.6@OS?@:%XY%NZ%QXEDWK0H$5.5MXE=3068D=,5`?Z6ES..\"(@)> M)(QV%9/@_8+X&I(_U9%FP0(H*%U0$'ZYP@,H%81\XW])\[-E(*[C6?U7W*UW M?Q$6'E#]E95KO=F,D@IJ,2CWC.-O2%NX#X(E*AN_I!RL0SU3*-'B;5IE%]*W.!(;"_"[#8'#S=!Q"L3&]6\0QN+IU"] M%AN^S]DU""4,7V'.";,@F%>_V8+36W0>Z?QK^G:F;]<.M\GACZ\%=K/`;BVP MN[W%->:<,-OLOR9L=:8:3!.OCB4E#IV;CG2I+K?SQ.-,/N%%WHL&'H5I9&?) M!9V?;!Q#C>C`M\_N[BEI_?M9$@6U"^%W'YOI2DV)PWY^(,LK+3X`4$L#!!0` M```(`#DT;$=[6;](H`$``+$#```9````>&PO=V]R:W-H965T5=2VR/MG1L.C-FZ!\7M'0Z@_9\6C>+.IZ9C M=C#`FTA2DF5)\H4I+C2MREA[-E6)HY-"P[,A=E2*FS]GD#@=:4K7PHOH>A<* MK"K9QFN$`FT%:F*@/=)3>C@7`1$!OP1,=A>3X/V"^!J2'\V1)L$"2*A=4.!^ MN<(C2!F$?..W1?.C92#NXU7]6]RM=W_A%AY1_A:-Z[W9A)(&6CY*]X+3=UBV M9IR:Y!:,%D.\QYP6P(YM5OMLCH M+7H6Z=F_Z?E*S_<.\\7A?P@4JT"Q%RAN;W&/.:^8_%,3MCM3!::+5\>2&D?M MYB/=JMOM/&5Q)A_PJAQX!S^YZ82VY(+.3S:.H45TX-LG=_>4]/[];(F$UH7P MP<=FOE)SXG!8'\CV2JN_4$L#!!0````(`#DT;$&PO=V]R:W-H965T!5)2K(T2;XPQ86F11YK3Z;(L7=2 M:'@RQ/9*])\;QF(ZWA6_QYWZ]V? MN85'E*^B4O76H9@HEBK^-J]!Q'<8_ M#Q/K-CZ=\.F"OT^B[[%/=/F-.U[D!@=B.QY&M]E[N`DB7IG8J.8-VE@\ANJU MV&RSG%V#T(1)5YC3A%D0S*O?;)'26_0TTM/_T[A"5N=J0+3Q)MC28F]=N.1+M7E)%WO(%?W#1"6W)& MYR<;QU`C.O#MD[L=):U_/DLBH78A_.IC,]ZH,7'8S>]C>:3%7U!+`P04```` M"``Y-&Q'+NQH;J$!``"Q`P``&0```'AL+W=OV!MLYU>\9LV8+B]@8[T/Y/C49QYU/3,-L9 MX%4D*;$))!37OI7O'X1FF+=P& MP1*EC5]2]M:AFBF4*/XUKD+'=1C_9+N)=IV03H1T(>R2:'QL%&T^+W.!` M;,?#[#9[#S=!Q"L3&]6\0QN+QU"]%)OL+F>7(#1ATA7F-&$6!//J5UND]!H] MC?3T=WHVT[.UPVQR>/^[P'86V*X%MM>WN,:<9LSN1Q.V.E,%IHE7QY(2>^W& M(UVJR^T\IG$FW_`B[W@#K]PT0EMR1NJ3%QV,T/9'FEQ7]02P,$%`````@`.31L1^SA;0^B`0``L0,``!D```!X M;"]W;W)K&ULA5/+;J0P$/P5RQ\0,T"RNR,&:291 ME!Q6BG+8/7N@`2NVF]AFR/[]VN81%(V4"^YNJJJK_2A&-&^V`W#D0TEM#[1S MKM\S9JL.%+:!`L@H7)!@?OE`O<@91#RC=]GS<^6@;B-%_7'.*UW?^86 M[E'^%;7KO-F$DAH:/DCWBN,3S"/A[/;[3W;1UF4_<\^5X@7P3RK4!^ M?<0MYC1C\J]#LLV>*C!MO#J65#AH-VWI6EUOYS&-9_()+XN>M_";FU9H2\[H M_,G&8V@0'?CVR=]?V#,51UHX>ZP!Q/^-&BU\"&U+7.] M!5$GDE:,9]D#TT(:6A:I]FS+`@>OI(%G2]R@M;#_SJ!P/-(=70HOLNU\++"R M8"NOEAJ,DVB(A>9(3[O#.8^(!/@C872;F$3O%\37F/RJCS2+%D!!Y:."",L5 M'D&I*!0:O\V:'RTC<1LOZC_2;H/[BW#PB.JOK'T7S&:4U-"(0?D7''_"O(7[ M*%BAIU6:M([3G_QAIMTF\)G`5\+W+!F?&B6;3\*+LK`X M$M>+.+O=(8\XQ9$2RHWVS!Z2TZ M3W3^-7V_T/=;A_O9X?YK@7P1R+<"^>TM;C'G!9-_:L(V9ZK!MNGJ.%+A8/QT MI&MUO9TGGF;R`2^+7K3P6]A6&D&ULA5/;;N,@$/T5Q`<4QW'25>182K*J MVH>5JC[L/A-[;*,"XP*.NW^_@"^U5I'Z8F;&YYPY,)`/:-YM"^#(IY+:'FGK M7'=@S)8M*&X?L`/M_]1H%'<^-0VSG0%>19*2+$V2/5-<:%KDL?9JBAQ[)X6& M5T-LKQ0W?\\@<3C2#9T+;Z)I72BP(F<+KQ(*M!6HB8'Z2$^;PSD+B`CX+6"P MJY@$[U?$]Y"\5$>:!`L@H71!@?OE!A>0,@CYQA^3YE?+0%S'L_I3W*UW?^46 M+BC_B,JUWFQ"204U[Z5[P^$9IBWL@F")TL8O*7OK4,T42A3_'%>AXSJ,?[8S M[3XAG0CI0OB11.-CHVCS)W>\R`T.Q'8\S&YS\'`31+PRL5'-.[2Q>`K56[') M=CF[!:$)DZXPYPFS()A7O]LBI??H::2GW].W,WV[=KB='.Z_%\AF@6PMD-W? MXAISGC&/_S5AJS-58)IX=2PIL==N/-*ENMS.4QIG\@4O\HXW\(N;1FA+KNC\ M9.,8:D0'OGWRL*.D]>]G2234+H2//C;CE1H3A]W\0)976OP#4$L#!!0````( M`#DT;$?UJJECH@$``+$#```9````>&PO=V]R:W-H965T<.3"0#VC>;`O@R(>2VAYIZUQW8,R6+2AN[[`#[?_4:!1W/C4-LYT! M7D62DBQ-DGNFN-"TR&/MV10Y]DX*#<^&V%XI;OZ=0>)PI!LZ%UY$T[I08$7. M%EXE%&@K4!,#]9&>-H=S%A`1\"I@L*N8!.\7Q+>0_*Z.-`D60$+I@@+WRQ4> M0,H@Y!N_3YI?+0-Q'<_JCW&WWOV%6WA`^5=4KO5F$THJJ'DOW0L.3S!M81<$ M2Y0V?DG96X=JIE"B^,>X"AW78?JSGVBW">E$2!?"/HG&QT;1YB_N>)$;'(CM M>)C=YN#A)HAX96*CFG=H8_$4JM=BD^US=@U"$R9=8^?7*WHZ3U[V=))-0NA#]\ M;,8K-28.N_F!+*^T^`102P,$%`````@`.31L1TPV/,6A`0``L0,``!D```!X M;"]W;W)K&ULC5/;;N,@$/T5Q`<4VTFVJ\BQE'15 M[3ZL5/6A?2;VV$8!Q@4Z"M M<]V>,5NVH+B]PPZT_U.C4=SYU#3,=@9X%4E*LBQ)?C#%A:9%'FM/ILBQ=U)H M>#+$]DIQ\W$"B<.!IG0N/(NF=:'`BIPMO$HHT%:@)@;J`SVF^],V("+@1_9E; M>$#Y*BK7>K,))174O)?N&8??,&UA%P1+E#9^2=E;AVJF4*+X^[@*'==A_+/+ M)MIM0C81LH7P,XG&QT;1YB_N>)$;'(CM>)A=NO=P$T2\,K%1S3NTL7@,U6N1 M[M*<78/0A,E6F-.$61#,J]]LD=%;]"S2L^_IFYF^63O<3`[_0V`["VS7`MO; M6UQC3C-F\Z4)6YVI`M/$JV-)B;UVXY$NU>5V'N,0V2>\R#O>P%]N&J$M.:/S MDXUCJ!$=^/;)W8Z2UK^?)9%0NQ#>^]B,5VI,'';S`UE>:?$/4$L#!!0````( M`#DT;$>+/RL9H@$``+$#```9````>&PO=V]R:W-H965T<.3!0C&A?70?@R9M6QIUHYWU_9,Q5'6CA'K`'$_XT:+7P(;4M<[T% M42>25HQGV2/30AI:%JGV;,L"!Z^D@6=+W*"UL'\OH'`\T1U="B^R[7PLL+)@ M*Z^6&HR3:(B%YD3/N^,ECX@$^"5A=)N81.]7Q->8_*A/-(L60$'EHX((RPV> M0*DH%!K_F37?6T;B-E[4OZ7=!O=7X>`)U6]9^RZ8S2BIH1&#\B\X?H=Y"XRMTA+]@M"LT8OL%<9LR*8$'];@M.[]%Y MHO./Z?N%OM\ZW,\.#Q\+Y(M`OA7([V]QB[DLF,?_FK#-F6JP;;HZCE0X&#\= MZ5I=;^>9IYF\P\NB%RW\%+:5QI$K^C#9-(8&T4-HGST<*.G"^UD3!8V/X:<0 MV^E*38G'?GD@ZRLM_P%02P,$%`````@`.31L1V]O39["`0``>P0``!D```!X M;"]W;W)K&ULC53;;IPP$/T5RQ\0`[N0=,4B[::* MVH=*41[:9R\,%\478ILE_?O:!A-:H6Q?L&=\+F,S=CY*]:I;`(/>.1/ZB%MC M^@,ANFR!4WTG>Q!VI9:*4V-#U1#=*Z"5)W%&DBC*"*>=P$7N<\^JR.5@6"?@ M62$]<$[5[S,P.1YQC$/BI6M:XQ*DR,G"JSH.0G=2(`7U$9_BPSES"`_XV<&H M5W/D:K](^>J"[]411ZX$8%`:IT#M<(5'8,P)6>.W6?/#TA'7\Z#^Y'=KJ[]0 M#8^2_>HJT]IB(XPJJ.G`S(L+T/B=7)S1CDA7F/&,6!+'JFQ8)WJ(GGI[N<#>YQ[O;`OL@L%\+ M[.&PO=V]R:W-H965T6C&-&\ MV@[`D3FN-"T M+&+MV90%#DX*#<^&V$$I;OY>0.)XHBE="B^B[5PHL+)@*Z\6"K05J(F!YD3/ MZ?&2!T0$_!(PVDU,@O81\$*Y0V?DDU6(=JH5"B M^-NT"AW797[GA9&!R)[7DXN_3HX2:(>&5B MHYIW:&/Q'*JW,CWD!;L%H1F3;3"7&;,BF%>_VR*C]^A9I&>?TW<+?;=UN)NZ MIX^?"^2+0+X5R.<1]Q]'W&(N"^;P7Q.VV5,%IHU7QY(*!^VF+5VKZ^T\QT-D M[_"RZ'D+/[EIA;;DBLZ?;#R&!M&!;Y\\["GI_/M9$PF-"^&CC\UTI:;$8;\\ MD/65EO\`4$L#!!0````(`#DT;$=&:$##I@$``+$#```9````>&PO=V]R:W-H M965T5=2VP/MG.OWC-FJ`\7M M#?:@_9\&C>+.IZ9EMC?`ZTA2DF5); M4%)#PP?I7G#\`?,(MT&P0FGCEU2#=:@6"B6*OT^KT'$=IS]Y.M.N$[*9D*V$ MAR0:GQI%F]^YXV5A<"2VY^'LTKV'FR#BE8F-:MZAC<5CJ%[*].Z^8)<@-&.R M#>8T8U8$\^I76V3T&CV+].QK^FZA[[8.=U/W+/E:(%\$\JU`/H_X\'G$+>:T M8+[]UX1M]E2!:>/5L:3"0;MI2]?J>CN/63R3#WA9]+R%7]RT0EMR1N=/-AY# M@^C`MT]N;BGI_/M9$PF-"^&]C\UTI:;$8;\\D/65EO\`4$L#!!0````(`#DT M;$<_&PO=V]R:W-H965TZ:EE42$Y*HD9:5_'Y)Z1"T,Y"+N MKF9F9_DH1C1OM@-PY%U);8^T%AA=#[*`4-W_/('$\TI0NA5?1=BX46%FPE5<+ M!=H*U,1`!40$_!(PVDU,@O<+XEM(GNLC38(%D%"YH,#]$RB\:E1M/F-.UX6!D=B>Q[. M+CUXN`DB7IG8J.8=VE@\A>JU3!^2@EV#T(S)-ICSC%D1S*O?;)'16_0LTK.O MZ?E"S[<.\ZE[EG\ML%L$=EN!W3QB^N^(6\QYP?SODFWV5(%IX]6QI,)!NVE+ MU^IZ.T]9/)-/>%GTO(6?W+1"6W)!YT\V'D.#Z,"W3^[VE'3^_:R)A,:%\,'' M9KI24^*P7Q[(^DK+#U!+`P04````"``Y-&Q'MN2*+\$!``![!```&0```'AL M+W=OJ(&ZW[ M`R&J:(!3=2=ZZ,Q))22GVH2R)JJ70$M'XHR$09`23ML.YYG+/$Z\M'6C;8+D&5EX9+/!4WG$@2T!&!3:*E"S7.$!&+-"QOBWU_RTM,3U?E;_X;HUU5^H M@@?!?K6E;DRQ`48E5'1@^D6,C^!;2*Q@(9AR7U0,2@L^4S#B]'U:V\ZMXW2R MCSUMFQ!Z0K@0[@-7^&3DROQ.-FK_W>Y@X-**&&6DG)JI4+GDR6:O M^6X?9>1JA3PF7&'.'K,@B%'?M`CQ%CUT]/`V/9KIT;K":'*/_D,@G@7BM4#L M6XS_;G&-.<^8Y+9)LFF2>('T"Y,9L[]MDFZ:I%[@_@N3&?/M'Q.RF@X.LG:7 M0*%"#)V>AF/)+O?L%+KI^H3G64]K^$EEW78*780V,^H&JA)"@[$/[A*,&O,2 M+`MOMWNSE=#FF0(M^ONK+>Y-_`%!+`P04````"``Y-&Q'G)[4[K(!```6 M!```&0```'AL+W=O6B?67MLHP#C`EZG?U_`E[C5JNF+889SSIS1@(L1S:OM M`!QY4U+;(^VT=]J#]28-&<>=#TS+;&^!U)"G)LB2Y9XH+3#@I-#P;(@=E.+FUQDDCD>:TB7Q(MK.A00K"[;R:J%`6X&:&&B.])0> MSON`B(#O`D:[V9/@_8+X&H*O]9$FP0)(J%Q0X'ZYPA-(&81\X9^SYGO)0-SN M%_7/L5OO_L(M/*'\(6K7>;,))34T?)#N!<_6:)C-ZB9Y&>?4S/%WJ^=9A/U?/= MQP*[16"W%=C-+:9_MKC%G!?,?[C#\MJ7#0 M;IK;FEV?P"F+@W^'ET7/6_C&32NT)1=T_OK$63>(#GSYY&Y/2>[M%#CLEU>X_@K*WU!+`P04````"``Y-&Q'G!WXN+(!```6!```&0`` M`'AL+W=O-'$]%)R_?L,`H&<>D0`_&QA M,*LY\=DOB&]^\;T\TLA'``&%]0K<#5=X`B&\D#-^GS0_+3UQ/9_5G\-I7?H+ M-_"$XE=;VL:%C2@IH>*]L*\X?(/I""%A@<*$+REZ8U'.%$HD_QC'5H5Q&'=V MR42[38@G0KP0]E$(/AJ%F%^YY7FF<2"FX[YWFX.#:R_BE(D):BZA"<63KU[S MS3[-V-4+39AXA3E/F`7!G/I-BYC>HL>!'M^G)S,]62=,1O=M[^VX ML-C-KW#Y%>1_`%!+`P04````"``Y-&Q'=X#6#F3WQ??>R;;H3\6(>GW2;76'V M]:[<1Y5YOII]@LL'3#ND)_[9F6,]VH^ZXA_+\F=WL-Y\^9[ M>;PW-`;9!7PJ\[K_CIY>ZZ8LK&06%=GO8;O;]]OC\(MF)',+D`1X$H#P"C@) M>*A`D$"$"B0)9*A`D4"%"A(2)*$"30(=*DA)D(8*NIX/G6/!DE.S(5ABVPW! M_0;;<#CO>#RLQ7XE7V=-MIA7Y3&J#UEW?<-EQU==G#9X5/?S612(&1\S2,C#-K"R#T\RU9?@T0T\L6&\3!?+:.FF0?+)"\SC9DO`X-!680SBZ`(9\LR&8UG.3`\11XV'NG,)"D33L_< MFG1PV MS:T'3@N=,JX"*@+F+*D_W>7S>,6*(,XE%SR9!M<$@A!")4F(@0&XRR*_9:FO M+'"N)$=9\-=EN8T5!M=$\&1;$@024R9T4&_^F[;)P6)DO8NP^$ M)';[+9#A@L\&"5):IU*&7!/@MEP@SP7NN9()8A<0ELKMN4!&",(W+NN66B6H M@MKG]DP@TP2/K2P)"O45<)LAD!N"FG:,KP3)?G5,/GMVEC\,YF%8)K[8EX;R-*T(J/[E,]MUIN`\7!\H3' MJ&Z(DG2)J#!F`VVJ1K!:TIU%H'53Y%\_=!.BI:N(6 MUCIM&A+#[9](_HD>M[XF"+B6*<>0.R1TFR:2:6*(\:+;"U&&5"Q/_V8LQ:`Y M=MLADM-AT.IQFQPF(14/$+0?+D70'+M]#O7?K`JW,2%9!'JNPVN"$B;P@R_' MH\?O0_9B'K+J9;>OH\>R:9_E^Z?NY[)L3!N'7;11MR;;G`YR\]QTNTF[7PUO MF8:#ICS8EV:G-W>+_P!02P,$%`````@`.31L1\_T?/)K`@``I@@``!D```!X M;"]W;W)K&ULC5;+CJ,P$/P5Q`<,8#`)$4'*"^T> M5AK-8??L)$Y``SAK.\GLWZ]?D&1D'A>PFZKJZK;!I'="/UF!,7>^ZJIA2[?@ M_++P/'8H<(W8&[G@1CPY$5HC+J;T[+$+Q>BH2'7E`=^/O1J5C9NE*O9.LY1< M>54V^)TZ[%K7B/Y;XXK7%G"%#UPJ('&[X0VN*BDD$O\UFH^4DO@\ M;M5S5:UPOT<,;TCUISSR0ICU7>>(3^A:\0]R_X%-"5`*'DC%U-4Y7!DG=4MQ MG1I]Z7O9J/M=/X&AH=D)P!!`1^CRV`FA(80/0C1(B`PAFIH!&@*(HRREY.ZP"Y+[+U@(.)4B0MEA2DUTF:G@2D9O&0!1ZMVDD,&` M)\Q:8V#2#]EJ2-"/R-M$L,-XPJ35*7!M+H`6Z$^QT8C8'_`Y*K(;%\F-R(1* MPK:2Z+GGH>;/7U/,%*31Q6I(`N=P!OMAVVFPW`KK-1U934>Z+_%K&OAL6D-` M$(.AVC8:%@HO0=*OMFUA(!Q2VVE8`H+`C\=K@];:H-F;$P1BJT`\VIP\-HON M)\EXEIDUR\S8G(T+S*T"<^O&>UG#N6EG%$$PL#C38+D5UFLZL9I.3-5#KXO& M^`-ORB@B_X[0-KVGCVJ-Z5F=?\PYD&O#]?O=1;LC=@7D1_E;?!TL-H$EO@T6 M.WV"/N2S](+.^!>BY[)ASIYP<12H[_:)$(Z%6?]-M+D0/PW=I,(G+H'Z\!``!$!```&0```'AL M+W=OH!P*`WSH0^)(,Q MXQYC?1J`$WTG1Q#V32\5)\8NU1GK40'IO(DSG*?I/>:$BJ2I?>U9-;6\&$8% M/"ND+YP3]?,)F)P.29;,A1=Z'HPKX*;&BZ^C'(2F4B`%_2%YS/9MZ11>\(W" MI%=SY-B/4KZZQ9?ND*0.`1B=<3V?TS_Y;BW] MD6AH)?M..S-8V#1!'?3DPLR+G#Y#;*%R@2?)M'^BTT4;R6=+@CAY"R,5?IS" MF^H^VK8->33DBR$KWS44T5#\9<"!S/?UD1C2U$I.2(_$;7:VMW+E0FPRTC[- MMJ1]\=%5KTV>/]3XZH*B)E]IGJ+FMJ*-BFJ18`NP29'/%,6:(O?^+-O].Z"8 M`\IU0!$`BO1/R)W7B-!&T#Q4'ZI==5O6;LINXI2;.&7$R=[!*?\/9U,6^TD3D`# MF-I.F+Y]O24EJ1ER$VSSG?-O")+WA'ZP$F/N?#9UR^9NR7DW\SRV+W&#V`OI M<"ON'`EM$!=;>O)81S$Z*%%3>\#W8Z]!5>L6N3I[HT5.SKRN6OQ&'79N&D3_ M+'!-^KD;N->#]^I4L(JU#\7'NO@:S;28)!?RL<,\&:T?F MOB/D0VZ^'^:N+U/`-=YSZ8#$Y8*7N*ZED0C\VWC^"RF%P_75?:.J%=GO$,-+ M4O^J#KP4R?JN<\!'=*[Y.^F_85,"E(9[4C/UZ^S/C)/F*G&=!GWJ:]6J:Z_O MP-3([`)@!.`F"*(O!:$1A,\*(B.(GA5`(X#/"F(CB)\5)$:0/`@\W5TUFQ7B MJ,@IZ1W6(?G`!C.!4VDBG!VFW,18F#I\E:>7`H0@]R[2R#!@P"RN3#C.+`TS M3JPT$?OCR'K29#-MLC4F$9XHAG6CH!K1Z)A1X"I-KJ/D2BFU=5J)H@3?QQ: M&2A)PW%HK2'H^^DXM#$0B(+IHD)K4:$I"HY'V6HFRT"2)=-Q(FN<2'DD#V&& MR%(C@U+^0U9VY*YO&LE$XQY&`(>-TQ2(0#Q=$+06!$WCXO%TUW`RW0TT#\S@ MJ1I-)+8F$IM$GAA-8C5(C,$7#]I",_YTB-0:(K5.?SB116J9VVB4S!HELX_D MKA#-I)8PWN`MV:$3_H'HJ6J9LR-1H,=M_(0V MU=HHK.!70P&?+K2BC)D@O?$?G_FQI3%. MYV/Z-]NMIM\122O.?C<'56M8&$<'>B1GIE[Y$WZ%C(3N.=,VM]H?Y:*MZ,E MCEKR[L:FL^/@KJRAMX4-V!OPU8#214/B#L@P'K3[RW3H,@RM'">QM2.1@P^:Q[&ULC5;;DIHP&'X5A@=82""@#C+CJ=->=&9G+]KKJ%&8!4*3J-NW;TZP MK`W*C9"?[Y1?DI#=*'OG!2'"^ZBKAB_]0HAV$03\4)`:\Q?:DD8^.5%68R&' M[!SPEA%\U*2Z"F`8)D&-R\;/,UU[97E&+Z(J&_+*/'ZI:\S^KDE%;TL?^%WA MK3P70A6"/`MZWK&L2<-+VGB,G);^"BQV(%(0C?A5DAL?W'LJ_)[2=S7X<5SZ MHG\QXI^>BKB\+Y3_Z:G*^/O,2<;6OTNCZ*0:4/? M.Y(3OE3BC=Z^$SL'I`0/M.+ZUSM M`,%#0F0)T51";`EQ3T#Q0P*R!'3G$)BYZ\YMLMBRR`G?]&&*V%H/"YR:QTR2V`N"K2:HQC>F: MQ:1A-`[:&%":(#@.VAH0B*,$C:-VU@_.$7H^+>2<%K+3N@N#AF$L9D+K$J=' M8CVB!_]/AXF?FZ1.D]0*3.C$S"DPF]`)@P'1$3@]= M5B83UA,`;@DPH1<6-,4%NEWLPD>S"1+NE0^B"0VUH/L7(QCLSC5A9WTN%52[^UU]#18;X*AOU5FM3X-/^3QK\9G\Q.Q<-MS;4R'/%'T` MG"@51*8-7V3V0GY-](.*G(2Z354GS/EJ!H*VW>="_\V2_P-02P,$%`````@` M.31L1TBYZW<$`@``\P4``!D```!X;"]W;W)K&UL MC93-CILP%(5?!;'OV-B`DX@@3:BJ=E%I-(MV[21.0&,PM9UA^O;U'RDS):2; MV+Z<<_S=@%T,0KZHFC$=O;6\4]NXUKK?`*`.-6NI>A`]Z\R3DY`MU68IST#U MDM&C,[4<(`AST-*FB\O"U9YD68B+YDW'GF2D+FU+Y>\=XV+8QDD\%IZ;OK,]6T+*08(M53^[*3C9%+&V*2(^723$O*%1]M];5$V;H`KS8H:-!$ MLPN:VXIJ3+E*@`&8I4`C!9Y2(.=/$+X?@,>`=!J`/4`.WT,2I^E\&UZ#UQB3 M!5DU*[N)D\[BI`$G>;]/-L7QFD\H27-,;NNJ40()LC>%Z=1\GG\7)`\["/KN@25?3MO_%"3*4I^@_7A>9Q2$!)UWX>KPF M103";.'K";)DG24?_QTP.9\]/;/O5)Z;3D5[H\^4?4$L#!!0````(`#DT;$=S,YQ3A`(``&8) M```9````>&PO=V]R:W-H965TDQA7_Y4*:$C'>;*X.K1N,SI)4%HX+0.B4**_L))9] M;TT2DQLK\@J_-1:]E25J_NYQ0=JM#>VNXSV_9DQT.$GL]+QS7N**YJ2R&GS9 MVCOX\@H#`9&(7SENZ>#=$N&/A'R(QH_SU@8B`R[PB0D)Q!]WG.*B$$K<^8\6 M?7@*XO"]4_\FA\OC'Q'%*2E^YV>6\;3`ML[X@FX%>R?M=ZS'(!.>2$'EMW6Z M44;*CF);)?I4S[R2SU;]$KJ:9B:XFN#VA-['3/`TP>L):S!)\#7!?SCXDX1` M$X(G@J/&+BMW0`PE<4-:B]9(S"?XPN&-$.'*%I5JO&A4=NY$[SUQPR!V[D)( M8]P!9J\PP68EF#"811PT(@S',:\=)IH/ZG5!_6&Y M/"VP_FH224RE3!3&`_PS;^,;;7QM\U3R(6:O,1$8QZ3_8T:#!,8@@1:`$R8= MQITW"8TFH1;PQHNZ5YCG@@PAJ99Q%^2(C#DBG9.UT62M M38)Y@8U18*,%PHF_I,,LF.<0&%UDMY!XFNG!L.(:!`&(O,T"*VBVTGM0M!FO M>ZI!8+5@CX&NV4>O_O74BNE!2WS,>P34F\1ZP42$YO4/?7-)Q/DWJ(G?U21< MLJ-!\Q*'P9*R!"-E<0:'3HF;JSSNJ74BMXJI,Z?O[:\4.WGP.@]X$M?HBG^B MYII7U#H2QH\^>4Y="&&8^X,5'T+&+SU]H\`7)EXC,39U#5`-1NKN5M-?K9)_ M4$L#!!0````(`#DT;$?;725Z4@(```H(```9````>&PO=V]R:W-H965TV$ M[=O7)UA2N8%#S%0-D[KP@1WD?;='SG5T+TVR#@IXJTF&]H3SKY MY$)9BX4T;P60>U38``2((6UYU?%GKNE94%O8FF[L@K\_BM;3'[)M_I:"341E$4PQ9WKEG2\IIW'R&7G[^'V`&,ET8J?-1GX[-Y3R1\I M?5>#[^>=#U0.I"$GH2RPO-S)"VD:Y23)OZWI)U,%SN]']Z_Z=67Z1\S)"VU^ MU6=1R6R![YW)!=\:\4:';\2^@\[P1!NN_[W3C0O:CB&^U^(/[['Z>'`KY4R92&>/:S>9(=>3>S5[+U$6 M%L%=&5D-FFD.1@,G12#=G0CDN\*1143+!N%H$,US#*U!_)ACJC6=@1@-C!*` M$%H&14Y09$')(RB?@XP&;,)E2.R$Q!:2/GD;HPF!_"UC$BK8F8PG#)%GSI=UE#.,URQ+_9UF"V5G=$G;5+8E[)WKK MA#FJI]FI[>V1/NL_Y671XROY@=FU[KAWI$)V#'V\7R@51/+!1NZ[2C;F:="0 MBU"WLM%XS+0J,Q"T'SOOU/[+OU!+`P04````"``Y-&Q'H-J&,N@"``#+#``` M&0```'AL+W=OR5(=I#/&P\*/8;$V[D,PFR9&W*BI9 MZT+542/7T_@.;I]Q!^D0/PMYT"?CJ#7_JM1;._FVFL:H]2!+N32M1&XO[W(N MR[)5LI%_.]%_,5OBZ7A07W3I6ONON99S5?XJ5F9KW:(X6LEUOB_-#W5XEBX' MV@HN5:F[WVBYUT95`R6.JORCOQ9U=SWT_[#4T?P$[`CX2`!RD9`Z0AI*((Y` M0@G4$6@H@3D""R5P1^"AA,P1LD^$I#^.[C`?^IQ-(5,D.QZ>JDWO=2E1\\#T5-#J0O$*,=B'/?LM#BG+,-P MW1'Q.B+.$;LN0+T"U']BIU8?:-")+7J8X/91(*[;85X[S-GAUP6X5X`'Y,-' M\SD[2?ZE?#*OG_-:*V6D54(W5G=KORR.DU*N33OD=MST[]K]Q*C= M\.EP_'Z9_0502P,$%`````@`.31L1WL;,E"C`P``5!$``!D```!X;"]W;W)K M&ULI9C!CJ,X$(9?!7&?!IA>B\GU59MR_^ MN>LNST'0[L^BRMLG>1&U^N4HFRKOU&5S"MI+(_+#$%25`81A'%1Y4?O;S=#V MI=ENY+4KBUI\:;SV6E5Y\^].E/+VXA-_;/A:G,Y=WQ!L-\$4=R@J4;>%K+U& M'%_\5_*<`>\E@^);(6[M[-SKX=^D_-%?_'UX\<.>091BW_4IP=QS*]E]U7>_A)F#*Q/ MN)=E._SW]M>VD]48XGM5_E,?BWHXWO0OG)LP>P"8`)@"($8#J`F@#P&!)AO& M]4?>Y=M-(V]>>\G[V2;/2M[T251FKQVRJ2&U0^-KW_J^I23AM8`YPPH86YAIH6$01I&2?PQ$K,B,8,$")+60$Q8S!A%D-A_1(JM M2+%!>NAIKMEI3804,M.23^MIN)6&&YH(*9#6,!HS#BF"Q*>YC1,@'Q,E5J+$ M$#&D/LG']=&23Q$+5]0FM9*DAB1&2%(KR5R2+21.#!):.8;F'H0CDS2*U/)+ MP@B9SLPH%VO0C47L6*,S)A@668U%[.O0C05V+#!8#[=J>H>E1>$3(VY5-JE" M'M[]K9E+:J?3+DLAQ.CH2(?!T?\!9S=P8APQF#,:,*;:< M)A%:&;H@=L/8S1>,^=*'!<7G=[`1D32F[-&/YL)LS!:R9+9S<3/971B,"].' M577WB!]%D7K")]@3W@@?X=U0=C\&X\<4>QTR(M47`,5>6L=L:PME-V8PQDP3 M;/*XNU#WD\>M\!HJF&UB*]&[T'G9JG3X@O,*P"?XMWVXN^4E\ MSIM34;?>F^S45GK8]QZE[(1B4.[G>V>1'Z:+4AR[_I2K\T9O^O5%)R_C-XSI M0\KV%U!+`P04````"``Y-&Q'H2>->3\"```3!P``&0```'AL+W=O&MJ*C5])V:V#0.PKTF#Q MR#K2JC='QALLU9*?`M%Q@@\FJ*$!"$,4-+AN_2(W>T^\R-E9TKHE3]P3YZ;! M_-^.4-9O_,@?-I[K4R7U1E#DP1AWJ!O2BIJU'B?'C;^-UF6F%4;PNR:]F,P] MS?["V*M>_#QL_%`C$$KV4CM@-5Q(22C51BKQ7^=Y3:D#I_/!_;NI5M&_8$%* M1O_4!UDIV-#W#N2(SU0^L_X'<25`;;AG5)BGMS\+R9HAQ/<:_&;'NC5C;]^L M0AQ2S^>Q&<:*WE(8(CNDZQF25:.)%D@6 MX1/YA?FI;H7WPJ1JA:9O'1F31"&$CPJH4C?4N*#D*/4T57-NF[9=2-8-5]!X M#Q;_`5!+`P04````"``Y-&Q'?R57%2@"``#-!P``&0```'AL+W=O;>#D!4E;A![ M(1UNQ9L+H0WB8DNOD'44H[-*:FH8^GX"&U2U7I:JV"O-4G+C==7B5PK8K6D0 M_7/$->GW7N`-@;?J6G(9@%D*Q[QSU>"65:0%%%_VWB'8Y8%"%/&SPCV;K($T M?R+D76Z^G_>>+SW@&A=<2B#QN.,9OI/^&30^Q%"Q(S=0O*&Z,DV9(\4"#/O2S:M6SUV^2 MQ*39$T*3$(X)8>A,B$Q"]%\"U,Y47U\01UE*20]8A^1I!SN!4RDBE`%3:J(E MIH('&;UGT2I)X5T*&2:<,$?-!,M$KHDPC$<&"@=6&Z%G*Q%J`4<)0SQ1(1HJ MK*:-1J;1];\UILQQ8#;+3#YG%HVLK$961F#[6""V"L1:(/8=G0Q,X.ADSBP: M2:Q&$B,0.HP,3.0P,F<6C:RM1M9&8.4P,C"QP\B<632RL1K9&('DL<#6*K!] MXFP'QO$EYW-FT4C@6YVH\*/3'2'7/\8"+9L)[&:")TYXA+8N,W-(FX&3V[/! M]*JF"@,%N;5<7YYC=)Q<=,/P'"=X]A=02P,$%`````@`.31L1R1*E.@- M`@``_04``!D```!X;"]W;W)K&ULC53;DJ(P$/V5 M%!\P@0`J%E+E;6KV8:NFYF'W.6HKU"2$3:+,_OWF@NBZJ/M"DN:1`.U>;,7DE-MCO*`52.![AR),TS"<(0Y MK>J@R%WL71:Y.&I6U?`ND3IR3N7O!3#1SH(H.`<^JD.I;0`7.>YYNXI#K2I1 M(PG[63"/INO4(AS@1P6MNMHCZWTCQ*<]?-O-@M!:``9;;16H64ZP!,:LD$G\ MJ].\I+3$Z_U9_=55:]QOJ(*E8#^KG2Z-V3!`.]C3(],?HGV#K@3G<"N8@8V!01E!*2I9/LIB)\]7-SD`?JH_WDFA-[ M.6[BBVBZC`;B*S/I_&"ZR!=Y0P_PG:X'&PO=V]R:W-H965TR9VI],>.I/IH3T36[:9`'*1'*?_O@(6@HU0Y(M!\KN[CX1X02PNO'X5 M1\:D\UX6E5BZ1RE/CYXGMD=69N*!GUBE_MGSNLRD:M8'3YQJENW:H++PP/=C MK\SRRETMVK[G>K7@9UGD%7NN'7$NRZS^MV8%ORQ=XO8=O_+#438=WFKA#7&[ MO&25R'GEU&R_=)_(XP;B1M(J?N?L(D;G3@/_POEKT_BQ6[I^P\`*MI5-BDP= MWMB&%463257^BTD_:C:!X_,^^[=VN`K_)1-LPXL_^4X>%:WO.CNVS\Z%_,4O MWQF.(6H2;GDAVE]G>Q:2EWV(ZY39>W?,J_9XZ?ZA/H;I`P`#8`B`R!@08$!P M$^!U9.VXOF8R6RUJ?G'$*6NN-GE4\KI)HC([HLVFAB3:SJ>F]VT5Q,'">VL2 MH09&FG6G(?.*3:<`B`:-IPBT&.#J2D"7P%`"%185@KY".!YH@`,-KVM$K:;J M*#H-T#"($@KSP@TF"]*(!L'G1*&6*$2BR$`4VA*%]Q%%6J((B>+K0F/-NM.$ MQ,#22;Y8P\1:F!AA$L/T=!H2J.D)0M/TQ/IYG$5*M$@)(E'#_"3:^1E+-A/) M+`;58E#$2`T8]'.,B606(]5BI!U&XALN4(HU:$((&&Z]37KG!2*^EJGM;J`, MZW.-(@LJ5-Z!1?18:+/)S1I-K[`ZD?]PZU'I%5*O"BVLD(`>!Q`G,.&`%0[< M@Z.W9H)V"H;5ND:1<45/-?,H>D\FZ*,`)I30`F6BF4?1FS%!-X;`A**WXVN4 MB68>16_%!+WX]EZY1HDM4"::>12]!1/TX,2P*-1#^'`;T70^_%IN?4(#+!#"(;&+T# M`[&8F5Y$?1,,F1#/P^C]%\!F9L`&!NZ`T;LOH/M2D_N"A?M.-?,H>O<%=-_; M-]UK%`OWG6KF4?3N"^B^],9]D_&-C:(PI31-C3SV%@QZ"P:T8!J:>&);GAD? M]D9;R)+5AW9K+9PM/U>RVT$.OB'?+4X90?V,ZL/>26<%R[51K;= M=>XYETR5]Q_42]:19;NA4;"];$X3=5YW6^ZN(?FI_X(P?,98_0=02P,$%``` M``@`.31L1ROON]:K`@``<0P``!D```!X;"]W;W)K&ULE9??;ILP&,5?!?$``YN00$606J9INYA4]6*[=A,G006:=N0"Q_Z"3_2A%W&$='?#W@@UVT* M4COQU!]/7$YD;9/-=?M^Q!/KR910?-BF]^"N@PI1Q(\>7]G-?2+-/Q/R(@?? M]MLTEQ[P@'=<2B!Q><4='@:I)%;^943?UY2%M_=6_8O:KK#_C!CNR/"SW_.3 M<)NGR1X?T&7@3^3Z%9L]E%)P1P:F/I/=A7$RVI(T&=&;OO:3NE[UDRHW9>X" M:`K@7`!AL*`P!<4_!9EVIO;U&7'4-I1<$W9&\K3!G<"I%!'*"5-J8DM,3=[+ MV=>VJ,HF>Y5"AH$WS(-F@)_H-`'ANTHF'#AMP-2U!-0"@24,$;%"85=8W6ZT MT!M=;?Y>XY9YL$SE9[HEXS6R,ULG8: M61L!&#!BF2)@9,EXC6R<1C9&8!4P8IDR8&3)>(U43B.5$5A_+%`[!>J(L[5, MX$WNEHS7",B=3M3T1Z<[0Z%OC`/RFP%N,R#BA&>H#IE90GXST&U&1U&QAA$2 M[C`",6D$8N+(`?G-N`,)F$2J(MY:X(XD$)-)(":4')#?C#N60$PN6:@*?8O` M?R03<$<3B,DF"U7!DUY"?C/N>`(FGZJ8E]\=4"`FH2Q4!Z!NAB).&KHS"L9D ME(7J`-0Y(+\9=T;!F(RR4!WZ/71`VDQVT^&-F!Y5Y\N2';E,7#=X\^S<7=_K M#O$=;YLS.N+OB![[B27/A(L^4S6%!T(X%NOGG\HT.8G^?QX,^,#E[4;<4]T1 MZP$G9]O@S_\RVC]02P,$%`````@`.31L1Q&^#`/Z`@``8PP``!D```!X;"]W M;W)K&ULC9??Y$GZDX>1*$_V18B`&B8)VDQFH[KL9_E M="R/5986XF<9J&.>)^7?F.^J-/5X;\G2LQE]CO=5'L=+1@%&[%-CEGU)D\OPN5`C.%:9JK^ M'ZR/JI)Y(QD%>?)EKVE17T_V$\*=K%N`G`"=!1`/"B(GB'P%V`FPKX`X`?$5 M4">@O@+F!,Q7P)V`^PIB)XA]!:;FMG+`6W(N-KR2A':7U'OL,:F2Z;B4IT`= M$M-Y\-[PI?'1YH&J#?7^4O7@@QG]G$8Q'H>?QLDQJ,7,+(/ZB7GC0OJ9QX:A M_6-TU>;YNLG,GWPH2Z-MT%0DV!<+M`R*4; M7T[":J:P2^L81@#PF"?JG">J/3``_?/,+(/BB&#:CSW[84L_;-6)]6>'.[/# MSN1J@Y)V/)8A$24,Q?W(B'9&1-TB,0\'UNG`;B_SS#(0,T!X/S9WF/E#_=B3Q2A&Z'KGMK&%M<.5&393`CB:&#.5XLAW?S0I]4@Z,RN'C:E0SX>L-L# M.H]HX-7GH,M7\?]KY#"**1QZ(SD,ZB_-:^ZB_QN.7_@-9-C]50.1RQ`/O)(< M!",0\>NYPM81Y)#LQ(^DW*6%"MYEI<\S]X0$``!P%```9 M````>&PO=V]R:W-H965TM MVN!:ZVY-B#K5P*EZ$!VT9J<2DE-MEO)"5">!GAV),Y)$T8IPVK2X+%SL29:% MN&K6M/`DD;IR3N6_'3#1;W",A\!S!%/NBTY7I04?*!AQ^NK' MIG5C[W>R--#F"4D@)"-AS#-/2`,AO1.R3PE9(&3O",27X@[B0#4M"REZI#IJ MNR->&[BT(D89*:=FSD"YX-9&;V46Y06Y6:&`22:8G M+"?8>\0J6H8<@DC^M8ET,)%.ZTQ]#5GTM4`V"&13@2PES'[ MCYA%(_FLD3P(?/O$2,#$RY##!XBW029-Q$%>W&U4Z"2NK?8_>(R.%WZ;V"9\ M%]_%Z[V_MW>9LNCH!7Y1>6E:A8Y"FQ9W_5@)H<&XBAYRC&KS5(T+!I6VTT&ULE9=-;Z,P$(;_"N+>8AMC($HB-+C2$TX<.]!##/O#.OQTHFRPNKWOF14F%]%GG) M5_91B-/"LW>U85J:@?JX/#3Q5-=RJHR!T$`'&*-"OM]5*M M/5?K)3N+/"OIC%]Z[MV3Q;XR]RX=?NY4-9`TTIULA)=+Z\D$CFN=2J<[\ M5XM><\K`_GVK_D/9K/"FX93E7 MG];VS`4KVA#;*M+/YIJ5ZGIIW@1`APT'(!V`NH`NSW"`JP/<:P">#,`Z`)MF M\'2`=Y/!:;RKG8M3D:Z7%;M8_)3*\P07-5Y)D5K9XDJMWC2N%I_DZL<:@W#I M?$@AS:`>LVD8;P*)&P1VA%,7,%@%LHV/`54S9[T3`//G8Q@>-I^LRF9<:1:!Z)YY'D#ADU0P;-$!V/)CI& M##M&3#M&3#M&OMLQ?]"DKTVZ7U-Y?9,-0_S0\UP_'`2.V343#AH)M3QWD3'0M.. MA:8="TT[%GZS8Q`,NE3+TB;YFBOLV]30`WB\+:F/13W,'2*(6)@ M#P[;TS^^T)\XDATT<28-F-B`2>Z9<4MHV!+2"L%4QY!9QY!9QY!9Q]!HQYS> MX%30ZJ!&5FYMV;D4S2C0K79C\9.:BF_6-W`1P8'U6([1:E"[RJ^7I_1`?Z?5 M(2NY]<9$/>ZIV6S/F*!UQ>"QWNEC/>AW#SG="WGKRQ8THV_S(-BIG>2[OQ/K M_U!+`P04````"``Y-&Q'UB*\OPD"``"R!0``&0```'AL+W=OH>'0JD:T2,)Q%:SQY;RF8M98.E!P3R68'\@4P>$\<8%U'R528/)'&>D462?;`4 M3NX"!WER,T*AO3BWVG^G8W4<0VMB[]*'^L:,)S]-;C)5V=$3_*+RU+0*[80V M-]5=JZ,0&HRWZ,DXKM7T/RI3_@(E@``2<7%)A? MKM"!$$'('_PC:_X^,A"W\:+^*7;KW1^9A4Z+[[QWHS=;8-3#P"["O>CY,^06 MZB!XTL+&+SI=K--RH6`DV5M:N8KKG':J*M-N$V@FT)6P>Y]09D+Y%X$D9[&O MC\RQMC%Z1G9BX;%W>P\W0<0K(QO5?$LV%A]#]=I6M&S(-0AE#-U@GA*&_AO1 M942]0H@W<-,%75Q46Q%"BS0/VGR8>(4:F-A/EP3^MW4-TM5#)# M-O<[L3-\9>;,E45'[?Q3Q7L=M';@58J[&J/13]":"!A<"!]\;-)/E1*GIV5$ MUCEM?P%02P,$%`````@`.31L1V!IIIU)`@``E@<``!D```!X;"]W;W)K&ULC97;CILP$(9?Q>(!%C`'[T8$*>?VHM)J+]IK)W$" M6L#4=L+V[>L3A*9`$XKP,AI[BS\V0XI0@,_<]+PWC-0 MM>\I_523[\>YXZD22$$.0CE@.5S)BA2%,I*)?UO/6THE[#^W[EO=K:Q^CSE9 MT>)7?A29+-9SP)&<\*40'[3Y1FP+D3(\T(+K7W"X<$'+5N*`$G^9,:_TV)@W MJ)4-"Z`5P$[@3PL"*PAN@G!2$%I!^*P@LH+H)H@G!;$5Q,]F0%:`[@2N65V] M-VLL<)HPV@!>8_7!^C.),V4BG0'7;G);N`XN5/2:AC!.W*LRL@SL,4O#1&_C MR,8@?D>XLH#!*J`SE`%J.1Q/L#)$[(TC:VA;01-U/DRT?9QH]W^BT7:#MMVP MO^B!-7A];!`.&H36X&Y+^LS&,H'W.$DTF"2R!OZ_29!F*K-QAO'&B94A_!!Y M;^/4QE+0]^$XM;45H2!XXDN+!YN*;5/PL0$:-$!/K(IAT-L4M+;0*XPFUL5` M,$#W_[X^M6LI&$5W;;F],Z$D[*S/>PX.]%()\W5VT>Y*64!UIMS%E_YL[0_$ M-_(*,C?&S3Y-:GPF/S`[YQ4'>RKD2::/G1.E@LB"O1=Y1F;RDNPF!3D)]2A/ M?<#,O6$F@M;M+=A=Q>E?4$L#!!0````(`#DT;$<:W1%YD@(``*`*```9```` M>&PO=V]R:W-H965T"FD2D5K M]V&KIN9A]SEJ5&J`L$G4V;_?W$`=P\4'29IS3I]N4M#)C=!/=L:8.U]E4;&% M>^:\GGL>VY]QB=@;J7$E[AP)+1$76WKR6$TQ.BA267C0]V.O1'GEIHF*O=,T M(1=>Y!5^IPZ[E"6B_U:X(+>%"]PF\)&?SEP&O#3Q6MXA+W'%,;>U@[TOR.D$^Y^7E8N+[T@`N\YU("B>4 MQ,=UH[Y5Y0K[.\3PFA1_\@,_"[>^ZQSP$5T*_D%N/["I(9*">U(P]>_L+XR3 MLJ&X3HF^]#6OU/6F[X30T.P$:`BP);1Y[(3`$(([(>PEA(80CLT0&4(T-D-L M"/$W@J>;I5J=(8[2A)*;PVHD#R"8"SB5(D+984I-=)FIX%)&KVD8!(EWE4(& M`Q\P*XV)9MV03$-`B_"$`:L+Z-HR0$6'W0G6&A'[/1X&13;#(ELC$@U7$C25 MA(_]#$P_P^<<$X6IM%&-`;[X#:<)K6E"DR9Z3O.(R1I,/)PDLB:)C,"D.\G* M8$`W9/,"Z;016VW$QL:TNZ4KC8%/+7UM_"C4UH;JM#RQ6IXHB6#6XUA#H@'' MHU!;&ZK3\=3J>&J:/.MYUM/!9[T>AF3#D,T+I+.8F;68F>:'([H!?*N""DN) MODH:4%\IKYAN*\!NQ;RB0SA"`MHEX)AJX(AJ7C#=5NSO1Q",.&@-J.^DCDN MGR8U.N%?B)[RBCD[PL4,H#[81T(X%G;]-S$LG,6XV&X*?.1R.1%KJ@&D M;N;!=BA-_P-02P,$%`````@`.31L1PE-BFSJ`@``OPP``!D```!X;"]W;W)K M&ULE5?1;ILP%/T5Q`<4V]B&5$FD)G3:'B95?=B> M:>(DJ(`S[#3=W\_&-B&5$[R7`.;<K.CG=-*=5EMT_$L6/EM@]JZ@0!0).FK-IX.>_77KKEG)]D M7;7LI8O$J6G*[N^*U?R\B&'L%EZK_4'JA60Y3X:X;=6P5E2\C3JV6\1/\/$9 M40WI$;\J=A:C\T@G_\;YN[[XL5W$0.?`:K:1FJ)4AP^V9G6MF93R'TMZT=2! MXW/'_JW?KDK_K11LS>O?U58>5+8@CK9L5YYJ^J[8]G^\K5Y2R7,X[?H[$L=3]!!\5O-,DBCD2/9LJFN@7G_3JQQ+C=)Y\:"*+ M02/,RF'P;#0(-B$3MP[L9Y#:#QYM!-@EZ+9'UF-9(&`S$ M%"`4()1ZA5(KE%T+S<9"!@,>TFD1[!7!IAAY0);$2T`,03:[SE*;Z)(FL6E" M2K-I(>H5HC93<"TTQCP[#)P6R;PBF:UY/DV0>PER2_"E'&14C97!($((G9:9 M>65FTTU8S(8F!&!:!P*O4+\\T86%!06U(81^'>MM`FX7KG"@G%)*`J3\!H;6 MP22@2Z#?FC"U74]O-V-A09@$>`OZW0FQWUW7U]F:.U,<,!#R>]3Y'QZ9_"L M+0@"$#02D-^JR%F5W!X^ZP$4IG3C4>N<&C`GD=^I*)VNR\J!8!XR$Y#?JPC[ M)^558Z[08%9"`D88\OL5$5N8@-Y&?BLB&E(8`X(4S;XFFXQ>!(_EGOTLNWW5 MBNB-2_5.V;\`[CB73-&`!T5Z4%\3PT7-=E*?9CI%\WYM+B0_NL^%X9ME^0]0 M2P,$%`````@`.31L1U<#<:$A.```V_H``!0```!X;"]S:&%R9613=')I;F=S M+GAM;.T]V6[C5I;/36#^@0@->:`ERF:* M(A4N=AS,5W0/9OXG7S9GN1MY22VN2KH'J(>D9(F\R[EGW^X?\[QP?U['2?ZG MS^Z+8O/E%U_DB_MP'>2GZ29,X)=5FJV#`O[,[K[(-UD8+//[,"S6\1?=3F?X MQ3J(DL_<,HE^*L.SM$R*/WW6'XP_^^J/>?35'XNO7J6+6%%'Q MY)XG/&:4)NZ)F]\'69C_\8OBJS]^@>_P>Q/W;9H4]SF\LPR7]5_GX>;4[74\ MM]OQ!_4?+]*'4[OUJ^E?/ M/;\X.VT9X0SFS((8YEJ&/[O?AD^M"[MYVE@3^)V3O[2^;IEE]$*4+V!+/X1!UCK[R8G?/>GY M+5!Y'<5AYI[!>W=I9H%DO@YB_/TZW*19$25W[EFZW@2)]:"$<;I>`TK-BW3Q MWG/GA%?N95GD!2`?O%Y_[28+\&MW_K2^36-KEZ_^>MX*<[%U`?K7\+6%P7_I M[7J;`-?X[ED*:)+DX1+VE.1I'"T!1$OW91`'R2*$K0$!YD`[[^:OW..C%]9$ MX0*.W"<*Z%MCO[N^GEWP<'D$:P$B3LM M[N&L@CR'I=4?O,K"31`MW?#G#6[+^OTF+0`>"X%7+6-<7U[-KF]^<*<7K]S9 M7]Z=7[V%;7AN$A;6@B]NIA=?G[]\,Q.[;'SJYO)F^J8-#`)(;\ZG+\_?G-^< MSZQ'IHM%5L*A;(*G+(UC@H'\G(4Q'5C;?N%=9)4YOA#79PU`)-'W3+: M_.;R[-MO+M^\FEW/_]U]-7M]?G9^8Y,-,8`<&0!0QU'GM-/Q`8Z9^Q#$9?@? M;K_3\3K\GY`[;E`6]VD6_1(N/7I*<>CO(!&L77@B(]P(]\`P<:/82Q1533Y3)"403P M0)HYB9*31;")`#XV^:U".(:ENP"V"'C6*,$`UBX#%?1(K()@8!/4+M/ MXV68Y?_>^BC1C$$5=+1['LX^/.WX*D#$N@^+"%CD"SQ%]XL6'6%>P`C$4`'Z MKZ,$QHF0*2-/0MWB;]-;%-J+XC^W(8JG$:3E,2%0+(39ZW%&F;T>3=M%50OP M%`0(`2\W848X`&!\EP0EX%&X?-$N)GI[ZUB6$#E/`.="/?\66%_/OIM=O+-) M'KGY%#F"._OKU>QB/IM_:1\P$O)MD._`\7D8QP`TS[T+$P!!S'07+-=10FH; M$EHK+[X&5A=DBWMZ9QD"2::;)CX*P@Z8<,1J*XV_1JWDE\85,4FE?"#`(=HF M?Y/FN;O*TK5\%@[/`M3--[-KU"TOW\[<8PFL%Q:TSI,B!#0JY&3-@J!M)>KM MB(ZV^>7FW[X&$\!%<@I`6@$>-LMO`1)C'/=8+L9"38++;0AZ>>ANLO0ARA'J M\*=\M0A^MO<`*L)WY_/SRPOW]:6"V,WTKS;R7P6K<<^F;\[>O0&OG9Q+K'&UMGVHGO4 MV4![3Q_WI'MZ?D7/FZB'@@QE$LE?"[LN0I#V<"JVN/JQS`M>"V@J0"(IL&%` MA$2\@-_BYP7.6N)6$%OVF7)J$!CN%J`*Y:0[69NZ#Y([Y+>)P#^B44.C ML(<7"EPD,-_")H`QJ3@+/($V5>UBGZWM.H$(-.Q\%SBN2N!2P`OIS($H8!XP M>G"7X4]EU,BSKK)T$89+,8NDS_W>G2%M`BJ5))H2V#^"P]J*M?^FO>S:_XJ% M]X[]5S8#?(1D*RD/L*F%(=+W?Y-@F:1%V*J*@_$9/$DE8Y,!^XDVR,>2[:\I ML!#W`O'JWCXU;K.)`P%7N)Y-YS-F&O-O&L$7%+23V_`N2A(<$]:'7SR!--OV M0HC**S^Z(?/56L'EQ0G."K-_-YN3A$8E[_7YQ11T=_SK[.;\.]+^K#,"+O4` M^J,@V`J$6&;6:`X_I%O/KCIB<(#1Q6.S,9!N&D7K_-W5U9L9VBB@U;XZGY\! M[W]WW;0O.DHT85D&-7.,^E/MDDHX,D#[7;R_RX"?6:<@3$0\V"O@^PM`E2U* MUL7ES0+8.?W2O0,M=@WI6D6N>> M"TK\7[F.0T\*S39H1-(&B$55(XN`)O`(H/X*ZBA3P MEO2F;@]UQ,[P%`:$KY[P*?S;<[^!)Z/(?1D!'BSN/0QZ\`:^`9=;O=[Q)UW@'K+H,03\%0I;F5O/[.(#O M^7[/&_3[]@`O]0".-0#A\7'T`$.`S3F8>+UNPQ!GV]:`8K8&;Y?A#2<8_KP@ M\4AX"!8>-+TKC`Q M3YTI2&IMZXXZ?:_;'>RS:YI;FN+(7[)"B^7B?OG("F# M[,EA\Z8S`H,!\,TTZ6T$\-R7;%>T+&A!C(I)!OG.3@PR\!:I#GW0X5*=T*8$ M$LQ#UGO(*"&YX6Z`R>&C4I##V$6`-`-G'&X8F/$3R/I5:-$1VE#(:V@R-PXR MP(@R68.H@IF1*8"BAF+R$73TT$E_1FT332`L>)HP!7(V>2PP`\AH`)"3I<#J"N:,=`PB@&*Q2JE(/%69 M+W`1M2M'(%;@`C/\W$T?$T3`\C:/EA%N<2%$T0*=[77WY[^?KU"\94 M9'N/L!D\]SKDU0CNO+R%UST7B![UT@(A^G@?(?\,0&+=";,9SAQVF3LX,(SS M8[B@)Q$Q@?LP*\W1%8R0AMW`<>0E2.CZ=CU7S^L^IF6\9"@Q#)C,85P^:,(L M&#Y!AR7L&Y]Q:%@+LOBFU,+4MT#5Y4:0#PR3EY)[`*8:PW@*KV@]MR$I3T$; M\!QXNWI8.'GU&QZ)!(7!CO%$*HI`1=!-A9(,XY!_UBVB=6@M5:$=3P&+@Y6N M@Q_3#.-00A;I*?$ODI4M_F/]9%U#J6R(B.!U>)NA[')'TIFL%H.T$H=2K1*G M8Z.UQZA%!`S,+A`4S(0O*1Z7_.L_A)IJH#9&Q8`'@%8N625-@(_SA%^2]H5_ M2QTW"Q#(,^))BM1&FMVO. MABBH)]QK-K3!CCJG0]!S@#?R.T+YQ+?87A)(DBHUQ>W)HQ;*N($[CC9)@5.4 M+):.NEX'EH51#I(:*!'KAA=N.4P3#_W9*5+D@H1338OI>;U!S^OW1JW[JRK5 MBM*S$*TVS7V;]GT0Y&$E7=\;FOJ\`*VS';1-L`4XLORP`>HV`G3L]<<3K],; MM@+4V0^@9&,,O=&H':+NX1!UG@/1QJ7L@ZU@IE2L:AC5T:,.O.ZD`^`:&J,J M.=\P?&>D1Q>:-!(Y*2-"T.5%5)!]0=NJSZUVY`R],9S28#`XB!K]075_L#W# M+FF=#3#(&P]'7G(Y@4$,!4.J$7&:(ZFB,YR7P`$5(\1&C&/J"E4!>@*)P;<4PX0G'*E(IZ1D5"%PI+]>CFRLC1S MM(98T;U,GE(!A3EUE//L9*Z(@?98A$'RCH8E0@!,?_?=Z?S4_7HZO7+ORHC/ M?SH_<\>=P4D?9#C@-:K="0A=JC\*#53D`%2Y.;$3K7ZICG6-J\1C!BXLN:OFT"OGDE M9'_!CG6J@3^6J0;H-)!OKR+BGNYKM+CG)WU-7_/9&9(>X=\:C7(#&VJ3$64A MBXJ`-0`W`IW<94,1U#;$IF@I[6I)>$M'L"5KJ'>;&NTVS\EG9Z8B5,0'+47H MDQ5=S$U*!(>CU3Z$:J/8VT\TA#^5<+#B4.K3;-,NJ_H06?3(FN[#F-UC_6E+#E?N<"AA$Q:_@*!4911PP' M_R'D$`PXK4,71<832``*E-;]<\M2O6)/W)I<@QA?)]7[8"F6%":N,HB`W:3L M38!]9XDTI%F"+82/03S`\59G8<9;-9?+=>3U/G@(>9X-2L:,=?9`^#KD5+=! MCHXMIG]-=F$N&'#%26E(4Z(#^"%?L1S#GTT)*P@M09X;P\!EEE=\Y`2X_!Y- M4_%H\T;=YHTZ>J,UB<"&'W(7%>%%-6/4!SMAZ+.>T07-$I.G?&6[%??`0NG' M!)9WLN;$DQ`33YK.UFE04*KS^3!\Q^N)5*TC>,%AB/*(OZ9$P@3RY%%7'8,F2MKT*5Y-.22K[D/(!2_2'IQTX6 M1$@:RY+U'O@1U@8JAHE([&@=5*D#2)NM!!K!M",$QZ.%@5AZ0LV]`E]ZE\[+ M:=Y/^Y#W65K>`6Z4&*RGB+X([E/&1!X"Y@JFH<+>`-$R>9\`>P"%XA8]MVA! M&(.K6+40R>4"7LN!B]=]X)8452QN25O"9[0G6'M%24<7*B=2#O!DI'545S=9 MNH*=8=#8\"&C&$U"7`5[YK,*Y,T#UR_)R)4"HMY'C(HU<+Z'4&"RP%\^_(^. M<#?"2;LGTZU!%E9`8@T(.RZ7K(<%9N8-ZAGKX$F2ITIT@!63(U71:XGKP?,F MF\0*B*.%D)$+V4/4UBZB[K[_-W;M]/K'S#O:7[^]<7Y MZ_.SZ<6-,ST[NWQ'><'NU>6;;53-J]F%8*-$[A"38@0-_?:U[BB(0P M8'4;-H&!Z>L@">XX?N`9 M#SO2`@F7-:X0`"5'615[E+V+U)%KC[(`B328V_01X7?Q^R`$X^*>N*T&!^!3 M'`%3S!TB0Y*C48X*->5.,8X0Z0F,/0A:R/:")=HC1A6+S&&K%9(`;D M$H`#<4BU+0!3IG8+QU9I6J"+J;)4!GG\)/D,.WN:5B5"E75B M.QQ"NHX*$A2&J;P;^V=GS$_KQTD:'\MG9_>19N1C4\@3T;:7%)=^".L8@\X7 MSB$F@TO.2-[5D!W'9IZ_@U/0(I]][J"[NA=T@4 M\]1S5JPP+\,X:;(#165'1D57:-&0$\'OG'PKW`HJ\V`VG$7@$\[88>Q')`B7B@PJNAP2L#9*:'/D5S.% M9YJDJ''P29]K7YWRT[V>SE\ZPLL]G;]S+])3^O4$5>NK&@_711XZ`_K7_V7; M_DQJ6JWE:^XKQ>IVI=+U4&?!_,>+FTO06O000D1)7N2L`!O31U4$]*73P&FL M`B#'2--V*#DU1YZ`&G`&F\O=(WJ^TB:9Y+VA+K%R]-9,Y1DH/,:"'?>H._8Z MDPF.;2;H&$EDZ#\#>D<4`^1=E@ODA,T%(J<6[6J[E36!)#6V)I3BNAUS8.V8 MI;%?FM(3`TW`>^-)5WUP7I=90OGL[+18`?,+C1?\CN9W.V'NN8ZWJY6J=$9TAHW%/SMCM@TKS M4?QJSR/@QRPE-SFRI4G7&TU&B$C"I2RW$"Y;P*T"&4%>$7$BUF`4$6K9YM0U MO+")&#$6H[[UA\;252BF'G_2P4ST1F"R8AS<8DX9\@B-C&R&$I[WV= MIDN*..#96J\<(-L'+-N;2L3-<0.Q%.1?IMAW/@[_XNHB%.*]2<_K`76K3S:W M,4L-DP&]A=;SAX!H=SFCA<^Y0C;PCJ#<9\!P8GI6?;S#S]=L4@7!3 M617M`.9-7"+]_M(7N%?T%2&IFRY*+GLC[4U&`,^)R;O@7T`#Q$ MRU(=C'V'U6HA!#*S4)E@%#XF46_!+% M%N.\0*EXU5R`]@I=__LSQ2$R1?IT-?UABFQ1ETG(S(IJK,/1>9WHJ\B*$P)I MG+++_ZC780&%X*,OK>PBX2O+1`B\]SGE105)4JY/09U4R4R)\0[G$:$H3)PI M6+^Q6AQ2BAQ8S$1:`)/\DN5]E%MK)5XPG$A&T#V,"3AMFM4-SD4.MJ:Z-Z=6 M,@*+J^Y&%)'HT$TM'L"Y9+T.@:P$;#MU9P'8*/A12JN06#":;)P>!7_HG(%J MGL*Q#X)DU)N(3((7<-*/J7N&/@+WEP$PNH#(S._M6*<8Q\RT;;5S*<#ARC)P_`MS^?OIA=G,U,CWP_1 M33S,TWA9B3!B!@2HM:L3[EE#.+@*,X,WZFP:P]O`L5:L6GF>YEZ)5Q[V,0(CSP27%@A M18%Z*#S@@^H+MDNOWVTE.&`T!BQYKHT>)>RT* M8B$M[UHIZ62Q_0;5(\1['7!X"LX=M!1-N6PM]12M)_0 M\B'*GW56*D.A=E1ZW?`U"ADP3CV_/R80L4XD'"M"\J@R*R-+U-*.A,G"185\ MS)+V#;^U`5?'@BMAQ+-(YUPAL' M[XGE4&%@"ZDA0)U;K*<*$E&SK#7H]3<6@O6FGU=3HPN9V:Y%(38D0G\[ M6G>UI<+_=>*QL6:_<D!H-#B:)]$J0N]UA.P+SC!6D1\!%]&B$E8N M?#G+A6M.=.-&!S`^)7GCSB*YJZEB M81'V0@"U<,&`=XQ.HLHR%IX]L^KIR*6:IM[I>((NO<[`&_L=9Z;/X_"7SRA= M&S9R;#SZPOE:G'=WY(U`>(V[_HFX,./O8ZS58AN2-.*GNP_),\4-?K M^0-:R,!WQZ<=#*#XWF38`QG:J^RC88"AY\-*!H,>#]!Q1Z>3@1B@ZW5[$[V7 M$[7^`?G[1MV)L?H3^+UMX0V^UE[/\_VQU^GW:>+^R!V>CD<(0J^/WX_[E94_ M:X2:A*NCAZ`C3EOD7AF1ZF$FG#WXD]D61G`9$:'GE'#LXX#N7V$;/0AI4\/M M5&8=+Z)-A.^*4F3*0U">F6C%C2TV.L;/.0H*SFG2&"5B/972V7%WE20J,_!+ M[)\=)L27GFKT7'W>0:T0.0*.+=8DO2W[1*$7-L",A[Q/I4,A8E9Z>.7SH6> M%E99)[^3!D)RON/'CPV,?K&+N*K3V-3A>X,)X/FPVX#YK--E&`M47Z1W2?0+Y2TJ;WP6(-$\:5S/0B[PPK:V MV8.0E2`Z1-87I3JB%-'K!I.W7(LERPX$()WE+JQFK4WQFI9>K>2I,\7/P:&> M5^A1QK9;3Q$6Y`"'_YS^YUQ'^?N3%7H9R0<*-G;WR&LS1DK(:5.=QAQRNT;48Z*SBWCYJ$(S- M1K+L.PX?X&&'5KW*@G6(0?2056PD/%RK<2!FHB>V\Q%ZJJ#X.@>O[!KLC(*6 M+I]>,I%S,5($JBZKC^NPN$^I9#A]5':5;5!:A!*>N;:XE;^[K M?"2D,$F?\"R3;J$F8N:P>K=S`K(*2+NF(#+O(PE+Y2ZFZ4],*>.<,ZR-:6.N M7#/+M;\5R&]2C/M@9M&*F7DI3&^>]8[]9=RY%O.*34RME\M1"DE=4+=UV^'JG`'9%[@GA MCN=8..'>AVQ^2_F>>5;##AP06%@BL:D'Q#OIC[V]#NO0Q3DM"0)U7Z_TE3?Z M@"?H`_Y^>GT]Q4;Z-Y7<$VHL)K3MAN83,@(@[>@O'>65_Q#[3B<8]- MQOX`5)/N&#Z?;+69V]_2QK)^QK"5QUZ_!]@][K:JUSML9#4`S3SLNWVTV.OK M/>C%!IO8[]'3O?Y^ZVS02?N^-QX!LG>50=L[I2RCOC<9`]9/_%TF\>X1/L3. M4,7Y'\W$8`ZM9W',600/(P6`RB))3,N4F9P\749[:;/#NRDO00-2:Q23JGX^'GQE_#88M-TF$[9##1-@E\MFR2#OS0-6R2ZM^? M;)(M-HG$(.>?:8[0@AUACE2F5G%GD@VY137B]W9UJL.*5)^B^0TLB#-;^LJ*@7PH&@(\@IQ48*O>966!1B'W1.;+'R(TM+87"XRCR?8L7MXH`P^ M=5_)357,]VIS)K,B0"E%4M^)BFIO#&5053L;P:*&_:[7K70^;$O5J<:X&<'M M]_KD\?\X$9DX>R"M]\9HV+]&\#;U?!V/A:\X:MFK]PSX$V-\[N_.[R'WG`X M:@)W!114WB([I]3:KS5"X!D4[O='7FFNKGFJ.:$NRM=F3""Y4LMKX*[33Q/T)>KB6RY[(&VV4X[)6KIK=R?P7JGHK M'D.1EM30GH";-9$])/0,F>)O$0FI=:8T$W5W)#U,9!9UM_6L51?45>-" MV,O4)+JJPI\;,MW!8Y:W89`/P2H?PM1R!MN/8#'FRVAA6!'"AAJ`7 M)"H297;OH=M8T)$!KY&4=XSL%'PW#A[MWBO:8R%O%:@L1'I MXCU!GB:X<:=4MLPBRA;E6M3:,8`-?B/F\MS[]!&)BE-.#/TL2\&.3:BW;A0" M(,5N'P`3T?R`,8B;\"VBA;@LQ#$BC;EZ%PW?VO.Q5Y1@)!U(=%EQ#J4C%B!O!HP;$DQ??DZ,*LK-="O'K_&8K'5)3H$\:6B:$5D2!EKM\69,T= MJWC08.FMHYGW`?%XHBVAQ"0W2O2(8KVINB.5?J7;0AJ;&56;]9DM#E43%%E6 M)`OZF0QHK49&'=&!_C7:\OW"M`*ZJ1L0K;@BRA#K_JB7;%=$L70I_:$+Z3&[<>3=NGCSZPM]&6LMVDJ9G72]CL/7ZY"P`#"7U29SAF9RJS8N&Q^C MMB-OOXUIXSICO:&-F5#$OG1NMF3':")%L-+5N<<7Y3JDIA(O&&;PU:LP2>GL M\RK^\+=SBB(OG>"%.3CSNG'''P_/O`I?];P$7W'WZ!%\4/?3`J^W)EO=\# M,KM64$5?AQ.3R4SY;='7LDZ_="[V,*Q_BT/2?:@!1'0ACN<#VC"(^K_'(>U< MP1Z@^6WP5S?,?N$.)E['GWA]RMN'E76'OPL"[UI"C0&;=YVTW%B#*B8HG>S= M#_E*$"X:5E9J#>5-S*XMT6P!E%>RRO&FP]#1>BH\M7:-!'Q*LL>0JH)<=2Q! M%@WF=Y@/AJJS(8I2_9Y1X9S8=WNE7ZO$]MA=GLXN;:[XNW=0* M9?$8WUG#6KRC^ZQQ;W0PP."+):FAL@&=;MZJ]-:02N+4D,J9`;J;>'V_I*^V M?')6DBO72W&82@?PQ#RTE",@A^Y@\,%-X=Y@P:/EY>-O=X*?.KV]P?NGY_(V MUVO9`N^,VEE5CJ-V\V*,DSA\OZCJ:V7T6R/MC'N(/KD3>7,PA1WI53/O#$UW,1+RD=J[.7HQ[D&+ M`5B-.B)-M#_R>@C!9\:7:TFI8%2G`:C^2?K`+'@G1B75"]5@O"1\)%VF>E3B M_'&9=50334=%O]I.>^`ZYFMD3?MIC6^*I`,W^'!KFI7A%W+,L$.B0EL:UG9W0;/==O[LT$Y/0VCN[421QU16COP!1**_U3 M)2/)N)7$`WE!4F/O;D=V3\SOPQ#]5S.1(8^65A&K5*=#G6I&GS5<(-^TG*G\ M>VJR@ZG9-+6>2:[9;N!6^-.95`$;M?:OA?-, MDHRY:+HRNI)E0`VZ"D*!4W3.O*[=)BRQZ-R\_=EJ>5)307Y,(XP8&=>4D'NK MI*":'I\\45;(I=M7 M88DV-K6@5'V]NA.Q<4&4T;78X0O]8*7W(9#SO>Q7G/]'9:T8!(G0,L.;TZR) MS2[(FTH_=#7<:3UNA3$.SN-R=$<]*V36!S!F-0 M4:/"312UDJYS!#\:GU%\2V;&PHKNH]NHK`O03=(U7I)V%FSR\@ZK;!5`+K7> M8UZ,V-*8UL7^(ZRP4P2T2B5J^'=SSWWSY@S)17XGKQ=!\##E:8ELQ8FC_!:"%\KC;TQC@-'*):X]]S!WL# M9Q%0`U\3LA:13:-YM.&X-\/GJH$,A8[1_WX;I2)QRF6L8FB3=93RD/*&,#&K)P^$_8'R)M?ZL7E[GI&C MSE^,'^J&0&$5&PWTIH6Q=T;I'BJR(C%;<:`*ZU'S(=`.T\"#W M^3S(L7F0?2'3;1[^5.+HLX.^3[F%[.9W]Y!WJO._MN)DO+%&\0 M@5M*86OP;7@'W61"%7YZF1QJ5&JIDNL3,Y5N*6N5#[E)A,MBS,YPNMD4'44J MK7?M5,26%$;X4"P.EZPOQCD5/9O4!?27VKG@F\MV:AH"\559%XE]?4@'^[AI MCI4D/ZTBH2,) M:]?6X+TAU)1(%1ZFJ[IBB8>`OLN!W^;N;;C`FZ?PAUYW,FA;(CY"=Z.*^W>- M7$R[WQ+=!"LO4=8/5@LFJ>)=`@]1S=!60<\_;D/V%[]1-\W^D(TBT4O3V=DE MUM_=!O*X/\:$60E56'IWGVZ78F3GL%Z7[LY>E_[63I>]+_K5;3F[NUNV3?]A M'6$EZOPF#2KWOJ[//9:?7C1%YVE-YFT[K0]]NI3/2HU3O2$_7S@?^-2_QPUK M&D7E3K^]$O#^Y2\&/+ZAF+RE&N&9IHE,\53/[[7I_S]W!AYPI5PKI.:+^W!9 MQB'KD?M>2=<,N4\WR7WP37+[7;&UUVGN=3M7&PE\NDVKY3:MW5<-['4XE=>F MHL_37F?SJ>WRI[;+_S_:+F_#?Z,5KDB'E;OC(*Y%5H?31M7@_M3"^/=J8;SM MV%^C+^$[AH;.6W8&F?.A#NT8'P@TH8]V)\>XQ8?_U3 M/>*G>L1/]8B?ZA$_U2/^<^H1M['SLRKF'E[HOH^*^ZD"\E^P`I+#/B^#Q?N[ M#%!\B110!%&=WAB*+FG5 M^Y6WCE:_ZG?7^^ZQ>+""W39SK5#[@HQ"L`JM]B"U>]%6^E'Q\O:!]24T&+/G<@;]?I3G57I;QI$H5<22->?^3A=BZW&1GYT#$')1+7J<2Q M19="YM@$8:QY$6PBY-0RB5(4EHC&P:0.8NM^,V]2<")KU*M,MA`4-_F>N7][ M2]+&2I8VN=E&O=8(7S'6U#6&)SBWC:VN$=[WA2V+40G."F!;XMR'2":_Z[YE M/7"&PKJI#E-4>5R)^@15)LY.`UVLT+8M49C?OFVUK7K M+7MM"*A;QG<]EGY0V/P0P).0E;VC[1^-<+&HW;4XLBA23EPN'NF&NQY[(U! M=5#D\H;V"5LB]\W8LB5H;R.RSD*XT5D(NX%:S46XY%R$W:^U9038B&HSK\VI M4M=;`&L^T]_C&3D.YNS:Z$#!=Z\:M^=T*8MGM6AF4_-56?'^7^Y1\U0`BRT+ MRYA"5W]L(QZC8B61P6Z4!K$!A*77G6X/R0W^'5N)5]7LY5:*4@);E*`; M580R6<%BW/=@G&-BW3*"?_X<@/GB3@%UODEA@=_B_]IFFY6(SYBKEP3+@-/_ M7F;!+U%\*)I5J7@'+FXC8`;U3E(U4:?US(EFV\Z\!9C;$C^LP\+,WBNI!!\B M$::;[!0M5R*51B.Q[.>N*^&WU&R4T[XVN;I&SBX(T6>LL(.\T>;;-O%0=O M\M:C*^J^6J?=$I=;W/PBGM@*E*2GP$+%! M?CY,EV[R$%[KHM=G7%-J8;'T;`AK5.@[S5J:[)'2KM>HRW7:'CC3UXVV/H.[ M%G;U.;6I0YL&P=CZAL[9T.@N?(3D4D#!;?1)VM@)95]=*?%I=D-1]Z8B[PMV M,19CC%IRICDF?7^?QK`TK`:7U`I.6T_JYR=%J?4)D[>VUXQJ[% M0W:[_165T#45"5W*BWR%F.H=".^=PQUV$#N':SN@G2^V'-R^ZW_&FZT'?=@1 M?.!Q?@AJ7*M"]-_1#T#+>M*9B)U7!%^ M[_J-#W[X"F>-INS06H#?^X@+:*:!^M@CN0A?+:+[6RVB&0Q:!SA7>9N4M]=R MRFV(M.I:M4,3WM(OVL- MV9#I::NJW:;%5/(^K7>X%D,P&W?8R&IV*8V47V]].6H$CB[8=?:]3IO;(U:]0<7WH]D5_KQQ:!VI;ZKT#U2KU7JO^I)YH4Y3J M4V][I%WU:=[X#KVD>=>_B9[[D?3;CZ'R?0Q5[^.H#AJ_VO/SO^H+\NXV^;#GM_52.YPVP!Z+L.WT+BC0SP.<5<;3+ M5HM9[G9S^)U&*<>";)_Q=P@S*K.POQS:7_J#2=-*NCLDW);[Y@^2>7\N$^W9 M;HPY=;HM,3'TB;?E5]"P\B)I2Y=HO:M<7K3,J5-*`%OKLB\K5Y<"UY]]76GU M9WH!;14G7'"2[=D]O+0.C)YAYMGOZU4U+YF7R[,\@`V7VM>?J=Q^>=#ASBHW ME%8O%K4X6K\)#=^U70I7?_"E552PK;*GR@_VJ0K:P\LGL^#[X?;TN5/%KNRY?>:8]F82^_)[RW"$Q4"2[-"H&F?N=NRT\81/O).&^=H MWFG>NM5ZW<,AQVF]^Y$W:(U_X#$>5@M7I9C=91)45V*4TNWT$&Q/X[=9G)'Q MK*1U.T,TGI;6^!;NJ2]#.HS??<>7`+6-?-EP@5#]&7&[3_.T]*,[-ZXDL.5# MNW5IQ)"M=H$R?I)N/1`_Y16J7-%1C>[K#O6@S;6E33;+MC1B_Y1WYIOLU=C*@S*(MHQC)+UMKT:X:6A%WEP8L66V MBJ/Z.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"``Y M-&Q'@(OKKQT#``#H#```$```````````````@`$N!0``9&]C4')O<',O87!P M+GAM;%!+`0(4`Q0````(`#DT;$=>H2P-/@$``&D#```1``````````````"` M`7D(``!D;V-097)PC$`8` M`)PG```3``````````````"``>8)``!X;"]T:&5M92]T:&5M93$N>&UL4$L! M`A0#%`````@`.31L1VHVJ;A5`@``V@H```T``````````````(`!)Q```'AL M+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`.31L1Q/T MZCY+`@``]`<``!@``````````````(`!,Q<``'AL+W=OX@Y/KGP,``!<0```8```````````` M``"``;09``!X;"]W;W)K&PO=V]R:W-H965T M&UL4$L!`A0#%`````@`.31L1V3C=-JC!```]Q8``!@````` M`````````(`!FQ\``'AL+W=O6+8C@0``.(5```8``````````````"``70D``!X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M`A0#%`````@`.31L1R17A[:A`0``L0,``!@``````````````(`!#BL``'AL M+W=O%2^H@$` M`*\#```8``````````````"``>4L``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1^T4 MTN"A`0``L0,``!D``````````````(`!E3```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1WM9OTB@`0``L0,``!D` M`````````````(`!'C8``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1^SA;0^B`0``L0,``!D``````````````(`! MI3L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`.31L1_6JJ6.B`0``L0,``!D``````````````(`!+D$``'AL+W=O&PO=V]R:W-H965T+/RL9H@$``+$#```9``````````````"``=]$``!X M;"]W;W)K&UL4$L!`A0#%`````@`.31L1V]O39[" M`0``>P0``!D``````````````(`!N$8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1S]R\B.D`0``L0,``!D````` M`````````(`!:TP``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`.31L1YP=^+BR`0``%@0``!D``````````````(`!)U(` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M.31L1U:!7A^O`0``1`0``!D``````````````(`![EH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1X!$DY1F`@`` MOP@``!D``````````````(`!BV$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1]M=)7I2`@``"@@``!D````````` M`````(`!'FD``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`.31L1Z$GC7D_`@``$P<``!D``````````````(`!H'(``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L M1YK@=S->`P``TA```!D``````````````(`!N7D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1^I>>5[A`0``'`4` M`!D``````````````(`!88,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`.31L1^-']_68`0``LP,``!D````````````` M`(`!UHH``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`.31L1PE-BFSJ`@``OPP``!D``````````````(`![I$``'AL+W=O M&PO XML 15 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Effective tax statutory rate 34.00% 34.00%

Unrecognized tax benefits

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Unrecognized Tax Benefit

-URI http://asc.fasb.org/extlink&oid=6527854

+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 16 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Property and equipment, gross $ 42,053 $ 42,053

Less accumulated depreciation (26,450) (21,442)

Total property and equipment, net 15,603 20,611

Information Technology Equipment [Member]

Property and equipment, gross 31,892 31,892

Furniture and Office Equipment [Member]

Property and equipment, gross $ 10,161 $ 10,161

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Intangible Assets, Net (Tables)
9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

Intangible assets, net, consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Patents $ 393,370 $ 393,370

Less accumulated amortization (214,637 ) (200,272 )

178,733 193,098

Patents pending 248,272 226,420

Total intangible assets, net $ 427,005 $ 419,518

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R50.htm IDEA: XBRL DOCUMENT v3.3.0.814

Leases (Details Narrative) - Lease Settlement Agreement [Member] - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2013

Hawaii Research Center [Member]

Lease expiration date Oct. 31, 2014

Operating lease rent expense $ 0 $ 14,709 $ 12,112 $ 47,331

Manoa Innovation Center [Member]

Operating lease rent expense $ 7,931 $ 7,825 $ 23,759 $ 23,255

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=CDXI_LeaseSettlementAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDXI_HawaiiResearchCenterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDXI_ManoaInnovationCenterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Stock based compensation expense $ 564,399 $ 10,783,948

Warrant [Member]

Stock based compensation expense $ 0 $ 0 $ 4,000 $ 5,229,589

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Issuance (Details Narrative)
9 Months Ended

Sep. 30, 2015

USD ($)

$ / shares

shares

Sales of securities, number of units $ 1,460,222

Sales of securities, price per unit | $ / shares $ 0.30

Conversion of notes payable $ 30,000

Accrued interest on debt $ 222

Warrants rights | shares 13,385,342

Two Class D Warrant [Member]

Restricted common stock units description Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020.

Number of restricted common stock units | shares 100,739

Warrants to purchase restricted common stock, price per share | $ / shares $ 0.10

Warrant expiration date Mar. 31, 2020

One Class E Warrant [Member]

Warrants to purchase restricted common stock, price per share | $ / shares $ 0.1667

Warrant expiration date Mar. 31, 2020

X

- Definition
Number of restricted common stock units.
+ References
No definition available.
+ Details

Name: CDXI_NumberOfRestrictedCommonStockUnits

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Restricted Common Stock Units Description.
+ References
No definition available.
+ Details

Name: CDXI_RestrictedCommonStockUnitsDescription

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrant expiration date.
+ References
No definition available.
+ Details

Name: CDXI_WarrantExpirationDate

Namespace Prefix: CDXI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants purchase restricted common stock price per shares.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsPurchaseRestrictedCommonStockPricePerShares

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increase for accrued, but unpaid interest on the debt instrument for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_DebtInstrumentIncreaseAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_TwoClassDWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_OneClassEWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R52.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended

Oct. 26, 2015

Oct. 19, 2015

Nov. 09, 2015

Sep. 30, 2015

Sale of securities in self-directed offering $ 1,460,222

Sale of securities, price per unit $ 0.30

One Class E Warrant [Member]

Warrants to purchase restricted common stock, price per share $ 0.1667

Warrant expiration date Mar. 31, 2020

Subsequent Event [Member]

Common stock 25,556

Sale of securities in self-directed offering $ 146,000

Sale of securities, price per unit $ 0.30

Issuance of restricted common stock, each unit consisted of one share 486,665

Subsequent Event [Member] | Two Class D Warrants [Member]

Restricted common stock units description Each unit consisted of 1 share of restricted common stock ([486,665] shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020.

Warrants to purchase restricted common stock, price per share $ 0.10

Warrant expiration date Mar. 31, 2020

Subsequent Event [Member] | One Class E Warrant [Member]

Warrants to purchase restricted common stock, price per share $ 0.1667

Warrant expiration date Mar. 31, 2020

Subsequent Event [Member] | Restricted Stock [Member]

Common stock 100,000

Total fair value of stock $ 45,000

Subsequent Event [Member] | Stock Option [Member]

Common stock 41,851

Sale of securities, price per unit $ 0.1555

Subsequent Event [Member] | Withheld [Member]

Common stock 16,295

X

- Definition
Restricted Common Stock Units Description.
+ References
No definition available.
+ Details

Name: CDXI_RestrictedCommonStockUnitsDescription

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrant expiration date.
+ References
No definition available.
+ Details

Name: CDXI_WarrantExpirationDate

Namespace Prefix: CDXI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants purchase restricted common stock price per shares.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsPurchaseRestrictedCommonStockPricePerShares

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_OneClassEWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_TwoClassDWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=CDXI_WithheldOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814

Basic and diluted Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Earnings Per Share [Abstract]

Net loss (numerator) basic loss per share, basic $ (743,461) $ (1,880,394) $ (2,443,881) $ (15,186,393)

Net loss (numerator) effect of dilutive securities-common stock options and warrants

Net loss (numerator) diluted loss per share, diluted $ (743,461) $ (1,880,394) $ (2,443,881) $ (15,186,393)

Shares (denominator) basic loss per shares , basic 67,955,379 63,610,949 66,000,101 59,019,453

Shares (denominator) effect of dilutive securities-common stock options and warrants

Shares (denominator) diluted loss per shares, diluted 67,955,379 63,610,949 66,000,101 59,019,453

Per share amount basic loss per share, basic $ (0.01) $ (0.03) $ (0.04) $ (0.26)

Per share amount effect of dilutive securities-common stock options and warrants

Per share amount diluted loss per share, diluted $ (0.01) $ (0.03) $ (0.04) $ (0.26)

X

- Definition
Earnings Per Share Effect Of Dilutive Securities common Stock Options.
+ References
No definition available.
+ Details

Name: CDXI_EarningsPerShareEffectOfDilutiveSecuritiescommonStockOptions

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted Average Number Of Effect Of Dilutive Securities common Stock Options.
+ References
No definition available.
+ Details

Name: CDXI_WeightedAverageNumberOfEffectOfDilutiveSecuritiescommonStockOptions

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_DilutiveSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment, Net
9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

NOTE 4 – PROPERTY AND EQUIPMENT, net

Property and equipment, net, consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Information technology equipment $ 31,892 $ 31,892

Furniture and office equipment 10,161 10,161

42,053 42,053

Less accumulated depreciation (26,450 ) (21,442 )

Total property and equipment, net $ 15,603 $ 20,611

Depreciation expense was $1,670 and $5,008, for the three and nine-months ended September 30, 2015, respectively. Depreciation expense was $1,783 and $5,241, for the three and nine-months ended September 30, 2014, respectively.

During the year ended December 31, 2014, the Company wrote off $992,797 of fully depreciated property and equipment. There was no effect on the statement of operations for the year ended December 31, 2014.

On December 16, 2014, the Company entered into an agreement to sell laboratory equipment with a net book value of $0 for $95,000. One payment of $85,000 was received on December 26, 2014 with the balance being received on January 7, 2015. Final sale took place upon delivery of the equipment in February 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants - Schedule of Stock Warrants Activity (Details) - Warrant [Member] - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Warrants, Outstanding, Beginning balance 28,435,782 3,395,833

Warrants, Exercisable, Beginning balance 28,435,782 3,395,833

Warrants, Canceled (3,395,833)

Warrants, Granted 13,435,342 28,435,782

Warrants, Exercised

Warrants, Forfeited

Warrants, Outstanding, Ending balance 41,871,124 28,435,782

Warrants, Exercisable, Ending balance 41,871,124 28,435,782

Weighted Average Exercise Price, Outstanding, Beginning $ 0.64 $ 0.45

Weighted Average Exercise Price, Exercisable, Beginning $ 0.64 $ 0.45

Weighted Average Exercise Price, Canceled

Weighted Average Exercise Price, Granted

Weighted Average Exercise Price, Exercised

Weighted Average Exercise Price, Forfeited

Weighted Average Exercise Price, Outstanding, Ending $ 0.47 $ 0.64

Weighted Average Exercise Price, Exercisable, Ending $ 0.47 $ 0.64

Weighted Average Remaining Contractual Terms (Years), Beginning Outstanding 4 years 26 days 5 years 3 months 11 days

Weighted Average Remaining Contractual Terms (Years), Beginning Exercisable 4 years 26 days 5 years 3 months 11 days

Weighted Average Remaining Contractual Terms (Years), Beginning Outstanding 3 years 8 months 12 days 4 years 26 days

Weighted Average Remaining Contractual Terms (Years), Beginning Exercisable 3 years 8 months 12 days 4 years 26 days

Aggregate Intrinsic Value, Outstanding, Beginning

Aggregate Intrinsic Value, Exercisable, Beginning

Aggregate Intrinsic Value, Outstanding, Ending $ 4,988,991

Aggregate Intrinsic Value, Exercisable, Ending $ 4,988,991

X

- Definition
Share-based compensation arrangement by share based payment award non-option canceled in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionCanceledInPeriodWeightedAverageExercisePrice

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award non option equity exercisable.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercisable Intrinsic Value.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisableIntrinsicValue

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Share-based compensation arrangement by share based payment award non-option exercised in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share based payment award non-option forfeited in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share based payment award non-option grand in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share based payment award non-option outstanding weighted average number of shares.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-based compensation arrangement by share based payment award non-option weighted average exercisable.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisable

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payments Award Non Option Weighted Average Remaining Contractual.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionWeightedAverageRemainingContractual

Namespace Prefix: CDXI_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payments Award Non Option Weighted Average Remaining Contractual Exercisable.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionWeightedAverageRemainingContractualExercisable

Namespace Prefix: CDXI_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payments Award Non Option Weighted Average Remaining Contractual Exercisable One.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionWeightedAverageRemainingContractualExercisableOne

Namespace Prefix: CDXI_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payments Award Non Option Weighted Average Remaining Contractual One.
+ References
No definition available.
+ Details

Name: CDXI_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionWeightedAverageRemainingContractualOne

Namespace Prefix: CDXI_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Company Background (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Feb. 07, 2014

Jan. 03, 2014

May. 31, 2006

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2014

May. 31, 2013

Dec. 31, 2009

Dec. 31, 2008

Issuance of common stock, shares 9,447,100

Ownership interest 100.00%

Proceeds from sale of common stock $ 3,923,100

Number of common stock shares sold 6,276,960

Warrants term 5 years 5 years 5 years

Warrants to purchase of common stock shares 6,276,960 3,321,600

Warrant exercise price per share $ 0.625 $ 0.625 $ 0.625

Outstanding principal amount of notes payable $ 2,076,000 $ 8,489,036

Shares of Common Stock issued upon conversion of notes payable 3,353,437 14,446,777

Warrants issued upon conversion of notes payable (issued Jan. 03, 2014) 3,321,600 14,446,777

Stock options cancelled 15,290,486

Exercise price of cancelled option $ 0.07

Stock options issued in substitution of cancelled options 6,889,555

Stock options issued in substitution of cancelled options, price per share $ 0.155

Additional stock options issued purchase number of common stock 20,867,266

Additional stock options issued purchase number of common stock, price per share $ 0.625

Outstanding principal notes repaid in full $ 500,000 $ 55,000

Net losses $ 743,461 $ 1,880,394 $ 2,443,881 $ 15,186,393

Accumulated deficit 52,336,163 52,336,163 $ 49,892,282

Additional capital through future equity and debt securities issuances $ 1,460,000 $ 1,460,000

Preferred Series C [Member]

Issuance of preferred stock 13,859,324

Series A Preferred Stock [Member]

Issuance of preferred stock 14,440,920

Series B Preferred Stock [Member]

Issuance of preferred stock 11,113,544

Preferred Series C [Member]

Issuance of preferred stock issued additional 704,225

X

- Definition
Additional stock options issued price per share.
+ References
No definition available.
+ Details

Name: CDXI_AdditionalStockOptionsIssuedPricePerShare

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
No definition available.
+ Details

Name: CDXI_StockIssuedDuringPeriodSharesStockOptionsExercised1

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock option issued to purchase number of common stock.
+ References
No definition available.
+ Details

Name: CDXI_StockOptionIssuedToPurchaseNumberOfCommonStock

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock options issued in substitution of cancelled options.
+ References
No definition available.
+ Details

Name: CDXI_StockOptionsIssuedInSubstitutionOfCancelledOptions

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock options issued In substitution of cancelled options price per share.
+ References
No definition available.
+ Details

Name: CDXI_StockOptionsIssuedInSubstitutionOfCancelledOptionsPricePerShare

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants issued upon conversion of notes payable.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsIssuedUponConversionOfNotesPayable

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants Term.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsTerm

Namespace Prefix: CDXI_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants to purchase of common stock shares.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsToPurchaseOfCommonStockShares

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of the total principal payments made during the annual reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentAnnualPrincipalPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of excess stock shares of an entity that have been sold or granted to shareholders.
+ References
No definition available.
+ Details

Name: us-gaap_ExcessStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Basic and Diluted Net Income (Loss) Per Share (Tables)
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income (Loss)

The following tables set forth the computation of the Company’s basic and diluted net income (loss) per share for the three-months ended:

Three-months ended September 30, 2015

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (743,461 ) 67,955,379 $ (0.01 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (743,461 ) 67,955,379 $ (0.01 )

Three-months ended September 30, 2014

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (1,880,394 ) 63,610,949 $ (0.03 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (1,880,394 ) 63,610,949 $ (0.03 )

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for the nine-months ended:

Nine-months ended September 30, 2015

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (2,443,881 ) 66,000,101 $ (0.04 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (2,443,881 ) 66,000,101 $ (0.04 )

Nine-months ended September 30, 2014

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (15,186,393 ) 59,019,453 $ (0.26 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (15,186,393 ) 59,019,453 $ (0.26 )

Schedule of Computation of Diluted Net Income (Loss) Per Share

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the years presented because including them would have been antidilutive for the years ended:

September 30, 2015 September 30, 2014

Common stock options 33,118,044 23,762,946

Common stock warrants 41,871,124 28,405,782

Total common stock equivalents 74,989,168 52,168,728

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants - Schedule of Fair Value Assumptions Related to Warrants Outstanding (Details)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Dividend yield 0.00% 0.00%

Minimum [Member]

Risk-free rate 0.12% 0.12%

Expected volatility 112.00% 112.00%

Expected term 1 year 1 month 6 days 1 year 1 month 6 days

Maximum [Member]

Risk-free rate 1.47% 1.47%

Expected volatility 170.00% 170.00%

Expected term 5 years 6 months 5 years 6 months

Warrant [Member]

Dividend yield 0.00% 0.00%

Warrant [Member] | Minimum [Member]

Risk-free rate 0.12% 0.12%

Expected volatility 102.00% 112.00%

Expected term 1 year 1 year

Warrant [Member] | Maximum [Member]

Risk-free rate 0.86% 0.66%

Expected volatility 159.00% 159.00%

Expected term 2 years 6 months 2 years 6 months

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventory (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Inventory $ 958,575 $ 958,575 $ 958,575

Research and development 216,228 $ 357,519 352,328 $ 921,106

Commercial Product Research and Development [Member]

Research and development 28,099

Germany [Member]

Inventory 924,452 924,452 924,452

Inventory reserves $ 0 $ 0 $ 0

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=CDXI_GermanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventory - Components of Inventory (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Inventory Disclosure [Abstract]

Processed materials $ 958,575 $ 958,575

Total inventories $ 958,575 $ 958,575

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 31 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventory
9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Inventory

NOTE 3 – INVENTORY

Inventory consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Processed materials $ 958,575 $ 958,575

Total inventories $ 958,575 $ 958,575

At September 30, 2015, and December 31, 2014, inventory in the amount of $924,452 is stored at one of the Company’s suppliers, which is located in Germany, with the balance of the inventory maintained in the United States.

During the year ended December 31, 2014, the Company utilized $28,099 in Astaxanthin as part of commercial product research and development.

The Company has determined that no inventory reserves are necessary as of September 30, 2015, and December 31, 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment, Net (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Dec. 16, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Depreciation expense $ 1,670 $ 1,783 $ 5,008 $ 5,241

Written off of property and equipment $ 992,797

Gain on sale of assets $ 95,000 2,426

Payment to receive upon sell agreement $ 1,634

Laboratory Equipment [Member]

Net book value of assets $ 0

Gain on sale of assets 95,000

Payment to receive upon sell agreement $ 85,000

X

- Definition
Net book value of assets.
+ References
No definition available.
+ Details

Name: CDXI_NetBookValueOfAssets

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2611-110228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=CDXI_LaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Non-vested, Options Outstanding, Beginning balance 1,595,762

Non-vested, Options Granted 5,365,729 27,756,821

Non-vested, Options Vested (6,961,491) (26,156,553)

Non-vested, Options Exercised (4,506)

Non-vested, Options Forfeited

Non-vested, Options Outstanding, Ending balance 1,595,762

X

- Definition
Share based compensation arrangements by share based payment award options non-vested options exercised number of shares.
+ References
No definition available.
+ Details

Name: CDXI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExercisedNumberOfShares

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 34 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Cash $ 413,145 $ 35,696

Inventory 958,575 958,575

Deposits and other assets 87,727 92,829

Prepaid expenses 7,473 19,862

Total current assets 1,466,920 1,106,962

PROPERTY AND EQUIPMENT, net 15,603 20,611

INTANGIBLE ASSETS, net 427,005 419,518

TOTAL ASSETS 1,909,528 1,547,091

CURRENT LIABILITIES

Accrued payroll and payroll related expenses 3,469,219 3,555,961

Accounts payable 635,365 651,991

Fees payable to directors 418,546 418,546

Employee settlement $ 50,000 50,000

Other current liabilities 85,004

Total current liabilities $ 4,573,130 $ 4,761,502

COMMITMENTS AND CONTINGENCIES

Total liabilities $ 4,573,130 $ 4,761,502

STOCKHOLDERS' DEFICIT

Common stock - $0.001 par value; 400,000,000 shares authorized, 69,011,494 and 63,885,930 shares issued and outstanding as of September 30, 2015, and December 31, 2014, respectively 69,012 63,886

Additional paid-in-capital $ 49,603,549 46,908,249

Deferred compensation (294,264)

Accumulated deficit $ (52,336,163) (49,892,282)

Total stockholders' deficit (2,663,602) (3,214,411)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 1,909,528 $ 1,547,091

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

+ Details

Name: us-gaap_DeferredCompensationEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814

Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2015

Jun. 30, 2015

Apr. 02, 2015

Sep. 16, 2014

Jun. 14, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Equity instruments issued arrears of compensation $ 37,500

Amounts payable to directors $ 293,546 $ 293,546 $ 293,546 $ 293,546

Options, issued during period 5,365,729 27,756,821

Stock based compensation expense $ 564,399 $ 10,783,948

Director [Member]

Options, issued during period 147,058 111,112 642,200 134,553

Fair value of stock option $ 50,000 $ 16,667 $ 597,246 $ 108,988

Stock based compensation expense 50,000 $ 185,640 360,931 235,411

Executive Chairman Agreement [Member] | Director [Member]

Consulting fees to director $ 37,500 $ 64,615 139,615 $ 184,615

Paid in stock option $ 130,385

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.23)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_DueToRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=CDXI_ExecutiveChairmanAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Company Background
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Company Background

NOTE 1 – COMPANY BACKGROUND

Cardax Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.

In May of 2006, Hawaii Biotech, Inc., contributed its anti-inflammatory, small molecule line of business into Holdings. Holdings issued (i) 9,447,100 shares of common stock of Holdings, (ii) 14,440,920 shares of Series A preferred stock of Holdings, (iii) 11,113,544 shares of Series B preferred stock of Holdings and (iv) 13,859,324 shares of Series C preferred stock of Holdings to Hawaii Biotech, Inc., in exchange for the assets and liabilities contributed to Holdings. The above shares were then distributed by Hawaii Biotech, Inc. to its shareholders. An additional 704,225 shares of Series C preferred stock were issued as part of the initial capitalization of Holdings. On January 30, 2007, all outstanding shares of Series A, B, and C preferred stock were converted into shares of Series A preferred stock.

Holdings was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. Holdings’ platform has application in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. Holdings’ current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has robust anti-oxidant and anti-inflammatory activity.

In May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (“Pharma”). Pharma was formed to maintain Holdings’ operations going forward, leaving Holdings as an investment holding company.

On November 29, 2013, Holdings entered into a definitive merger agreement (“Merger Agreement”) with Koffee Korner Inc., a Delaware corporation (“Koffee Korner”) (OTCQB:KOFF), and its wholly owned subsidiary (“Koffee Sub”), pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings. At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of common stock of Koffee Korner.

On February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the “Company”) (OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for the issuance and sale of an aggregate 6,276,960 of shares of the Company’s common stock, together with five year warrants to purchase an aggregate of 6,276,960 shares of the Company’s common stock at $0.625 per share, (ii) the notes issued on January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into 3,353,437 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled and substituted with stock options to purchase 6,889,555 shares of the Company’s common stock at $0.155 per share, (v) additional stock options to purchase 20,867,266 shares of the Company’s common stock at $0.625 per share were issued, and (vi) the notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off agreement on the closing date.

The share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information of Holdings and Pharma. Under U.S. GAAP guidance ASC 805-40, Business Combinations – Reverse Acquisitions, the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Company’s assets and liabilities.

On August 28, 2014, the Company entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with its principal stockholder, Holdings, pursuant to which Holdings merged with and into the Company (the “Holdings Merger”). On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There will not be any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings will receive an aggregate number of shares and warrants to purchase shares of the Company’s common stock equal to the aggregate number of shares of the Company’s common stock that are held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings will be cancelled upon the closing of the Holdings Merger. Accordingly, there will not be not any change to the Company’s fully diluted capitalization due to the Holdings Merger. As of September 30, 2015, the Holdings Merger had not been completed.

Going concern matters

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss of $743,461 and $2,443,881 for the three and nine-months ended September 30, 2015, respectively, and a net loss of $1,880,394 and $15,186,393 for the three and nine-months ended September 30, 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $52,336,163 as of September 30, 2015, and has had negative cash flows from operating activities since inception. The Company anticipates further losses in the development of its business. As a result of these and other factors, the Company’s independent registered public accounting firm has determined there is substantial doubt about the Company’s ability to continue as a going concern.

In addition to the $1,460,000 raised during the first nine-months of 2015, the Company plans to raise additional capital to carry out its business plan. The Company’s ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Patents $ 393,370 $ 393,370

Less accumulated amortization (214,637) (200,272)

Patents, Total 178,733 193,098

Patents pending 248,272 226,420

Total intangible assets, net $ 427,005 $ 419,518

X

- Definition
Patents.
+ References
No definition available.
+ Details

Name: CDXI_Patents

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014.

Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.

The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015.

The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

Reclassifications

The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Recent Accounting Pronouncements

Recent accounting pronouncements

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company’s consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note Payable (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Apr. 28, 2015

Jan. 28, 2015

Short term loan $ 30,000

Loan interest rate percentage 3.00% 3.00%

Debt maturity date Apr. 28, 2015

Interest expense on notes payable $ 69 $ 222

Conversion of securities, price per unit $ 0.30

Two Class D Warrant [Member]

Restricted common stock units description Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020.

Number of restricted common stock units 100,739

Warrants to purchase restricted common stock, price per share $ 0.10

Warrant expiration date Mar. 31, 2020

One Class E Warrant [Member]

Warrants to purchase restricted common stock, price per share $ 0.1667

Warrant expiration date Mar. 31, 2020

X

- Definition
Number of restricted common stock units.
+ References
No definition available.
+ Details

Name: CDXI_NumberOfRestrictedCommonStockUnits

Namespace Prefix: CDXI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Restricted Common Stock Units Description.
+ References
No definition available.
+ Details

Name: CDXI_RestrictedCommonStockUnitsDescription

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrant expiration date.
+ References
No definition available.
+ Details

Name: CDXI_WarrantExpirationDate

Namespace Prefix: CDXI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants purchase restricted common stock price per shares.
+ References
No definition available.
+ Details

Name: CDXI_WarrantsPurchaseRestrictedCommonStockPricePerShares

Namespace Prefix: CDXI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_TwoClassDWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=CDXI_OneClassEWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment, Net (Tables)
9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net, consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Information technology equipment $ 31,892 $ 31,892

Furniture and office equipment 10,161 10,161

42,053 42,053

Less accumulated depreciation (26,450 ) (21,442 )

Total property and equipment, net $ 15,603 $ 20,611

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014.

Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.

The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015.

The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Recent accounting pronouncements

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company’s consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Common stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 400,000,000 400,000,000

Common Stock, shares issued 69,011,494 63,885,930

Common Stock, shares outstanding 69,011,494 63,885,930

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Basic and Diluted Net Income (Loss) Per Share
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Basic and Diluted Net Income (Loss) Per Share

NOTE 12 – BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

The following tables set forth the computation of the Company’s basic and diluted net income (loss) per share for the three-months ended:

Three-months ended September 30, 2015

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (743,461 ) 67,955,379 $ (0.01 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (743,461 ) 67,955,379 $ (0.01 )

Three-months ended September 30, 2014

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (1,880,394 ) 63,610,949 $ (0.03 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (1,880,394 ) 63,610,949 $ (0.03 )

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for the nine-months ended:

Nine-months ended September 30, 2015

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (2,443,881 ) 66,000,101 $ (0.04 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (2,443,881 ) 66,000,101 $ (0.04 )

Nine-months ended September 30, 2014

Net Loss (Numerator) Shares (Denominator) Per share amount

Basic loss per share $ (15,186,393 ) 59,019,453 $ (0.26 )

Effect of dilutive securities—Common stock options and warrants - - -

Diluted loss per share $ (15,186,393 ) 59,019,453 $ (0.26 )

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the years presented because including them would have been antidilutive for the years ended:

September 30, 2015 September 30, 2014

Common stock options 33,118,044 23,762,946

Common stock warrants 41,871,124 28,405,782

Total common stock equivalents 74,989,168 52,168,728

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 09, 2015

Document And Entity Information

Entity Registrant Name CARDAX, INC.

Entity Central Index Key 0001544238

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 69,623,715

Trading Symbol CDXI

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2015

X

- References
No definition available.
+ Details

Name: CDXI_DocumentAndEntityInformationAbstract

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 46 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Concentration
9 Months Ended

Sep. 30, 2015

Risks and Uncertainties [Abstract]

Concentration

NOTE 13 – CONCENTRATION

The Company purchased all of its inventory from one vendor in Germany. Although, there were no purchases from this vendor during the three and nine-months ended September 30, 2015 and 2014, outstanding payables to this vendor were $86,255 as of September 30, 2015, and December 31, 2014.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6442-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement [Abstract]

REVENUES

OPERATING EXPENSES:

Stock based compensation $ 256,959 $ 786,747 $ 1,534,468 $ 10,783,948

Selling, general, and administrative expenses 266,018 724,454 681,059 3,327,010

Research and development 216,228 357,519 352,328 921,106

Depreciation and amortization 4,373 9,435 19,373 28,196

Total operating expenses 743,578 1,878,155 2,587,228 15,060,260

Loss from operations (743,578) $ (1,878,155) (2,587,228) (15,060,260)

OTHER INCOME (EXPENSES):

Interest expense $ (477) $ (1,619) (117,042)

Other expenses $ (3,069) (14,585)

Interest income $ 594 $ 830 $ 1,762 $ 3,068

Other income 48,204

Gain on sale of assets 95,000 $ 2,426

Total other income (expenses) $ 117 $ (2,239) 143,347 (126,133)

Loss before provision for income taxes $ (743,461) $ (1,880,394) $ (2,443,881) $ (15,186,393)

PROVISION FOR INCOME TAXES

NET LOSS $ (743,461) $ (1,880,394) $ (2,443,881) $ (15,186,393)

NET LOSS PER SHARE

Basic $ (0.01) $ (0.03) $ (0.04) $ (0.26)

Diluted $ (0.01) $ (0.03) $ (0.04) $ (0.26)

SHARES USED IN CALCULATION OF NET INCOME PER SHARE

Basic 67,955,379 63,610,949 66,000,101 59,019,453

Diluted 67,955,379 63,610,949 66,000,101 59,019,453

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents a sum total of expenses not separately reflected on the income statement for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.7)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4,6)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Issuance
9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Stock Issuance

NOTE 7 – STOCK ISSUANCE

During the nine-months ended September 30, 2015, the Company sold securities in a self-directed offering in the aggregate amount of $1,460,222 at $0.30 per unit, which included the conversion of the $30,000 note payable and $222 in accrued interest. Each unit consisted of one share of restricted common stock (4,867,394 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. Warrants issued to date in this offering totaled 13,385,342. “Most favored nation” rights are available to the purchasers of such units as described in the Subscription Agreement.

X

- Definition
Stock Issuance [TextBlock].
+ References
No definition available.
+ Details

Name: CDXI_StockIssuanceTextBlock

Namespace Prefix: CDXI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note Payable
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Note Payable

NOTE 6 – NOTE PAYABLE

On January 28, 2015, the Company received a short-term loan of $30,000. The loan accrued interest at the rate of 3% per annum. Principal and interest were due on April 28, 2015. Interest accrued and expensed on this short-term loan was $69 and $222 for the three and nine-months ended September 30, 2015, respectively.

This note and accrued interest were converted on April 28, 2015 into securities of the Company at $0.30 per unit. Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020. “Most favored nation” rights are available to the purchaser of such units as described in the Subscription Agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventory (Tables)
9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Components of Inventory

Inventory consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Processed materials $ 958,575 $ 958,575

Total inventories $ 958,575 $ 958,575

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Leases
9 Months Ended

Sep. 30, 2015

Leases [Abstract]

Leases

NOTE 14 – LEASES

Hawaii Research Center

The Company entered into a lease for laboratory and office space on May 9, 2006. This lease amended on September 7, 2011, and October 30, 2012. This lease expired on October 31, 2014, after which the terms converted to month-to-month. The Company vacated the space in February 2015. Total rent expense under this agreement as amended was $0 and $12,112, for the three and nine-months ended September 30, 2015, respectively. Total rent expense under this agreement as amended was $14,709 and $47,331, for the three and nine-months ended September 30, 2014, respectively.

Manoa Innovation Center

The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $7,931 and $23,759, for the three and nine-months ended September 30 2015, respectively. Total rent expense under this agreement as amended was $7,825 and $23,255, for the three and nine-months ended September 30, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 47

-URI http://asc.fasb.org/extlink&oid=6584217&loc=d3e38847-112698

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496975&loc=d3e45424-112738

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6453916&loc=d3e41460-112716

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496975&loc=d3e45377-112738

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6452767&loc=d3e37045-112695

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453916&loc=d3e41457-112716

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496975&loc=d3e45437-112738

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718

+ Details

Name: us-gaap_LeasesOfLessorDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Related Party Transactions
9 Months Ended

Sep. 30, 2015

Related Party Transactions [Abstract]

Related Party Transactions

NOTE 10 – RELATED PARTY TRANSACTIONS

Executive chairman agreement

As part of an executive chairman agreement, a director provided services to the Company. The Company incurred $37,500 and $139,615 in fees to this director for the three and nine-months ended September 30, 2015, of which $130,385 was paid in stock options. The Company incurred $64,615 and $184,615, in consulting fees to this director for the three and nine-months ended September 30, 2014, respectively. This agreement was amended on April 1, 2015. Under the terms of this amendment, this director receives $37,500 in equity instruments issued quarterly in arrears as compensation.

Amounts payable to this director under previous agreements was $293,546 as of September 30, 2015 and December 31, 2014.

Director stock grants

On September 16, 2014, the Company granted its independent directors an aggregate of 642,200 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $597,246. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.

On July 14, 2014, the Company granted its independent directors an aggregate of 134,553 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $108,988. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on June 1, 2014 and were fully vested at the end of one full year.

On June 30, 2015, the Company granted its independent directors an aggregate of 111,112 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $16,667. These shares were fully vested upon issuance.

On September 30, 2015, the Company granted its independent directors an aggregate of 147,058 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $50,000. These shares were fully vested upon issuance.

The Company recognizes the expense related to these grants ratably over the requisite service period. Total stock compensation expense recognized as a result of these grants was $50,000 and $360,931 for the three and nine-months ended September 30, 2015, respectively.

Total stock compensation expense recognized as a result of these grants was $185,640 and $235,411 for the three and nine-months ended September 30, 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Option Plans
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plans

NOTE 8 – STOCK OPTION PLANS

On May 15, 2006, the Company adopted the 2006 Stock Incentive Plan. Under this plan, the Company may issue shares of restricted stock, incentive stock options, or non-statutory stock options to employees, directors, and consultants. The aggregate number of shares which may be issued under this plan was 16,521,704, which was increased by 1,456,786 to 17,978,490 as part of the Series B Offering in 2007. This plan was terminated on February 7, 2014.

On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that may be issued under this plan is 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares.

Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years.

A summary of stock option activity is as follows:

Options Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value

Outstanding January 1, 2014 15,290,486 $ 0.07 3.89 $ 305,810

Exercisable January 1, 2014 15,290,486 $ 0.07 3.89 $ 305,810

Canceled (15,290,486 )

Granted 27,756,821-

Exercised (4,506 )

Forfeited -

Outstanding December 31, 2014 27,752,315 $ 0.51 8.02 $ 1,963,523

Exercisable December 31, 2014 26,156,553 $ 0.50 7.95 $ 1,962,239

Canceled -

Granted 5,365,729

Exercised - -

Forfeited -

Outstanding September 30, 2015 33,118,044 $ 0.47 6.87 $ 3,418,084

Exercisable September 30, 2015 33,118,044 $ 0.47 6.87 $ 3,418,084

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2015, based on a valuation of the Company’s stock for that day.

A summary of the Company’s non-vested options for the nine-months ended September 30, 2015 and year ended December 31, 2014, are presented below:

Non-vested at January 1, 2014 -

Granted 27,756,821

Vested (26,156,553 )

Exercised (4,506 )

Forfeited -

Non-vested at December 31, 2014 1,595,762

Granted 5,365,729

Vested (6,961,491 )

Exercised -

Forfeited -

Non-vested at September 30, 2015 -

Under ASC No. 718, the Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options outstanding as of September 30, 2015 and December 31, 2014, were as follows:

September 30, 2015 December 31, 2014

(Unaudited)

Dividend yield 0.0% 0.0%

Risk-free rate 0.12% - 1.47% 0.12% - 1.47%

Expected volatility 112% - 170% 112% - 170%

Expected term 1.1 - 5.5 years 1.1 - 5.5 years

The expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The risk free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend within the relevant time frame. Due to a lack of historical information needed to estimate the Company’s expected term, it was estimated using the simplified method allowed under ASC No. 718. In calculating the number of options issued in the three-months ended September 30, 2015, the Company used assumptions comparable to December 31, 2014, with a 20-day weighted average stock price.

As part of the requirements of ASC No. 718, the Company is required to estimate potential forfeitures of stock grants and adjust stock based compensation expense accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized in the period of change and will also impact the amount of stock based compensation expenses to be recognized in future periods.

The Company recognized $206,959 and $1,169,537 in stock based compensation expense related to options during the three and nine-months ended September 30, 2015, respectively. Of these amounts, $206,959 and $970,069 were related to 5,365,729 options issued to employees, directors, and consultants in lieu of salaries, wages, and fees accrued for services during the three and nine-months ended September 30, 2015, respectively. The Company recognized $601,107 and $5,318,948, in stock based compensation expense during the three and nine-months ended September 30, 2014, respectively.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants
9 Months Ended

Sep. 30, 2015

Warrants

Warrants

NOTE 9 – WARRANTS

The following is a summary of the Company’s warrant activity:

Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value

Outstanding January 1, 2014 3,395,833 $ 0.45 5.28 $ -

Exercisable January 1, 2014 3,395,833 $ 0.45 5.28 $ -

Canceled (3,395,833 )

Granted 28,435,782

Exercised -

Forfeited -

Outstanding December 31, 2014 28,435,782 $ 0.64 4.07 $ -

Exercisable December 31, 2014 28,435,782 $ 0.64 4.07 $ -

Canceled -

Granted 13,435,342

Exercised -

Forfeited -

Outstanding September 30, 2015 41,871,124 $ 0.47 3.70 $ 4,988,991

Exercisable September 30, 2015 41,871,124 $ 0.47 3.70 $ 4,988,991

Under ASC No. 718, the Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The fair value of warrants issued with debt is recorded as a debt discount and amortized over the life of the debt. The range of fair value assumptions related to warrants outstanding as of September 30, 2015 and December 31, 2014, were as follows:

September 30, 2015 December 31, 2014

(Unaudited)

Dividend yield 0.0% 0.0%

Risk-free rate 0.12% - 0.86% 0.12% - 0.66%

Expected volatility 102% - 159% 112% - 159%

Expected term 1.0 - 2.5 years 1.0 - 2.5 years

The expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The risk free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend within the relevant time frame. The expected warrant term is the life of the warrant.

The Company recognized $0 and $4,000 in stock based compensation expense related to warrants for the three and nine-months ended September 30, 2015, respectively. The Company recognized $0 and $5,229,589, in stock based compensation expense related to warrants during the three and nine-months ended September 30, 2014, respectively.

X

- References
No definition available.
+ Details

Name: CDXI_WarrantsAbstract

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants Disclosure [TextBlock].
+ References
No definition available.
+ Details

Name: CDXI_WarrantsDisclosureTextBlock

Namespace Prefix: CDXI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes
9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 11 – INCOME TAXES

The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed.

The effective tax rate for the periods ended September 30, 2015 and 2014, differs from the statutory rate of 34% as a result of the state taxes (net of Federal benefit) and permanent differences.

The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes, which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. Based on the available objective evidence and the Company’s history of losses, management provides no assurance that the net deferred tax assets will be realized. As of September 30, 2015, and December 31, 2014, the Company has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred tax liabilities.

The Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of September 30, 2015 and December 31, 2014, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods.

The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Intangible Assets, Net (Details Narrative)
3 Months Ended 9 Months Ended

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

Units

Sep. 30, 2014

USD ($)

Patent, amortization period 15 years

Amortization expense | $ $ 2,703 $ 7,652 $ 14,365 $ 22,955

Patents, Units 20

Patents expiration date patents will expire during the years of 2023 to 2028.

United States [Member]

Patents, Units 13

Number of patent application pending 1

China, India, Japan And Hong Kong [Member]

Patents, Units 7

Europe, Canada, and Brazil [Member]

Number of patent application pending 5

X

- Definition
Patent application pending units.
+ References
No definition available.
+ Details

Name: CDXI_PatentApplicationPendingUnits

Namespace Prefix: CDXI_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Patents expiration date.
+ References
No definition available.
+ Details

Name: CDXI_PatentsExpirationDate

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Patents Units
+ References
No definition available.
+ Details

Name: CDXI_PatentsUnits

Namespace Prefix: CDXI_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=CDXI_UnitedStatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=CDXI_ChinaIndiaJapanAndHongKongMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=CDXI_EuropeCanadaAndBrazilMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R51.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Payment for license cost $ 10,000

Percentage of royalties revenue 2.00%

License revenue

License payable $ 20,000 $ 20,000 $ 20,000

Employee settlement $ 50,000 $ 50,000 $ 50,000

Revenues

BASF Agreement And License [Member]

Royalty revenue

Capsugel Agreement [Member]

Royalty revenue

Revenues

X

- Definition
License payable.
+ References
No definition available.
+ Details

Name: CDXI_LicensePayable

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Perecntage of royalties revenue.
+ References
No definition available.
+ Details

Name: CDXI_PerecntageOfRoyaltiesRevenue

Namespace Prefix: CDXI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: CDXI_ArrangementTypeAxis=CDXI_BasfAgreementAndLicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: CDXI_ArrangementTypeAxis=CDXI_CapsugelAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

NOTE 16 – SUBSEQUENT EVENTS

The Company evaluated its September 30, 2015, condensed consolidated financial statements for subsequent events through November 9, 2015, the date the condensed consolidated financial statements were available to be issued and noted the following non-recognized events for disclosure.

Stock issuance

On October 19, 2015, the Company granted a consultant 100,000 shares of restricted common stock in the Company. The total fair value of this stock on the date of grant was $45,000. These shares vested immediately.

On October 26, 2015, the Company issued 25,556 shares of common stock in the Company in connection with the cashless exercise of a stock option for 41,851 shares of common stock at $0.155 per share with 16,295 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

In October and November 2015 (through November 9, 2015), the Company sold securities in a self-directed offering in the aggregate amount of $146,000 at $0.30 per unit. Each unit consisted of 1 share of restricted common stock (486,665 shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020. “Most favored nation” rights are available to the purchasers of such units as described in the Subscription Agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 59 0001493152-15-005299-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-15-005299-xbrl.zip M4$L#!!0````(`!@T;$=MVV3@;(4``.M8!P`1`!P`8V1X:2TR,#$U,#DS,"YX M;6Q55`D``]]X1%;?>$16=7@+``$$)0X```0Y`0``[%UI<^,VMOW^JMY_P'.6 MRE11,ELM$M=H:Q?Z&7=OSOSS>CHOMA^'PXOS\[>VM M[GJOYIOG_QG4+6^]XIZ\R+?PN*S+JS]NT3?J%5)EQ9#;FHP4^5?TJX:N;N[J M[UUHRY49PG/T-CRF*.R/9Z5]H2L7NK9FG:$91L&X3OF])F#7B!J'I6O@L?G M'B6YCS;B1TGZJ(UGG@NP5>]YK^=P`YY7])JLU#0E?=S'W84B-\[A;OH@"3Q= M59K+VA<_D;X0!;6>:0['+W3-X(4]G-R@PAC3PL`=WW-PD/L.NY/SDNNY;C3( ME\L._?-P-,3G\%`-GL(^L<;OK7YI^@60@?Z<+QV[DR,='3KC%RS3M\WW8=_T M!R:,Q<%Y.I[.TO%!.741,.8^XBYB=+SHLTZR['=22U^HOP?V67*;5OWQ+"!4 M?9RA\[2H>+Q8GAOB]Q`1^^/9C>\-4@EE)?3BZW9M4O_X->R&)!R-?QW_3FQZ MITM`7S$I\12$*=4N;_]U]@,,7<70=55K?7\^^_*DNO/<^I+:A@"_9\]+`>/( M#ZG*^6'2G+2DR;VYUT!'9EZB[9Y4;T^]DOX^)4#Z8P+I8IP[P7VWM-C&6BK, M`2F]LU>0])JBTN%26I"2!A0)DMPJ.4AI`PH%J5UVD-K%@Y0.Z?\D-O@_-Y'O MDC#R<<>U;\@[O0I^P8,7[!\-QXF6Q[T!S@`POF6#,.]#AU@DC&5%-H$G8^\\ M:=G%@^\!4N'HP0$0H777?T5D2,O[-'H&@]EY)\'9#^G#BV'X_CRWQJRTY_GB MED+]SO+A&5M]UW.\WFB,UPG282$*%6=#8LN$=BB!=CB`WS''!Z$=>-4.A_!" M&S79R++A"0K#P>4#1*?8][']%'K6G]7@`YV+PO3]2\<,H/6L:=,L6-+ZX_$@ M[:-B>)#,'^B9^8-9#?$+<\RHB?U. M>ZQ##_.]VO3(MD_08\W91Z$]#DX/_B9-UZ&'T!ZG3H]IXQ+3PXJ"T!O\Y](; M##R7N6&_F[X/;D]%8M6Q,TK#C7!$UXD]%_X:Q.RA*TP7"QM?1B-T'"TC:,0K MC4JBC:9=W02_&*=J>C@K&)4^-H7$:B)5QL?BU@7?@K95\KSXI"TWOA^WM%T6 M&@AM>^K:EELG80O:"FU[,MJ6/]K.9`8D85&<8%P-2CYB!^"R'P#JT3.P+C"M M$!X(/HVR=S)A4;;Q54T!F/B&:DUNI!,L<-TL64;5K#-#F[/Q#`1M]P%\<#7% M&:ZUDN-,F[,QSK3=A:JQ1Z,\).5_>@EP']%U&B_'C_'8Q\0 M9L?S`1;%RYCX78J9VSC!(<;Y)!-2EGO1'"6E9.F4]MI&=)K-93EX<,;`NQ]2 MU[`:)*+9;?1;NQG.S#93Q$-Y-E*+V5@RI9ZQ@EKQJ6%K:.=.I;7SJG3!W-8+ MS;P=E3Z=-)5R6R^HM&[2B##R1S3RO$87>;-?Z03H\YOWW/>BP'3M&R_R0XSC M/`GJBD,?F!1:BGT56<0F07,`F`0C\P@>;=D7@>+& MW/M@K5Z)-:..IIIZ;*:49[4[445?7!)2LP]U5BTW[4?L]7QSV">6Z61TSWR+ M19"Z:5YCG[CFK6L3\V=S:+H=U_[)/U\V5D519_,JBA&3H#S1-Y9;'/K6K0UK_A4`ILE M#3_^U(JB;S&UHAC%S]+MPJ=JYFH6R+)-Q.`Y8?,D.%VE1$Z..'G%ZP MD\M4NFW9F5E,BG&9_;QE$P'7[]B*Z`B][)N$>KZ=GH_Q9!>;,4>NB(^ML"I) MOW0?G_MNAU*@QUJ;T6.K(-FO!GLFH0.BT+F(5V)':2R2WIZ&74Q+;/@9N*"W MH'?9ER&7:._/V`SP$PX!8];+,^1.GOK)?#,)><0!-GVK?PGW<45XSMJ?H?ED M>S9&]>7P[-D3W?0SDL6](K3\AEI>#`,Q#(0U6',8_&*ZGGGKTF-`:,^(<<#' M.%C2+<(>Y"]&*B!8F]//E/8UF3'=J/GM9W-;?=3E2=8K!4]G*/)$!:[!@LR$ M+4NDO:K87DX%D62/LV[I!'$>_$=6;XQ+FZJW*9(79.>W)/F]BQG*U]6:U2T) MQ_/1%Q1?N`RA-,;NJ_GBL@:9E15D[`ILBH;4-&K4C?:L$!GJ>DN7A+[#S$_IQ+K-G278(W0-?G^;3GWTIW>?+CPK_?9F%=;Y04I:4#1GG-SQFJ5 M#+!9/=_D5<\W:Y7:"7MSG`^A&9,5LI)A>ZC$P8EFU,NN&?4C:,9Q+L9@Z'@C M7)5]QC;.T9YI_[$]>SXU_K)<'L$?GOA3ALA0;%3`SQH:)F!H(F!(`9"P0-!VV8@:(<9"(H8"&(@''`@;+.;3>$#(3X* M,1X(\76I=PU*F[,1SFF[C[;0*G)CQ7+KABMH@C)B'6VG%7I%;1J&HK;TLI-G M$Q>!SX43/D/%]3.#*)4:&CPEJ'1L*O%IR)9,OUT"O)$35N>.<2M'FIG$D=$EA$?9&EODSAR5*.5OYV$N M>MS:JR4K[TOHHS5UXWA[=YT>?3A>L5;DFI)^64>O5YU,F-Y]Q$'H$PN\A*?0 ML_ZLACWCZF1"=FS#?9?!.RU%+O9'UH^,1YOJ1T:XX@FN&A."JXTU"PP*C2AT(2KR#R]I6N6E<6=!;^1 MK4XBG=])V.]CQQ812V)>?WFZFJ/A`)M!Y.,?2.#IJM*\ M@&?2PM);TU70TA:4_]0W?1PLK"(!@3VT=1T@W\.">MBD7PZV]-V[:(#9V9?S MU-L`@UD9\TK-5'J%76]`W%75KL9EMMZ\@M/[4RBL`>@#]BV@N-G#*SIN")?; M=QM<+&8&&[WLD?4KL#&YN&9#\Q'W"`2@H/_OS`%&R1AXQ-UEJRB@,CJ/5YT_ M)'1[=UG__GQ1<=GJKCPK2F=XUJX&!O.O[VN7GYW86UA: MMKH.W+7I$S>.V5N[FJ[I!#BN8:J`;,F7D>_3GTE@FEOVI9:^HG/9[=T-6-JZ3*?+-JAR3U*FIT4?7LJXCDX4]CV?_(WM]3!<()DN)__D2C=; MU8Y2S6-V&*EN@R#:$:=&6U84O:TO$2BN90=AUH:GH;5:1EM;ALZ:PMQ'(?7/ M;>+VBH8G4]6N8NT3J"5B+5KVO@+%YWC4"CZ#8)\<*&MM1?JM$WX8HB`<.1`^ M#$R_1]P+)`_#LV][X0=Z\WS(KKY2M.2/[`M=J.4"*?`\>@8O/$!W^`T]>@/3 ME>(?)/0$UJ7[`8V+_H"H7#73(3WXZW\A#B+=$:OM[O[Y&LI"WYJ#X8>O%`,> M?;S^W'F^OD(/G(YN::[JB.GB=_0<2U MJ(MBHZ^UIF3(,E0'UXK6EAJ*`7=1%ZW1-OTUB=6GU8C2UK+0&\F;2ZQ:7T!U3?(8]%O ML$C6AL[$@SJ9%%\K+?:#1`NPXH0:J@\7RHXVEEN7$&C`(90`W>`P$*',"9.I M&+09YB`NP'-19^@3!REQL^OH"_R>5(S]04!A8'*9J21?$?`%^\Z(B0*/F@"5Z4/Y`4`R&&+0R133NAAJ,T-M MX$44QZ$Y,E\(&:<@=L]&O`"DQNZ*JF@>>)Y'?J+/UXFIUH%=&;21:!PYFQ,Z(6F M@[I@L=`K#=B8$*G:2_1\_)J=U,4T6Y*JMY@)04XE>`-0X@91"__!8'I M2#613X(_Z:N@U;N8A.!ILL$&>C/,:D4TT8A,#"H\=BUJ)4"&GR,7)YI:9Z^S M>KJ1`R\F)9DADQ0@H[5Y;GP;C:!$,8[G^?AS!-!1$LY1$24TC.W4VE14-%TR M#&U/5$RM+Q-B%145N26U6ZT"J(@F-(P'AZ!B$50$A";NYQZHJ"B2HJA'H6)# M:C2:>4R<8D@TA"*H8VBZ%A:<6&8NACK^>2OVD$297M.XV@XC[QX\FN)*X&N&/_%/EF"!'$"'FO2:#GTW`M(-!9 M22R.X@5/Z";6UW&G9J.SM)Y)]38-*DQ*)`AJ8UV!$SF2:C/]'T?O6D.6VIJR M7:!KS`2Z@B,S'%G1RO:#TNG@T&/-FM(&="-W=KBI53T&U=;RK9A8SUZM](ZDS^ M3W#]CGV+!#,K#$NFI.=;\!Z0"YSQ\EZ['/=*;G>"L2YZ[G0W/WJYC&;60SH"0(DRG&6"-U M/$(:/4#8`X\!QB3_?W"AF@%MI%FUII]O*\ MK$:0LL8#\!#8G5Z/3`WA7W@#F"7?B$CQ_ M;-BI/`-VI%[=@J=@@F!4]WPO7E]?7.SC,*)$3.H#=NDX;M0 MY<'W+!Q07W4`D85/P'';D#*IZ?UF'QV3*6RUHBP`CJ^W:[RJKB5PME-]*G8A M;6@;+-.9;'RS8ODS^+N#%TT0DB!#$5%\Q?1TR>^7Y4[T=T-:]=G://SME$QLS\QMR\R^)IIU,_8ZKO@+O1&XW?7$%I36FWUX+U?,JAGI3X"U!W+B@816_*Z MPD,?RF7+`5O?"0(< M!AGXLS!OS6%%;VC-7`'7K+D8V=4MD$WG-I.IBO\$MZ./TRX,2T^J3&6#[,I/BDLT2Z-#\(!*.JKB2WD%!-(!71G0!/?L]4OS55=)R M1-BW-?'">B`6U,6">NF61 MN\/'`Q,\G^2#>A\4?@3:FGZU2?.V1^P;(M%'!^VCSCC-GD"/$#<@5I(DSWT" MRFX+^WKK@`O[V;TD?C;=B+I`VR7Z\+\R/)LP4=QB@V)(:EN6]%:C4AJ MX-PX\P`1!RJ"6WO+0UX M**`AH\2C@Y-U:*>'Y,]?*JL0';!1VU*3:,AM52E M5D*,*C#@^"U!0,,O--7SR,<;BY10#1W()=>#D'++\E"&CXA:9JWOA- MO/?I$93\UM]Y[[6.PQ@*X*M'?T5J-S3)4+4".ZEJL5,V?TN8 MU8.;U8:D&`UZQHC0*_SJ%3"K1>;!\%O"8>!MUMO"J^28_M2LJI*J%9FN5[UX M5>2"B?E$'F>&^"U!0,,O-%4+>T0"UW)\#$EK&%)3K5"*?IF&&[\E"&CXA:9Z M3K1(WQ)>M,"65VQ+UK`*0%,U-UQD;@D]5MG!RF$`AI^H:F>$Y_-W-KY.$6Q MQKPI_)HF*4I+DO4R;LAR,HMLUBM1150N> MLJE;PJX*NRH4B["KPJX*^G-@5XLX=G#;\T&6G#A"W^U[#AB4@)X&%8[NO!#_ M;OHT.2"X]Q]I\X.*'33RW,?)^2$T'J?GB:0GCS!1O"X*X0D*L>F.D@[7&Q\" M]!;C@M*S2,3I(^+TD=Q2>=[3/QW<.RAK@?LVN+/2Q/$CO':'.'Z$NSX2QX^( MXT=*>SZ"I+4-J:5M^ED;_QB>ZB$)@RZFKKA/JBV@-KT^0< M<>[(W.*'.'>D6*O,`T(;=XNLH@=CCEJF("FRM!4+=H1GZNOV$>K)>F:(35;%=J?KTSCC=\2!#3\ M0E,]?UQ\KRZ^1>1RJ/%;@H"&7VBJYD:+S\V%BJ_L8.6W!`$-O]!4SP<7!X4< M=4?S"L[$[(('GZMLET67\5Q3/\2+#)S$S.)`T*$.17Z1)A3 M84X%_E.N#KS5H[\NM5LMJ=U6 M"NRDJ@5/XF`/85>%8A%V5=A507_.[&HA!WML=@S'XO,\KDV?;F$>/&`_/2R$ M6!W7OB).%&)[^EB0*I[FP3HG0`$.F2!=SP_[[#@/RQL,H]"DIZ2@Q2=\O%"\ M$`3TR(X10RX.$7'A;8R^<[P@^`<:@B<24'"A6I\5%/9]C&L#:&<_0-BUL2U. M!CG\R2#[M2O[W%I?D?G;6_]YCK.[.]I'V&>_G(3@\*R%.]!SGT&_H>_NH@'V MS=#S-]VM3YQWL6,?,),-/7"%76]`7-$'1^B#A[%U-P?>_[-WK<]MXTC^7U'E M:K;V@^PAP/?,;JH4R\YZ+XEUMC-S^31%BY#-6XG4\.%$\]BZI^=B"^V3DJ7`JG,D$Y;52E M$8:=!I2;M,(ZD],NJ(#TP.O M9<@_:,VWZ>TN,\QLOFY/U[[.811X.83VAM!>3XZP:4)[K(E=0VCO=$,:0VBO M^S$80GO=C\$0VAM">V<9-@!C31/&HLZZJ0_!O=X&]\2Q`H2Q+@W!O;.9I=C+ M9;V"=0CN#<&](3C1XV.]87R&\3FS\6G/31F">T,(H*X+TP._90COM>;=]':? M&>8V7\>G:V_G-,)[';*4JKH,&8IBC1[RO5$[59Y8A'SB6)'&L::=2U-4+G>AW8%89"X(P M!@W4Z74-XIN=I<*E<"J9$YRVJB$P.P26AL#?,#[#^)S0^+3GI@R!V2%X4]>% MZ8'?,@1F6_-N>KO/#'.;K^/3M;=S&H'9(;HW1/>&LLLW'M48HGO=C\$0W>M^ M#(;HWA#=.\NX`9#'0%/&HGXJ95V]4(I>A_=D?2P`?2S)_(>T:Q#?[#05+J%R M(A.4TUXUA/>&\,00/AK&9QB?$QJ?]OR4(;PWA`!J^S`]<%R&^%YK[DUO-YIA M:/OR$4CM$5OM,`X9%6,)@M" MT\;%K@YT@PP7_QS3(Z?#YN@)S8W`0R$?EDW>'UX,^H)6H^].L#1'+P9V3I\0 MLK'CN1_2@_<-%:4=Q9R'>$O-];;SDM)A!$XP[%\SYB7\E+.>-0!OUADB]P/> MCH_K(6SM@%P4QP!H8T'B7P33WYA'KT<$BF-5@6-=XA^W:'*Y*`T[=+)`#(&% M%C16`F--!6,`.>63=G^P<*8#!;6Q),AC58-G<93=UHKRZ/C8M18&Z$X9 M>1T/Q@>05]/_O?WE@2PU=Y&+<^MY`3)O[8?@"2]T?A"]Y\JPR1D/,K=/99TN M2A<"O!"4\'0Q^JR^&P6V%3T4Y@AE@IOE(R3DS3(H\8R^.W-BF-`F-IJ#DX M'IOHH2G66OL9/V4Y9D0O^:+K'\B=6QXR`3&CYX==T-]V/Z`N<+?&]VCM8,-%/LY;E3XCY]S7GU,.?([0CXC MEN_VQ^(I1B;>W2(D#C`C.L5MKHB0&_P MSS)7BDQH_D>,Z.:^Z3!F@9X,AWS7&HPWC"#(V^^>C,`KS<&Q[Z M$I!]EHS:SC3C9BD#&>J"I"G'C@L%%TP3X\Y_P7;P,=^"O)O;3PA0B]^8ML!]N+Q-^?6&G\P-N2G&<<4@G:TP698_W)JPM"0 MXL6>3L/>P82NPM^M34;2<3>DL4/F:0[%T8"L86]QST?RG:ST)`JY>=+;RA?UG8(5.?(V1![(B)'S% M(A)UV:%1#"@H`%1CA]B5ED]^Z>$GL&3Z7G]8VVYX:'7%/^`^A!K'7U[]-U: M+D>(O`.-S-"0263A.XL1%*`X\AWRMW:Y]7XS*6<:=5ST'1MVBJ@D)UVY)O%3 MZ@L18F\2')KJF=2CLX%=3/K&L-S?C&5`AC!81:&S>[0T2-6+$Y]_).)&Z5*8 M\RE4P7(^(Z),"PS(Z)4@,C+VD(0\N1$N1-7BE,%D60M^GKS@.+D^[%XP1?/M M3T&4\#V.ZEL,;ULDXPVE)$,IR>D7,@RE)"V/P-'"TO]*DG.O3I+PR>'FIL35-26U`P(H98!61]F3>3\;"L3E`] MVU*N2P'K%KR4HUC`"0(U0%VE;H^]Y1?7J,=1(-KP2"H_^>MZ7_([\:_PBS;X MVR&ERL%C(`(ID9]!18P;AS31)U%6=*4K!H]3>S,R&2"4@-`=A.6#K(JBF"P0 MJ<3A/7I%=I"=E4Y1)%*6"%'T>HI*D#JOS^`^3N^Y,M9>\(R6DV?LPJZR,@*; M$*Y%ZA2E+C6%*ZMGXU"YIBD'=6YO= M&VBR!;M%G\.R4&OHZRX:DQ6IH?YKV^K@QK(-FZ017#E>F,TWM;PYN0FJJBIBO%P5V$S MU-Z"PCQVI524Y,Y12I0+E^Q@RJ*<=#(XL'E+O'GD^=LO'.9R5\03>T-%7!X3 MY<4H.Z18(+EP&N4S&SK\AU^X0;N"S4=G:KEHCG=]WEM,3T2=SWWJM`]OA9%`%)=F`@YX^7\Z9`9=TH&FRQ(-S_)4Y0J9'6,DP M6I-E*3Q`!^F2,`;JG!FOYVO5X#MGJ$AIE->$D@,M68%%3YTOWQ4L*06J//B^ MQ[9K6%KHE73)IE4T53A`D#ZJSI_0O%ABGJJ"JM1F MBA3YDBYTI8TEF%=`J0"R3*I,2EN;L"7.*)1G0VF]DZ*SL1%M`>&:I#?=;$H1)??:3%9Y9E' MIAX[83]`ZG8(73/+J3]%6:].N8(@A8TDMY=`(9.T>,1Z%![7'==1YK?KB0^7 M'[\[CR].X!FV>>,$KH]0M/XDWTNL,-H6#Z(@$2*)I:ZJ(`T"$G65`=*^PPR0 M,P!YL'Y$1&V2N&"](A8@@")#H`JTO69.%8C=]/ALV=8J6-%W%Y(55:-M>7+Z MZ!@_F-!1=563=-K^/2SP9#XZ<7`BZ23JTD6W M*>7V8<,>E9!JR,2;OTX`.$Y+R>O[HZHR%(%\;@#0=[3;-84[&0"VG9O#`]T^ M3H$C_CH!@'X**$!64N?HYP%`AU.@<0`2<^SW,&L2F9-7Y!K/*&YK'MJV'!P6 M26UD92CBND=@9:8WYH.5:H;WYL#*3+7,!TLX?]1F>$9@*MJJRS#D.^Q,MZ[W`*N/RJ@$K>JQV$9)M5>M1A*08P3<' M85:IX0!A5"!M>?^Y<1&*,RRJ:&%>%+,$0G"X>S4I4_]!S`EV%H,(N)PQG12( M19-YT$0>(`Z:6'\ZI[:503];@+:2U@H*CPCB24%+;0P-6ML"M-6TEDO[0?FELE)%5$\A&Y*U#/#'T_`]_` M9V7*(497RFF/,4EIU/N9_$WY?/Z(T)N';T=+Z&V]MZ(E=4>AO:5-N[_QG:D0L31%(";7Y$#G@0T%0#((XW[ M!,$3ZVF>*.JR)O+(^ZZ`7=2-GQ/!1`9IHS.T*::[`(7;S#LG4'C-J*8Q:7#& M[J]+I^B+5@NMBS86H(0XW8-7);,P!J^Q+.9\:3X2AA!%HZK^&T!;4;H%K<[P M'QZCBA@T43H7T.+:0>ZZUL&L*93EQ%:`&\==(,L/#FLN3G-D2J1I8FPX&0+Y MQ>^IPI@ZQF]A!;'"S\ZC%*4_`-*J0FEQ_UL%D-:H+@90/G$`LZOEZ[JL;8^X&QK&?8D."C^!F`:0UP MV'GN"4ST%M/[F?0-*F$8+(+#.]IT3=/UP_9N'8G6=Y@9+(K& MG>/<_B&-*7\7C'-0[*;9[A(>+@H9S[;KQ0*1^UDPW;FS0H_&#Y))>H\PW;FU MM"))_!MDXNU@^>`;?D"N#DT]S+7GQX5P*29BW!S8:TGBXOLL.I7X"_*CWY/[ M3R>OAK6,KDB[VE\0\N(L\0L]K*'6G,O=1E"21$U+;#&,3#0@0X5+#H&FB+K8 M)R%8+PNY4"514OHV#F7WZ1Z,@Z8)HBYQDV%J+0,RPQ[0/'";O.J/CA"'Z^2I M):I[BS*U1'5O3*8?XI`EZA!48ZO6EHU&Y&AUY6I2D!97KX;'H[45[$".T.#, M.[Q?$DG>]?N_6%V*<+5?RO(8%2@I%6?7ADO.?KSX M5JEF%2QY)-\J6Z7+:S=LE2Z6G:%5O/B5LA4O@A/;M\PC+JY_S)>!B4Q"COC3 M@1_Z/'A"'`@R69$+QJLO9`=^F"KIF@Z4Q%UC7/AK3>@,+8ZOETKL*MO#`H\A M94U(IZR=%BI91^GU43E.QC\M5.CVTP.A98AGAPI/=H(4156*KF/,S8`^O&KI MM.#(6B]JP`%%58&ZI#0-QWQ.?AQ?$[R]N'YBD[/4>?2/HB/E[=3_#=FFXU(< M*&L*3%ZW24&=$\/QX7W[#.\NIO^$#`]Y]_B1[>VRV&EA7&+#5SP@WU^&Y^"3 M9Q>%'[:%A-NG_F5\-RSK'GG(<..YU>-'J3GCB`D M>Z]LC"6QJ>[1*[(#OH%8(6P-54HS!Q=L83P@]Q7_ MHX@Y#I$/)GHU`B`A$%MB6V.JZG5#,!KJC#\+'VX[7? M=RW2<2'A):=NF,_1>B#L`09X>C/@,RJUZ,I_/C=N5H:GC?-]<0+ M$W9!+&(%.7J%PYV-0ARN*^4M`T51^P9$KD5Y..2G/N*Y@O9M3/>5N]/<[!W. MTQ@O0Q"_4;P005J6-"\MM/45K MQ[/\,$ESXGF(CQUU(8-D2TL:LKQ898_2ZYI>C]4I>O*OR,5AKD<,W_`37@[V M.;#1(1IMOZ>2N_`@3"!+2YHGRZP(`P"@#!2U.M>I=9T]"UZGK<'>_ M]+:_]7*NHHSDH:WO2[JCE9AH4A(RXL5;SAG(R7@3,S])(A\4[RGXEU\Q[2K[ M!/G:<<@BMB&3+Z]+-=X^R7>021)T488SD\D/$!ODY^K%LHU;V[2,?QMKP\8. M\[\<^_F_\7^4W*ETS$W6ZZ4U#^V`&0J+*MI"+\5?#AN-,7P=N,X:71FV81H8 MVP^N\9>UI.1<9N%\5R9#C/U;SPN0.0U<_!2V^2W'C.;CWC,('PN+#3ZZCL?' M6:6(CVN*HB3F?S5FCT0VEGB="!_".[=GF2BR-^_1'%FOR+RS'_$*XAES\D,N MAW*2DC9ZF#AH@/WJ`Y4M7.JZQCJR;4U5+S)3KTH#L<4Q3%6%*9LMX]V5&:`Y M--.A!G5&!F8N6AN6N3TQKHF`*JF)W-W,5U>F3W<)N):\0IF*`2Y#CY52T6%" M*PLQYS+8``B*GI2VD.2M[1OVL_6T1-%C7Y`?933@1>VCXYC?K>6RJO`25`5! M3GJ$Y;1X\4>#E`1T&6CU^,MPGUG40Q=T.96!E.D6YQ.A4@B9Q#%!*9',U(JJ MDBFB+"JEB1O5>:`17)%!JBJ8CH=I@!Z=>[3$QHLY,UP2&ZJ)A00T.9E(E$^A M'B]T.E^5E^O5>NEL$-H^_,DRGLA-'?7AD=.APE(Z7!BCP:HN8^%!5RV6F")*LB$%-A8S[$J6:&J@`Y>=9:3CP1IB@K_BY> MJ/34'9J'KZU"EFI]%+7D_9)E9.^1;U@V,N/$1KR#TP7)I(#I-BF>5MAI$%9?^C8I=3AZJ> M<'JIB9>JY(P<3+G^9K8TPLQ?TB9EO3I<^/D5/==C@#G$HR2;)]#3YLTU'F$@ M[T<;*+L4-N/)<0VB<+LWT*1QRRE3BEVN\$`1.V0?'"?:G>X6)5Y179;CP_0L MHID]?KSH0#"5L-!X@$5(S+%<+K@UZ+W;W5X3]TJ_M:.C3_[UMRTS6[S`Y>"/ MYPC4!8G++=WY[/)&)&P.OGM[P3EZA:I#XO6KD,<]D?G,=H1')0V!JBHK&CSL M378N@.C[78)\5G:+VA0OZG,_H\0G!R=%@E#@<:5S'U%2L+;$*.'/4F64@"C) M,H];-WJ'DDR0@7J\V"C)ZCUFE,@?'O6V;S&ZMG=4PEF520%OGW,^V;RN/6V^JL]A2MK*%_/Q._`>$S M!.>%6*(A)"4+U#F>[V?J-P`^`\@1L0KL]A2QMG2L!XC]ACQ,-741!#^_YD+1 M%2!QZ3%9YYST##LENK;+F![P'`O`Q+;_:V*]PGFWK+V0^&C\^(!LM#O-) MZT6Q&2CDA![**$15OANVNN+X^!@;^(M=I?;$-K=EI]7Z4Y=S4M"9HV5.BK*O MC;47/*/E005[JVAPXF&R)J"R0TJE0A03KL\<W+Q#X;/NEGM6&HJR2!?/)9ND@F,.:_-FT)Q0GTACU'CYC8AR7^`37EORW] M7]?_@N(V_\EO[#`5'X9`?S\ MZ-%:X;WS"_H^NG=6ACV.?C`>/2#76OPZVKWZUQ'AZ$86L_XG_^'%R!KL0FI M?;G[__;>M;EQ&TL8_KY5^Q]8>3IO=5?1"JF[DDRJU+8[XYVT[6V[9S;UU%-; M,`E93"A2PXO=RJ]_SSD`2%`76W=1,G=GIF6)!`[._0;@_M+H&/\?&XU_^C]V M"YZ\N[\Y_X=Q=7?WM7]]?KDW:.277N!R'-"JM;Q`X$.`UK9V@AGQ_[4ZS+88 M26*3A)$,N0&1(#\;P3S#V.``JPLCCA/2W`1/PS(-)+5)3Z//Q(*)$8>^:\3Y M(=U>8##XVQ^>AYPP)""\0A[K10$ZVOQ*'P&_>`9`@;T80PNAC>:`%"USC M'8Z,L#D.&!L7/B80X-VHAD7QK/<;68:'&=*0F,L=]4OFL,HC"_0 M80MTT-,F`4$X,3@6);GQ&8]/,AHV4J@.=,(EX^@"B$L%1&'V9`C6^6P0IA%2 M?/&2YX+3;G<(BAPH0P?>R%R96BZJ*OZ:JS$+2G7N^0FTV>J" MYW/LY7R$!>QNOT[Y]_^WV6V;[7;K_^6,7E^&S9<8>PZ3&Z\RN/TB>S=^:"ZY ML)RE%TT_P\Z2]$O1=5N$\>>KYG0[863O.S:3*/`3I8X?4Z9A$?N*13I&"IZ1-L?&_J_J_^!*#+@ZI5;DEM_-X5%<^31Y966#Q*%BO"7TH$EIWQYJ,PW\P= M#GB,X3GS/_&53[.#P1TZTOU\B!L46#!]*.NK_55S$KZ-7MO64JK3(*ZSA!<2 MX3M90K>Y]26\<,3Q+I;0Z+0*>PZV0X1%)U'O8@7MY6C@_H!#__,/,^_K`%Z%#J=Q/7NPP_W?.HD_PS=)U$4H2BRD6C/1R8EH> M:89)]/R<,_)UYA[J)//1R^Z>T/>:+CWO-,#7/#EG\1"H\^2YW/TX^1KC"6R? MO(`%#N"TC]>?;G(MXYQC3C2XEY]^NX"O6F9J-9N]1F\K@.-K_<#%?W!'SQ/S MT:Z('LOI8P>W#FT%?Y+?!HD>A M[\-P\I,,2>3!*O%5D(0;WZ$VO;&P`Z%73_H?6X!I'VO M/):+Q1XHOEO0;A@DXK>'*Z;]$(1@]_QMU=1LO:9V?O/YMG_]N_&Q?_Z/7[_< M?+V^V#=@VRVOK0K24E6V<_"KV3?C%JS=B#D&986'/":(S;);42!1Y;AUG-"V#]9\IP!C)+66]@EM)JUPZX]B.@ MS!7B:X(H1&29AKB0Q/CHA0EWAJ+2AE0R26@C[X%N:J6249!XL+2!ST8CVL)J M&C&`YQNCT`>'T^>&#WH!1WZ0&@*+CJ&AZ%O+/JF2V'OO@]$SF\V.:5N63+S# M^[,E1QA3O6O"6_":W83W++-7U]XCA,"GOC&.^(!'6#&;_SX.8)NVW3#!%9@= MX&,^`,$R,PBEYM][3Q^P:-=M]?G@13(5,#V/5:>'\(GKB![YA$607E@N%Z53,;DJ,>!AT>`-YV5QVF$9RP@AEW^Q/UPC'1CQAC\&7P4#"F,?PZ_,0 M*$Y0A-\\EV&<#%B)4%TAAV0*#OD/X)D8'HP;)5AX^-\+G`%5<^A![KH=\X,BN)Y`?[%$I^'724&BNG/A><^1J\E%=$8"" MQ<0JGEHTAQN%9(XE$\?&8X@,`Z]BJA;D@[,G_"*WQ"BV(%S8F4[<.12_*,@K MWGB1-\"H7H.+@/D_H]XSYW$(I\XQ:1H9:((!66O0@B,.2C8RF$HOZJSP6?R6 MI1X+WKV7#(U_8`,4AW\BT%C2]6&Y7Z]\?]1DVK#B+8)+O*F/^_[F_OR_/_[X MCYM/GSX(W8D>S#-P!&J?:=:>&14;H+3A3.RRP"8GZKB@Q@@3&_B`MT(\C@XP MG0!F!))P,AC[#^XDJO<*G`KA)8$3!58(6!A6#3Q/75C3Z#&-'`;C.4Q]5V!7 MX$H8)AA72%,-T(7#!UP<:(S/"#N"0\]0!=^.1*H@_Q88)AU+Y8[=,JFR>:I/ M3`QC9@),,#UP$"MP*Q4W3?.(/$?KO1H<437.*6JBQ?:["3_N'%V!N3:P4N?9G;V";W!2'$(`\2-%JGH3<"1/[M9:>Q_%20DL'J+7Y9"O MB7V^#0A2&Q3@S@GLB.6PC9*8+F8^5_$O&+5\[+99[[3-7MLB=B\P[M32VC\5 M1<@$U#QR4E>TJ`$*SH2#KZA:V@H]A/JL2I;SR5>:63:8M2$VU/K+*'BGYFN( M-;-$0)B%=D9#L8;,^&B"J!S4P/'&P)U:+W7=M`!$[(,F1Q&=XJFV9QPKXB'P M,$N3$%6=0S[I5.37,!NMAMEL=%Y=ZVR2(E.G$Y^%A):H`5'7;;.LY M$HEJ+3VQ"-WS\`VX%89^%LG&7`1WS6:W9UJ-]D($RT[$99!,N9NVV>F\CF5C M=0P+E*R!Y;E@+3)FA0"5! M+KCT-$"Q)I2_H:5-SU]L$&V;7:!>J]5:2X+M5G&]L%PM_[-P9N`PVB=0;ZM5 M*X6RIO+0\T?"NWO_M)"YK2X]`1]Z2ZL2H:];K4R1O&M9M+O"Q";:L?`Z_(FY MA)(A4,71_CC[(/5]F9#+DG@$@I[(FW&;:!`]52>VO*X+%`0CX\<[T^F2.79BZFUFP=33LP`)P>9S1+V..U`5+T!K5Z`(;L( M"]!A&5-I-D83$0H]FX[&`0&Z"H=^6`$13G5GDI<*BK\!@ MD?&U=EEVL1OLMRV`]<,3T*_PAV".`D-I%[B-9E5@8@LQ#K((YRXQDZ/7V7DPA0E.V. M-.RNMC.2P%%##SSR48Q/F`*_.VOF5NKN\AP-&&FH$6;)-5TQ!0&92C3X>*,* MV';C`2.3B0BN'/T&I4Q%NW*SY-SA\E487\=3]G`^!(+\&OJ++AL!)F/`0LQD M!&FV?30/U9`($+2K#1;1`)VX"_IA/OMA4I=)-LU<7@].7-44E1H4-Q@3,M*(8,E?"R@,CRX]4 MVOQ%;8YSI?CAUU`4`H"!HB!+UR)TZ8X;BDX`BQ2M.+**(O'H8I^9VA(>Q*&/ M!52N>VI4;:3\,O`N*$=BW#%&0I'(\S!9T5%4(9]&I?1RX\!CZ406F@&F'!S2 MT?!C/)`W^\$C>D0ES8'$CA.F45SH3\%J)>@DS`^KG?IS%VS,7ZQ,OJ@%3WFW M(J&(MC#@B>%C3?GSA=()<<8B"Z6QP M6IS3ABDLVK!/L\)[=K<-?S?6F[99C(=%5XBF_*GTG:T?H0!:`,8=[/.0=7P< M(?43>4@"H\!675M")2:\)(7"\;K9:+1-N]U`3WJ!^E0,@1.3RD3+B+:9/(:! M'SZ#^H["D2$+B]ALD'<43X%6,&14=49G##ER@#ML86*Y)&^F-*XL&WIQ!29C MT.*HDQ)TT!HSSBMF;$ZSA]\#V'.#8-:$D#3[0= M$!0NQ[0`7@PC[1Y$#I0VP@6!-+AA^I!@?U":+`PG2)`F:-=0,#T\%XFBF8($ M5\;HM>*[RI8I!T$>_6%9EA!?AF?/@0>1'4P"A(101)=$4;N?.HD$]*1(N=$( M>E)..B=$.?`[)YCZ*C`EO4N,KGOO"XB_>/AA%*:/(&`IGBV,_BF^@9SM:@EI(T^#,`G5LS;AX2L<-*!/+Y!`/5>"_]\-2!5V-PP*;[4!:ZS9D= M<6FIM"L^:RK(:\.4V)&Y"51'X".@$E6YC7$4#F"E>*"&UI*`_G+`$2+1*1,5 MJ*)+2_Z2:L?+D)JOR<=,#)B7)RY5@U0(.7/L2G()IA6MW!36`1IR4.4Q->1) MYPF-6`08(S91^H^TL$S&4BDY4X@IPH3\,)6OR/<+K-YX/G,(`8BG![8%;W;) M].8MMF'!G"?3KEXO'`'U]?/G_I??C9M/QMW5K]=7GZ[.^]?WHI'S_/SFZ_7] MU?6OQNW-;U?G5Y=W94P,ER6:^*BR;V.-U?8231PKZF9"B#1@J>OEITJ]K'E> M"2;F5$,T9T@FT7Q8C>B)1#T+OZ/WJ+83$!1X<`EZN0FY>$#>_HAC[E7O#\HR MRGJ^#A4_57Z\T8)4->5M,8I)?9D%`O\M]:49D8KT+K.263K[4M4=\"00C[99 M3N?L[B[/5X*%6H9([X[!XN:9MSG&`\C.Q)9I,XNR5HJ+=+I%?.!C3Q25RW*[ M8*H3>F0:1W`?QA6J151_.`LX,>^'QV`5C"\#@^E%!:G,:Q!H=.*\VT*B2!4R M%L55LG9H-VNE$*8C$/6^GPS)%\RY!\35]\!=BR47,>&NN%Z,^3N\C$**(1E_ MJ1A68BXZ\LS%M&C"15OIGUS2.1="R1=2YZ"O`B+E<]IC#&PH?(X9L1V$84)G MZNG@"L3Y$R,[E`]KN_,@DPW-TSI+):DUO947J_+'8"!A)3V$+KX33DIZ\M)/%0=FYB,LV5)9@_P-O.BY"DX?.AEP@" M=!&)18(!]PMI8D%Y>GD-,G!_&%$G`I6%;.OL'[)0E.W>LT7?5ZOBVMTF956< MIHRZ:GO1NR=?;9TVY^T#R+-PHH;)71**,)IZ>FHWJ-$'SR#.XS)AH]6V@P?F MB[0!N5)Y%X;N$(*5&6'UGBOFEBA`KZ?BIJ5"FR_53R-S\%&9E3H:VB,EB?]Y9HVW*`@9FV4X"J4=U%U<9A=D)1,U0]LD; MLF-)V"%4P]S-#%(A*8:^1IXNKR1G:4`Q,!@] M6S4&W6>4"5,$$0B3OD7`F6K6DZAMHT:A.#RJ< MP`3-'%B%5SWU]JKA7Z$Y2Y<"7H6@54?9M3'N1,Y]- MJQ0N!QPUM&0`FEE6Z7V[,)%@6)I!9%$D1>3YP125L`'0).\#RF+XA=&X.M@! M!]3.(I==D?+G#[(8DK.<.A,=Q8T:;[,]7BI(8D&`S4\21ADM"?"RF`E5`@AJ MVY3A251\*\^O3:>!*'ZAP8JU7X`HER>!+\5Q'CSAR!*4!#P,%F74=+><@)B' MO[DEC^4*%M-ECJL`ST(W(.$#Q$ MGFG\G?M/'&-0@!54\)D$^-ESD^&/M`_^)^,AC$"+GSF`)C:.^8^&^O1=#A#" M$JF)Z(@^,*AJG0]ADH2C_&D44'K#56_H6'&HN_@G.D'G;$CGD`(D=NO[>3A) MW/V-"LL&+`=_^ZZ>H52B1BP0%NHST"IVK04H)BU7I/EX/QEP"PSOQ_4^ZE(7592S]%G/U`BH_!5";,M>VL@2U[RA-+:B]L>XQ0/Z^11MAD-WO5#1_45 M_,KQ)@VY-2#KFI']"?DQM@HD=<)AW@Q3Z#.MRJO+7M*KNJ,`=8H'")R<#_3= M"&GB^=Y?'+?6=4VKUT/DZR>2:L<.X^YCO,P'ZP-1Z*8.]BG%G+J1Q!:6;*=) M1:V5FB#RK6=Y;3((->%`/$=/?'HGS8O[^XP9#3"W8/)2Z6/.-3MC\"0G>'9# MT@]_GE_G>C?WUA7/[WUZO;SY?7]T*U!3PYHEK` MOEAX3[M:;`A4Y2TG.4RN8?$JC MP*-C1:C_=3#P'+ZVDMI12GV9JN%6Y]@/V]J6:;?M4ZE[5$0J>\]*"1IT=C7" M?GBA63>M5N,(!;9"\(E:[]]H+U3A2+]QQ!V/96?F5,9[-ZSZOMXVFRUK.SC> M!)#]MXV^+3+;9K.Y:FRQ5S*7TX'89*VBB6N\N!94#I:O.GU><)M;9MLZ1E>I MHO2*D-@5T\ MC-I8-"L>N]OI-M2,]:8\86D[1V`?#M7'P`CKMG,]1R%=/X$=?;VZV>EUL+]" M7L2@Z,S=!28YNT:$Q84#4>3='FI_?>$4E`)+S`%V7O=11?*Y-^KD^_+;&FT) M$D7?Z3MU\EO+\(1DO-S<9P]X&@9VC65TE6=]TAGW=#\2GC)!/9CO+%(B[WIT MAUO-N`FX,6831>9WW59VZK:X/53>XAEJT-8EM,9,D^<#1R[67U*75G;DX65T M\(@O[O%,$+(QV#\N3NYP.=WM/M%W8>=+\K3;4:?.0KC[]=&OV[N\O[N]Q!/XXVK)WB*^<&>:>&:&73 MCPJ0O9M5*UO5RG;\C515*]NA*5"ULI6"'ZI6ML,CMFIEV];!`Q#"J3,62]LO MM<_LVP%:G'H-L]%9M=Q4M:Q5]'P+56\VPM,N_ZJJWGLHAS;-=J.S'21O`DE5 M]MXMG2W+K'>JNG?5.+>5:G"G:W8:QU@./AH,@S]A];H[Q/"I.1$RJ#'&XI#C MRISLLD>@V=V>-3E\.\BI4@E;&NM;:FD\HE[W37"FSAN;5^8IATJI>I=>ZC?O MF)95'3WV%DAM]\R6O6<'J>I3*QSN(CTNNDY29&SPNK,D8HC?,\0UP12")2C< MDS'P!@G>0(9]0G'-Z&O9GF+G6=WL6++SS&Z:C79KC68W`F%>P]OB:3MFNU47 MT];K9J^USK15M]NFQV$Y;.R!,4:F(EB<,)9W3L9X*0YVE$L&S&[Q@<%\7T4` M\NK>,,;SY?"Z%P=!2Z9FP5M?(H[7BF+>$6]AU]BB<*V):'_"">@(-.QLTI\5 M-\N(:UG'NF2,\3(>[E;47YKZX7,0@_S(:V\(%(E14[OXR&[,/2*0A+,C;OZA M&W+.AUY`=RVZ'OSS7VR,H.)#?P]AE'^$R"GW!;(1D4$CX(T_+O5@9DT]I+)0 MA]6M>@.[[>#?KHD7"OV!39+4CC>1`XD;GV"]H%GT2V;QIM,GSTTS#B[>GH-< M::LA&!ZN*&ZH$WB05_@L7'D+)00,7#!GA"PXQMXG%BR(NT M(D;]S4;C>W0KZ+ZJ4=@5QEMU7A.\^S":1.LX0PRTAB MT"N8VY9E=AH]\73\`83A.33.\=)1XP*X)XH8 M&32.\P!PXS1R0/7S13,8A=$%P+8`F)Z6)^S2$;S2=HDKHD7C6-T2*AY'%T!< M*B`*LXN[O`=A&B'7+E[P7'#:[8ZT4@HH0PJQD[D/>0'"M^E#_C-F)RV MONJBL;Z^'`&<:&8Q0R M_!Z?``\/&>4JP&8VO-\1MS+4P/USZ9Y)3]R*68QN1FPB/&BI@:;DEP27_&DY MI)#DD.0B%MH$+%H0!F>XYR>EO22%9U``^6CLAQ..F'!!PAUX*A:*!K5FZN,M MF[&\M_(19.T1#3<8ZP`VG61BZ!IU-;[7 M^#2S;[DL"`-&(`BV7LS.[I,7K\78E)F8P]L3_""#%"X`Y#WQ5S%1P9F6W`76%*)I3AFW-XOX;GC!8%7),XM8P11,3X ME5A6Q>TOGP'VB7_#RPAB M/@,N_*_O$]"P2@UN>R[D`1+X@]1SAH>R;$_CKYI#%M=O>XX?$F3;`!@$J?JDBUWG;J M\N_`F]Y(NM,SX>H]RVQVVR>'Q%)M8]PC2:V:M>I>L&,F9JG%JU'K]MX0+4Y; ML!I6R^S:U?[@M9!WF6>@-C3?96CU+KEQ+@.*2J`B2FMO2TR?T@G!&B:T#,AY M,^R_GE4L9UR[+V-XCHWL/G>/D*_W=-;!MDW?)L#L_UB+?9*I#%JQ0DTY1C@X M:DXMZOE5U.!/6H%L@I]ZQ^RTVF:W;I\=(8Y.0.#*.T*%FO*BYO0\JE3U M8I>\:;:LRAL_3H$M[P@5:LJ+FE/SQC^%T8![A_#'W]*1594G7^FQ"C5'@IK3 M\^3U/K%-+]XXZ)E@6YYECPF=NME8^9*9,DCCFZG96;76+F\'+>$^T%OMV8= MX[FJ;X;];;/7;IBM^BX/OSZUV$GOWZK,ZM[-:MNT6VVSU3JA\]I/3Z^`6=UE M'TQY1]@/>CNU7N55EIC]T:S6S7ICE^UZIQ>O5KU@53ZQC)FA\HY0H::\J#FU ML*=JX'H9/RTZT;U3/Z$6_6,2M_*.4*&FO*@Y/2>Z:M^JO.@*MV7%[9$M[`10 M-6Y5>FQDQ76\HY0H::\J#D])U[OW)JYAVW_E9^W5F-N-$S;[II6\Q@/ M9'DS13:KUJQ.&]D=>MNU[@FA]_38OV$V44=U=ZFC3BUXTENW*KM:V=5*L51V MM;*K%?N7P*Y6E[%/WY_,%AXFCM#(VUG$)1GL(7S"*ZF,!X[W!:M;@O$G+W#" M$3[WC:L[;,81C^5-VWBHOX-7P+`1."SR,A;Q=>$B'GFI3\0=;^SANP3#%./NC5GR%P`B@?9@'3AVJSO88+;)']DM$I&$Q;OPY+T MH;NN\@N'Q$VM=`-.=2G["E?&S$\L?]\+FZFV8W=].4/-=WG?,:R'!U(/#A"S3[BGHELW?K M>[P[8KTNOO*?Q-[:V]GG^4%M^T'BEKBQ1!KOGZ3M*M6VZ'BI;6]QVP28Q6=, MG6ANL&+,(S[W[/1T9=7N4WF3Y=*3Q7CE\!O@CT5[VF:KUS([[5V>AW%Z^J_: M=73X74>GIL&J^.-E-Z]M]MJVV>QMZ6"DRM6K`I#*3:L"ARIP>.O.7#%TJ!JP M]MZ`M6=VK7H:].+S5X`M,OIWY\9U6#,Z=M!P9_#@B$!47U.97T9XX-'UB@ M]_WP.:ZJZ+NIHB]K/QSL:(BVH3:W/"HL&[`<_.V[^G?K>1&OP+")7M[8%%84 MV)`"F^8Q-T75&L[>*4KDGJC]_FO`4A>CHU7OT'D#B-TCW/L+<:1);%E[[+6Y M$X\<`I<8^)Q_^1:;NK3;4L[E%>K9GV_+OY*@:P*\Z>=;?OBQ7^>#2).`1,_ M\@3N3MG)KG]OG(&+U^RLRE=E0%.%Z)-/4EY^&W,'2R1$RZI[8 MS)9#7B+$ZC",I1[?"/N\R=XF``AZ`<1&_&:<9%R!(@9E#8&F#7B>,$` MN88*70'GKB@ZJ0+;HEVU!2R8AI?0,M1;KJBM"3@0/=YH['L##WX8\608NKCU M-WS&YZ9K?37C*C`43ZGZ7)!2RAD`5^CUXCC%3<1R<_,0N&'!9E,"(M\]K".8 MF$6ONA$/1E1L`AS,JZ$!L@&-=>O,92`"I&)P###Z[%&R@=@)76TP?GF#<0RL M'"5*?JA8&O%1MF,]P#4@>CI22.A;P192(S%UG;F M(BSR>Z$ID/0\B(4;#ZNWVD3/GN^CS(O!4?F\5@I& MZ(5*0<#%WG3F)&EQ!02%ZX%JBDP#E!#NB,[%+S343X,H'!EQZ@PS"..:<3[$ M0G-,RBT3SGE09Y7M3*@DC+!*AP:1%6]7O,+\.#1`K`%>>EJ="S!X%:M*-Q9G M'*0(CYPTKJ3G59NLI$%#X[NZU39[K5Y&J7>V:;=[9JO1012_1IAY30QS*M=D]T*FC`9+W; MT^H?I1\L2SCAY#:`1G#`K,%''`[-?.JCH11J/(/:EL\/ M.!Y\X3A1*D1$">LF2#`*""`P%M&N;0&QK([`!*P8M%ZO"9IO&<*M"J!N$YO3 M0&:\_?,/:7SVR-CXQPLO=OP0G"=^,SC7`/@B:'0>QDE\-P3%]!%AO&434N3W MP+T??0#]E__\#W32?SZ_^)^K'__%(E+$^9C9?>6"K&6B,TZRP&.??2VB8^_F_M+H&5)%M.#)?_6_?.E?W]_M M&YPC45^B"PFY%LPY4\>-*-N_P.M\%KR#1A+QTS,4DM7JU;OOB%:G+9@K;K;[;`'M)6H;2(_)+\ZCG*W M5KD,&"J!;BBMH2TQ?4HG`VO8SC(@Y\VP?W56P2K8.F>!P_WJ,);%>^BV;/,V M@67577S'1:4RJ,,*->48X>"H.;5HISI@\)7CSKMFL]$R.]U=GEM9WA$.+F_E M':%"37E1'4ZXB'CN_*.<'!1*^$%6K*BYI3$2K4 ME!#ZQU=A[_XXZT=WGN*F9A-\%'.*IM5:Q]CF\2Q!+G-FE7=GEYB]C^" M(G-I8B:]T:HRIY4YK?1)94XK.1RR00%)HWE"`E[KPTW;;/;L4V[?D*UQTWP M4<[BF%5KGE#QLG11;J/6L4X'O:?'_DVSU^V:O9Z]0R*=6O"DMUQ5=K6RJY5B MJ>QJ95[#HI^&3`O$H=XXTTX\D:-6-R. M)6[,X\P9RDOO7'&GGKI+,67<9#8S'Z-`I=[HM+LO)9"`1] M)GEW#UVEYO*'1-SGA9=LT6UL>+<=?NMZL4-72M&%7:,07*B_]$NU?&_`U?5A M^(*\&Q!OJJ*;N?)ELCB[X8V`T6X6RH`*M3P"HTO#9KT>@F3>I7!X71&$*XT MB:M+2:I+2>:.6N:3_C?V\2L*;$B!33>V'.".A5.4R#U1^_W7@*4N5B=7/9+Q M#2!VCW!O*6^S_,TBK>ECW7>9Q;DHW#2\(J.5_KS^>OW[O6EGJV9]OR[^2H&L M"O.GG;#]XL5_GM&EZ'B9^1&F3?;&3G;]>^,,HJ1N>U6^*@.:CA#1[9TB>G\6 M?'^U%WFY]U/HL\3SO61RA(RZ)S:S+>(RN]6KI'F7:+;W@>93,\J9).,MED?( MGOMBKIH%O%6OM=:ZY;,,B*I0755NUKD%G<^:>N.9B3(%J#HG%96*!Q:+T@P6 M.X9>G(01:L+\+8]3S6*XT^,)&)831ES'AD.E8(\A-/EJ(B`B##D1*\3 MR>()Q!`&Q1`>,B"/$U$O$44@K-FPN`C+U]H=O!IQ%J?1!._MQ2)*`HA(T@C7 M$HF[8PT^&,`Z#9;06PE@#<$5-:9!*`HZ7%>6JK*C"C0$2!(:#UP4=5P!6*%$??Y$X*) M0!,4@XB-^-3TZF)Z<5MQ/%.@DK_7#LAS1R(1BE!8$7P,J.3WSB)(L/KVKFE: MEH4L]L=7OFVK"Z($&R[#H77%':G0]R=+X[[_/Y=W^X;IR*23.52;)XDB0#SB$B-A MWV#"O&&`Q3$7%7S?8P_"OHUX,@Q!?XO.!5"TL?P*[=.`1Q%P=#Z<&"(NC('6 MCD5<,V<$@Q"P="QMD^N!T8EXX'"P&LDSY^+K@1>PP/$`.V"K0&P`WX8#XB!L MP$@L"VV020B=];4J]$/%_IUY$ MJHB45!R35H/1'D*8*."/C'B<&"B,/?J#DZ^+P`Q!,PK%I716P*5*18>)S5M> MS?BHQP'LB7D^*;#PX0\I4=D$2IG.H8&(928(JL"G";0-V*-0RX0=EPO:BMBX];!C*F`SUM8=M M:G-)SAZ9!Q&0X:'[-@+2_23MO9K@-T8QEU"G9+$L\^A5,Y_@&C$KN=0#Z$0^7'$QRP2 M(R"IT'QPB'J#.!='C95!?5!,#:\1X^;Q831_P1`W^<3`N>,9!( M0=H+P"@5`.X8A+U,/$D229Z,`FW,O)F0GT#XG(%(D0I&\&":Q+)(2R$O$PN[ MH*C"""8<>-C\J;Y7B\[2`MDRY0)(5-%3>>`@.D_*4T')C,.`$D((2"J]06XX M7N2D(TPD.$J_:NZ@G,\TAN$SBHI)8^>T-:(P!?U,@N1Q0*A<]1.H\S`EF,G1 M2\'CC(04@6H@$(">2C[C['T8?_H=<&'9!/M3V2/&980F&6XI,T$X)TU+*&!_ M@HI]F.@,\5ZIP0XLW>%1`JI#\67^JGJH^],'I48C#DJ9$PB2T0J:"@`8PT_8 MO8DC@$R19U$S?X/?*3V9/PZ]%,E4J"+7%`/1$.+&1/6NIX&6^*%`43CJ4F?-9(>D!X$L279? MBH_F8"X<$9GTF8-'@^(3Y$YI)G:HN[,1)NQP MI9&R6)C0)[U"+V/:`WX!82C,LD#J>3C)L!BA!C M-*E`WV-(^@&UEA$C4Q;+!X6J0;7G9_][?@[?/#XU:M;T;EOEVUYR/\.SF^_K M+]F6D_(R1`FW&UV#GOL-])OQ_CH=H;<71F]E)TII:$"N#E#@@@/Y$FAQY0[3"OB1CAC_F3BKR72H[8_]T'HX@/)+->N)L$U%1R'I0 M5Z-4=8[T*D0ZQG.D*_I4]'D+]-E?D+*3,Q!$8G>CT.2@)UCNTPDJSQ&8:P8P M)8A:JN-.]Q;;E-;*5)*]W;#GT+'.<6Q=K$I[56EOP8ZP%>6M*NT=;TFC*NT= MG@95:>_P-*A*>U5I[R3+!K;9[5IFH[>J4:^*>Z4M[C7,MFV9O695W#L9*84H MMW$D`KHE4U45]ZKB1%4\JNA3T>>(Z+._,*4J[E4E@$U#F!+$+55Y;V_136GM M3"7;VPU\#AWM'$=Y[X`@%79=$D"BUDCGVNQGU^7,48W5ILNJ,EONRNSU$J>+ MKJ@IJ\+L\1:DJL+LX6E0%68/3X.J,%L59D^RY%,WF\V&V>T>RZ:N4O!$N0NS M;3QPWK1WL$_OT$A\LU)JU:QCZ9S8DJFJ"K-58:DJ_%7TJ>AS1/397YA2%6:K MXLVF(4P)XI:J,+NWZ*:T=J:2[>T&/H>.=HZC,%M5]ZKJ7K7M\HU7-:KJWN%I M4%7W#D^#JKI75?=.LFY@MTR[VS8;O6/9UE4*IBAU>:_5,RV[9S9;VR?IH9'X M9L74JM7;1R*@6[)557FO*D]4Y:.*/A5]CH@^^XM3JO)>50+8.(8I0>!2U??V M%MZ4UM!4PKW=R.?0XC1U5X??<3\^GN M7KJ2E7_#.[K!.HM;JF>W9>J[+HL6/-ML*2Y\'<-\F()U\1ILEL;B_MG\#G!X M0_:$5[SS`**[Q,MBPN)XU;;-`Q5VJZ+&ADKMX/LV*PH<86U]P\*2 M]?T"?;8#],Y+U&T]BWK@G'B]OKET:Y#Q,([1;%LN50+2><'.PTS5ZW9]KM[JFHEQ,F5JN.A#([]5T2:[W\ MG#U.?L"!7TUZZ+DP7':&%9%Y^?F'-#Y[9&S\XR6+`B]XC&]Y1`V=]X#BCS[H MAU_^\S]PA3^K!\_#`".YB#);7[SXSPLO=OPP3K5W0,$$2*,O?/"W[SY%X0B# M]S/+AO\DH?C<.VM8W_U26%L&ZPR8K^:L-DM6B5;BF_M+PVX8JH\"'CV_N3Z_ MO+[_TK^_NKG>&S3;S9EN/UDJ#Y==MFO06O4@9X M=DR3!KW@COS:%DF2VCP!6T9NIF7M-XZ(N!G\QN,XC$Y*T)JZH/UVV;^[O*LD M3-(BQ0]_9\_,\XPO/.8,),(XI_09P97NBFBO05AFQ.FJB5`%BLD#-60PPT4WG`P\!QN8*V!@ZXR/K.)T4,YMMHUXQXU`KUNL)'8;P2/ MY(J@0P)O"SUPXR2AIAWJA=?YM[$72>4$0V3/2I4!(PP`9DP]..)83_AK%*-\ M8YP!\\)*2,N=):%0=SA\ON0GYC!Z;*C6`LKV$W^(4@8+154`SY/S'P%V"`P` MB0<`&D0J/!+*CSV"6H6%)JCRU(J?X?,[BY;XS@:?"/Z;U9A>T,-S]67$XS%W ML$SE3VH$10Z4L1)`@+..U1-0-3MF`S&Y%E1-D^`H0E8)UWRM])D%(3.N@B!\ M$J7-2BVMJY8"@Z40XC!*(O@3R80!?Z;Z9U'6I1)!_I[65_WT$:8#SY68V:H9 M7Z7T*!5"9P(K/63JYP,;(WQS'(5/G@OB0A`\1UZ2\``\L02G:;8,ETVP*NVA M;(5"SR@O;!SQD0<>BJY:5I/BCMEKV$*(,5G;`@V&GD)PAZ7P2?<2L.`YAJVBC'8Y\]7]Y\A#%O% M/SQT#\.^FEFO:"<,_"R`-X`&[UT@-_!,T/OIEP,.)CATA4U*BV8"2H,/9.%9(M1*A,T^J)HPI,[CW2B<,!]WA^#`]>_17N`P M$8E/JGSK&])3DW@R["7S@W+3\'"]#J877=+Y&>V9X^"FV5B) M#Z))M'`A[V*&`SY1=0/73&`\,)\%:(:'G"?Q*O[B&Q2S3$M=CL9^..%TA4'B MD_6M5-72JFHNLV=^RAR&US5'^(Q<3RH.GN&*$`Q(`0&FX.6,*)D@>$(0Q*9R M!.!=2\@>.D,@-E$*HPJ74,KG`ZB&@0-R\OBQ?_=)=X0!A M7>32(8JIO[H_?=`=B.SEHN!+.2)8!+T#T:T<8Z_P_"2`G8)"EEN4?WNRRQ-O$B\A&9@^C$&K.P) MBP!2%7LCSV>4.L`Y8>#(/4.[,#&>AR%@E6&S-TA4"$-4>GLYO7W.QG'ZR/U< MYBM]O1P*;_*$65=SDPB.!=4#VAE`)0/495,J.J/$USO3^.VWJ&"NZ0)/4%ZA(N#,,0C]\A.!8U"U`P6*F MS9$*V@N@LSU,86Z@IT:0_0F@2G(DK3@]X(")O^8U)DAU)F@`-5P0C'L((VPMJUF-A61Q"UL<1)Y M#VDR0TIS2;HIV@B^D',`XM/,(RAP;BWG50).[#W*0GKB9MTZ9&:P8/^R^1!Y M`AL17V;R:RU]L,`8&NL;0H)DUAC.K\._E#R=3K7>I0\Q_W<*3U]B4T-\.EG6 MMIYEO?OZ\>[RO[]>7M\;E_^LF)^2'ZJ:7N85.^?GCXR!%T`#$;5E"+XLQ>FIL\KSA[6*B*O.M7YZ,!%`J8I\\_@=0?G&< MRC@:7$992LYW1@9A<(;IL\>`I%8"B&"[F1A5_MMR_ML=Y3P0X9@0J7RWI7TW MU39AZW)0<-Y4VH@)L^HG\"?N^:2L5;Z;%_X!\TN.2J$96B:\"CG\A.J(`^9% M!HH]SRJJ,G459$"00,*O!(0H)C9;.#,-%',%@$Q9>>#]N1Z\LUK'P=LF?;V] MB/12@=5;9JO5-A;LW"X2V!!A;H#U67@D*K]#N::D\F5E_ MO\@"?RAFV<#@NMIA;,A7F%KW!V>N%XF`*!P,.'FU*JF>$4E+KT/4)6I;Q#8- M2SCY,&T:>$G-N&009>%'TFY>+,8U;,E8+RBV]\UNVVRW%<,!^'7CW&?`XA?9 MSC+3X#A^DC?AJI%52+IH=,GE5L[D*B04?6_&9^IA%*6)NB7ZY6P)P*4"H#!S MXX=F<6FJ2^LE`-KMSB(0XBD8:D8>J7\.(91-H(`>R/F"12S4^8;8RAD3S`X.,_:QY`"MW(I&2R09!\35` M@(P[G(O(VQ_!6AVF)]:^UNYJQJ_]_NUT9LU#H^.--)B](&OJ()V#(ABE"`:U M1_!'F\)7"69'<0:,SHHNE2JU8ENDSR'J5`$&ML+W66J&Z40 MIB,0=;6Y1N,>$%??@Z@]EES$1#$H#]YC*8;4)BD5PTK,10;216(X#;+\=87^LBT8?H_=$54%?5BJ7YU6`]ZIMFE8/E/D5 M"5_E!K^B)F@'69(I)(]XPZ5BY!.?UD(BZY75*_13LW`*U'IZ3PV!(/=1;"`D M\9".[GJ@!+@KX\\_TF`J`-6&GC.@"#@UR=-$)!;[Z43Y)1,+"FI!EZ,B`.X/ ML2\G,#X!)8&F9_^`H7V1[1=.LNPF;U5E%&G+D3@TW,&^NB; M"5Z"4Q/!$L836##WL94KX"XEBSW7`[-KRL>-6VJ"D&]E[@N^"1K/):$(HZFG M5Q)N22E\X0Z&D@0TSM+/W)4+GH=;IQ4`3:\YKO+(JQ=R M(&Z'MUVN/`^99)C"+-H*8![T2:0XX6X8:8]R9QT+,DPY!$K;ZHZP,AVS$PP9 M5ET,3B?\BVQ+(*T5*FML4))F"[1#..:1)/W)G_JWWT41D)D[OMW7XWK ML$9/G&&&'P'T:'O+5#3Y*3.F=YDQS2_`^#5$.M&&^PADCI;N*>=3 M4X*4_3OU9+Y3BYVP$2B.L2"`W9/`!TDA1E?M+$)-`)>D7.PP>`RE5X"0X&8) M,/AA-*:N"(RJJ6=Y+(\B2,=HHV0$E"=,\G@-_5NI5LBS%=$*N8KX/IUI`+8] MKAEWHJ^1-A::LH4;?%KA=+RW/^2;_@R7@V?BZ6$Z[D0A]P)K9]2;%*8/,OOP MOOY!X8A0(>K@^#*V=T^DNB(Q(95CY`?73D7[IO&^D<.AY8=43R%F%U03"`1= MM`E$=BGR["*4G$8Z/;"]!R=HYL`JO.H!Y/,0_)69A6(7$^"-/WGDMQ$=A?(5 M51H!66%'RLM0M(HH^X86(/.$D6:D7`0^#13FZF>U!\_`WUSJO:EUG?6!T!I+)+?!:T@_<2R`_M;B= MF#U6ZQ0J4RW2Q.8T+1\9)UG*)6]PVN/Z)3WZ^TVE:^A2)W:E9DO=._R'2? M1\C;9K>WZHG"I3_QO2)G=?;\RKC[E$:!1QM@M5/RUE52U=GFJZ#>MDR[;>\= MQ1612D6D_7E!JZB4O?+3=EW1'=X:43>MH[SOL4+PB5KOWZA6Y3@I[=;FKN'R M<<0=+^^2KHSWCFX$K;?-9LO:#HXW`:0D5_V>+)EML]G:H$&?(W=3G-X.K(&'!HP>0]..8)S&\_FL8NGCLRCW"=SRU^9?ZN=0: MJ7$"]Q!A+=[0ZO#9=J6J%E_5XH^]$ES5X@]-@:H67PI^J&KQAT=L58O?$I>) M:Q-*?NGZ/L.'`]1H>PVST5DU7U;5W"MZOH6T/1OA=HJ_JK3]'O*Y3;/=Z)0Y MH5O1>1MTMBRSWJD2]U7E?ROI[$[7[#2.,9]]-!@&?\+J[?D*]J-V(F108XS% M+KK*G.RRR-'L;L^:'+Z>=:I4PIZ,^I9Z,HZH66\3G(E:NS>WS%,.E5(57U]J MF.N8EK5JC:*T>JDB]0NDMGMFR]ZS@[2]0OL:9?/%E??K,!!GJ]_A`0[9 MJ8YXRF3X7%7X=U/A+[G+<)WS&DN,_V)!BORY7K6V#*9H/_K[K/QNZ:NAK63V M[G2989?<]JN\V'(U[)6_<-3:6ZD&?,1.JVUVZZMVZ1VV6E,BC?=/TG:5:GMA M+X0-'-;:UMZ=38#9>;Z]-`G`2WGI2\68"QFS:;:L]AO@R1+IRD]A-.#>(=3E M6TIUGH(W>9AX9=/^TK>C/6VSU6N9G?8NRQZGI__6BU?>#E>US$8;N*K>*S]7 ME4:#5?''RVY>V^RU;;/9V](VM,K5JP*0RDVK`H?)V MI^QDU[\WSL#%:W96Y:LRH*E"],DG*"_5O?9/H<\2NI[T"!EU3VQF2R[KK&PE MRH"D"LTG;90S2<9[>8^0/??%7#4;>*M5:]%VI56/]"H#HBI4'VKGX3:J'ZJV M;*?ZDWN_5._>)U_@8;IRW;WE M$;(8>^3+K3)_7@?FZOK3=[]`=-;(R;+\Q-,@GV,)+,*[W8&D2+S^"&]6OHKQ M4FI[V?+42XAK6/!_.:@O3UB@&+'8`[(8;M3D02RX*:)2$R[TXR1_1.="R8`W M>6WI7R0[W.W#W("%+WS$O`"^!VB2B#E)ROQ[,!5++_B7V_;OMO79;EQ(CC@` MK&7$55/#E9*J7VZ[OW=.!4^R30O5V)+SUP_&4VO`6D9>ISN^V_=FNEP!7 M2K/U?;!I3'43?)R&!7W2(.;;4*FM=K/1Z^4Z=;F9MP=OD2*OPVM;G6ZCU^P> M%.+.%,3_*T?]WW\QY)+D,U4!7UR'=;@%M+0%M(YT`=,\GBW@PHL@7`NC)5;0 M:%N]AEU..JRPC%;1*2J!`*^SBGJCU;0/2(R7I'J%9=A=4*@E%8WE9;M96HY: M?@VM>KW7ZFYLV;0H%.^B61'U3AHGX>A_P2-PTL1[XN=#YD40U?CF7H[$?3CC_R`,^\.B0G_GH6+#"QEF]JU8(M*F_K&`[ M+9V/EIY[A@8;.F1BF\Y5`*&K%[J?@`283^"+HH[>F=W*F<]NKZ64>YUZLZU1 M9T=+.#"JVN!#*U3!Y^9:C&QU>]WN::.JA>BI]Y3DM->U+NUVNW/RF.IIF-J2 M4[0O3/W&80!0O5Y$$UR`N5DV#Z1L!0UQQY/$)\"F+85\ZN_LF7G>%QYS%CG# MPGS`6.C,"#SLFY"M=EK M6^#?Z<;XU;FV`]TRZ=AFNV=UZQM"YSA1"JX%\UGD\?@\C2*@R;KX:@!(=5L' M:.[PZP.Q#%H:K5:KU[97!0)^YC(=>YTB0\K\?BS2LE?!/0A=S)Q%3@9Z%:`A ME56!SQT-3#'43`J[7>^T@<PF2R M.MQST-NK-VQ=1[T^[0R]GYCG8YKI4TC/W8&7&0'C\K4K'W:S/15-+ISBM8*% M$Z'*D3RCR@C;R%C5Z_7%U8JYL\ZJ$BP8XPOQ?;A`UN=[IGI-Z@O>?1M[">`D M>O(<+FS#%^Z$CX'W@@N]TF)MN]UK-3JZ:MH+["5"V:H9PE;#[A83A&\.97,R M2R^+E`5<_!S'BS":J9+KGK,!`3GF.\Z.=)JJG6`W4FT&T$L"S9&K%,U>56 M1>3?8N_'P//_]AW$8OP[XX>2+6_-PMB^EH>GTYTJZ39:6\GIEAVU=:*TVWA] M):=?=KC5B=)OX_7MBGZ%RLQ+2XP7K3'KME-%C7B+:SSBU(D&T.TU(:M32"ZYEB7#$?\MS">2[Q5:X)G]6:ST>UJE?G" M%"O/OVJ![O,-L2=-_B;$L0>;MK>XVFR\V&%,4Q<<>.%Z1>\'@SYM)# M_\@'8<0SJ#AX)$G$PLCU`A9-KA(^(K6`>WU"WX=7M]D&,:L%=@CP@7&S!0UU MNLC96'N>+FHVU^Q[Q`T\%8I1\1D<;HO;_.QFH]'4^A463K815*O+:;UM-QJ[ M!FM5";'M?6!J-'UIF_H; MKZ]AS9:^O:TP_CH+W(HR>&6!*Y&S46@Z M>'%]RF78ID/0UO<73$VPQOPKD]?N6,WZ-B%85G:[=:JT'RX:ZO9CK M7,@L"[7O,F"LK!\6\\E&<*S*(PM99%-LK,0>B[EC$1@7?!S!"*)R$[C]41@E MWE\O;>U>S7ST&IW"H6$+9]L0L%7YIMZU>^U]`+:RN=D?PE9BK1XP^%IPW7%* M9_S*`V!%'Q]V1U[@Q0DRYM,VDQ?MKFWIO:[+S;P]>%>.;1KUCF5;AP-XY?T_ M[;9E=P^*X)5XME-O-EO-C>%=Y>"+U;1CJ]%LMJ?/-%CNG(NE`-K\U*QM0[0R MR[6*_>L[P-!J+-5M=YK39RN\"L\EB_`XM_B61^H%S]FL.6.J2']FU?2,V]P) MUX;J539Z`:IZ>U=0O>G>`;U'CE+3KD!9+OB MKLTAVQ6';05G.^&R!9!-=645CTK0SD==4Z\M:I/"0P9L'9$KP;'U1;S,J`L6 MT>I9=J_9:I1E$2_S]")*='JM5J/3*\LB7F;_18MHM&VKU]SQ(J0$S8RQ?ZE8 M!,D.%K);R=CC0G8K'?NER`XEY+6%4*>H>O@+AP#+P[LQM#[1KP#*LGE(M5WS M_CD\]UD<7RS:4+)@6;9E=;`JOB14T]2@.6\&=6BL..+N#5X%&T8=.Q951KFD\CVSJS MU0&/^+F7;?:Y2Q]B_N^4!\GET^S!E3G6:>)ESAAM%4]H>PW>`@NJ@WXNN/A7 M7*+PF^=@G'_+)N)*Y&V4*\1Q2$M/.J?AJ?#.58"%VR`)H^E3FM:%L-ZU>H5* MW@L3+FRHY#'N;K[F.^]*?7&B#9I"7.[]>!DD7C+!L_`BYE\%+O_V#S[WJ*YY M"_H%C6^KV:PWNC__L'`TF.[G'[X]1+[W(_XO_/G_`U!+`P04````"``8-&Q' M7*+5YGX/``!TP0``%0`<`&-D>&DM,C`Q-3`Y,S!?8V%L+GAM;%54"0`#WWA$ M5M]X1%9U>`L``00E#@``!#D!``#M76U3XS@2_GY5]Q]T;%W5;-6%),#L#NS, M73$$IJCB@!V8O?VV96P%5.-86;\`N5]_DE\2VY*E5A)'HNKF`P-)=^OI;JF[ M+;7MC_]ZG87H&<<)H=&GO?'^:`_AR*G5U>[J$D]:+`"VF$ M/^U%=.]?__SK7Q#[]_%O@P&Z(#@,3M"$^H/+:$I_0=?>#)^@+SC"L9?2^!?T MFQ=F_!-Z04(R+8N`3=+3_P4.#`4#L;S@*:/SMZ^52[%.:SD^& MPY>7E_V(/GLO-/Z>[/L4)NZ.9K&/E[+.)K]?HK\?3-#!:/Q^='PX0N/1K^C7 M0S2YN-Y_G3)=)E[*Z/C7C&P\SG_#0: M_52P?PQ)]/V$_WCP$HR8@Z+DY#4AG_9JFKX<[M/X<7C`.(>___OJSG_",V]` M(NXH'^]57%R*C&]\?'P\S+^M2`7*UX9?S<@C$-\5<\1?Q_-E^6H_I> M''BO\R1L%YE))TP3W&*#A@ID0N\2G&TT][?O!* M!M7\X,/^`.%-%W.V=A+"I_X>&FZ`]+,7/6&<)CIH4N*>L-QZ,3/"$TZ) M[X5&P*2[[/!4I:U;FE(?(+U M!C22LCWTE]$S\QJ-%SJ``N'V,-S&E,WG=,'CU9\9F?-Y=(U3'2(-VS9MQ'+' M(WD(\6F2L/``P*9@V1ZN:YKB6V_A/7!!:CP2TFU&#.I_OTR2K,RPFD@A(=XR MEILYCXVW+*(#`I>$CPGQD3?OX, M`=-%O^M*9;L5RPXJEWN>U0!Q0TK>>Q4#0P=B[K6B@5I1P]A?)H.`&XA&Q65Z M&P`8,$A*[W'5U-Z&8GK'/^![I$$6XINI&MJ:BAG+[S6[F*\.L(A><=>LV`UI M#66,Y/:R8V#J$0!K3SL*IDA!S/W5*6O!!?#WA[@V&6M?G;*+_6>20M/#1D)W MHMLUC0;/.&%535[%)%]X28:#;U'`ZIHFV^8ZKS_83FQQX9$X/^]C,2>;Y23) MYDH#I&Z_`C==;SJ^[2-L+X7J<\,5MJ:X7O61>;S<-KRG%?U-EN8']B1Z7%_5 M#4?J?S?5=!Z:RNEEM]6\+M.R[O:JMC9#5.3`>=??B-:LPB_6LC3?Z;V9JGCZ M,=&ZP_>T,VZ^HP!@WO;.N2E(-53>NR('\*L2^%_I9F$^; M*_9W@P._IIC5@!`YZ"^U`[&,N9U3\&Z,!JKCJO[+LB`H1J"&C5_CRMI\& MW@,&8L7C9L.+Y'F M?5Q3+WG(F[FR9/#H>?,AGPA#'*9)]4D^-0:C<=G3]4/Y\1_%Q?I9%O-6H6J` MT'O`83[L'R5=BVQH#S!ORV'3A__'=X&>O9#/[=/TC$WK!2N8\N*J6Q$@>UO! MVD0ZC7U$8W;]\VEO7(WCQ7YC^H@-=B7%,.''35S,@+`Y4O%/8SI3V;NT+5U' ME;I?&(H]](+)XU.:H[?HQ^6.:ZVG1'17DPKFE0.K7I'IY9SQ)WA.$\(F"VSU M=Y##W'%HU1U*39WSRVV,YQX)SE_G/&=H_=)!#O/+D56_*#5USB^%1KKTZ$K: MZ##Y6UD"Q2D/WY1+.WHB92M!Q>5&WNA<"7J%G?.2Y+3G_-4/,[YE]872X(6$ MH2JK0[C=2"^=:1YN`.>\=T6\!Q*2E&!][I?1VHS$16M64I[AZ2]<.NAM1^IN M%[2CME)AYZ;6),/WM+8G#)EB*A[;H1OL)[WBSOGJ?#8/Z0+C$K5)5`"PV@[? M8,^!S>"<`V_2)QR;N*V3P?8E`]A9&I6=GV MG`5*VW.HV^SM/>8.)9V;2%_YX5:$@W,OCM@E6,+"4#;+\H0^P5/B$T7,A?#: MKD/!'H,;PCD?,GR8A:N`'[;C*,FMH@L**A[;%2C89WK%);X:6"YL@H!PG%YX MZY'@,CKSYB3UPEK`4!0Y`%[;%2G8>7!#.+?@:H7":128Y&(]I^T4!]6MNW8R MQD(3#GZTV%]2`HH>RY,^Q566A-1J09E@MAAXA\4$ M/^.0YF-+.'<^ZM8!J;A.;#49/^,H4Q4/*PIG M4JQH:"')-K5R\T(#KD_WRG%N]^*:1K2IE[8X4+!8;J--\CL2"DQUE*H&'!67 M[16D=8ZDY59G`^?B\664XIC!ULX[@=!V0#!WCU13]X)"?K8,N$YMDMFN*4W= M(=7246<4^FA<41'9+AS7BU!>/1#SCWT1W7OT9+'FSZK)3M=M!4'[; M[0VFOC.SBW-N795R%\P29Y0_ZRYCJJ^V#S_C*8UQ[3[I\]2&Q>Q/I5[5K"[-Q3[GB M6J1)9GOR2U$+56#_WG?-FTM=RFGW&4=XJNI$Z62PO7;A'N[45E-B[OZ`4?VP M_\99W/MUSN*X3)0+=>0LCCF18V*URC-AIOJ\^,8TN(R6B:1\\HZR%=)$QO_C MJ/DJ,W10.^%)EZEK8='6N4ZOX7$SQ[W%`Y\ZR)OI!)7//,)`@WS+T?WI)[NXVT10]+'@HX M^?U2<-D%QM4TNZ<3PHI[)DD6:3DWE!GFLV,'?6:BY9M9E'E15]YA";J/U$`$ M<"MBY*"OS95UU.-N'7Z.'=YWVO@XU/;-;&$NO'S*O=#4J;W^@?(#/>WP1I69 MI9Q;TK*BH7A>HV'@;K`!W>KP]A3(+MM;<#&G/@/+NQF:CPE4.%O/ZN@IEX&+H>9QKT(4H*^SG@UD M.'K@M8&OUUG-MN\2D1MA>7JW0<*2RG`D854OGZ)_F@>`U='DI'"D(CDI MS>->2JHAYR\_U)\-=',XFH#6EW&4OXL/XKUN#D=3"MQ[.F.X MET#DK^BXQ3&A0?M2KMNE9E)LQ]IU=!;;V$R+#R<[WOLSA6K1;&"*_A9_?Z90 M[9PX]D@CX<7N2Z"-;N.?^(NN2.*'-,EBG+<;YWRHSMCOLA>'Y\S0MS0D?MW,#?0_M]&7PGA+=$T<6LE#*X&]:K5\-8\<^("1:MN)$!>LNX-9>_2V' M.6[#Y!Q(J)]ZNAFA]K9O.;P#86%Q'K1BZA]@[7W)\59O4-7 MCN^HC6]%WBNJKK?DRE&^;Z,LV5'.CYH">E[BR[NQY%"%7%5PH)*E5W"0=[C* M40LY*A>51]!2&(]'E2[ON,`?$1.)2IF]JM5X6:LTRH')F2G MBKAGBRU?RRJ%=2`DH`9'SZ54\RVL530A40H5CZ[@EW5-"JX0@:LF'8%$I*\50H(*=`HA>]*2^&*O_,EW`WE MA#0J[@"@=Z4HM)2UL]`)4N)0\=;^LKGCK="-U1S;7^RH^B`+7>A^E.6 M'SL/`!VZ#>[\)QQD]78CN?9RI85"4:4TJPG*P7BH@)C'0GD&<[90:W85:A8" MO:!2S#;*.+-M'PYN[V=!L[C5'*'11UJLZ/H=7 M<'>!")X/O=_)6H8/B?WYU\MO'5Y`$BLWH+M9?->.)V$UF+#C5#^NM%!Y-8XP M82J(O0*-(TU;2M2V_&!Z")M1TMT_Z\K4"N':5V7?C'H/1-B1DBC8+((;!-48 M.[NR4:A^S4(+;R0K[V%D\=6+V!_?V`AQBTUEDB-A?TMKDM7(Q2YD@LJQ43ZX M*,`%*7#F7%0TN`>!TK#GA(2=KNYK=A@;DIS-9FH]^,U7Q**VYX5ECTYHU2/Q/ MB0#.7S^JW)%I&SU$L.4E.:>LR;"POHIV(Q#X]T+]5C!;0%WK1H)!%TJLF@0; MUQFM'B>8$I)VH5;/4[4Y__'`G,8^^1]02P,$%`````@`L1W7G13=1 M(```73X"`!4`'`!C9'AI+3(P,34P.3,P7V1E9BYX;6Q55`D``]]X1%;?>$16 M=7@+``$$)0X```0Y`0``[5U;<]LZDG[?JOT/7$]M54[5.K83YSHG.R7+=L:[ MCN6QG9QY<\$D)'%#$3J\V-;\^@5XD4@1-THDT8HY57O6L='`U]T@T.AN-'[_ MV_/,LQYQ$+K$_[)W]/IPS\*^31S7GWS9^WZ[/[@=7ESL66&$?`=YQ,=?]GRR M][?__O=_L^C_?O^/_7WKW,6>\]DZ)?;^A3\F?[6NT`Q_MKYB'P;BV6WTRB:?SXX M>'IZ>NV31_1$@I_A:YOH=7=+XL#&R[Z&I_^\L/[SS:GUYO#HW>&GMX?6T>$_ MK'^\M4[/KUX_CRDOIRBB[=B?:;.CH^0_=T>?/A\??3Y^JSEFA*(X7(YY^/SQ M\/#H\/#P?4K^N^?Z/S^S_SR@$%M407[X^3ETO^P5.'UZ^YH$DX,WE/+@G]\N M;^TIGJ%]UV>*LO%>3L5ZX=$=??KTZ2#Y:]ZTTO+Y(?#R,=X>Y'"6/=._.M&2 MH-CXW4'ZQV)35])U`73H?@X33BZ)C:)D2BH16<(6[%_[>;-]]JO]HS?[;X]> M/X?.7JZG1-@!\?`-'EOL_].IM1S51H&#GN=3%,P0G5*S`];@@.HSGF$_&OC. MF1^YT8(IE[9@@"D328_3`(^_[-G.L[N?3R4V[%]T:*/%G'YFH0O3I#]=#`)B%I#M<5B?`U6J`' MUI$<#Z=IDRL&L7]>A&&<[;"*E8+3N&$LHSE;&Z_IBJZQ>U0LEIVF3]D/HVG0] M.76]F').O]ITN$L2AMM@O6F3=L%#B/^,:>=GCSI@1.V[ME2:M5@ZL%SNV*ZFL6YP MF[=NQ>BATR)NU:+1E:*"L+V=7`^@G*KY75T/%;]UM_N6'M+Z/;5XNCO%$7*] M\(I)+W(?E5NO=@J$WMX-)9#VY"QVOVWNKO4_SJTNV@5=T&*8D@;,%.KWU8\!G4UHD':DD>A M+E(MXO;LE(W@:M"WA[@P&0M_&M##_J,;Z6X/6W7:"6]7Q-]_Q"&U:A(K)OS* M3#+L?/<=:M>4R;;G>?/!.I'%.7*#)#1(UYQXEC0)MV=:H]?F+?"ZWYN*KGF$ MZY]"_ON:7]B&W;7*#T_CF=OPCN3M1W&4Q/9=?[(YJUN.U+XWM>X\K-M/*][6 M^G:9DK3;4VUAALB::\Z[]D8T)A5V6(NCQ-,[&LMHVA'1IL.WY!FO[U'0(&[: M\27%/: M16#'#WC?<:DHPR1XDPU4E,JR%]>/#FC3@ZS-`;>#]G$O!]MWR`RY-4%7J3M` MG(RT/\.S!QS4A%LF;1\K\KQZ"!."]G'Y)!K4A9;3=#HG\1C%7K3QI,S)RYCI MKUW?9;O&)?UG"3=^CC`]!BY3D5B'#60#TE^S?@[3_QU9^U9.5?R1&L=6VH55 MZJ--]/RDOQ+<-Q3C,H>,_DSW78<*&#OLIY!XKL-L92OKR/2-ATR54T]+/'T;A.> M6)]6TFEW/(G3%DO\O&=?MAO:'@GC`"<,)716D;!5V=?+6BR!_[`./NN,R;S0 MG;7JSUIUV"93U4S'$NZ/Z[@+[=N$I4IW+('\M`XRITXW@)S^OZRDAW:E*T4M(.T/+R)$LHC]91,@IK2=+N0L?+G"RA>U/YIAB-M2)J'1\O ME;($\2T?8DIG981MPJSD69;@':_#6S5O$Y0RU;($\MTZR(S<2NBM<@?M?MS5 M9,P2TLH.E5)8&4F[]EN-/,P2Z,K.E'25K)Q99VPAREEYQ3K\S:)=6EF?[5H& MO-3-$OS*!K5&TR:\M:3.$J[*GI0W;MF2JJ1X%E&]J6P[)8IVC2=!PF<)7V7# M69%9.9UY$T]JZKVI;DO:IAX](&4_M6QRB_)#2XQ4-J\EE?4JI6L9I5Z>:`ES M94>3F((=<:'.(BUQ4-GN^)9A1^`5&:8EY)7MKVKL=(1:D(%:0EO9]W*BCC!N MD'M:PE_9^&KMVQTQJ9^C6N*MLGE6C_K6JZPK:]G7;_D5Y)P7C]@E!CQV!YH$ M7"=JXOP:U/0``_:YX$)3`OBN?_JHS9Q#DX#,/LJ:;/G5;?[:) M']&Y=N8EHWW9"_&$_9`C&P=DII1G)CLBY:`H8`IDSR*!@X,O>T>'*RQT"F+G MRUX4Q!R636AIZ*$PS))A!L^NSCRKDC2J.VZ@3:6KL@H$>A+QRE&94>44<9YF M<3N15GAM&U5'-82HTH50S$2)7*2/-X<[K)#[(P[ZIG221]"V7>PV5EK"G4AO M;\WJ[18']/`SN*9=XB#`3@+[6Q9=%JYS8J(6-%F.>`NT)/E42"WLPO7.[(*7 MPC[91$]>@%/3V+LPG40@IZ&F^B)2W1_O!-Z$F,7Z>G8L)[R59UY**+% MZLZ9IH7')]L1*T_&,^>+,JJH-:PJVT+0W+"])Q4XT6$`J-G7A'9VPOC;5H/P M;<`&]RP>/QWL6?)/1W_;>BM3E>EM*PO28^DG;'-5C@`:A5\FSC,$QX2!&GG$AV/CX! M?#U)@0M720!&R3<<38G#(JAA$FX?/?DX"*?NG$XTEJ^`)A+7NW87.Z#`>JP( MSVM&57H=$!MC)SRG8LC3S4;!+6)WP%(&Q;I4T\)7HBX/(NV],[O7H>5MXJN8 M"83^H["67/B%E#+)KE>C%_@:K<^-2+?O-]0MYQK=Z3\O[I>A?!S,.,I@;8I- M`$N:#U4DQ@\MB9%JI*OC'97!*_F0:21CQ`B6AD?H^#& MG4RCLV>Z7;HAO@Y[9$:O]D5.VG^"&Z\,,H M2"ZTG2,;#V8L:U"L61$%?.7)D0O/S8:]5;*#XY#XV4L@;+5A/T'!4L7FF<+_/B5\$R.[$A&O7:`0[J+H#P(K;A!&AAC;U MEP@T5$A33:&M]OGL$N*8V84:H+;,.E.)!)-G#UR^T<%9/$0E@ MK>E!%^IH4X^(^HM:G@'998S(C>*TOLV0G?H]#SM9*_57I=D18!UMPY!00T[ M8@:.D\@)>=4YI_,=:M,#5U1-/H3J,>N5*1]9![X?(X^B]VUW3G]`BV(VA^JH MSJ<&K,;:7`B5:-;'4KIZ)=96J1E\M7#@"H/79ETH-^PBEX^=,Q3X=,4.![8= MS^+DCO\I%:CM2CXA-2U\3>GR(%2?V=21P2-R/7;D/R=)"%#'NR6F@:\N%7:A MF@H^C]\/UMBB@_[LXKZWUOW+MYSJ-,N;W_VUR_[:95U7[R]P[?(K)I,`S:>L M<)UF4GZ59$<2\D6\@DM:3&=H$:XJY5M"8C@I7RCT]4QA!<_@S+LFM;03R?G; M:K*=Y'R!/^(KIH:"OQ#FU[-&I3;WALPSY;PG$L`PUZ_K@#BQ'8V"6QP\NC:6 M[RO\UK"W%!F'T)*H,ZSAP'&6C5E:Y2,U,7Q-5?"5ZBWY.:L5!M=N3G3DG-I=ZQP9]4!:J;VI9[_ME*"5%H% ML_?H]A[=E^/1S3\%5H\T*GY=)XL[.K;R#*XF!G\DU^4?FN4DA,Z`:QP%U<3& M3NW:*M%49E4B$(_SK6H3^!&_/8UWZC^^1`\D8*T72R127[*P_?T[8R=\[4^( MZ/(ADOX[LPOH*9X'V'9+SRGPTM)6K>X_`C^Q5,"*1&]VL;N8S9$;)*4.QI?$ MGUQ2,]M)R[G?D1-,C?4YLX]&8\FQ4K<+\#JKQTG3MHA@(:-'H1-"?B:O;H_& M*1K!&L9K"E?H4L0PO2Y?*>,L;7'DIW4)2FOT=A_@]5F3%9%.C\UYVP1>J<(3Z'*_%=]=57EH1N:N MVK?RP9A?3L>QU;NS>G=6[\[JW5F].ZMW9^VN-GMW%L!4ECML3WWBD8F&]RNC M$9(82JS
Y;^[.%$M+XSF)$@LE(E2=Y10_:]GE(O>/FY3AN M^INE@%TS_NC"]]QT?^@.6('@;\3?_*_]/^DPE:1F4K#JB5Z+29$BM@X!TN@B+.8 M6?-#Y",'420G`?J7ZTEU(*&X?[\#XE?A%TG^O>&+5_34H0B(%9K`MJ@JO$`[ MU2<`5:[54B,S5E)5D!Q!E_D`9P?5E35D6Z>&/B`'ALZ9+'&2V+CF./D>XG'L M7;ICRK*R+/E+31VI>9*1F[47W4#-:PR>#[5_0XAE:U&8- MJRH6(&AN.%HC%3CO+64!O^"\%$UH![+GHC$-=AJEN7LBR:.9I]G3;E+'-;^Q MJ9"!?/H3+=A=!0E&/DX@G.F(F=_85&A`6\P2V$`C`K=3$D3L+>83$@3DB3V^ M(-G/JXWA'M84F&&ZW,HOR=`C$PYP&-U07A.&G6MJX]`_H(G$5-;O`[SR:K(" MTR8K,_$-1>RMC(7`"\5EO$BS8SJK0(<9J\NG5E:.D?$@5@ZG,7BMB#`W[21L MXY,IO'^\>FLW>2%-\KR[=A?@55>/$PWO8Q/6W`V=2W10N@87WM!-?*"G.+0# M=RXHL,.(M6CAJJ4>"T+SNN':+=F+QF)@`F6H"6%K0A._T/QN5@WYZ^#Y0]-< M5*7''45ZV:`GV(K:E"&1YAI^E32#IQ4FY+;=">G7"!-^-!>N6CYARUXDABEL`6SF;#`9ND#F9BW0X)704HINR5$ANS1..1?T<9"9$MKW!/;0#C$(\L&UZ.G/R@(A^')5+#EY[^EPT'0HR%CD`JY)Z+'04 MR6DS<@!:$YKX.PK@F(T<@%;4I@QU&_/9(G*P"]+G0&XZ,M.0E<;.^]E,[I"C/;5UTW54YVY*XA#YSJW[G*:`^"R[FVZK#)8J MRJ-!;*J^/'_"DTW@-[U&J95Q3N(@PMA?Q53H=$2Y.:6K%9U>3$6+:NE'FQ&@ M\:.^!%C7PNY+@(&4->2=^ABYT>YL]FR,$*(XR&;YR[`;9IWRH+H-S.U)M!:O&+X0I#D$V7FJ??'OV>6;Q+7EM^ MO9VI6V%Z,XG6\ M37N\/X(>R]V.,YB!D`3VPSKL`8M"3Q*AG"Q63;*'Y@=/*'#RO)$D160T+B:- MI/5#)#.DM3%W8`ZUS'O3+CM1?=IEC9@L?34-X7]ER0O8N2/)[Z;$HV,+R]76 MZ`*P7C=CI>G#F5)-9\_T1S>;/I(,^#([7*J=488$O4C^#:>!KK"LTNN2R7!' M"K:$B\-Z:JG3V5=AKVING*R;&QGSR1867O@ITRK+O_G!X$^RUI@6GL+A9'T6RMT7_C2P(_>1 M5:>3E;O_Q"\M4LH$+9>Z+S7(Q^BJTKV$\ROB[S_2O0MG!\',ZOM.1PC6R&02 M.3ZL+9'5R%8ZM)6-;26#5SL`(*USY`8_D!>S5Q'B6?H)2,5R5%LL;`@K&<,J M#%+@'4!*;F55Z;.)^VSB/A&I;B(2@*RO/A$)I*Q!QR'[1"2`&3'ZB4AF5YT7 MFX@$(%"RR3F/9_&R@M',TW5*#S$.M:YOI'7+6Q_:5)"Z_4-V+0G`M#(:Y?W& M#7^>!Q@7J_YW-/%X0[^LB2>40--!.X`3+__H?A"/=N.YT<+`FE<>_&5-/HD, MF@Y&&LY,D''/WJR1%)5J;\S=F&SML:X1<.W:FYW76M"J77#\9MT/F9/W!0MZ M%^-+!;L9):J*.&?MRG60`5=O%N&%N<`-O*3S M+/!>.2AEK[))$J6TZ,&7&*O!ADB/A^:M\/5\.]-]Q[P[TWW'O#O3?<>\/]US/<-PYL7!$_3?Q,A;(JP1^.XBB, MD.^X_B2MKMM":*G&Z*:JKK4?6ZHK!(TC1Q,WK9KB)[LS)K!CV5`MC`1WMK3) M\(M9FU95WMNX/*,U+MP9UAW[OUB6A9CQ[!9(IW,M&_,ESK,BZX!3*9K^N-*[ MU=W.LN6H+W&>E9G72*CX-6;:.0G&V(UB_ML\[8F[,.Y+G&WK[(OF6\,O-FW/ M2>$8\@=FCZA@9_"(`S3!RV=7)$46.AL?[ISJ7@RBN?4)VMQ:XZ2+PZ)XR%]] M!BDXEX5>8,V:(?)M[+&'(=-+_GS&TC(UK3JPE*T10'=U.422D<3"8!GE"=7%"QN'[HVLD] MYH+G6A%P,H0*[OR%(ASA5`9WNBU\AV66VG:<5$>$.ZVZ8%PX90!4*%#43\T* MI=^1O'WAFSK6O#8EJ*B:C6M%9$58&+J_5=7?JNIO5:F4UM^JZDA1_:VJ M_E;5%@KJ;U7UMZI@WZIZ8;6_#;]+W=?^!BMKR/M`7_L;8A%J_=K?9E>=%UO[ M>T?O:/6UOPW>;>AK?_>UO\%,O+[V=U_[V_BJU]?^[FM_"R=;>ZR+YIC!R%KA M;>'%'64S1'8"7J\6^+OUN%D>"4OZLXH=]M7!^W#82PJ'W=$!1N/"TB%W2`J: MPW9.2GF$=H0HP`P'/LN&0*O?%%^-,AZA>3DJ8/]PHVEBR[,I.'7G=^3,CUCQ<44Z M0NV.#.V-4N4H%*DG&W![HRD=@]X;VYL'D(.6IVZ`;=JWR@HJMS.T4V[Z_1$% M*S!7XNN`C''()C?RSK<M=ZR_NC]\"]:WS$,$V4Y(&,-%W^VD/J)U3X[>'K M1(8;YA=R-IM[9('Q"?:I'!/KF1\CD"1-ZG8!7W\U68$9Y3B-\1TI>*)='-(# MD1T'06'SYFQ/,C+XJM.`KQ$PV*68:'9W+:D3&^8E,[X&)&RCH*5X,/A3HS6F M11-JT^*5AJ.<&;L_<%BHP;*,Q;41XU2,N"-3JS7.1?/K_4MX'P^\[NOP(=+D M!W.QZ@N?_HCOT#/6#$^_7P]/ISU821?<@/2*MQ;P4X&[-C703ETOIDJXPE&* MYY(NS_1S2I12N.$J:RZ]S?IAG>VD)POYCN6D?5FTLUP8KUA_OUD4@)4@6+OR MNJ(]%=*N[K="DA^;VG&4S.S16$8C%>9'L3#%`A$)LP")_9/3`:,OD/.4>7N7V]G)F+#E2A?Z,#C,)O)'7(4 MI;9N(,=&"@Y157BDTM10A$0P\86.7NCI`7TE">U*$H9=\7TE"<`;35])0E.# MG::QT;%GQ$]6X[Q6E#1_3=C>U"UBK8(1:N3"K<=PEK`?N8F3Q'W$M]B.`Y?% M9;2]VL'-.A5%R*YRA@-637+H2!C,2RT)6C70/_AI-R&'Q+TT!/D,T((6.ST-_*#6AR0/E[4I-C'D8)),=2(& M"G.U&M@VLR[#:[1@J_(P3;=*K^`H,\XTB.$6CZ[)@TA]A^9,[TN,0LW8_[O# M=9L[)>Z-[=[8?DG&=G\-'=K^TU]#[Z^A]]?0X5]#;V8J#)FMA8,Y,YW5.2[\ MUK!77QF'T`*6-W@>!_:4&H++N_+K\-7G8^TNS"RX4GVL'WYKB@/<2MNE0B&O MKFTH'?*RFASF"ML$VUWD2ZN8`O;RJN(4VET^'E[5)RBC,;.(*J6N5A+PE;-9 M/4%>&QO39:>>X03&+8ZBE$V]8D=R(D/>8XV/@]1A`>:YOH]J-AW5-'O)N8]J M]E%-4SO6KDD.O>X!#34:9#S`X7TGU+3``ZXBF'W;0+1"#L;\@GZ,+W MR6.23:8A;0G%_3%D>:N`"W<2PV\(Y#OF5TPF`9I/75M5\E!"`GOC5_(*KO9$ MNA87X:HV$PF)X;L,0J$370:`[O5-:@GRSM^8)L$[[\Z>YVZ60TU9EI1JX;6^ M_P0\R48(&N;A=41W`0K4GZ1),C?L4DU:#.0*2]*AI&3@=:1&KV'!=7_[8#9S MHR0RJI<'=52]>[#LH4^&ZI.A=B,92G#VT8L`L::[%/D1XFUZ\]"3JM#0XN`T M9`>K)"86;&MV;UNR!6F];BO_3KU3)R@<+\,*`]^Y=&VVZ4M=)E*:^W<=6SKJ M>4SJ0!<>S!M>5X9H'L83[.G%L@2M.[_\6DO8,M`B,7\P:_MG\V%(PDB6/E%H M=7]DZ"5E_>-7!:U(^`VO+=C6_(`GGLXO,-?L1^S+,*&8V,!+"D M]:##/.YFTX/5RL;!(_V'1$7E&54E`:PB/>@=A2DR%-FM(U'^0JD18-&*P`IM M&!`E\[,HRZ6+'MCCM_1C':INO"E)`2NI'@O"X)'9('>RK"Z4ZU.Y'7RE\/#" M#!!E$*5I.VF+'9!Z":E(WN_-N3=OXX<0_QDS5^RCOH_SS;J/<]6-E?;3>SI[ M3^=N>#H;TE+Y.U*GQPL)@/I(5;!A'CPX<)5A;#&)H60#A:M"@CD`Z M:YO5(^1$@S70RGJ^O.:&$A#5WXU4/]"SY9>+^]!#83@:)U4B-5/BJB3`]R@5 MK]!NR19QJI8^7EO#27!",1,EOZ&@^8:"X=A,_X8"8,NK?T-!4X.=9G#=/9%DU3[5>D%! MT-I4%7WM]Q-DN$62_M#PGC[R<8+A+,,@%32_\?U'X'*6P!:)^:/IS9W:*A=A M&&/G-`Y!A3EP>1^@"\,%9%GSRCO)GR5J0[ MJ[MU%H"Z+1%[6#9A84CH#NS@]'[7#;:Q^XB=D5^XKB]18YUN=D"E]=D!ZAQ8 M,7(=N#;.'Z31TF2)8J>4QD'>]%E)8%ZLG$>%QZ*^4Q&%ISBT`W,TU.'A"@?,U(*'4_[!)?X"UW`!?(LUOFA8G@*LP:TX$NGN?2NZ*U\XEVNGW'8WY,_#+#P)JY,8L]^S M_SQ0I=+?_#]02P,$%`````@`L1X1_?*KM3@``@+L$`!4`'`!C9'AI+3(P M,34P.3,P7VQA8BYX;6Q55`D``]]X1%;?>$16=7@+``$$)0X```0Y`0``[7UM M<^2VE>[W6W7_`Z[WWEJ[2K)G/-Y4[$UVJ_4V[D26M%*/DZW4EHLBT1+7%-DA MV1HIO_X"X$N3Q#M%`J?;NU6;3-3G@,\!'AP`!\#!'_[]Y2E!SS@OXBS]XQ?O MOW[W!<)IF$5Q^O#'+S[='2_N3I?++U!1!FD4)%F*__A%FGWQ[__VO_\7(O_W MA_]S?(PN8IQ$/Z"S+#Q>INOL7]%5$1_0!]QBO.@S/)_13\'R9;^);N($YRC MT^QID^`2DQ^J#_^`OOOZ]P$Z/C8H]F><1EG^Z7;9%OM8EIL?OOGF\^?/7Z?9 M<_`YRW\MO@XSL^+NLFT>XK:LT[._+M'_^_8,??ON_;^\^_[#._3^W7^@__B` MSBZNOGY9$UO.@I+(T9^)V/OW[#]6[[__X;OW/WSWP?";95!NB_:;[UY^_^[= M^W?OWOVN4O]#$J>__D#_XSXH,"(-E!8_O!3Q'[_H6/KYP]=9_O#-MT3SF[_^ M='D7/N*GX#A.:4.%^(M&BY8BTGO__????\-^;40YR9?[/&F^\>&;!DY;,ODU M5LAWD!3Q#P6#=YF%0$NT5,J?=%_;?''*_%8)(\_X;J?Y/B!]+@$?W0]_1#[W]' M/_1/]9\O@WNV752M^X!GN#\SB+SM-QJ(?:GN"3OI.7;S"@ MJ^_U^[[G^H__T(F"$]9>E=FX:\_X:=[W'Z$6?C' M+Q1RWPQ14XU%WD`/\E!C?RWQ39B1T6M3'B=535?JZSQ[4GZ^KJ!,(?1+$\LQP6;K%@U9!>]KO9J9$$D:33/YP>?[K[XM\J.<0$T?]]]S69 MY__>&;W3?\,8=.K?`33LOSOV_C\I7.-,F<-2V+Q4M<2.I! MH^.244;PN^Q2*H!AF@G*(>LJ4;2317^CTD!X=K'-T[C818KJ,FJWV$:+:H/S? M"H>/:99D#Z\M2J7[4\B[Y*`6=I=Y4F$P?-,A'+*,!J'R)Q:#03M=L,[OCJS8 M<7%Z0XK$>8XC_8)`J>%T(J>'WIO&R<7!D$V/D7=JM2BJ=-$I-((U\]+3)"B* MZS4SR62EP,M[627(8`M7"$-A.,32(.36HU0,9>MZ10II6/PI3N.G[9/21PUD M7!)'"*]+EIX`&(*(4`U)4M;@:8-K]:TCL/C.`IH]>-!K!AHH:E=!<#&9?N0@BOZRYZ M`MYIHD(U9$[J`ZMR#U$_W=G3D$$J_4#W1^]MZD,T;`]*Q%@W?L6)^P` M0I"7KRM"MR((:0BF.'GM_J*:)EH4X'0>:6U8;Z)IK.V=?J,AH0&R_G-O8A@=F/>0R$P!!(ADPY:ZGDH4U:Z$8%/<^HVH/JB3C= M;!*`Z^TJ=7X'0PX!*"ZD2OX7.T4*RW>P\.[".E`OT7`?J%="YP/U0G$P--)C M'+*J#L\O4"=B7\5607F<"N:)-U!AC*&<$)3':66C(.?TKBDT\&@E)R)EDHY&\WD$-L!BQ?QWOQJ7,.6KP11 M)0G,9;1'?C[B["$/-H]Q&"0F!Z]X>2\'KV2PA0>OAL+>>62*<,BHKMB\+N3T M,4Z#91K%P9^"39`NTNC'+'WX,_E_Q2Z[5L?=9KLA_-V>NT;!.V5L4'(S&ZIV MA)CB$6*JB.@BJHRH]MP+LX^8+A)?Y=09"#CCB1!82XK>KS`8((+$>PDFXW"U M?1>_L#C2DM1V6L;/V'B1K=3TL;8V,$6TI%:HP2".%59^`?WN=W6DL%6:=O$L MX=CY"PZW]&M-H&GQD&,LO>QBJ..,5Z;P6T;I%&!PR1`E=Z&T44.-'FH5@4V/ MZ76OZ_6"'DUZ8/@44V.)K--;52JXO1M5(D'OI#)!-R03NY"7K5%'FJVPK[+T M..C\K7M(!-26;1,55T;ZAD(N224&V&537P(,C82P9)L2T!Q/7":D#]"I^G,< M;95KC@MMS/")!,(Q1H>,<#Y6EGF]2_!('!;[#)?DL\XGZ&9!. MP]G\QPQZ._M1BWMGBSG&(6>8$MII@9WW,*"=(563XD`N[M()Z4!W_9!,UCNY M#`&*F=61GS15@<0C_1A\#N*XV1P[)5_%BJ/U*FEGGD@/N?5"UO2_PW[Q7JL3=;57J0>]V*>6R,%BB!\CM33*-(U3I'+&MI$K- MP3&*WMAG/MGP/MQB%."RPGA4;!&3>, M@+<444K#8(H)Q"%A3A9W%YW8/CUC5ZO-S1M]S%XNYHPCFAB]3`8&'\QC\HZC M\:?!IM@^D!;3;PQ*1=T=S%6#W9W'%8=-/PHB;QR!_"N0T MZ/_NK.U%L-H&[_X(HY4%B+B[/4P$6'3S9%O$*2Z*14@6/$5,X_B*Z*94VNE] M:37DWD5IL:AWRICAXR8,M33JB,\/SR6G\C4)-SF.+HA[1$7 M1?YZE96*V::-MKMEB;5)NZ6*L:IW@HW#*SC)_7O4ZJ%-I4C#(U05A@,[P_?E M,BW*?*LY>2L2='I"4@JT=TJ2D_+.)2TT[K0D$40[R=GW7YJK"E=9^A-]]Y2H MQLGK:98^X[R,[Q.5B[+0]G'!Q-`DT243C:IW6HW#RT5=LL^&!\:>5+5(^[6@GDTC4R22"@3[]PPZ6 M/F9)M'PBD\1G%K=0/["GU'!^'E@-G3L2+!;W3CMSC,*#P50#=56`D8PF8]J6 M.+_+UN7G(,?+M"0VT`%^4118?;+/4-?Q<[3FY@R>J-4K@B&C#5KN.%>MX_!R MNG"IG&DC'78%^%A)F!LF6DSHM;T3;C1D3=3CIA_U<,C%JSC%TD5-"]"8F?;% M>5GQCC1:N`2V+`L-)'DGTMDJOK:Y/LTHY%:PR*!W MR*,2A$;`XS"C*L.*7/^M$FR5ZQ*=\B)N#M:*0:W.T[9_QU&LXM!<<!77(N#<6:]&Y&_XL"[?U M:>GSM(S+UV6ZSO(G=I5\<4]<0!"6(E/,])P1P\:,EB@F2C"(8X&4.P92J[*3 M[94RZFA/.1TH"`(DHF(LD>!#8-?C=%1N$L!H6]'X$T?HB1-RQND8&42$?;7VZS7.*,2[" M(/E/'.1R9R`7=<4`'=B&##(Y$+S0@.."BY4XJN015?#J'*K)RD6CR"8(4+$73:I9%`EY'.54@U]U<3X@OQM>.E-(^MZM2*% M.URQ<((@N*%#)UVYU#.4>@'#5/RSALZ7S#C3D?3#&`ZJF"^M&$"V#+'IN,)F MLY,S98*W'Z_7%W$:I/3)VYNLOJLNWJ:Q4_7R(J2!,<+'(15ZWKDW`BR_\5NK MTBQQ)@2"2$Q<5J[N[.5W>0 MJ%"'!HP8PWYU'0T6@?CS[&461DDEZ9S8FG:(IHG M)JPW,F$YE&R#\_*5/MC-3GTV*4?DLQ2UBEOWH@??]S)R>4#.1@N2\SFWUS?G MMZO_1(NK,W3^'Y^6-S^1E=<12G$)@V6#+!`%,>7$4RV='OE8Y9%G^-$/LDS M474[5S8WIC^'UNN!8:$%6&[.?;5:7'UUVM_0$2LC%%ZJ"<4.6@+E$5\O%R?)RN5J>W[&Q\6YU??KG'Z\OS\YO[_X9G9U?+$^7*W!< M-8MJJQ0\\=$@OBV7AL@YNTAWAVTP.+4(PWR+H[L@"?*=-3+?+A%V.AHJ`?=& M1Z$D&`XIX7'[:I4PV@2OI."$A9Z:?^C5:&#AA##,MFE9W`2O`9DB:HDE M%'9,+`7@`;$$DI"()892DPF5&8KB'(>$)D#<4I-QIC:)'\@E]6"@YY)GQF9T MZ:95`L,Z4Z2R?$*(K$'+A)U;@D&[:[I-9$PVJ;1+BFD@=XDE$05#)S4^[D%@ MMJ771.*3G1H,*AFSR#>!S+CCF3;:>)8Q;?H;..!H0^^IQ"7+XDT/RF1I&:28^1BR!<__33GUU6IY]?'\ MZA1,+*'35?2=R9LOTC@AL-Y'Z7;`N1OK2#J4V+E=M'P/XN/6$7'`$?#.-4WE M.5Q.S/5P)0(Y'*.Z,F#8(@'&9_-DMUX+EA;P&/W?=U^_>_>>+/MS]$RU_A5] M]^[=T;OJ_U%178H-MN5CEL?_P-$1^MWW1^_>OS_Z[OOO6"CS=Q^.?O_[?SGZ M_D,K'!<%C7>R(W:[R[0H*.@]E#O2`BP3'?KP[@A1KAPQR3,/ZKHP6F+QA#53P$1@_Z'$I==+,)P^[1E<3R".@YCV0S0 M1-%MHF530_I9EW5:8/R;,53!IE$CB*)*$@;W^+FN\:38]RK#;'4!:W4JQ2=> MI!8=\7^&11S=(:*19X]@'?L:<]P+%N$,T8J/'>[12:_.%/,FR*]S=@L_8@NR M&YRS)$/Z]9M*9($L4P,SCIIC52VCCW;+9W`DK-):+=H%O+XB>`U/ MI)-!EY!M*`Z19!*,$G+5FT$AIIK^3J0U82JQ*%2ZH>/B-" M58$ZH&22YUWX:\^J'Z0J_H- M#"$&@+@'Q,Y_/K_Z!.6=_O3F_NCN_^P$&G=C`>A(4_>T#63A-[;QBGI%]93E9?P/ MU=BJU'"JGB?^1A-^6#N' M,GCBG>JLD08V]K565"&-RZS04J8KZ84T/%0A;79B0(G#`>0RB9"?$*V$ACY9 M"H0V5UF:]X$F\&"@YY)2QF9T":95`C/$F2+E`A.K'\]OT?+J]/JG<_1E M$YSX"DAT8IF6F-249H+.23G.UB:".$C,UA6!=GY4#(^/@U=2S:`&@R#LNJUN M`M27<7X-6CGQZ0I`(X8(G/B^,ZR)#DW*7;#[D94G[/I&:1]0J;C.E*X#/\R< M+I,',SH9@)3ZFYAIP&`68WME@JK/-!+.74T?&N=HJI_!L(+')/8ND!CP,8A3 M.E>_3N^"!%^O>]ETVU2Z$H--E5WRQLZ@+J7,-,&PS0KND(A4&='#ED257B*$ ME&);.O6W72H`69!9+<1@K?=U,"4!HXZ70U\V/DPS53".R0ZOC(GHYOP6W?VXN#T'S$F;&@#`-V-V MP>:2A#GL-YADJ:EO:&0K[9,P`\@JRM2B8$G3Q\<=P*E^A4&R MP'C`5UN:)^IZS5U*T@R!]L6XI-I8([LEP;%6`4U(30/=9@54K MC3'@`8_B$G/J`?DLN#&?0-0/+WL)IKP-D:427$M,!="K[")45W0V/5$8Y. M7C\5.%JF[7G4!#1T+G4"9?.:L;E[ M#IGFS6V+4!X+A1/H_192ZPAP<=$U7**$",#P'8OHO[?58:V"OMY$FR=.<,^2 M53:-=YGG4V[S&,]76?W,Q]-_!TPOF=$X/KMR^RGZP%C>?(P^(&6WK>F)W]L?:'#WIJPPNM),7>?7'T4R%39:8^R,JC71XPTH2UUK%#O5UZ` M[D7+Z_5%G`:DKZ4/IUG!7JXYBXOJ_4A9S1BK.^6GI5$]AAKJPO',=H`Y;]M1 MIRNF"-^7**J5/,TE9S_PZFCV:7Z/PQ+W/IU])1.$'!/O=X:K_^Y,">H'%_3) MU8P+<'PDRM*PP2DI0VTPGL8:,K=^?23_B^:43&N&LGO[G;>M@$S8>$//\"8K MXI)==E@PZ,9U)%+U2U.Y,6J"\GK0W*@%9D$Z"2I84;(Z[@W;B][DF#X^H[MW MJU/S2T6Q$6H:]G7@4U"(ESMF6@F!NZ8Y-(9>$TS)U^1O0&IT_/)-`%]-MHX" M?*;Q8/DKFY4$D+?2>!,689AOR4([2`(KCG%Z?GDF,4/-M8$2M"B(*6#!:T)4 M"FV"5WJ5@PVPS;_SZ@%X\&Z/V,`6T3?!:W"?F(^VG)YW6HK,T-*RJ[07M!0` M%M"225$N4C&HU&ON/=767&'S=;)(U??X*S-&-PP/]0"OBJ5@99XQKA7>2L$P M>HD9L=Y]_^$=H]7IV5^7',(+C)N^L7=6MDBY MY2D314DE"WW(9-&>TVV>,_/:Z*)Y6%.F[SF\K#9+$UT6*T/Q>6.!B]/1A)5X M-[0,@ZOF1\'>?)8,ZB&_MQWN`W=#V`ZWZ%B9]A@+:.I6><,F.*^J+`@`E0T, M-:"THA3ODX0W0]>=5XV;$N"=T2+3G_IPVR+\^Y9,EWL[\(LTTB4.LRG`)9OM M#>NRV%P;6G3<&CDWY26@'LD,I*`'*C:U,@M>XD83"'7S+,0X8IEV!*='3+AK M4X)3\MJ;UF.ON3H8YVN/F=]*K$JH?&YS)`@T@X=]=9F6Q**8+#&5ART,]+RZ M6ID92@\[5`+O6"6`A[1D^]]17&[9>Y\IVK"0PMY-;M\\9X(ZF7W;)'8OUF5R MW-IUF6CJ"IJZ[4'@MZ[+E`4!H+*!H0:45I0"9FHP&KIN7;9N2@"X+NM,A^CC MY00GF1)UGITVF$9)]'Q-9)5FR*:O0B4PS#1%JIZJEH^8/3=/M>F4-:Q>"B]H M`?#8>)656',>1"[NBWLBT#+*=65!,DT`T)Q@;%F?TA)@[6;=XDT]P;Y>&U!, M+N[VT4LUZ/Y[EV)9:.L<#4[^L%,.A+C5VD$?TO&@Q[#A+:36]P'F?1<`-94F5V M1;BD\!CCNB2VT8=%XQ'(14EPEU>GM^>+N_,JO=_=CYXNL8JM69">FN>OI%?] M'"1;BP8<*#I.H+)AC7!7!GEIWX(RZ,)E:5"R:=H]?HA3FHR4#J?T#Z\XR`^S M)3]X:,GS5#GWL0.N:D=,;]-5+5A]&@ZMN+=3W23%$)0\J_I4PP"\V)#.$&J.NK8SHHD<'IY_.[U?+J(UIDGLW-(%S^*)WJ-X M+ZE'"M_W5;73!KGDA=$F@L('F]8:\0#6ILNF*=G5F?L!+:(^T3E.F= M_!,;HNX4@<45QZI[L'Z!L@V@5^3OMIM-PC*G!DDS^BW3=98_L>1`ND2XIMI. M<^+:F=1+CVNFZIWGX_!R2GO8.@B`"5M/<49SX!3T:EH\CY:583M#+ MNWD<4.&3>:T4(*)(H.GH`NW1Q?J^-UFVW61)'!IDOE4H.,UFJ`7>RU\HE09# M*2U$R55]&@UL-,"ELWD=F6/21SD*>H07%W1DIG]=X9?R M))&?7!E3D$LZCC>T2U/[4L#0=S1T?@WQM`G25W02A+\^Y(3A0(*C=_%#&J_C MD!XWY[JJCKZFRDZ7`58&]58!1II@J&D%EUL#;)^>@OR5KF<[Y2"!\X5!TS:7 ME7%X7JGA=E:HA=Z?'DK%P5!/CU&:BPSM5,`-ZP*S=!Y0K>*99DIOIY*'ERA` MBQ5X\COIO2Z-%S/05-]\IHJW^$KC"0*.#'+(L^QVPS9W@)T7A.:%F& M2]Z.,J_W&H)-`6"8.P8U]R!"70:C[JX45!4#>\(I,UD_[S30=+PQ8FK*8+]$ MIP:&J^98^075G?&)W[ MDDK[(Y+234E$@5))YX[H#2=T`^F.$IUPEJ\:YS,4S!Q297C6X*\\9"G8Y0DU1`;R![4XG>>3VI&=P4:S>[ MHJ_)=XI%=;F(%7R$6-''U3.?3>'P9F2F=732K2/MS.VMI8+L/^HJ&-6!Q$7N M7P]2VB$>1:K3U"P6/E<2^K\$>1[(G;U$QMGL00:OG3<,!;SS0H5JV,J-V,QM MJU].ZL6=M[AF0:F3A;+S:HAS+F9,E5Z%^;*;("]?5P1707,;9*ENAJA70 M;=`8)=^QU.EXIEG MFCU.N3QDINEW-1NJ03DE?![D-(T,32/$UJZZ#06IN-.M!0WHWB:#1!8,C30` MN8V'6AP1^2JJ!LY5#2W2^2F%O$]6*3V45!@LKW2^B=[0"=F!H+,XV=()%TU[ M5WNL+R^SHOAJQSD81+N-BU^+11I](FV;ET&<&J3QUN@X70V8P._-_U4*8(AG M@I*;XU,=1KZ>%CC7=DI;-2WS*O!+0)O/QLQ4G2:XLC"FE\3*0`\,&RW`"I*8 M[%1A\.^2)G?4N;BAD$M.B0%VV=.7`,,3(:PA(RHA<%ZI@G6]OL1%D>7F+LE` MSSUW#,S@Z:10`L8P/5(QZ6`PC;Y9$)?5T8`T(@Z27GS%:6B5!=*N#+"V?E,&F\?U2H$<6.L`MYG,J94\D=9X`J?2@$A+FTE;JP2# M7W?;^P+_?4L`G3\;'+:3B[O-#*<&W4\%)Y8%PR,-0#[10R..*GEP+FMHD#;I MB%S>)ZG4J45DPF!II4\@,N`5##+5F7D&"5%>J__49F,R5'::@R>]E*1Z M[(MQ>^M^G)']F_=V98!A[DC@_,F0OBX0CWJ%/W?Z9)ZEY)\ARSU;V/A6^V+< M/B4USLC^@U)V98#A[TC@`O[B00JQ7EDPZ'P7/N)H2Y]:;S,$G6[SG/QK1:]# M:B>?QNI.YZ*61O6FIH:Z8.AJ"5B4B#%+V4J(S!?V)4W4Z(0\T-+PC$N^`X^% MQE"YA5--WVJV"CSI3K>O]9-?$).;O"O6CM.X)%\^U-)4F3LU+`8,I\=C5Y$< M+>D^OF`_[']K18@[P]A2`?:--YJBZBJ]ZY-- M*=!ZRE7&GD?#477`+Z)G+X25A:`SG[CTO/@=YU.WA]$W,*L!3%-NGZF^CQX6W?,3W&/'V M"M*-%^._`+"'36B6J@=>!'&.V+NMJ%.,XQ=U1UZ$=_O6L>D5:`Z>[.8S8HT% M+MC%*/:8)<3_%E6V)YH$K`%]G=_&#X\&6Z_CR_/DJ,:9+?%)=H5!=#^C+-#/ M6%OR3S5GE>4/:RVA'HXYN(Y_JZ_6KK+6H&U9D+5G%*)APJHH[SUD&ORJ/F%P%0]:!UBD91Q1L/$SOL/A-F?OOI^_A,DVPM$%X1`- M_6RK8R9\C9GWC>D^Y*?;3%U1XAXUU5<`=K:)35/UPTY!]'_NS;W8.X*9G2!@ MGD=6HP,AI]U!"+!'Y9X$'!J*8/$I_6HA]#Z)#'T%+>$%4Q_#\AY73[B?$S=U(I@ M2-DSQ)B03&L_R-B%JB+BAE`'YSF9>S$NPN`@F7+BHF#V5=945DKJ02KM-,6- M&G(OP8U8%`ROU/@LR(1BIHB"*(KI3#](@-"+19M_PN5C%BW9+C.=*%Q_3G%> M/,8;THWHX>'@03:_M]!W_RR(A5G\BR$&RG!H:HEX2-Q6$L5IB0DZ(,?`;O(L MQ#@JZ'J[Z5S7^5W`PF',9ODI4*VBXV.WAH8,CMUJM,`PT!BJX'U+IHAHA:$B M2+@Y(0PJ5J:PD>!J^W2/\_K00#TB+--.REC9),6J"*?SPQ'&]6:*%OI@*#L" M-/=@%],;$K9>PZ`B2Z*94_&OX\V7X7%G>BA/[HG00R1-+C(V18 M?)J[,;,;8MIC4%1/?SS5AUWILQ M!7GG]Q3H)91'N%8GBV*BCS9DR"S@[&/1-SJ7:5'F6[IHN@A"O'BB-V4E%207 M=_U&J@KT$%4D2P8SFD`$" M.KNXZ\8@MQORE[`M>O(NHYGF5L9^(B"ZYM$#KT7]]K%JZF6B[7S":VX2-^O5 MJWJGZCB\TOFO(0O1E[7@GX+T:_3NPQ$BE/KNS4?25"\@5U<]*@MW4_PF.-"9 MZ(LJR+8$MR\F6YO6?TG96!T&64=A%K^9F=5'A4,:T4P2_.:(SD03BDZDBLW* MFY-GLF%&+N]T&J"#W1OA9<+>26:*D'M6I;\0HJO_AE8UT>9W;VUXDV8*+.-R M6YU@/&V`U%*:;F5?M*=1._/)KW1U.'M%0=0;9*[-9),\)$PTCL^&+<$GZ< MD7V2VY4!B-BC@`_)O&B/&-6;"@->MYL/J7#W-\GW5*"E^ MH+>L+Q5M(X;'';?!)4J(@'J'?,9JOL7TS4`<-=?]%F&X?=JR.^1G>!V'L?A! M1:V6J^0JY@UB@9GS]SM1%%6R,%SVXCF($QI:OLC8R43M!IM*P:5[U@/OTDTN M#<85:R$JYA!AL(E+\M_E8YYM'QZ)URWI@T^8'3)EU]DCXNA1T1;)YAETX0;D M7$V;VKA-*76+"YP_2VFH4G#[OKH.>/]U=9DT&!IJ(?(OJ]<***\%@5'J8]X9 M_V76UD)>J-,#**0+DX!'D2XLX1EV,BV)T!,9]?(X2'Q-4%JX9*JDK&7RN^., M;F5&O+9JRB'$-JSJ%2V%3+8KT1A*!SS#FQR'<:`X_=\7<;NZX\'U5W&[W\%T M/`&H(1>Z(@B_T)2_0((#RR>R)LS9':SU998^7,;/.*J2;*^R$WP6%YN,N(OK MM:PKF.L[]>*V9O550`-X\*S!1N)3[T M),M^92G/KM<5:%%P3RSG+(BJ@MG&2T5"WDFB0R:*7=P36?3,LM`1/@1,W--$ MH8YW$2(O0D+%'$O?S1#U97-MQY,,57<>`9J;Z%5%T"L<9.3!Q!]4Q]@*G"0H M>,@QGJ)+S_QDC6J-H%,"\52-=`VAUH!#1!.8@C6&8/0X0@]4!P;C>C'"W=2, M_#O!+'-V&BV>LKR,_\'^KO4XPZ#19,4[C=U-7"F]2-]$94,+/D]LU[`K79*U M.@IZ4>K=1WR-QS(;)`MYE3R<5.U6:,5+??&L^0BE4)XJNHC3N,1L;3!XG>E3 M@=?;Y#)>RP[EFJFZ]%8VQG3I:*('9ORU`,M/`$O&OJ#C?NC)A#@#2)_4``>"KIN7S'084/WI4"U MN!":I.EI3ZZ%443^-"L'%IM-4K]G0-9S^CE!<%85ND,-5MDR4J!%M@9;8$VA--=D($GMZ%[E*@!(:Z)PQ3J MP#IU8HA6.HEG4:IY)_&*6:?[B;IL:NY]/!2`D4V_HA@3LQ'[-6GF1YGGVF1_PE%2"4=)LS0@JU MGRV"$_/ND_38^,Q-1)(E&T5)!N4%[O[-J66=(OR6>%/VM$RDS1)O4X"_>V\F MALEOOZFTP1#1&C(W\2:D;)/$HYSHT.V/6@=1(Z[%'KL(KTL>[*%OC]_96"6W'TIE,'0 MTA;QD*RGO5R'N_N)W00'V_3MEV4EP81;TD_(=\@@WTE]QS8@SG`1YO%&$%^U M4706B+`RI`U3&&EYYYHUU"')=KK]Q/*46`6*=OISW3NHTRO*;1!9;*+E[DZ" ML0F[&PI:%1C,,L8IWXS,502;.7-PD\-3"+^7BD;Y7(95, M6,01SNL$!>S:471M]]Z821F>'APS-T_RXIB^`._INH\/<"LJ]Z+J7(22M^@ MTB@Y?6S*R(#>JU)*#3",,X*ICHR`#^`MTS#'9%JY",.<)2"N@I"&6RX279_; M7DIS5#M>0D4P7+1!*TABEU=)H.L(,YT=DO)@\%'X2%O[B&GKO$\#FJOZY'7X M7INL[[ZU5._/]=E7@?;A/O,BP?!^&CND"^N<2<'H".JLV?0_3TB7IT$$NC_$ MYMJJPY?CBP/SEIJ!T<:OJ"G*`D/V-QK`^?V'AYR=8^XLJ>KGG%D:27J8:YN2 M=1LJ'V,R2TF@G-%AIMX/35W0/OO`LI*8W;ZZ"7*ZH+`@EEU)'O@VQE0!#6V*@<;.$=@5I.ULP5;>D.70 MJR[O;:H283[TLHC^>UN43>;`-@_]31!'R_2T2D8O7F=TG\NYI:F+BKC$=SA_ MKBJ.K%)N<9@]I+%B#\_9UYWF>'%;I;UD,6X^[;TO^[&7/XW&)/[1=GHVYZ=G M,-K/M$=W&V=`_,)$CTI.N+#F:H=?SIP,ES-UW7VLGLU.JSI31I_F^)+SI?0\ M5<6MH:?]#)C^.I]MW)M6S0N6]3-L$8N>@4IF]M;*Z#S;586_9ZITP7?VJ=M) MJVG*3L=]Q&F7JUA]5Y*)YN6,O4]FI*3OH8[\$3K!#W%*']LBHV1"WRLZC$Y8 M+W)IY'S63BCXSCYU0FDU3=D)N8\<8B>4&2GKA!WY`^Z$S1G7=FXP6^T+OK1? M'5%:5=-V1>XS!S,)E=LFG816K[9CY<03,&D\KES`)?N>TT@I?^J]&2#>VOHM M]U&'&\0%P3F)HC+4_`R*J!0XGG(L="F16T$@5'YC9[[(\C6.Z0NM;OWNJO[].< MP;)*9QH35)\^Q`BCG>G<18I:!=4Z[90?,:VCW]JN@`=?8/SU??(%EE4ZTXC^ M6_,%=J9;^X*#V)PH[./%8QW-I;F.RB[)%? MZ.\$^'`)-@CVRAO85^VDCL#\\X?C`ZQMMN[^L#;!WNXS*^L\SPFL0.R5#QA5 MP1//!RP0'(XG&&/VV)7#P;@#P=Z.#X=@#6.O7,+(2I[4*5AB.!RW,,YP:\=P M0#N>4&/>![B?96OZVZ+>A[:9"C4@>X!$M37];2%9L/NT]_H:O+?NZK?X*8AI M`/HT2\L\",MMD-!GS;Y5M:5K)'N1/.CM53U)5J'Q,&!-N[S8KO4<;0&H4P*B M113HR__$05Y\U1OW=AL\,Z7R<%]7PV2\_F`X2R+BL9+;#"0>,'AW")X-G]X; MG`-ZI?BM]2J?E9EZ#J](]FE.\8:JGG).,0*&=Q?BW_9IO(CXU`C0285]90V7 M&_Y@[,VDX@V5/-FD8@0&[Q[!L^$SN`-PLXII@I)+8GV<%G'X!I49ZP\W7@KCIB\)"ZPYQ%Q(,0[P*BWWMB1U#O$`'=G M/.Q7EH,U)_?!/5U:2BINIA7DX&M@AXXYK;7HP)VR8(T=A\`]J*/'O-:.9-\A M#A]7]+FZ@JS"VC>5J+0RJ^L<7]NG@4-395/V7,FG#G'(4)O*O>&>I<>5.)GA MO3D!)>!5AL=D7!^MO/[GR^^%/[Y/!5E36EMQ=] MQWO0V(%Q)KVO4@>ZZ]..7<,$:[.[8UF9D^WH&'[7>X?T8*Q)!X5X M16?""FHO&KA=)^F^OD_#J&65SK*.4G_:>]_V8Z])]P9QT6:_%^T'&&O3F6J] M;`<;8ANS\+P(XIR%$1=%L7UJDV=@^G#<6?P<1SB-;H-R\@U^\^_NQ4:_;35. M$AI%CNIF`Z<./KGJL^+M[VV-5 MU3A;CQ5]]#![K,)2[B%#(GJ\)K(H)T('V&,;[_5SEI!BDKA\=3W*#K^\M[U6 M796SC[3]SQYFSU7:.NR[C3!Z;J4!=>`Q*PE5EJ<!A:]UIWFX& MY$['C#!765H%5L[_OB6#PS(MRGQ+?YW_`5FK3^_%C&A$94XR);+X+MBC0&[L MYNX4!3D[YC%WXGG51O($EG=.'4IW_Z;^C-L-XGDJJ;\9/.TW(/6TF6V4]ZJ# M2.%N[WXZ*:_=^;S>1_=\O!14X,PC9>>+8*:N3LR4=]X]RZAN7QGU$4UWM=]^ M<,^[YZ#B9NZ:]=<.N5OV391W27B'BJ=V3YI'@6?]Y)[W2O5#PS-^[Y![IN[Q M8FZN>\"]LY.DV5T#]#ZZYSU44($S]]'.%P^YE_)FROLIB*.)AQI>A'IHT97= MA@%&KSF^]SJJ!HA@L]MH&%>;]A#L;*%J>7K1WFG@>2K9^.-[%-:VK-`)NZ7A MEP\P!&YG^43/'X/MTN)'!N;;AE)];X\ZKK[:)NRK\H\=8/?4&CO1(\1@>V03 MLQ_Q3)@7!'O4:\=4[83]V.;S3GLV^?Y])L[%X<]T;\\'S]:S:>C?8[>V^/P> M]6GK2IVP0QM_^\!ZLZW=OIX"GN_,5K-1X*\W6T+8HQX]JG*GC%C9?/_`>O88 MV_V][3M;_VXW&/SU;TL(>]2_1U7NA/W;ZOL'UK_'V+XW3_3^9H*RA[>#8FOY M%._S[B<[H40>#X^#!L9.\=HNH$E/H:P`T>L^4]7\F"^#GN*,K\HW=5?[SWH_ M0^3>UFF>H=K=?>F,)7O=F6?8['LCB`/KXE,/SF]"\%OJ^"-V#2U]0.<+>^T# MKE./?9]]_,#Z?*="'?=U\N6]CU:\Q>K_&>:USM!K;Q_B.+".+ZYF?^/];],= M""L`\.#O.1<7?RZ^?,3YZC&H:[QH'\KJOZS5\8VJ,_O>(.U%/J\)*W^2C%\3 MX(%T(!%0?8Q[O70?3BM*W]Z;=7]:]#G0TPG+2IO^-`/_+4A=U9&MXUZ!-.R& M_S/"N/&H@#:>0-7'V#%FGS=#83A20(QT9NM85SK-'N@TJZ:;/%OCHB#V!LD% MEF9$X,5"CC/=2O`38D#UET%]NDI$OK-9%"98:B., MBHMBBR,4Y#F-,J)LW4M1#8.\9UN\RFYQ0E-PWY`57(SI,V#AEF!.2TE5:71< MDM0(?I>82@4P9#1!R*73L>Y`6\#@VNBE5+U@JEX-;DXWMPG^ M)W]30ONYO8A`&U;:]$]>\]\"TZ]F-G#8):D`>J82U/D#G+FLU\0_Q,]D(4A& M)KP*7NAC-;>8TC).XJIRR@L(R*XK%_PV3!$M.UBVR5(Q!T MNGB4`NVM&#DI,"R30C,B$F;#+9V91G4YJ&@+.@X94WN3U@(%:80^UVD.89#- MO*.QRI*F+A]1#DQ7.C!SG#.M"P%#]+'(C?I!5*EP+K7^NZ=S`:JKLMT,M]*A MTZH`0"\"CL/-/0S(Q-&7$4ZSISB5#YT%FFCPE!S#DIA3K76NU[P+#W>'M;OGG(.%0Y05`=\E:I$; M\4$\_!6^Q[_S(*>G\HH;G#?[<.)Q3BCHN/$4]R/,8'*[W4T[H(!MZ\RYZI,, M7$/`;QVQWE:>LZ%J"K/;,>HMA7GW/E-9H.7V?HY(PYI1++PDHO"=U!"HMBG? ML)9R%S-8I&4<]$T54%OV-2O\7#.I5SX)2>FQ, M+.J2.BJP7>J(Y,!01P%N2!TFBG`KBR(P!SZN-W27@+A"AK&X)6ZS/J9^A67# MG4;')9.,X'PT2NH:[Q<\X%60^^10Y;X&AX8>_4 M,D7(33]KMS,1E22>I_Y*O1X7]8JAA#/O(H;6^I/^S]Z;68Y)UK!U%`.&CZC\ MW:O:,0R%7'H#,<"N"^A+>">$$M:0$[6026>?LXZKKPMGL[3,IB884"^G1(8[VJ*5+RUM>9O0OIR$D%"5AW,&IJ:)(YP%72\ MQ2&.GW%TG:[R("V"4);:P*H`@*YC%'SN)!DIA;5DNQ'*R/^99(8O3C2T,P'AA:+#Q#$9:$O21Q0S^D.ZT'/I6-(L2M;J] MHQ5'"`?A(Z,^^3MQ@47EK5"6XNJ\DI?]@"B*2Y9,JWN$KJH6J?^RT_PERD)G M+4Z^Q=+@B#(?C8+-;2>T^H.S@77:G9V38VWZ]3YM\L!J*"E`Q0X/HJ(&VSMS MU?Q)4*P7#SEF8!9I5,>"?L+TZ#S7!DII6*UA`G78+B>+NPO4*K'#LTUL[&^5 MHIYF`G&_S;(-/@S2(`D+[ MDSSX1YQ(^K1"%E@+:X%R#<@T4*6"B`ZJE+SVWX\X?PK25TEK]'Z%5?\B:,,: MKV6\5O"/P><@CLD*$A.-QU-,SZ=*:ELN"JOJM3B'[5`IT*4PTT`A4VF;Q8M3 M6J9A3L_@G>'JOVGVZ'HG=Y6=-3DKN38R4X/57E:8N5A&K8P:;4354:V/5AEJ M2_#2CI?!?<9R:+S2Y+<;Q0Q>*@FKM70PN0,&K3QJ%;QZ/'8>]@Z795(M#S4+ M*[4XL+8QP2H^6;[3`K+?@C0C:[XT>V:V*$=_A2RL MVM<#'38%TT!QJP)B`G"%RY,L^[7:.UXOB@*7_'`O$H+5&@J$HL13]T1VMP<> M,'$OU7^=XM.$?/_\+]4->DFO$(O!:@(E1NX*2$J6@%0:G:-:WNLP8';M\E,:"_J#4AI6JYA`Y2\"E"PVO5-"FTJ+[=3YZ2D5J*)_C4W2 M,@,IB"TBABANB6)X(<]G`ZAZ1`&V`Q1ZOA>(R7BIVO9&1?V(%U9O,VOD@36` M$5C%)9-&]7>#73R]H<=5'?ZJ0\DZZ@>M675(!8U7JPBO_/EI'<*+IT"R8.K^"*SV>61<;3,1K^LANJV1AX^+ M-#HC39QD+)ZJ"RV;*,%J#`O$_`4;ILH.(724@42?=RZVDY>;S6_/&7\B0AYG"M/%7!L(@PL57'K,A+TEQKZ`.I]HIS!D M-M-\I?L$.%I56X7D0XA]R0^KWOQH]2D]TYWLGEX;9$3N+?)X[CG]/#"&^K!= MF'?ZF#VJUWL"%06=`\/WKW4JT4IN4R<&"2@8E&;I<;UN"VL\],)1]5XZ^EQ# M0D&%">%F]\IYZL793LOK,]`;.X;A\9>F8%"BJ(W4K0)+>#J+6"\^^J^ M4G!GP3(ETY:TB$,V!LU!1=FW#HZ2&D/%U&3EH>XW4?>ZQZOO'QKO MQQ@_*^_7#:"#YSW=_O'%>>-O'QK?;0V?E>MTY^[P>=Z)XJB>Q)N!Y89?/C2. MVYD]*\.S3@2/8W?*T+#];)8B84_Y+?8B,\4YY!\[-!9K+9V5N#)7O%L_5> MJ%>@3>H_NA*MD+1_VFT(P8B;-,DNZ2D6Q7$YH1@PUJ@P;^UVK[7Q?9LW[T.P.YU>=WABQ+Z+R M$:/Z/=(ZG.^/#Y6U586LLAM2WX_$US0^K'/45TP%8W6`++#%+N[>=1"P3L!: M9FA3%]3QO=U,O+Z;NLXVNTSOMO=%&9=;M@VPKDX\)NUPIFINPR+`-KD=?E6S MMXEW:2+X3F<9OB&MD]:7GU=;LWEK?OG#"Y@"LRV9C*;1 M.5TK?4I9#GV:G3I[(J;DKU=9* MEVRTP;6;-711:S:%R`:HK!FAJI+\S#QVMC9.N;K)T@W0W22*$DSSLOX/L$M,\WZLVU9 M8!M]I"'*OD[+9-L?G5)1I]B.&P`P.]U5A:P:#.B@5H7;^D:XU8W=*Z+7S$#: M]2Y^J:*O*'632AJ`R?NI6?/WQ30\,3E`FL):2!U49=.QFA;)DHC.G5V?(X$]=]A M-60?E"31_UZ>HI=?B1==7:#CE>"8K'L,L.CAKP*$)^WOS2Z0W`ORB-6`>@E& MC>Z1H,3;7.:MM=^YZF58^]].W@5&8#BL+C"^`N;J`MT;@(97J;QU`8(U9'-% M^J`Y?997]RZD3@$6N0S1!W6"TB!L>-18V4WVU$,ELIMDFI''$&$K!J M6P9/$"!IY#QOW,;EXR-.ZGFNI-)%0K#J78&0&R5JT28/@=?J7Z9A3I\(/\/5 M?U>Q&LWSW"9*L)K'`O&PN1I5U.BB^J'6YHWO&S\[@-OB^"$(-K]4KRZ?5C>( MNTTE%/CEVU^2^\19P_1PUPVBQC6L_DKJ"-5R7BM97KO@JE53GYZJ\3(.[N.$ M;=4H",M+`:I>!;AA57=$??.W`T53XS"KVJ2./57M&5YCTK2]N%YUZ4)4TW)I M0!5O`'+8#HU*/Z98*7EJF.[CN/(&X:4`-80"G/">>2WZS\VMGT5)5K+WVY(% M:U"B<$J!GD MV(;UWDJB1M1WG9.E1O:$+[-"7>L[,8CU+D`GK_E*&'U)Q;_R5/W+M,0TYE>S M0%3U`Q%`U2Y#QJ]B*[F&Z[ZH7C[B7.E:N@*`ZEF,BR,VE?+M3JZR-.MW1@6S MI<*`ZEZ/D0OF=S1:'U,K^7,SC5^\('^GV^)QNB7X:F>8I<4)7F:9S*D&^I9DK#*J#JUV&7-]CE`U'!AI2`@N!NS$&UD MM/LPVGT9W;-/-_QC'S]"O<\C]OTCU$>`&@C^F-H+EB[3,[S)BKAD[DT>"C/1 M@\4=<[C2J/"7C?I7-.U;70+R&F7C#;O)\2:((^4,1ZT#NMTD4`W;K-;V/#/B MK5JFSV2QGN62F)U2`71SB7`:ME5'%4P[U2?7[X(D,&^K@1+H]I)A-6RS6ATU M^I`:+MO2FV/\-J>Q$O2&$V(U;SBFWNQP0MB?OL#MS@#^V9*;V MRP?OC3<&K:SYU.I@NAV;7M7;89I]*6-ET-U0A]FP.U;!A;H)-GSW&$HY/73^P5[#:XMPC+^%G:M.;:@-IV!&@N-(%+1,M`32'T78VK=Y.665+<*_;V.ZB"Z))32)E'P-J%4"U)KF6/D;;?6C,F6& M:EVT4_:[^I-P=,D>*!G;+07:@!IR!&C+;MD6Y;];WN+ZY9="GKM#)PNH[;00 MARVU4Z"'M9F*IPFJAGX7<1JDX=@>)]`&U&HC0%OVN+8H_SV.HERD$?TONC?_ M'"24?=53,GG"-4E80$LUUO2Y4JN/2J MR6%E(@^H'8U@\FN06HE+9(6J3%;[G&,,R++?!*+LBIE`Q]?1Z##R._:W39BRY5B3L^6^SMER+$C:2Z8I9V=V2^J/GU`9+6UV)D/Y7)?-7@0`[2GW);G&YN= MVX:?/B!NVUKLS#T?)K<[W9?,R/,X+>+PYR#9SNVI^Q\[(/[J;73FC=OO(P;` M)T.GR?;8K]#W4HK.\C5H')W72&=N]3!(>I6Q0Q$X:G*N\4D`9_[4`=%39^&< MW&R_W:S'Z,&*ZOO[-L(34RJSJDOTR[0H\VUUNF36<)7%=Z&1UI6Y,S"8P#BN MDZC5"2\Z2""$NG:IGR>HY'K.&B+83R:+`RHS.5'YQPZ'KP8V3D]1^4?WDY6G`?E"0K>2 MJU.0IC%6#Y\',%_U:?7T7+:!L9_L_DA$?5';^-N'PVM[DZF-X5;?/QR&CS-[>H9;X=@7AA?*183H MX;3K=!INC_KR/K/Z;09/P>=1"`Z7R9TELC]2]T'\MO@ML=T/U?M@]FW#F=]E MHJE05H]!70'%XN$AQP]!.=C:[P0V)]V5G@`/@+X`JAIFV!WDMP3K%#HE0;C; M_6Y!#H]E]#80]V6@$*Y;^$,O\RU1^6\=3NA;;^)L2T_^FYZ<^/EZC6E"AEU* MW5O2=VXQ58V3ZJKIHKS`$1F+DKLR*+?T%GE/6.2+)R@6T&6Q*:WA7DILRNXD M%D94`_7+/T)!B>I/H/8;0R66AB'$PBN^W3]=DG^1/S=_(O]!?2[YR_\'4$L# M!!0````(`!@T;$&UL550)``/?>$16WWA$5G5X"P`!!"4.```$.0$``.U]:W/D-I+@]XNX_U#7 M&Q?AB3BY6]WML=L[3Z<$44C^_B:,WOS;__V?_V-"__>W_W5R,KGR2>#]/+F( MW)/K)_G?SJ!!G[373E!R2>G$>K=4!20O]0?/CG MR`:7\EH1?%7^ZOM],NTW3]\]NW7[]^_3Z,GIVO4?Q'\KT;P:9[ MB++8)=NYSB_^<3WYW^\O)N_?G?[P[M.'=Y/3=_\U^:\/DXNKV^]?YI26"R>E MX]B?Z;#3T_P?CZ>??OYX^O/'#\!OIDZ:)=MOOGOYZ=V[TW?OWOVU`/];X(=_ M_,S^\>0D9$(%%"8_OR3^W]]4*/WZX?LH7KQ]3R'?_N.7FP=W25;.B1\R0;GD MS0:*S<*#._WTZ=/;_*^;H:V1+T]QL/G&A[<;=+8ST[_ZDO$53!+_YR1'[R9R MG337,^5G)L(1[+].-L-.V*].3M^??#C]_B7QWFR8GW,PC@)R3^83]F^J+]NO MND[L.2_KI1.O'*HGJ[=LP%LJI&Q%PG0:>I=AZJ>O3&)T!$.8$I'/N(S)_.]O M7._%/]GH!_OLOT!@T]3M'IB>.0'C[,.2D#11H<8=;`B7.R>F M3%B2U'>=0`LQ+F1_6+(%1YB`DME\MF:[$A6,DG5R*#/8G3O)\BJ(OFHAUP+J M#S>V53OAZYGC_K&(HRST5'@)`7KD5[9:.?'K;/[@+T)_3E6&KCS7I1]+Z:EU M%P6^ZQ,U`[5FZ0_[Z_"92BV*7U4(M@;VA\-='%%]3E_9?O5GYJ^9'MV25(61 M`JQ/'M&S8^$_!62:)'1[`.`F`>D/K]LH)7?.J_/$)I+CPQG:YXX1N7]<)TE6 MGK"*G8(SN&=<9FNV-][1'1VP/GFKI MZR/]1N*XH!-'!=?G"J,_DD?G1;U1;H\V2DRRE,8Y"!R!W<'RXWA-K"2D'61_5J(ZS\-+=%`-9!?2")S"P"^GB MJ@0T@.,)8U`4%M?T)@)@A$&S&-]7=?FM.8UQ_$^8C]3+`C*;RU'K2)CV_$9/ M%_W5`9["*-X5+HI1ZD",UKQ&/`:Z$@&`&O(HZ&(*`C9GIW1"%P!O#N.*,E;^ M-*67_6<_A1X/>TUZ$-INH_#DF234JLFMF.0S,\F(]R7TJ%U3!]N?YNX?.P@O MKAP_SM_[Z)Z3K?(AR?Y$`V;MWP+776\JN/XQ;"Z%S>\U5UC'Z8S2PY-XZ39\ MC#;C9UF:/]C[X:([J7M^R;PW55]U58T1#8M2UR M(+P,XS6U^2ALKC/+NM`S>^A?ZJ]\+'.[) MPF>?#E,6,,?!G`[ECVPB6M6*:>Q.HIA>!ZC$-G,ZL5O3A7:\63GB[3H/43IQ MEWZP5:-Y'*UT65FR+5(04N4N1>'@(CC/-^'@FJZ:E_\DKS(9M(8"A7"*3PH" MJFV(84/'(YV6S_WZ""#3WV-B.H]&F[RFII$?40H\%N0K9WIC*)#['S!RGTNU M#3%,*38>P^@J&`-G^$1/;N53:8/=Y%C,2K_S$=8+_1YQ8JOCBT4`A M_(!)""K:[1V\>8K$.45E40G]Y!V[C8%`*?P5DQ0D%%NT?.C-*0IS1U_A2:[X MN*1FD!0.*)X?\8D'P@\;TGJ,'8;"P^OJ*0KX@FD,`+=(XT_O:6ZR8RZD/B M)U_5G$;O)R>3;2X/_?D\HM\($^*QGY(H\#WV9C$I9YJ44^VK87,G>_;W&=S:_\D.+DT^40);["U52"PZ#W7D#= MR2LB0M2$-,=9D+E?K('HEI$2U3:=8 M8`!0J-R,W:JUY0;F!P[QS=(EB76$)@2`BLK875E;5`K:<0A(1S;[B,78?5A; M+"")#/*>5LF*8<\V45XYB835>DF<=RL9$/AM$:DM#^`(NF4(6G]PT1A[E._O MFG4LZZ^+9Z0'7\A[K#?IH7A`*C&@JD?^UDBHC(S=GCOMB3QJ<Q^[2VO.`[)%CL3Q5AEKWESFX MG`]QP]_SHB'E3:\Z8#T>G]]SI!:<_Z%+8 MQ;*;I^_TD%Q#!>-O' MCIK=$8@.5+(A0R@_SDG2L`F-)J4160'C;J83:LM/B"PY9 MWE.64AQ89NH%W:N#*,]%48I0`68[\5!7(0_F!IR*]6'6LQF[RI%+[O"ER,JG)'D\<,&,*GMDRU,&93W? ML?M:53,#QT:::V.!I&+I;0993VK<:^'52<4A@\^.'S+#:A8^.-4ND'E5B&U) M"+%XH/#6$QZ[2DZ/03B$*J2U@U6)(`NRJ^B4;!CZ+6)W+[JB/"OR8#)*[.YM M[(S,HYA4^G%=OE".48GYH1._7E/S/*%<JIG*T,?M9ZYJ7=S M.8``CD-'*>GEVCLC(9G+PHB%`-931;OHAI!P)"=%M':KI7^`1 M.?1UM8E'WP3&-3KNJ?U(X`FLIR3J25N3,3C6(1=I3=G!)67,+Z'+>X#D<,NI M)`PNJ2V`]2S0?F758`0.:?U&_,62T?),S;$%NS5NQ<^K-4G\FZQF) M>KMF5U8-2]"*;55S&NLIC)V%UDWVHOU8SWZB'WF*$F+?@A*07>YD&O'&VA-9 MSX(TJS@J#O:L.K;#FUDA_:L@^BJ(;OZA2W0SFW.23XHDNKD2M;ZE5RL;BP-E M]][+$+J+HV>?2O[L]0L5R'6XC3B8NJG_7"07JA_D.\R%)T=+*,WV);HCQW"8 M"&8]'<9ENM9KYF._2^-STQ M*0P7> MYFJ&B_,HR96^Y/!I0U1H'!HT@ MHT-7-BKABIETC'M`O;.=CCHT(6VWL#*@"GSF'*,:;#J`2BM%*\`PI/WTK0$< MOARC^!N];W14H`5J/SB#A@);3W7J+BD=,NTO7J"0[ZCI$*8WOLLL4?'>S*.=#VH](ZI? M`E$2?M8%P;6EX=2#^F-"`"UGJ6VAWC$-H&43_C$>ANE1/VB(X:P MGC%F1(@\KN"0W3U9E_;);`Z3G1C">D>]WF2GXLK1FFH<5O5Q["+HPM>;;NAS M;NBF&B.7M9^G_V)WT6=Z2V7/TB3V(Z_I.Q=KB]XLX%031.99%SX=IVY,Z1*) MXU>Z&E0-R6'@4&TX1+>X_;1!P)G.:K#.M8NB%Z??AC+\_AZN#H=H1]>K.C#B M>E&(RQ"!C;%A#:O[1W_<.3-"CW-:LGR8($JR&%`:?O^9H2ID+.JDHPKUP4\< M-X\+\I2>1Y2&.*$\+WY*F25%D.>X?BYB>VCOUJ579^NOD9+([(?(R6SG5DK,1=9;K);K[) M=L)QM?9A/\DNAUC(2`EA>.G)9<-[V\*^+ M_#UI$Z/,7QGO6[X1!C/9`EELLWG M8_6U4DXE)ETNWD:9T=#,KZ MPY=2/J)0*?RKIM'+M]:^8=.QE[^<6A$;^53Y,U8Y&?.<;Q;9=VS"OTSHE)-B M3HM.BT9#8OT&Z"A66A,IP#*3@-AV@"ADHN@IC75UG4>A2^>+ZVVO:LNH%8M1 MA[%H,?G)'ZS-SA>*3IPZ?@@K):(`LYE-564L0U/KB()!VS;Z(#)K)D5IL`7) MLKIA"<`"*Z\58%$.MJ=W!0+JE=,<9W&I%*C,YCE0A;"Y*6^Q8,F]41Y>24)7-Y]5;QJKI]`64\WS M1PYG>5%UDF/K)(*P!LF">\B>$O)G1J>\?!:ONE90PPYL4L+93!BLDP#)$!1! M6,U[K",%"587@]CNMZZ022NK44$[FM4"20V1IHB\;X=!@%-$)M]M?OK+F"W2 M2VY7D974P.ZU^"K/!&Y$AT7`79F%0]2WY&N%XC@*Z8]NGA&<:"Y@_9G`%>JQB+HKLY`< MN=OLFT<60"LX4UNQ6%NHR7<%G,T#\ZA2PA[<)?$R5I]^BV'9("=G-,1J!<]@ M_<5,-U5,ESE(UI@@]4NVXEHA3Y($,`QK\-O+!-LG_PO/&NP]ZPOK&N3D>LG6 M7RL*BY_QA6'I?7.I7]53H(XHQ7U#1I?3$CS9$:2&[<%$)"NZF48@6\ZMH*YV M,@&&I3QF%4@6^RZ:O4I"M=!>6=OO57_M=Y_[&',+^N,Y#G_&CI[;**\)2;PB M?*BSOL#FL>VV,JP<.LS$I@BMU)CI5WK(5!6;%8HN))4DV:KXW3X;RS[?L>T4 M.]@NL[\PD!@GF\P6F5'2"HW=`.UGBJ#(;^I]O3)E6$8!U?.D2(-E>?\;9&?Q MO;]8PMYTNT]I;3N'I%/M3UX_&[4H_7J+UY7CQWD1_LI2+O>1QVB+7I8F]%;B M^>%"N>?F><^]36]MJX7FS/7-220;)B3#0+:9M@*DM?(,,%S^CB3A8*>?3?0: M(M8WIC0G'%:RPIY\PV9@3\/4]QC"_C-Y(&X6YS7W+U_<(*,;`VO6QPS)K)!& MFV8MO>CO6[9O;)UUIF]V(SD56L6Z+TCJ^$%RRTXW1BO_,&A%][>+=T^^*Z>: M;.<:@[[ZV0,V71<>Y0TNF^-4:Z^EF#CB/YID;+>(=SBD0)`:?($36 M0G^[G$:S8V.-:J7Z!M_JN*V-K6YV945:XEUD,;M6%YVTF=46;XKQ-[=>0Q,G27U.M8L5VG(7$?:HQA>VC M#2X[7;;@D.9='+F$>`E[9MD47Y_%#T[^F)>3)!8C!-;V%0PL/S@C<`BNP"S? M*VXS9CV5L6CEGG$=5FJ;2DXXK5F`PC36)!U^UG5@CJ'HH6TT'8E7BKBU8@B0 MR3_:8W(;Y\-P,+K+8G?I)$4DYZH,YBX$JV*M'!;(<_/=WF$\AS`"QRY5>L!* MS,O(OACZ";F+?;K'SIMQ?:?*UPS=Z8#B-=.2Z8J]2HN%*H8`7XRM"TY%-0[92*^`YRPE(D[R&)OBYY0EUNTB MDP'S0N6,W`,"YJ#A@[+`[\LZ"JL8L1#JI-&?3G!:0B:`RLRBXT.7)*/"J:2$ M%+CL3O&-B5HYRP4"TIT$*B2+KH\N9*':4ROWBOR$;M:4YVR78A"HP.S[.Y1T MFU]'V]LLZM[$!"O'*5>2^")H.*QZ,[H2AHRH:F64CT[#,',"BF[H^FOZ0Y&5#+U]BZ"A$K3O0M'A!@[Y MU?(%Q8)J#`._.UN7")>^"NN!O1$_%6DU(5FP+-%&;T0;W6-8#DY(O$T^TM1U MLU66I[!>D+GO^M)&@FI8J(#M.T7@G!B^U*?/CA\P=\%5E#\.0MQC,ABHE.W' MCZ@I1Y)XMZO-"4FX^]!J&U(I$(LJS^ZX:L4..M.N0_G7,=4.2^3V#=Y4N\\D M6L3.>NF[3@",J&^##%$F;2IPI-H]D$43/54TO00$F61$VM:*V!82M&=$O<`S M\9G0\SQ\%0;%LT&-,=9#J%5Z4O4S<.G#<1>]BR,O<]-9_$#B9]\E\DV(/QJ9 MELOV'SX!.))X2MQ83=L2NT2U]4A`<`A%IEY\T?!H09''4^*GRMQI#+,=BJY4 M*KX4,&Y56QO\ED#N/_DHZ\<$]++-(PX'V^\IQR@.2U;4B3R3(,I+YU^^L,*: MDGN<`FPP630@\G%(:JM#VPJD#/GX6>:JDL'8WKOT%X^0<&R>JI-=6FNE/TSI M?>*[K5I]-W=NJZ)F5#$=:QW8=FB-;JR^B?D<2Q]OFN,&U[Z(3RBRC6Y`EL`> M$N";!,#WE`_%SI-&J1,T7E,0M9>">>Y;[5*EC:90^?*/MN?4L/WZ75M*C=Y] MVYX:-@-HN4$\M/U'7D>>GV4Y=N1 M1JQAFS8<7+]>K1T_SBM0S&^B<'%#[5VOZ)'W&)T1:C6OHX1XL[GDO@2?PO9E M"NX9TF6+H=AK>B$YBZ(_\@X8LWF!@&#CX@_%[R\5XXYIG7RFFRL+2YV%11]]8.`"K1)N4YXI.8T&%P( M@_3G=!+7Z-M!YC-`[-L9,X''3&`+DL&:"?R%WE59BRB*IOB^SD;R!EIO/:&3 M$RRFU%`(POG2#YWKT/.=_W#6#KM-_'L4+OZ3_E_*:#68[7`J+;9#N6!(")<9 ML^K/G=#Q'/KML]CYIQ](^2^%L-XZ0H?U`-IQ>#?NJ9VG>%6I#$&VL\O.W`K6 M.%+>+4X06.':GJ]V/YHO6;J,2+JH`;C',(3C$-!&EZ M0[]#=UMJ^*RB,.]1G+]M7Y#$C?VUX(V)`0-AK4=,@][YM1AAJH!;Q@S)V5R, MBT`2$$#;-QA@<3)`/)'R&CP\C6)WO-^/#"%K9C`\CX\/(P1]&C'E*QH<1XTZ-XWH8R0M0 MY];E>10F/F5=V MXID_-\!?*@7@MLV&SH^44G8Z*1'\58R.NF'\)3R+3OI<;R/F,G0 M[LDF8Q>UV;S$=!;?^XMENEG8#\1EH1T^2V>M&FJ* M4QLU(,[7$M0!8FK*(M30L+=4\OF$-,1"FP6VZX>+>GH M,`;'Q6HL['E03H^%/0_`Z5_\T%]E*Q6O&\-L/\]P]*/!:2Y=.+:17YP7$,OK MPVP_JP!8SJ,+!\O+^^*=$Z>OE6?NY.RU^A?%UJXQ!X[="+;W:Y!5T3$DPE3= M&7AC<0A'7R4E@C-[L[A3QR.?>O"CXE+YU:= M%QR0H9_LZK*00!S:O$T>(=Y%%OOA MXH[$?N05#Y3Y/\^8&[=Z%524-NP^HVU'!CP.;$^F(1']UDE?173*GLT6I.CU MW/+C3[\ZL;=YXLY?L_-'@.W[=E%#0*((]1_KME%%`^"VMG:DUA^X(%+%K>@2W&)73Y0G_T2UV11.?6"1!` MV79BZLI!2KQQUN]"?W+)/T852\$GB9Y$]"8;1D3;?JS"<7I.O?_.DC1_VWZ, MII[G,Q8[P9WC>]?AN;/V4R?@FP*5+2*Y)W]F?N*GY('$SP6MU)"X)VZT"'UY M3L3!$,`??W=HCF#20SY!;6/BK&E,E.3FIU1R'19DJFQ[$Q^S[9/0L]O,L!II M5%JEGTGE3U,W]9]9*2I9/Y-/_!(#M4BU>B^3VH#--U"T,AECV'K?=F99FJ1. MWMNGB.$TM^EP/F4Y0=!,")TIB72N)K\NO"(IM>7L]^K8ESWEE8*]VIA66,ZG M;+O&4&JL4"2CQA;LV>1#;&T.DSK+^9AMCQQ2K16*9;Q1'/1&8H! M#E#NQVR[V;P;__[>OL,7I=9Q.=7+=>,R1-#*9$ M1JFS7$Z-.LM9TK\1EB1.O"FU:)OOQP?9?>4(V`YU0ZG=FN(;G4*-+<&.SH,1 M`+L\ORFEUY3?-Z+TB;[/S9#V]XX)=!DO?D$0'*9"7UL&ITP@:KI0)S/ MUOB(;O/MYY9\3>GTP\1W?W6"[#">C>8GH1IZ9)ZX?67TC;QN#TB5-?P3[[]9 MMUR;9:-'@G,PU=ET&-NW]4VH,@\PL-2HE(YH:SX:;=;9G+\M?YF<9X9V9V0% M/FZC\.29)*P4$V-54I8O^T*_$#?`9(4_/K[3+ORQ^_*D^/2D_/8D_WA[@K$H MB&3>`6^7MZQQ+].#;5NW7!W,[97"#QYM@1!STCFB$W\/,W\PR>\#],F:$4MG MO4U)C"+U?<]E_>M!=US^UXZW4(@AP2!]*-@>$:9S-?OJP):XQSX3_['K7/[^D.:^`I`?YIVP\+ MYOMTZ(KA"+7NWD_^N(H)"X,@5+[I`;6._VG;9X`=K9.)X0BU;K/(?HWHIQ@&)].P MW(%\/H[>/92>)L3>O2UJEW]F]'!E^V@4YBYCJ<=/`39$V?`IP>$9;.!V$;&D M2+%T!,.1246F<0TA"0A"X4LL=V&58ZLQS+;W0JI1#>YS*<1A>D^#?/(R2:!U MZ6`V79A(3G4HO.4`;'C/82U^(+-NF^U=M_8-H,'KQP]"HY?7UG7[QYX:NXX& ML>W3932(D1WOHT$\&L2C03P:Q*-!/(AWD-LH+$(<"T9AV6/ON M\0K9I56)@=5 MM-IW;:<)VE0UC@".5MF075LQ=#)'=7/%4FCR&&^N&%J06[N['KUBB5L5U)*\ MC:D;^/NV^X0?2@4U!6+;J6),,?F=CHQN?;)/6F_9?2C]4_/]:%7NW`E=$A"O M8[/+?OBOAX3U%MJ'4LLNLNFLJ'3.IVB_`GC&E)2YD>QJJ`8&UGMC'TH]M:5R ME+JY]3Y9U4]-+*PWOC[8Y::+=(Y23[?EU*SJJ286UEM:'TI/.TGG*/5T()=S M%`VKD=W/C]YQA.I^CJ)WM/T;^A$J72*EG=?1KT?UZ_)QZUV;S:EA=UF8K.EM MG`@S6]N>>%CONHQ)S>1.RN%IW"RTJVGY]\$!@=^"AE4D(][&&%53Q MD4346I;>T;Y<"IL\FG:R\[YHO>/W@1WJ8J[;UK=QWS6#%8I6X(/8>8_0(X5V MY]71RL$[0:5<,*1Q2.K9<(OJ%BT['J/-^,H:E):Z^0@L=2/H2U-^=Y)&.\#* MI\=*.&,E'"PU6%H;TE@)9ZR$,U;"&2OAC)5PQDHX"N9_0WVKWH]]J\:^517$ MQ[Y58]^JL6_5V+>J!Q_D(<1PA%HW]JU"H75CWZJQ;]78MVKL6X6QB)11QB.I M[%\^-=PY94W1WLB'!*4:F.S4Y`NB7LZ0`5Q`9U\4J\ZRYCC;&V-'S6S(C$\]CIWP+H[F)$DH.4YP162UCMLC;4L'[,,0$8E# M!'F7OR+J]"YPU'T@1>.'XS:7$HQ#*)>K=1"]$G)&0C+W<[.([W.5A"_!IQB, MWUF;+3BD>9&1QZCB4_%)0HU<-XL9;R3'D1QL,#Y<$/DX)-7Y8:-,&KR=%$2^"M)*E7"MN\9)EZ,E%\<5CE^@TS' MH5K(>GE;+(RO21"J)[_KD/Y('IT7`GSE^VOSE:^889)/@>Q=;TO<#F'UDYX4 MR*8Y/I\3UOV<;!%D(0KWQ*5FC!_XQ7I(KPA=#4[`E#:CB+S6!DL,]3XFMWT9 M!HB[:O5)O^U&P+V%,"5^$_C^)1XG;W&_$2B,$L'T- MUU<$!>U(-FMZIO@NO6]>^$%&5>:6I`6E-]3NI,9"?NY4LEAEPZ49JS\V]_A\ MIHD3>A.OF&M")]OL_-^Q^?XRH0A,<@P:::T[V`LA['XYK#WMKT[,JOQL&:D^ M*<00%E=Q3E<@OL8]5MI[)]VAI; M>`UFX9"UK")UM22$8G?5G,:VGU53QIV89*B>J`"7PO2?S=M[B[M3Q-(A(XAJ MZ65FV[Y2J&1[(W@`B[G<>%KJJKV,]2VDYNO,^)`8(RQ\6-125!12 M^LL-I'2D@@9,N]4T3'VOY?*X?'&#C-Y4KRCYM3MERR9?19DL%KZGZ6V?2_"` MQC[9B22$YCP*7<+Z.+$)81&/GYH>A-H60DMEI+RA:(84[Q")C)`'1,Y M&`8+9)#7?I`XQKL_5J,/W]U?5!7G[+7Z%T4=98TY!B0U';)P>!6J>*F,=MY8 M',+15TF)X,S:[K]2=PHUI.">0F,HWQ$F`64$_O&O:R`4P,N.X0$IM#3?'8;"Z M!FG^\AD^VKO(+"?$]NY8L0^3P3I6[,-;L:\?"9\S(X7$:V9PJM^8^:-QR`JT MVO@$X'C5N2?K+':7]`3=%A)LHJN^-(*GP"$TF?JU;HU@VE"LK-P6JFP*;"^1 MKRXQ!`YA@5:8F(A*12=D8E$M*QD,#M&HE`T@)+.>F/R+#R2EE\C\'`65D54! MV?;6J'6IZK6!L0"''V=T._?I=OYHV[`8WOSAAY%R'8?2<5Q"0B.C4C/Q=:FHJ)"-B5#%DWT5&>#!`299$3:UA22F"`\5\C+ ME[5?AB]1ZB25&/FC;1\?X`\RDT!Z`U?`6*N5(V%>F\L@P@TY/LR8X)'ZF_R&13EU]>""#N?LJR3:T M'LKOED'$HF?2QB#\K95X6&/2\DW/I](;?^,[3WZ09T.>JX+8`:"VBWMJM[Y2 ML@&'U(J=\U6Y(37'V7[S`,!-B-L%\.$,[Q!U!$497O(GA+R M9\:9D[1)IMH?*H;`X&$;I.M3)831RXG%'V?2RVED M0:NC:84`0Y*'B`8!=9[(>+.Q+[T:9W5KI4VDT*V*%$C\#Y8-.P,BKS7YT@(]U$7@6U?8G9 M5^1M-B!9J0YK/Y0C?1Z%B>^1(@7EGKC$?R;>+*SDFTHDJ#?-8&)?.K'G"-;R MCNP[>B,GFS+7(`5H0-B^]':1-9=HA'??G<>D4K7^2^BSI^W$C?VU8-4R8""L M[=LQ+*!*BQ%(=EZ9;=!PA4V_.K'W.8X2Z3VZVWR#B0#:CV&&[AZ;B\Y=69^) MJXBU[4388;G+3/BCB3J3=@BQU5-NY8)IC@6R_D<4K.<3JI6P6OZ%_>.)RI#^ MYO\#4$L#!!0````(`!@T;$?>G'*SA@\``!JG```1`!P`8V1X:2TR,#$U,#DS M,"YX$16=7@+``$$)0X```0Y`0``[1UKZQQPFC[_7[-JM&[H[YGHTC6MW>KWWK'X<]Z_"@X@^\"]H>?EE-#CYX_B_;S_@K]/[+^>+T2]? MT1_+R?\^__.-N%I>HT,`ZX_Z-[K)=]R>XAFRP/J4O]]+:/3A:)]YD_8A<-C^ M]>/5G8+;TX"G"Y?0KT7@G9.3D[:J#4%SD(N1YX:DC]JR>H0XCBA#+3'`$\H% MHG8*WA$10A+XN*TK4Z"D$/2-!B4AJ(,S=$-SG MK0E"\PAEC/A(D0XJ),IQ#L5C+N:%.*JF`(DR2OU9L780Y:S*?(FR$8D[-V.*Y@7G'Q#%-QR;Q9 M#X^1[X+Y?O>12\8$.WN60-X$"]GC^1S9N`+%<.@@2AF,,)A7@A)9-I\3&$)0 M\)=WLJ^=2MT.00)+?H#9I)R^!&C#&/0EMV?4N:""B*4O(CHHZE:5D)8N_:63()XC['S@W]47V>>Y@# M&85T!04!8@!2@F0CU_;=>C@Q*X4H04&H\;5M<(Y<.>3OIA@+KI6>+C)K^1!4 M*V=>'*BYRZB#*7`I/W'F$@?J'"L@:6F:.V5++0R0![)-L2#`<8'FT_5F,QRM M8P;K5:J)[[;6+)'F^,WX9B[]*V@Q&`PE=69SO*YFCIBVQ<963-UZ]8DBWR$` MLS.*5'P7\>FERQX*;!)7F4URO(Y))'%+4=^9!$PB0PQ$E^?(_CKQF$\=;8Y\ ML=D4;^1R#.ZVR[CO864+1<"**6RMBN_\V0QYRYOQ'9E0<-IL!,Z/;8-.!$2+ M`^BG-L'A,*@&:S;&]UEC!%1E]T_0M6+"5DAY:XW4I_<@#O.6V@[Q5[.JWV95 M'2%NK28''H-53RRE?_^[3^9RYKW&0NNUK-*LY9.LED,RVO,/"?W+`E);J_<^ MR$(G9.3B,\[!%8QT7E1AU'?G(-^K0Q*6IK'=JKYF`@_0$H$^M(J3!6;5=K*J ME:A6@+NU"KT3S/[:Y]S7J2KM$":+S$H]S"UX$MD*L;=;K3=SVT&RR MU*SS0E]G%1KB;:T:;[$K([4!@B5]"*K@ MR$Z$ZZ6U9C4?9]48B/HUJ*=RM5>@Y MXL0&Y[9'7!_Z&CA)6BU7C/,!]NX`'(=YP0J09A/DXCQ%4_G$`57II86&>24I M?VO)5"W5I]W_HCCWWT0Z>(^5FJNU*S97+@6XUN: MP!;KMTJJA9^V-_,?92J',O7`,WG/H-!L@5QH&*%; MKS2![55O2:8SJ6PSB%GUN2#2D!+=&:,@!9KN]6759B/D0LSB/.E._]F44U+Y M)75FS>>BSWQ2:J?U,*^4U':FS*SE7(`98N]T6R5\3^J]!KS9)KGPLU;0OS-< M[F1##PM$7'XMN[8@][CD`$0.S&RF7'2;/Q!AO0IH6A'1[35+Y#D6FZ.\VFB& MHX*=S,A#W6D_K_V6[*:,ZG-86:5G3&&&-=LE%U?'=M%#1=.5H5S>8MMKIY*( MH7C,5`4V6RH791L#C=V86F6KEKP9XO@NOAF;#60T8G4J9NOF(GB3=<'+#EJ5 MX[)*/]A>ZQ>$E&4KVVI`LPUSJ8"R*'0W.$WF20RIP MA@G*;)!<>J(P,[>S2JE5$@M)HNK,!BT1D8[$UD,UVR^7MR@P7WK]20&$C>V6 M'Y-AKQEMW6,NL*.2(6="Y1FX% M3%B*BSR!72\A"^!M?R#=/Y%,\J^R[+CVSZ4L/^%>;.<-SZH+%B`D>=CVC]+Y` M\4Q;&=ILU1KW"79SB:36ZX M\^!4./Z0GH"K')W8S;8U;2QW;WTM_N2AFG2O2O`FOQ80 MD/C),SE;W\525VC*#N280,SF+3B,DR"V6RARUWB*35!29]3]<2Z/I*GLE%Y\ M]:?T-%HI@%G]N7Q.@M3.!H;K0B6[(ZN@S-8HN+*2N4[TY[:)_$>^7GJ+QY9Z M]?14/H[Y?H\3^=#M7E`V]?#X_9[M+$@K?+/R-Q!M?S%S0Q!)VO#JJ;)H5AM! MPR$)Y-DY*KE768&(.N5",&^'S(<$!!$2?9!HQI+M@$?3WH3(+AK5%1E0L/N$ MLEY)^AL5$GI?72$S'?:)1.W&K6Q48!@Z=05.C[8GDK<7-9(4-W@5MAT_"QM\ MSSX=^PX$9YZP:.X=6M.;Q/HUY2MF*U(&%/FM%>*U9%&K<]@ZZNPON!-S6H>) M6`WUF`CQUF"B^+'EBLV'"++=XUHMEKW%7-)P(8[\T(J1J[9O?-C9U'XA8AN[ M@HGQU%:PU^*KQ'7:5S)#&O-:+L)">R/)*9]1A9Q47P MI+7V;7N_]G]+[&5R>7@'.WTJ?2.8G'P=Y'?ER'==<#$TU)Z2(;4+6AV3N*X\ MJ?5^3WB^G`CE(^JG,$$2Y@S5/.[XX?,0>E[7$%QM:_<%GDDH4$JBG0\>\^.H-0>Y>5D*1:Z#T+1PT<$V M[/1\3UYP5VWKPQ%)]B\6V+,)N,^=E&5KHS;=K5K.6AA-BY?0N^9WR`:^9T_!&X!Y=X0]E9><,:H`"P9I-:RFQ1P@(2/1 MB\6W)O%L/Z_\O<32PAJQ'/&P+YD5K:F7H&J+INI%^K1XJ\(B(=%^`(8`% M\I:;Z`UR+)P#YXY,QF/*%1-GTE83!7J^C$%`,O5[%`_(<8&Z^IVTU[` MHT7-R/H06X4[Q9B&4*AZX"W(3QD"U_^7,?ZNERKM367S+#TFU'L MAOKK8QO^-M6=63IBB?I4NDZ#J9&BB^CSPK*M]R?Q_,1Z#HQ(<#R#W M^`[;$$K)'*@=^]N9;,)F2#7MP5\@3PZ%Z!#$.IIX)(VF8V]@&]M4@`UOQK=L MB5S)Z2V^QS0>+"M@UA5!GBS8@`17Q)8_9I,)F'.E:X])<.V=IQR40604QKJW M6,9ZME`S4]A?4AD;GDT*U$-MNL<%7!>'S665ZRY*@+U!&PVQ-\LJ/RAK?M4, M,@Z?*!$\DX4(R]9DDE"!)]C;&(]G\[E+=()\@%5D4L!T.5#C4EQC<<[85[7: MWXSU9?*0^9*Z%^H1J#$]6NT&C;)N4+"`77W?\HV5HO$IP\3.IOS@ M]9IN?D9XK-R)2:ZBW(>;4OEZ3;\0E3\JT:V/1LDC4_IL3?$.F'8C-Y=>K]EJ MTTFMQPLLPXIGUG&=)K]]!4?)@N=58B"O/"T6)TBJ038N3/>"EG=KB':>*L"_U*%A"^V%G M^XBEB>(8K!Q@W?C#8=)WV@#WGS%UF)=F.%/6.(_#!S:<,I_#HGO)?$]@'!QQ M2\YX\N6PM!CUT1J75`Y?F7>#$9#I1(4UC?/;G1**^A!/H7^C.:)GU/F9T^(PN]'Z*>&B#WV#@$S-"-RP5.AJV. M?72GB$B=GTT\K$E6`:UP6]0#!'19"5Y1(LA*J<3E^1@^($/`S,`+7J0MU M.+-2&"$:Y_\CH@QF'1U,XZ#4(7]+LKP)J7(HNFG-_@MV2):N\NG'.!^JUE32[ MF;+&>92N&)6^V(7,KWP"R]N^)V^5LAGAW%O*VXB9_EX'HWGY8F_SFE%86ATY M3Q)WJ7DE27A.*2_M:)(A1YC5(O"0-#*=$)4/./>),\!4S!(T&T!<@$7Q=AIF= M`L``00E#@``!#D!``!0 M2P$"'@,4````"``8-&Q'7*+5YGX/``!TP0``%0`8```````!````I(&WA0`` M8V1X:2TR,#$U,#DS,%]C86PN>&UL550%``/?>$16=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`L1W7G13=1(```73X"`!4`&````````0```*2!A)4` M`&-D>&DM,C`Q-3`Y,S!?9&5F+GAM;%54!0`#WWA$5G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`!@T;$>$?WRJ[4X``("[!``5`!@```````$```"D@22V M``!C9'AI+3(P,34P.3,P7VQA8BYX;6Q55`4``]]X1%9U>`L``00E#@``!#D! M``!02P$"'@,4````"``8-&Q'--YU@)(S``".L0,`%0`8```````!````I(%@ M!0$`8V1X:2TR,#$U,#DS,%]P&UL550%``/?>$16=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`L1]Z<&DM,C`Q-3`Y,S`N>'-D550%``/?>$16=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(``!))`0`````` ` end XML 60 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Option Plans (Tables)
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity is as follows:

Options Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value

Outstanding January 1, 2014 15,290,486 $ 0.07 3.89 $ 305,810

Exercisable January 1, 2014 15,290,486 $ 0.07 3.89 $ 305,810

Canceled (15,290,486 )

Granted 27,756,821-

Exercised (4,506 )

Forfeited -

Outstanding December 31, 2014 27,752,315 $ 0.51 8.02 $ 1,963,523

Exercisable December 31, 2014 26,156,553 $ 0.50 7.95 $ 1,962,239

Canceled -

Granted 5,365,729

Exercised - -

Forfeited -

Outstanding September 30, 2015 33,118,044 $ 0.47 6.87 $ 3,418,084

Exercisable September 30, 2015 33,118,044 $ 0.47 6.87 $ 3,418,084

Schedule of Non-vested Shares Granted Under Stock Option Plan

A summary of the Company’s non-vested options for the nine-months ended September 30, 2015 and year ended December 31, 2014, are presented below:

Non-vested at January 1, 2014 -

Granted 27,756,821

Vested (26,156,553 )

Exercised (4,506 )

Forfeited -

Non-vested at December 31, 2014 1,595,762

Granted 5,365,729

Vested (6,961,491 )

Exercised -

Forfeited -

Non-vested at September 30, 2015 -

Schedule of Fair Value Assumptions

The range of fair value assumptions related to options outstanding as of September 30, 2015 and December 31, 2014, were as follows:

September 30, 2015 December 31, 2014

(Unaudited)

Dividend yield 0.0% 0.0%

Risk-free rate 0.12% - 1.47% 0.12% - 1.47%

Expected volatility 112% - 170% 112% - 170%

Expected term 1.1 - 5.5 years 1.1 - 5.5 years

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R49.htm IDEA: XBRL DOCUMENT v3.3.0.814

Concentration (Details Narrative) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Vendor [Member]

Outstanding payables $ 86,255 $ 86,255

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDXI_VendorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Option Plans - Schedule of Fair Value Assumptions (Details)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Dividend yield 0.00% 0.00%

Minimum [Member]

Risk-free rate 0.12% 0.12%

Expected volatility 112.00% 112.00%

Expected term 1 year 1 month 6 days 1 year 1 month 6 days

Maximum [Member]

Risk-free rate 1.47% 1.47%

Expected volatility 170.00% 170.00%

Expected term 5 years 6 months 5 years 6 months

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities:

Net loss $ (2,443,881) $ (15,186,393)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 19,373 28,196

Stock based compensation $ 564,399 10,783,948

Amortization of debt discount 4,592

Gain on sale of assets $ (95,000) (2,426)

Changes in assets and liabilities:

Deposits and other assets 5,102 1,989

Prepaid expenses 12,389 (50,194)

Inventory 28,099

Accrued payroll and payroll related expenses 883,323 (198,989)

Accounts payable (16,626) (153,510)

Accrued interest $ 222 (101,553)

Fees payable to directors (50,000)

Patent license payable (10,000)

Other current liabilities (12,613)

Net cash used in operating activities $ (1,070,699) (4,918,854)

Cash flows from investing activities:

Purchases of property and equipment (1,634)

Proceeds from sale of property and equipment $ 10,000 2,426

Expenditures on patents (21,852) (20,419)

Net cash used in investing activities (11,852) (19,627)

Cash flows from financing activities:

Proceeds from the issuance of common stock 1,430,000 3,923,798

Proceeds from the issuances of notes payable $ 30,000 2,076,000

Repayment of principal on notes payable (550,408)

Net cash provided by financing activities $ 1,460,000 5,449,390

NET INCREASE IN CASH 377,449 510,909

Cash at the beginning of the year 35,696 222,410

Cash at the end of the period 413,145 733,319

NON-CASH INVESTING AND FINANCING ACTIVITIES:

Conversion of notes payable and accrued interest into common stock 30,222 $ 11,125,167

Conversion of accrued payroll and payroll related expenses into stock options $ 970,069

SUPPLEMENTAL DISCLOSURES:

Cash paid for interest $ 188,382

Cash paid for income taxes

X

- Definition
Conversion of accrued payroll and payroll related expenses into stock options.
+ References
No definition available.
+ Details

Name: CDXI_ConversionOfAccruedPayrollAndPayrollRelatedExpensesIntoStockOptions

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increase Decrease Fees Payable To Directors.
+ References
No definition available.
+ Details

Name: CDXI_IncreaseDecreaseFeesPayableToDirectors

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase Decrease Patent License Payable.
+ References
No definition available.
+ Details

Name: CDXI_IncreaseDecreasePatentLicensePayable

Namespace Prefix: CDXI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in accrued salaries.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedSalaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDepositOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Intangible Assets, Net
9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

NOTE 5 – INTANGIBLE ASSETS, net

Intangible assets, net, consists of the following as of:

September 30, 2015 December 31, 2014

(Unaudited)

Patents $ 393,370 $ 393,370

Less accumulated amortization (214,637 ) (200,272 )

178,733 193,098

Patents pending 248,272 226,420

Total intangible assets, net $ 427,005 $ 419,518

Patents are amortized straight-line over a period of fifteen years. Amortization expense was $2,703 and $14,365, for the three and nine-months ended September 30, 2015, respectively. Amortization expense was $7,652 and $22,955, for the three and nine-months ended September 30, 2014, respectively.

The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved.

The Company owns 20 issued patents, including 13 in the United States and 7 others in China, India, Japan, and Hong Kong. These patents will expire during the years of 2023 to 2028, subject to any patent term extensions of the individual patent. The Company has 1 patent application pending in the United States and 5 foreign patent applications pending in Europe, Canada, and Brazil.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants (Tables)
9 Months Ended

Sep. 30, 2015

Warrants

Schedule of Stock Warrants Activity

The following is a summary of the Company’s warrant activity:

Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value

Outstanding January 1, 2014 3,395,833 $ 0.45 5.28 $ -

Exercisable January 1, 2014 3,395,833 $ 0.45 5.28 $ -

Canceled (3,395,833 )

Granted 28,435,782

Exercised -

Forfeited -

Outstanding December 31, 2014 28,435,782 $ 0.64 4.07 $ -

Exercisable December 31, 2014 28,435,782 $ 0.64 4.07 $ -

Canceled -

Granted 13,435,342

Exercised -

Forfeited -

Outstanding September 30, 2015 41,871,124 $ 0.47 3.70 $ 4,988,991

Exercisable September 30, 2015 41,871,124 $ 0.47 3.70 $ 4,988,991

Schedule of Fair Value Assumptions Related to Warrants Outstanding

The range of fair value assumptions related to warrants outstanding as of September 30, 2015 and December 31, 2014, were as follows:

September 30, 2015 December 31, 2014

(Unaudited)

Dividend yield 0.0% 0.0%

Risk-free rate 0.12% - 0.86% 0.12% - 0.66%

Expected volatility 102% - 159% 112% - 159%

Expected term 1.0 - 2.5 years 1.0 - 2.5 years

X

- Definition
Schedule Of Fair Value Assumptions Related To Warrants Outstanding Table Text Block.
+ References
No definition available.
+ Details

Name: CDXI_ScheduleOfFairValueAssumptionsRelatedToWarrantsOutstandingTableTextBlock

Namespace Prefix: CDXI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: CDXI_WarrantsAbstract

Namespace Prefix: CDXI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 107 235 1 false 37 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cardaxpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://cardaxpharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://cardaxpharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://cardaxpharma.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cardaxpharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Company Background Sheet http://cardaxpharma.com/role/CompanyBackground Company Background Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Inventory Sheet http://cardaxpharma.com/role/Inventory Inventory Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment, Net Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets, Net Sheet http://cardaxpharma.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 10 false false R11.htm 00000011 - Disclosure - Note Payable Sheet http://cardaxpharma.com/role/NotePayable Note Payable Notes 11 false false R12.htm 00000012 - Disclosure - Stock Issuance Sheet http://cardaxpharma.com/role/StockIssuance Stock Issuance Notes 12 false false R13.htm 00000013 - Disclosure - Stock Option Plans Sheet http://cardaxpharma.com/role/StockOptionPlans Stock Option Plans Notes 13 false false R14.htm 00000014 - Disclosure - Warrants Sheet http://cardaxpharma.com/role/Warrants Warrants Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://cardaxpharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://cardaxpharma.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Basic and Diluted Net Income (Loss) Per Share Sheet http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShare Basic and Diluted Net Income (Loss) Per Share Notes 17 false false R18.htm 00000018 - Disclosure - Concentration Sheet http://cardaxpharma.com/role/Concentration Concentration Notes 18 false false R19.htm 00000019 - Disclosure - Leases Sheet http://cardaxpharma.com/role/Leases Leases Notes 19 false false R20.htm 00000020 - Disclosure - Commitments Sheet http://cardaxpharma.com/role/Commitments Commitments Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Events Sheet http://cardaxpharma.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Inventory (Tables) Sheet http://cardaxpharma.com/role/InventoryTables Inventory (Tables) Tables http://cardaxpharma.com/role/Inventory 23 false false R24.htm 00000024 - Disclosure - Property and Equipment, Net (Tables) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://cardaxpharma.com/role/PropertyAndEquipmentNet 24 false false R25.htm 00000025 - Disclosure - Intangible Assets, Net (Tables) Sheet http://cardaxpharma.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://cardaxpharma.com/role/IntangibleAssetsNet 25 false false R26.htm 00000026 - Disclosure - Stock Option Plans (Tables) Sheet http://cardaxpharma.com/role/StockOptionPlansTables Stock Option Plans (Tables) Tables http://cardaxpharma.com/role/StockOptionPlans 26 false false R27.htm 00000027 - Disclosure - Warrants (Tables) Sheet http://cardaxpharma.com/role/WarrantsTables Warrants (Tables) Tables http://cardaxpharma.com/role/Warrants 27 false false R28.htm 00000028 - Disclosure - Basic and Diluted Net Income (Loss) Per Share (Tables) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShareTables Basic and Diluted Net Income (Loss) Per Share (Tables) Tables http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShare 28 false false R29.htm 00000029 - Disclosure - Company Background (Details Narrative) Sheet http://cardaxpharma.com/role/CompanyBackgroundDetailsNarrative Company Background (Details Narrative) Details http://cardaxpharma.com/role/CompanyBackground 29 false false R30.htm 00000030 - Disclosure - Inventory (Details Narrative) Sheet http://cardaxpharma.com/role/InventoryDetailsNarrative Inventory (Details Narrative) Details http://cardaxpharma.com/role/InventoryTables 30 false false R31.htm 00000031 - Disclosure - Inventory - Components of Inventory (Details) Sheet http://cardaxpharma.com/role/Inventory-ComponentsOfInventoryDetails Inventory - Components of Inventory (Details) Details 31 false false R32.htm 00000032 - Disclosure - Property and Equipment, Net (Details Narrative) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNetDetailsNarrative Property and Equipment, Net (Details Narrative) Details http://cardaxpharma.com/role/PropertyAndEquipmentNetTables 32 false false R33.htm 00000033 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNet-ScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 33 false false R34.htm 00000034 - Disclosure - Intangible Assets, Net (Details Narrative) Sheet http://cardaxpharma.com/role/IntangibleAssetsNetDetailsNarrative Intangible Assets, Net (Details Narrative) Details http://cardaxpharma.com/role/IntangibleAssetsNetTables 34 false false R35.htm 00000035 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) Sheet http://cardaxpharma.com/role/IntangibleAssetsNet-ScheduleOfIntangibleAssetsNetDetails Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) Details 35 false false R36.htm 00000036 - Disclosure - Note Payable (Details Narrative) Sheet http://cardaxpharma.com/role/NotePayableDetailsNarrative Note Payable (Details Narrative) Details http://cardaxpharma.com/role/NotePayable 36 false false R37.htm 00000037 - Disclosure - Stock Issuance (Details Narrative) Sheet http://cardaxpharma.com/role/StockIssuanceDetailsNarrative Stock Issuance (Details Narrative) Details http://cardaxpharma.com/role/StockIssuance 37 false false R38.htm 00000038 - Disclosure - Stock Option Plans (Details Narrative) Sheet http://cardaxpharma.com/role/StockOptionPlansDetailsNarrative Stock Option Plans (Details Narrative) Details http://cardaxpharma.com/role/StockOptionPlansTables 38 false false R39.htm 00000039 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfStockOptionActivityDetails Stock Option Plans - Schedule of Stock Option Activity (Details) Details 39 false false R40.htm 00000040 - Disclosure - Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfNon-vestedSharesGrantedUnderStockOptionPlanDetails Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) Details 40 false false R41.htm 00000041 - Disclosure - Stock Option Plans - Schedule of Fair Value Assumptions (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfFairValueAssumptionsDetails Stock Option Plans - Schedule of Fair Value Assumptions (Details) Details 41 false false R42.htm 00000042 - Disclosure - Warrants (Details Narrative) Sheet http://cardaxpharma.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://cardaxpharma.com/role/WarrantsTables 42 false false R43.htm 00000043 - Disclosure - Warrants - Schedule of Stock Warrants Activity (Details) Sheet http://cardaxpharma.com/role/Warrants-ScheduleOfStockWarrantsActivityDetails Warrants - Schedule of Stock Warrants Activity (Details) Details 43 false false R44.htm 00000044 - Disclosure - Warrants - Schedule of Fair Value Assumptions Related to Warrants Outstanding (Details) Sheet http://cardaxpharma.com/role/Warrants-ScheduleOfFairValueAssumptionsRelatedToWarrantsOutstandingDetails Warrants - Schedule of Fair Value Assumptions Related to Warrants Outstanding (Details) Details 44 false false R45.htm 00000045 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://cardaxpharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://cardaxpharma.com/role/RelatedPartyTransactions 45 false false R46.htm 00000046 - Disclosure - Income Taxes (Details Narrative) Sheet http://cardaxpharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cardaxpharma.com/role/IncomeTaxes 46 false false R47.htm 00000047 - Disclosure - Basic and diluted Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShare-ScheduleOfBasicAndDilutedNetIncomeLossDetails Basic and diluted Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) Details 47 false false R48.htm 00000048 - Disclosure - Basic and Diluted Net Income (Loss) Per Share - Schedule of Computation of Diluted Net Income Loss Per Share (Details) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShare-ScheduleOfComputationOfDilutedNetIncomeLossPerShareDetails Basic and Diluted Net Income (Loss) Per Share - Schedule of Computation of Diluted Net Income Loss Per Share (Details) Details http://cardaxpharma.com/role/BasicAndDilutedNetIncomeLossPerShareTables 48 false false R49.htm 00000049 - Disclosure - Concentration (Details Narrative) Sheet http://cardaxpharma.com/role/ConcentrationDetailsNarrative Concentration (Details Narrative) Details http://cardaxpharma.com/role/Concentration 49 false false R50.htm 00000050 - Disclosure - Leases (Details Narrative) Sheet http://cardaxpharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://cardaxpharma.com/role/Leases 50 false false R51.htm 00000051 - Disclosure - Commitments (Details Narrative) Sheet http://cardaxpharma.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://cardaxpharma.com/role/Commitments 51 false false R52.htm 00000052 - Disclosure - Subsequent Events (Details Narrative) Sheet http://cardaxpharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://cardaxpharma.com/role/SubsequentEvents 52 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. cdxi-20150930.xml cdxi-20150930_cal.xml cdxi-20150930_def.xml cdxi-20150930_lab.xml cdxi-20150930_pre.xml cdxi-20150930.xsd true true XML 67 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock Option Plans (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Feb. 07, 2014

May. 15, 2006

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Recognized stock based compensation expense related to options $ 206,959 $ 601,107 $ 1,169,537 $ 5,318,948

Options, issued during period 5,365,729 27,756,821

Employees [Member]

Recognized stock based compensation expense related to options 206,959 $ 970,069

Director [Member]

Recognized stock based compensation expense related to options 206,959 970,069

Consultants [Member]

Recognized stock based compensation expense related to options $ 206,959 $ 970,069

2006 Stock Incentive Plan [Member]

Aggregate number of shares issuable under this plan 16,521,704

Percentage granted to employees at a price per share 100.00%

Percentage of stock option granted to stockholders 10.00%

Percentage exercise price per share 110.00%

Percentage restricted stock to related parties price per share 100.00%

2006 Stock Incentive Plan [Member] | Minimum [Member]

Aggregate number of shares issuable under this plan 1,456,786

2006 Stock Incentive Plan [Member] | Maximum [Member]

Aggregate number of shares issuable under this plan 17,978,490

2014 Equity Compensation Plan [Member]

Aggregate number of shares issuable under this plan 30,420,148

X

- Definition
Percentage Exercise Price Per Share.
+ References
No definition available.
+ Details

Name: CDXI_PercentageExercisePricePerShare

Namespace Prefix: CDXI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of stock option granted to stockholders.
+ References
No definition available.
+ Details

Name: CDXI_PercentageOfStockOptionGrantedToStockholders

Namespace Prefix: CDXI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage Restricted Stock To Related Parties Price Per Share.
+ References
No definition available.
+ Details

Name: CDXI_PercentageRestrictedStockToRelatedPartiesPricePerShare

Namespace Prefix: CDXI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Purchase price of common stock expressed as a percentage of its fair value.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDXI_EmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDXI_ConsultantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=CDXI_TwoThousandSixStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=CDXI_TwoThousandFourteenEquityCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments

NOTE 15 – COMMITMENTS

Patent payable

As part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting from the license. There were no revenues generated by this license during the three and nine-months ended September 30, 2015 and 2014. The remaining obligation of $20,000 as of September 30, 2015 and December 31, 2014, is recorded as a part of accounts payable on the condensed consolidated balance sheets.

Employee settlement

As of September 30, 2015 and December 31, 2014, the Company owed a former employee a severance settlement payable in the amount of $50,000 for accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully vested and extended.

BASF agreement and license

In November 2006, the Company entered into a joint development and supply agreement with BASF SE (“BASF”). Under the agreement, the Company granted BASF an exclusive world-wide license to the Company’s rights related to the development and commercialization of Astaxanthin consumer health products; the Company retains all rights related to Astaxanthin pharmaceutical products. The Company is to receive specified royalties based on future net sales of such Astaxanthin consumer health products. No royalties were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014. The license does not prohibit the Company from purchasing Astaxanthin consumer health products from BASF for consumer health applications, similar to any third-party wholesale customer.

Capsugel agreement

On August 18, 2014, the Company entered into a collaboration agreement with Capsugel US, LLC (“Capsugel”) for the joint commercial development of Astaxanthin products for the consumer health market that contain nature-identical synthetic Astaxanthin and use Capsugel’s proprietary formulation technology, which is expected to increase the oral bioavailability of Astaxanthin. The agreement provides for the parties to jointly administer activities under a product development plan that will include identifying at least one mutually acceptable third party marketer who will further develop, market and distribute consumer health, nature-identical synthetic Astaxanthin products developed under the collaboration. Capsugel will share revenues with the Company based on net sales of products that are developed under the collaboration. No revenues were realized from this agreement during the three and nine-months ended September 30, 2015 and 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a)(19))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
Income Taxes (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Effective tax statutory rate	34.00%	34.00%
Unrecognized tax benefits

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Property and equipment, gross	$ 42,053	$ 42,053
Less accumulated depreciation	(26,450)	(21,442)
Total property and equipment, net	15,603	20,611
Information Technology Equipment [Member]
Property and equipment, gross	31,892	31,892
Furniture and Office Equipment [Member]
Property and equipment, gross	$ 10,161	$ 10,161

Leases (Details Narrative) - Lease Settlement Agreement [Member] - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Hawaii Research Center [Member]
Lease expiration date				Oct. 31, 2014
Operating lease rent expense	$ 0	$ 14,709		$ 12,112	$ 47,331
Manoa Innovation Center [Member]
Operating lease rent expense	$ 7,931		$ 7,825	$ 23,759		$ 23,255

Warrants (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Warrants (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Stock based compensation expense			$ 564,399	$ 10,783,948
Warrant [Member]
Stock based compensation expense	$ 0	$ 0	$ 4,000	$ 5,229,589

Stock Issuance (Details Narrative)	9 Months Ended
Stock Issuance (Details Narrative)	Sep. 30, 2015 USD ($) $ / shares shares
Sales of securities, number of units	$ 1,460,222
Sales of securities, price per unit \| $ / shares	$ 0.30
Conversion of notes payable	$ 30,000
Accrued interest on debt	$ 222
Warrants rights \| shares	13,385,342
Two Class D Warrant [Member]
Restricted common stock units description	Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020.
Number of restricted common stock units \| shares	100,739
Warrants to purchase restricted common stock, price per share \| $ / shares	$ 0.10
Warrant expiration date	Mar. 31, 2020
One Class E Warrant [Member]
Warrants to purchase restricted common stock, price per share \| $ / shares	$ 0.1667
Warrant expiration date	Mar. 31, 2020

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Oct. 26, 2015	Oct. 19, 2015	Nov. 09, 2015	Sep. 30, 2015
Sale of securities in self-directed offering				$ 1,460,222
Sale of securities, price per unit				$ 0.30
One Class E Warrant [Member]
Warrants to purchase restricted common stock, price per share				$ 0.1667
Warrant expiration date				Mar. 31, 2020
Subsequent Event [Member]
Common stock	25,556
Sale of securities in self-directed offering			$ 146,000
Sale of securities, price per unit			$ 0.30
Issuance of restricted common stock, each unit consisted of one share			486,665
Subsequent Event [Member] \| Two Class D Warrants [Member]
Restricted common stock units description			Each unit consisted of 1 share of restricted common stock ([486,665] shares), 2 Class D warrants, each to purchase 1 share of restricted common stock at $0.10 per share, which expire March 31, 2020, and 1 Class E warrant to purchase 3/4 of 1 share of restricted common stock at $0.1667 per share, which expires March 31, 2020.
Warrants to purchase restricted common stock, price per share			$ 0.10
Warrant expiration date			Mar. 31, 2020
Subsequent Event [Member] \| One Class E Warrant [Member]
Warrants to purchase restricted common stock, price per share			$ 0.1667
Warrant expiration date			Mar. 31, 2020
Subsequent Event [Member] \| Restricted Stock [Member]
Common stock		100,000
Total fair value of stock		$ 45,000
Subsequent Event [Member] \| Stock Option [Member]
Common stock	41,851
Sale of securities, price per unit	$ 0.1555
Subsequent Event [Member] \| Withheld [Member]
Common stock	16,295

Warrants - Schedule of Stock Warrants Activity (Details) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Warrants, Outstanding, Beginning balance	28,435,782	3,395,833
Warrants, Exercisable, Beginning balance	28,435,782	3,395,833
Warrants, Canceled		(3,395,833)
Warrants, Granted	13,435,342	28,435,782
Warrants, Exercised
Warrants, Forfeited
Warrants, Outstanding, Ending balance	41,871,124	28,435,782
Warrants, Exercisable, Ending balance	41,871,124	28,435,782
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.64	$ 0.45
Weighted Average Exercise Price, Exercisable, Beginning	$ 0.64	$ 0.45
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending	$ 0.47	$ 0.64
Weighted Average Exercise Price, Exercisable, Ending	$ 0.47	$ 0.64
Weighted Average Remaining Contractual Terms (Years), Beginning Outstanding	4 years 26 days	5 years 3 months 11 days
Weighted Average Remaining Contractual Terms (Years), Beginning Exercisable	4 years 26 days	5 years 3 months 11 days
Weighted Average Remaining Contractual Terms (Years), Beginning Outstanding	3 years 8 months 12 days	4 years 26 days
Weighted Average Remaining Contractual Terms (Years), Beginning Exercisable	3 years 8 months 12 days	4 years 26 days
Aggregate Intrinsic Value, Outstanding, Beginning
Aggregate Intrinsic Value, Exercisable, Beginning
Aggregate Intrinsic Value, Outstanding, Ending	$ 4,988,991
Aggregate Intrinsic Value, Exercisable, Ending	$ 4,988,991

Company Background (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Company Background (Details Narrative) - USD ($)	Feb. 07, 2014	Jan. 03, 2014	May. 31, 2006	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2014	May. 31, 2013	Dec. 31, 2009	Dec. 31, 2008
Issuance of common stock, shares			9,447,100
Ownership interest										100.00%
Proceeds from sale of common stock	$ 3,923,100
Number of common stock shares sold	6,276,960
Warrants term	5 years	5 years						5 years
Warrants to purchase of common stock shares	6,276,960	3,321,600
Warrant exercise price per share	$ 0.625	$ 0.625						$ 0.625
Outstanding principal amount of notes payable		$ 2,076,000						$ 8,489,036
Shares of Common Stock issued upon conversion of notes payable		3,353,437						14,446,777
Warrants issued upon conversion of notes payable (issued Jan. 03, 2014)		3,321,600						14,446,777
Stock options cancelled	15,290,486
Exercise price of cancelled option	$ 0.07
Stock options issued in substitution of cancelled options	6,889,555
Stock options issued in substitution of cancelled options, price per share	$ 0.155
Additional stock options issued purchase number of common stock	20,867,266
Additional stock options issued purchase number of common stock, price per share	$ 0.625
Outstanding principal notes repaid in full											$ 500,000	$ 55,000
Net losses				$ 743,461	$ 1,880,394	$ 2,443,881	$ 15,186,393
Accumulated deficit				52,336,163		52,336,163			$ 49,892,282
Additional capital through future equity and debt securities issuances				$ 1,460,000		$ 1,460,000
Preferred Series C [Member]
Issuance of preferred stock			13,859,324
Series A Preferred Stock [Member]
Issuance of preferred stock			14,440,920
Series B Preferred Stock [Member]
Issuance of preferred stock			11,113,544
Preferred Series C [Member]
Issuance of preferred stock issued additional			704,225

Inventory (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Inventory (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Inventory	$ 958,575		$ 958,575		$ 958,575
Research and development	216,228	$ 357,519	352,328	$ 921,106
Commercial Product Research and Development [Member]
Research and development					28,099
Germany [Member]
Inventory	924,452		924,452		924,452
Inventory reserves	$ 0		$ 0		$ 0

Inventory - Components of Inventory (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Processed materials	$ 958,575	$ 958,575
Total inventories	$ 958,575	$ 958,575

Property and Equipment, Net (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 16, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Depreciation expense		$ 1,670	$ 1,783	$ 5,008	$ 5,241
Written off of property and equipment						$ 992,797
Gain on sale of assets				$ 95,000	2,426
Payment to receive upon sell agreement					$ 1,634
Laboratory Equipment [Member]
Net book value of assets	$ 0
Gain on sale of assets	95,000
Payment to receive upon sell agreement	$ 85,000

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash	$ 413,145	$ 35,696
Inventory	958,575	958,575
Deposits and other assets	87,727	92,829
Prepaid expenses	7,473	19,862
Total current assets	1,466,920	1,106,962
PROPERTY AND EQUIPMENT, net	15,603	20,611
INTANGIBLE ASSETS, net	427,005	419,518
TOTAL ASSETS	1,909,528	1,547,091
CURRENT LIABILITIES
Accrued payroll and payroll related expenses	3,469,219	3,555,961
Accounts payable	635,365	651,991
Fees payable to directors	418,546	418,546
Employee settlement	$ 50,000	50,000
Other current liabilities		85,004
Total current liabilities	$ 4,573,130	$ 4,761,502
COMMITMENTS AND CONTINGENCIES
Total liabilities	$ 4,573,130	$ 4,761,502
STOCKHOLDERS' DEFICIT
Common stock - $0.001 par value; 400,000,000 shares authorized, 69,011,494 and 63,885,930 shares issued and outstanding as of September 30, 2015, and December 31, 2014, respectively	69,012	63,886
Additional paid-in-capital	$ 49,603,549	46,908,249
Deferred compensation		(294,264)
Accumulated deficit	$ (52,336,163)	(49,892,282)
Total stockholders' deficit	(2,663,602)	(3,214,411)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,909,528	$ 1,547,091

Related Party Transactions (Details Narrative) - USD ($)						3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Apr. 02, 2015	Sep. 16, 2014	Jun. 14, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Equity instruments issued arrears of compensation			$ 37,500
Amounts payable to directors	$ 293,546					$ 293,546		$ 293,546		$ 293,546
Options, issued during period								5,365,729		27,756,821
Stock based compensation expense								$ 564,399	$ 10,783,948
Director [Member]
Options, issued during period	147,058	111,112		642,200	134,553
Fair value of stock option	$ 50,000	$ 16,667		$ 597,246	$ 108,988
Stock based compensation expense						50,000	$ 185,640	360,931	235,411
Executive Chairman Agreement [Member] \| Director [Member]
Consulting fees to director						$ 37,500	$ 64,615	139,615	$ 184,615
Paid in stock option								$ 130,385

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 393,370	$ 393,370
Less accumulated amortization	(214,637)	(200,272)
Patents, Total	178,733	193,098
Patents pending	248,272	226,420
Total intangible assets, net	$ 427,005	$ 419,518

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2015 and 2014. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. The results for the three-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the current report on Form 10-K filed on March 13, 2015. The accompanying condensed consolidated financial statements include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
Reclassifications	Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.
Recent Accounting Pronouncements	Recent accounting pronouncements In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company’s consolidated financial statements.

Note Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
Note Payable (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2015	Apr. 28, 2015	Jan. 28, 2015
Short term loan				$ 30,000
Loan interest rate percentage	3.00%	3.00%
Debt maturity date		Apr. 28, 2015
Interest expense on notes payable	$ 69	$ 222
Conversion of securities, price per unit			$ 0.30
Two Class D Warrant [Member]
Restricted common stock units description		Each unit consisted of one share of restricted common stock (100,739 shares), two Class D warrants, each to purchase one share of restricted common stock at $0.10 per share, which expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of restricted common stock at $0.1667 per share, which expires March 31, 2020.
Number of restricted common stock units		100,739
Warrants to purchase restricted common stock, price per share		$ 0.10
Warrant expiration date		Mar. 31, 2020
One Class E Warrant [Member]
Warrants to purchase restricted common stock, price per share		$ 0.1667
Warrant expiration date		Mar. 31, 2020

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	400,000,000	400,000,000
Common Stock, shares issued	69,011,494	63,885,930
Common Stock, shares outstanding	69,011,494	63,885,930

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 09, 2015
Document And Entity Information
Entity Registrant Name	CARDAX, INC.
Entity Central Index Key	0001544238
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		69,623,715
Trading Symbol	CDXI
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Intangible Assets, Net (Details Narrative)	3 Months Ended		9 Months Ended
Intangible Assets, Net (Details Narrative)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) Units	Sep. 30, 2014 USD ($)
Patent, amortization period			15 years
Amortization expense \| $	$ 2,703	$ 7,652	$ 14,365	$ 22,955
Patents, Units			20
Patents expiration date			patents will expire during the years of 2023 to 2028.
United States [Member]
Patents, Units			13
Number of patent application pending			1
China, India, Japan And Hong Kong [Member]
Patents, Units			7
Europe, Canada, and Brazil [Member]
Number of patent application pending			5

Commitments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Commitments (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Payment for license cost			$ 10,000
Percentage of royalties revenue			2.00%
License revenue
License payable	$ 20,000		$ 20,000		$ 20,000
Employee settlement	$ 50,000		$ 50,000		$ 50,000
Revenues
BASF Agreement And License [Member]
Royalty revenue
Capsugel Agreement [Member]
Royalty revenue
Revenues

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (2,443,881)	$ (15,186,393)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,373	28,196
Stock based compensation	$ 564,399	10,783,948
Amortization of debt discount		4,592
Gain on sale of assets	$ (95,000)	(2,426)
Changes in assets and liabilities:
Deposits and other assets	5,102	1,989
Prepaid expenses	12,389	(50,194)
Inventory		28,099
Accrued payroll and payroll related expenses	883,323	(198,989)
Accounts payable	(16,626)	(153,510)
Accrued interest	$ 222	(101,553)
Fees payable to directors		(50,000)
Patent license payable		(10,000)
Other current liabilities		(12,613)
Net cash used in operating activities	$ (1,070,699)	(4,918,854)
Cash flows from investing activities:
Purchases of property and equipment		(1,634)
Proceeds from sale of property and equipment	$ 10,000	2,426
Expenditures on patents	(21,852)	(20,419)
Net cash used in investing activities	(11,852)	(19,627)
Cash flows from financing activities:
Proceeds from the issuance of common stock	1,430,000	3,923,798
Proceeds from the issuances of notes payable	$ 30,000	2,076,000
Repayment of principal on notes payable		(550,408)
Net cash provided by financing activities	$ 1,460,000	5,449,390
NET INCREASE IN CASH	377,449	510,909
Cash at the beginning of the year	35,696	222,410
Cash at the end of the period	413,145	733,319
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable and accrued interest into common stock	30,222	$ 11,125,167
Conversion of accrued payroll and payroll related expenses into stock options	$ 970,069
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest		$ 188,382
Cash paid for income taxes

Stock Option Plans (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
Stock Option Plans (Details Narrative) - USD ($)	Feb. 07, 2014	May. 15, 2006	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Recognized stock based compensation expense related to options			$ 206,959	$ 601,107	$ 1,169,537	$ 5,318,948
Options, issued during period					5,365,729		27,756,821
Employees [Member]
Recognized stock based compensation expense related to options			206,959		$ 970,069
Director [Member]
Recognized stock based compensation expense related to options			206,959		970,069
Consultants [Member]
Recognized stock based compensation expense related to options			$ 206,959		$ 970,069
2006 Stock Incentive Plan [Member]
Aggregate number of shares issuable under this plan		16,521,704
Percentage granted to employees at a price per share		100.00%
Percentage of stock option granted to stockholders		10.00%
Percentage exercise price per share		110.00%
Percentage restricted stock to related parties price per share		100.00%
2006 Stock Incentive Plan [Member] \| Minimum [Member]
Aggregate number of shares issuable under this plan		1,456,786
2006 Stock Incentive Plan [Member] \| Maximum [Member]
Aggregate number of shares issuable under this plan		17,978,490
2014 Equity Compensation Plan [Member]
Aggregate number of shares issuable under this plan	30,420,148